No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d2b7aA_, 1.0000, 0.00, 1.000, 284, 284, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
2, d3tjcA_, 0.9986, 0.23, 0.996, 284, 284, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3, d4hgeA_, 0.9975, 0.31, 0.996, 284, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4, d4aqcA_, 0.9973, 0.33, 0.993, 289, 284, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
5, d3fupA_, 0.9971, 0.33, 1.000, 284, 284, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
6, d5cf5A1, 0.9963, 0.38, 0.996, 286, 284, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
7, d3tjdA_, 0.9949, 0.50, 0.996, 284, 284, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
8, d4ji9A_, 0.9948, 0.45, 0.996, 284, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
9, d5cf8A1, 0.9943, 0.29, 0.996, 284, 283, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
10, d3q32A_, 0.9938, 0.51, 0.996, 291, 284, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
11, d4f08A_, 0.9932, 0.53, 0.996, 288, 284, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
12, d4e6dA_, 0.9932, 0.36, 0.986, 286, 283, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
13, d5cf4A_, 0.9923, 0.47, 0.993, 283, 283, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
14, d2b7aB_, 0.9917, 0.58, 1.000, 287, 284, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
15, d3tjcB_, 0.9916, 0.59, 0.996, 287, 284, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
16, d5cf4B_, 0.9915, 0.60, 0.996, 291, 284, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
17, d4zimA_, 0.9914, 0.48, 0.996, 285, 283, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
18, d3fupB_, 0.9910, 0.60, 1.000, 287, 284, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
19, d4f08B_, 0.9902, 0.65, 0.996, 288, 284, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
20, d4hgeB_, 0.9900, 0.67, 0.996, 288, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
21, d5cf5B1, 0.9898, 0.67, 0.996, 292, 284, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
22, d3tjdB_, 0.9898, 0.68, 0.996, 287, 284, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
23, d4zimB1, 0.9897, 0.67, 0.996, 292, 284, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
24, d4aqcB_, 0.9895, 0.67, 0.993, 295, 284, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
25, d4ji9B_, 0.9889, 0.69, 0.996, 288, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
26, d4e4mE_, 0.9887, 0.68, 0.993, 296, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
27, d4e4mA_, 0.9887, 0.67, 0.993, 296, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
28, d5cf6A_, 0.9885, 0.62, 0.996, 285, 283, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
29, d3q32B1, 0.9870, 0.75, 0.996, 293, 284, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
30, d2w1iA_, 0.9870, 0.77, 1.000, 284, 284, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
31, d5cf8B1, 0.9864, 0.67, 0.996, 287, 283, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
32, d2w1iB_, 0.9863, 0.80, 1.000, 284, 284, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
33, d5cf6B1, 0.9860, 0.86, 0.993, 288, 284, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
34, d4e6dB_, 0.9859, 0.67, 0.986, 286, 283, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
35, d4f09A_, 0.9856, 0.79, 0.996, 288, 284, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
36, d4ivaA_, 0.9855, 0.79, 0.996, 290, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
37, d4e6qA_, 0.9842, 0.83, 0.982, 296, 284, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
38, d4e4mD_, 0.9842, 0.82, 0.996, 296, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
39, d3krrA1, 0.9841, 0.75, 0.996, 290, 283, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
40, d4e4mB_, 0.9840, 0.83, 0.996, 296, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
41, d3e62A_, 0.9840, 0.76, 0.996, 291, 283, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
42, d4p7eA_, 0.9838, 0.52, 1.000, 281, 281, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
43, d3e63A_, 0.9838, 0.77, 0.996, 290, 283, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
44, d4e6qB_, 0.9837, 0.85, 0.982, 296, 284, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
45, d4p7eB_, 0.9834, 0.63, 1.000, 285, 282, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
46, d4d0xA_, 0.9815, 0.83, 0.996, 291, 283, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
47, d5aepA_, 0.9808, 0.85, 0.996, 287, 283, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
48, d4gfmA_, 0.9808, 0.75, 0.996, 289, 282, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
49, d3e64A_, 0.9807, 0.87, 0.996, 291, 283, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
50, d3lpbB1, 0.9780, 0.58, 0.996, 283, 280, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
51, d4d0wA_, 0.9766, 0.77, 0.996, 289, 281, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
52, d4ytiA_, 0.9759, 0.87, 0.996, 284, 282, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
53, d4gmyA_, 0.9746, 1.04, 0.993, 298, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
54, d3rvgA_, 0.9744, 0.63, 0.996, 285, 279, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
55, d4jiaA_, 0.9741, 1.05, 0.993, 298, 284, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
56, d4ythA_, 0.9740, 0.92, 0.993, 287, 282, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
57, d4ytfA_, 0.9725, 0.79, 0.996, 283, 280, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
58, d3lpbA_, 0.9725, 0.34, 0.993, 278, 277, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
59, d3io7A_, 0.9725, 0.78, 0.996, 282, 280, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
60, d3iokA_, 0.9724, 0.80, 0.996, 285, 280, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
61, d4ytcA_, 0.9722, 0.79, 0.993, 284, 280, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
62, d4bbfD_, 0.9718, 0.83, 0.996, 288, 280, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
63, d4bbfA_, 0.9713, 0.85, 0.996, 288, 280, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
64, d5tq3B_, 0.9696, 1.01, 0.975, 285, 281, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
65, d5l3aA_, 0.9689, 1.04, 0.993, 290, 282, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
66, d3kckA_, 0.9689, 0.88, 0.996, 285, 280, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
67, d3jy9A_, 0.9686, 0.89, 0.996, 282, 280, JANUS KINASE 2 INHIBITORS
68, d5tq8A_, 0.9679, 1.25, 0.986, 291, 283, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
69, d5tq5A_, 0.9663, 1.31, 0.986, 291, 283, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
70, d2xa4A_, 0.9658, 0.50, 0.989, 276, 276, INHIBITORS OF JAK2 KINASE DOMAIN
71, d4bbeC_, 0.9649, 1.00, 0.996, 288, 280, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
72, d4bbeB_, 0.9649, 0.99, 0.996, 288, 280, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
73, d4bbfB_, 0.9644, 1.02, 0.996, 288, 280, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
74, d4bbfC_, 0.9639, 1.03, 0.996, 288, 280, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
75, d4bbeD_, 0.9621, 1.07, 0.996, 288, 280, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
76, d5usyA_, 0.9620, 0.98, 0.996, 287, 279, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
77, d4bbeA_, 0.9617, 1.08, 0.996, 288, 280, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
78, d5tq3A_, 0.9614, 0.92, 0.975, 282, 278, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
79, d3pjcA_, 0.9608, 1.57, 0.611, 286, 283, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
80, d5wevA_, 0.9600, 0.97, 0.989, 293, 279, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
81, d2xa4B_, 0.9585, 0.64, 0.989, 275, 275, INHIBITORS OF JAK2 KINASE DOMAIN
82, d4py1A_, 0.9583, 1.20, 0.512, 289, 281, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
83, d5tq6A_, 0.9566, 0.59, 0.989, 274, 274, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
84, d3lxnA_, 0.9555, 1.09, 0.509, 287, 279, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
85, d5usyB_, 0.9548, 1.21, 0.996, 287, 279, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
86, d4c62A_, 0.9542, 0.56, 0.989, 273, 273, INHIBITORS OF JAK2 KINASE DOMAIN
87, d4c61B_, 0.9541, 0.69, 0.993, 274, 274, INHIBITORS OF JAK2 KINASE DOMAIN
88, d3zmmA_, 0.9541, 0.56, 0.989, 273, 273, INHIBITORS OF JAK2 KINASE DOMAIN
89, d3zmmB_, 0.9535, 0.71, 0.993, 274, 274, INHIBITORS OF JAK2 KINASE DOMAIN
90, d5lwnA_, 0.9534, 1.40, 0.606, 290, 282, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
91, d4gihA1, 0.9534, 1.15, 0.509, 287, 279, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
92, d4gj2A1, 0.9531, 1.15, 0.509, 287, 279, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
93, d4gj3A1, 0.9523, 1.17, 0.509, 287, 279, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
94, d4c61A_, 0.9522, 0.48, 0.993, 272, 272, INHIBITORS OF JAK2 KINASE DOMAIN
95, d4d1sA_, 0.9521, 0.84, 0.993, 280, 275, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
96, d4k77A_, 0.9520, 1.03, 0.552, 282, 277, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
97, d4giiA1, 0.9519, 1.18, 0.509, 287, 279, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
98, d1yvjA_, 0.9517, 1.62, 0.610, 288, 282, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
99, d5lwmA_, 0.9512, 1.44, 0.606, 290, 282, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
100, d5tq4A_, 0.9499, 1.67, 0.986, 290, 284, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
101, d4k77B_, 0.9491, 1.05, 0.554, 280, 276, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
102, d5hx8A_, 0.9489, 1.02, 0.554, 291, 276, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
103, d4gvjA1, 0.9489, 1.29, 0.513, 288, 279, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
104, d5wo4A_, 0.9487, 1.01, 0.554, 292, 276, JAK1 COMPLEXED WITH COMPOUND 28
105, d3eyhA_, 0.9477, 1.16, 0.552, 285, 277, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
106, d4ivbB_, 0.9470, 1.09, 0.554, 280, 276, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
107, d4i5cB1, 0.9468, 0.98, 0.556, 290, 275, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
108, d5wo4B_, 0.9464, 1.11, 0.554, 280, 276, JAK1 COMPLEXED WITH COMPOUND 28
109, d4ivdB_, 0.9462, 1.12, 0.554, 280, 276, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
110, d4ivcB_, 0.9462, 1.11, 0.554, 280, 276, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
111, d4e4nB_, 0.9459, 1.15, 0.554, 280, 276, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
112, d5tq6B_, 0.9457, 0.61, 0.989, 271, 271, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
113, d5e1eA_, 0.9456, 1.04, 0.556, 279, 275, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
114, d4k6zA_, 0.9455, 1.01, 0.556, 279, 275, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
115, d4ivbA1, 0.9454, 1.01, 0.556, 290, 275, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
116, d4e1zA_, 0.9453, 1.36, 0.498, 288, 279, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
117, d3eygA_, 0.9451, 1.05, 0.556, 280, 275, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
118, d5walA1, 0.9450, 1.26, 0.500, 285, 278, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
119, d4c62B_, 0.9450, 0.65, 0.993, 271, 271, INHIBITORS OF JAK2 KINASE DOMAIN
120, d4i5cA_, 0.9448, 1.07, 0.553, 279, 275, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
121, d4ei4B_, 0.9447, 1.15, 0.554, 280, 276, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
122, d4ivcA1, 0.9446, 1.03, 0.556, 290, 275, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
123, d5e1eB_, 0.9444, 1.03, 0.556, 280, 275, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
124, d4rioA_, 0.9443, 1.41, 0.619, 285, 278, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
125, d5hx8B_, 0.9440, 1.09, 0.553, 279, 275, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
126, d4hvgA_, 0.9440, 1.27, 0.617, 281, 277, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
127, d4e5wA1, 0.9434, 1.05, 0.556, 291, 275, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
128, d4e20A_, 0.9432, 1.16, 0.507, 282, 276, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
129, d4fk6B_, 0.9431, 1.22, 0.552, 284, 277, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
130, d4e4nA1, 0.9431, 1.11, 0.556, 290, 275, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
131, d4ehzB_, 0.9429, 1.17, 0.554, 280, 276, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
132, d4ivdA1, 0.9416, 1.03, 0.558, 289, 274, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
133, d4e4lE_, 0.9413, 1.10, 0.556, 280, 275, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
134, d4i6qA_, 0.9409, 1.08, 0.624, 277, 274, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
135, d5tq7A_, 0.9407, 0.82, 0.985, 275, 271, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
136, d4ehzD_, 0.9399, 1.23, 0.554, 280, 276, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
137, d4ehzC_, 0.9399, 1.13, 0.556, 278, 275, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
138, d4ehzA_, 0.9391, 1.16, 0.556, 290, 275, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
139, d4e5wB_, 0.9388, 1.00, 0.557, 278, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
140, d4z16B_, 0.9382, 1.13, 0.624, 276, 274, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
141, d5tozA_, 0.9381, 1.32, 0.622, 278, 275, JAK3 WITH COVALENT INHIBITOR PF-06651600
142, d4fk6A_, 0.9378, 1.19, 0.553, 285, 275, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
143, d4e4lB_, 0.9373, 1.11, 0.558, 279, 274, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
144, d3lxlA_, 0.9365, 1.17, 0.630, 281, 273, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
145, d4ei4A1, 0.9360, 1.08, 0.560, 288, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
146, d4hvhA_, 0.9357, 1.19, 0.624, 278, 274, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
147, d4e4lD_, 0.9357, 1.17, 0.558, 281, 274, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
148, d3nz0A1, 0.9356, 1.10, 0.505, 283, 273, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
149, d3lxkA_, 0.9352, 1.14, 0.629, 279, 272, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
150, d3zepC_, 0.9344, 1.15, 0.612, 276, 273, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
151, d3zepA_, 0.9341, 1.08, 0.632, 274, 272, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
152, d3zepD_, 0.9329, 0.88, 0.630, 272, 270, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
153, d4hvdA_, 0.9327, 1.18, 0.626, 276, 273, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
154, d5khwB_, 0.9323, 1.22, 0.560, 276, 273, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
155, d3lxpA_, 0.9316, 1.39, 0.493, 285, 276, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
156, d4e4lA_, 0.9314, 1.17, 0.560, 277, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
157, d5tq7B_, 0.9309, 0.94, 0.981, 269, 269, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
158, d5khwA_, 0.9307, 1.26, 0.560, 276, 273, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
159, d4qt1A_, 0.9305, 1.21, 0.626, 277, 273, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
160, d4hviA_, 0.9296, 1.11, 0.620, 274, 271, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
161, d5f1zA1, 0.9293, 1.16, 0.518, 280, 272, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
162, d5ttvA_, 0.9288, 1.30, 0.618, 280, 272, JAK3 WITH COVALENT INHIBITOR 6
163, d5khxA_, 0.9283, 0.99, 0.556, 276, 270, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
164, d5w86D_, 0.9269, 1.10, 0.619, 272, 270, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
165, d4v0gB_, 0.9262, 1.28, 0.618, 272, 272, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
166, d5ttsA_, 0.9250, 1.18, 0.626, 274, 270, JAK3 WITH COVALENT INHIBITOR 4
167, d5w86C_, 0.9243, 1.34, 0.620, 273, 271, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
168, d4z16A_, 0.9243, 1.03, 0.621, 271, 269, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
169, d4z16C_, 0.9236, 1.06, 0.621, 271, 269, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
170, d4z16D_, 0.9223, 1.08, 0.621, 271, 269, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
171, d5f20A_, 0.9217, 1.09, 0.520, 274, 269, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
172, d5ttuA_, 0.9203, 1.11, 0.627, 271, 268, JAK3 WITH COVALENT INHIBITOR 7
173, d4qpsC_, 0.9195, 1.13, 0.617, 276, 269, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
174, d5w86A_, 0.9192, 1.01, 0.622, 269, 267, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
175, d3zepB_, 0.9146, 1.01, 0.624, 268, 266, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
176, d5w86B_, 0.9140, 1.25, 0.622, 267, 267, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
177, d4v0gA_, 0.9102, 1.24, 0.629, 267, 267, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
178, d4gfoA1, 0.9089, 1.32, 0.517, 270, 267, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
179, d4qpsA_, 0.9073, 1.34, 0.607, 270, 267, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
180, d3nyxA1, 0.9067, 1.88, 0.473, 285, 275, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
181, d5vo6A_, 0.9061, 1.15, 0.615, 271, 265, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
182, d3ugcA_, 0.9036, 1.56, 0.989, 274, 267, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
183, d5wfjA_, 0.9006, 1.31, 0.614, 265, 264, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
184, d5hezD_, 0.8919, 1.87, 0.936, 289, 267, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
185, d5hezB_, 0.8895, 1.90, 0.936, 289, 267, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
186, d5hezC_, 0.8887, 1.94, 0.936, 289, 267, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
187, d5xgnA_, 0.8847, 2.04, 0.340, 302, 268, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
188, d5hezA_, 0.8828, 1.97, 0.906, 287, 266, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
189, d2jiuA_, 0.8823, 2.05, 0.340, 303, 268, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
190, d4rixD_, 0.8822, 2.02, 0.333, 297, 267, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
191, d4g5pA_, 0.8822, 1.98, 0.336, 299, 268, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
192, d4riyD_, 0.8819, 2.00, 0.337, 297, 267, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
193, d5cy3A1, 0.8818, 1.78, 0.342, 274, 266, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
194, d3ikaA_, 0.8797, 2.09, 0.340, 310, 268, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
195, d2jitA_, 0.8776, 2.05, 0.336, 299, 268, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
196, d4riwD_, 0.8767, 2.08, 0.337, 297, 267, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
197, d2x2kA1, 0.8737, 2.05, 0.357, 284, 266, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
198, d4li5A1, 0.8723, 2.29, 0.332, 303, 268, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
199, d2ivuA1, 0.8715, 2.03, 0.358, 283, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
200, d4ckiA1, 0.8710, 2.04, 0.358, 288, 265, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
201, d3gqiA_, 0.8708, 2.15, 0.386, 304, 267, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
202, d2ivtA1, 0.8704, 2.05, 0.358, 283, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
203, d4ewhA_, 0.8702, 1.85, 0.395, 274, 263, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
204, d4rixB_, 0.8692, 2.09, 0.337, 293, 264, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
205, d3bceC_, 0.8688, 2.27, 0.363, 286, 267, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
206, d4riyB_, 0.8681, 2.09, 0.341, 293, 264, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
207, d3pp0A_, 0.8681, 2.17, 0.337, 286, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
208, d4ewhB_, 0.8673, 1.85, 0.397, 273, 262, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
209, d4ckjA1, 0.8672, 2.17, 0.357, 287, 266, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
210, d3r7oA1, 0.8670, 2.10, 0.322, 295, 264, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
211, d2ivsA_, 0.8670, 2.12, 0.358, 284, 265, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
212, d5eg3A_, 0.8662, 2.06, 0.376, 301, 266, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
213, d3q6wA1, 0.8662, 2.10, 0.322, 293, 264, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
214, d5cxhA1, 0.8658, 1.92, 0.341, 273, 264, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
215, d4jq8A_, 0.8653, 2.15, 0.335, 303, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
216, d3bceB_, 0.8646, 2.26, 0.362, 286, 265, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
217, d2x2mA1, 0.8645, 2.04, 0.357, 281, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
218, d3pp0B_, 0.8641, 2.12, 0.341, 296, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
219, d5flfD_, 0.8630, 2.37, 0.388, 290, 268, DISEASE LINKED MUTATION IN FGFR
220, d4riwB_, 0.8630, 2.19, 0.341, 293, 264, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
221, d2j6mA_, 0.8630, 2.24, 0.335, 306, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
222, d2itpA_, 0.8630, 2.34, 0.333, 305, 267, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
223, d3clyA_, 0.8629, 2.41, 0.382, 289, 267, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
224, d4gfgA1, 0.8627, 2.06, 0.343, 273, 265, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
225, d2x2lA1, 0.8621, 2.08, 0.361, 282, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
226, d3bceA_, 0.8620, 2.24, 0.362, 285, 265, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
227, d3eqrA_, 0.8613, 1.94, 0.398, 270, 261, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
228, d4iwdA1, 0.8612, 2.18, 0.322, 295, 264, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
229, d4jq7A_, 0.8611, 2.10, 0.336, 303, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
230, d2ivvA1, 0.8606, 2.06, 0.363, 277, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
231, d4jr3A_, 0.8605, 2.12, 0.336, 303, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
232, d1u59A1, 0.8603, 2.01, 0.337, 276, 264, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
233, d4j96B_, 0.8592, 2.19, 0.383, 305, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
234, d2itqA_, 0.8588, 2.37, 0.333, 300, 267, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
235, d1pkgA_, 0.8587, 2.02, 0.347, 290, 262, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
236, d5ugbA_, 0.8586, 2.33, 0.331, 307, 266, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
237, d5cavA_, 0.8586, 2.40, 0.333, 306, 267, EGFR KINASE DOMAIN WITH COMPOUND 41A
238, d4rx7A1, 0.8583, 2.00, 0.342, 270, 263, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
239, d3eqrB_, 0.8581, 1.88, 0.404, 271, 260, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
240, d4jrvA_, 0.8580, 2.17, 0.333, 300, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
241, d1m17A_, 0.8580, 2.28, 0.335, 312, 266, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
242, d3eqpB_, 0.8579, 1.88, 0.400, 270, 260, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
243, d5flfA_, 0.8576, 2.15, 0.389, 296, 265, DISEASE LINKED MUTATION IN FGFR
244, d2j5eA_, 0.8570, 2.38, 0.335, 309, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
245, d4wnmA1, 0.8569, 1.97, 0.347, 269, 262, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
246, d5u6bB1, 0.8567, 1.89, 0.313, 289, 262, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
247, d5cxzA1, 0.8566, 2.01, 0.345, 267, 261, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
248, d5ui0B_, 0.8565, 2.19, 0.381, 304, 265, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
249, d5ui0A_, 0.8564, 2.23, 0.376, 301, 266, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
250, d5u6bD1, 0.8564, 1.90, 0.313, 289, 262, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
251, d5c26A1, 0.8562, 2.12, 0.341, 271, 264, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
252, d4xg6A1, 0.8561, 2.03, 0.344, 270, 262, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
253, d5tr6A1, 0.8555, 2.01, 0.349, 268, 261, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
254, d4k33A_, 0.8553, 2.00, 0.373, 293, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
255, d1m14A_, 0.8552, 2.18, 0.340, 307, 265, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
256, d5c27A1, 0.8548, 2.15, 0.341, 271, 264, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
257, d5lmbA_, 0.8547, 2.04, 0.349, 264, 261, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
258, d4j98B_, 0.8546, 2.16, 0.386, 304, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
259, d1xbcA1, 0.8540, 1.93, 0.346, 267, 260, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
260, d5hibA_, 0.8539, 2.19, 0.342, 314, 263, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
261, d4rx8A1, 0.8538, 2.01, 0.345, 266, 261, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
262, d5hg5A_, 0.8534, 2.51, 0.343, 302, 268, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
263, d5flfB_, 0.8534, 2.28, 0.383, 292, 266, DISEASE LINKED MUTATION IN FGFR
264, d4rssA_, 0.8534, 2.22, 0.345, 269, 264, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
265, d2g2hB_, 0.8533, 2.02, 0.359, 272, 262, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
266, d5amnA1, 0.8532, 2.18, 0.363, 282, 262, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
267, d4xg3B_, 0.8532, 1.96, 0.342, 267, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
268, d3vf8A_, 0.8530, 1.94, 0.346, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
269, d5xdkA_, 0.8528, 2.52, 0.341, 307, 267, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
270, d3srvA_, 0.8528, 1.93, 0.347, 262, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
271, d3eqpA_, 0.8527, 1.78, 0.403, 268, 258, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
272, d4puzB_, 0.8523, 1.90, 0.347, 265, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
273, d2itwA_, 0.8523, 2.29, 0.336, 300, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
274, d4i23A_, 0.8522, 2.03, 0.330, 304, 261, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
275, d5j9yA_, 0.8521, 2.20, 0.341, 300, 264, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
276, d2pvfA_, 0.8521, 2.18, 0.384, 285, 263, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
277, d2qohB2, 0.8520, 1.94, 0.365, 280, 260, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
278, d2gs6A2, 0.8517, 2.16, 0.338, 308, 263, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
279, d1xbaA1, 0.8516, 1.96, 0.346, 265, 260, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
280, d2j0lA_, 0.8513, 2.09, 0.330, 274, 264, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
281, d3vjnA_, 0.8512, 2.09, 0.332, 297, 262, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
282, d1m52A_, 0.8512, 2.01, 0.359, 271, 262, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
283, d5hg8A_, 0.8511, 2.55, 0.343, 300, 268, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
284, d4j96A_, 0.8510, 2.32, 0.380, 302, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
285, d3dqwC_, 0.8510, 2.04, 0.305, 275, 262, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
286, d3ue4A_, 0.8509, 2.09, 0.365, 270, 263, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
287, d3srvB_, 0.8508, 1.96, 0.351, 263, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
288, d5tt7A1, 0.8507, 1.98, 0.340, 270, 259, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
289, d3dqwD_, 0.8507, 2.06, 0.305, 276, 262, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
290, d5lmaA_, 0.8501, 1.95, 0.344, 267, 259, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
291, d2f4jA_, 0.8497, 2.15, 0.365, 287, 263, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
292, d4twpB_, 0.8495, 2.16, 0.365, 271, 263, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
293, d2v7aA_, 0.8495, 2.09, 0.365, 269, 263, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
294, d4zogB_, 0.8494, 2.04, 0.364, 268, 261, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
295, d3kulB_, 0.8492, 2.15, 0.344, 271, 262, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
296, d1m52B_, 0.8491, 2.08, 0.359, 272, 262, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
297, d3vf9A_, 0.8489, 2.00, 0.346, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
298, d4i0sA1, 0.8487, 1.85, 0.342, 263, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
299, d3fqeA1, 0.8486, 1.99, 0.347, 265, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
300, d2z60A1, 0.8486, 2.02, 0.365, 280, 260, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
301, d4xg3A_, 0.8484, 1.97, 0.333, 262, 258, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
302, d4px6A1, 0.8484, 1.85, 0.345, 261, 258, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
303, d5em8A_, 0.8483, 2.44, 0.336, 303, 265, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
304, d4xg9B_, 0.8482, 1.98, 0.347, 265, 259, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
305, d4fyoA1, 0.8482, 1.81, 0.346, 263, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
306, d3w2qA1, 0.8481, 2.36, 0.336, 306, 265, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
307, d3w2oA1, 0.8478, 2.29, 0.330, 304, 264, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
308, d2x2mB1, 0.8478, 1.91, 0.358, 274, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
309, d4pv0A1, 0.8477, 2.02, 0.342, 266, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
310, d4xg7A1, 0.8476, 2.15, 0.330, 265, 261, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
311, d2eb2A_, 0.8475, 2.36, 0.337, 305, 264, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
312, d2gs2A_, 0.8472, 2.47, 0.336, 305, 265, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
313, d2qohA2, 0.8470, 1.98, 0.367, 270, 259, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
314, d2g2hA_, 0.8467, 2.15, 0.363, 272, 262, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
315, d4j98A_, 0.8459, 2.31, 0.383, 304, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
316, d5ghvB_, 0.8458, 2.09, 0.338, 265, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
317, d4xg5B_, 0.8458, 2.09, 0.338, 265, 260,  
318, d1qpjA_, 0.8458, 1.99, 0.354, 265, 260, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
319, d4wkqA1, 0.8456, 2.19, 0.332, 294, 259, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
320, d1u4dB_, 0.8455, 1.79, 0.402, 262, 254, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
321, d3vjoA_, 0.8454, 2.14, 0.333, 298, 261, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
322, d4xg4A_, 0.8453, 2.02, 0.344, 264, 259, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
323, d3lcdA_, 0.8453, 2.12, 0.338, 290, 260, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
324, d3b2tA_, 0.8453, 2.25, 0.375, 288, 264, STRUCTURE OF PHOSPHOTRANSFERASE
325, d5gtzA_, 0.8451, 2.33, 0.349, 317, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
326, d5ghvA_, 0.8449, 2.11, 0.338, 265, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
327, d4xg5A_, 0.8449, 2.11, 0.338, 265, 260,  
328, d3w2pA1, 0.8449, 2.42, 0.311, 307, 264, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
329, d3fqhA_, 0.8449, 1.88, 0.340, 262, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
330, d4dfnA1, 0.8447, 2.15, 0.345, 268, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
331, d2itxA_, 0.8446, 2.40, 0.337, 307, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
332, d4id7A_, 0.8443, 2.08, 0.402, 268, 259, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
333, d2fo0A3, 0.8443, 2.23, 0.361, 291, 263, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
334, d2jiuB_, 0.8441, 2.38, 0.300, 309, 267, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
335, d4puzA_, 0.8440, 1.94, 0.350, 263, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
336, d4i0tA1, 0.8438, 1.98, 0.346, 262, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
337, d5lmbB_, 0.8435, 1.87, 0.348, 261, 256, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
338, d3ug1A_, 0.8435, 2.04, 0.337, 296, 258, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
339, d5flfC_, 0.8433, 2.34, 0.371, 283, 264, DISEASE LINKED MUTATION IN FGFR
340, d4rx9A1, 0.8432, 1.92, 0.339, 264, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
341, d4j95B_, 0.8429, 2.36, 0.383, 282, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
342, d2py3B_, 0.8429, 2.54, 0.373, 284, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
343, d3lcsA_, 0.8426, 2.38, 0.302, 304, 265, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
344, d3kxzA_, 0.8425, 2.04, 0.354, 263, 260, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
345, d3kulA_, 0.8425, 2.26, 0.341, 267, 261, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
346, d4uxlA_, 0.8423, 1.92, 0.345, 288, 258, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
347, d2j5fA_, 0.8421, 2.26, 0.346, 308, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
348, d2v7aB_, 0.8420, 2.23, 0.365, 268, 263, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
349, d4j97C_, 0.8419, 2.09, 0.385, 283, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
350, d1oecA_, 0.8419, 2.19, 0.385, 280, 262, FGFR2 KINASE DOMAIN
351, d4j99D_, 0.8417, 2.09, 0.388, 281, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
352, d4zogA_, 0.8416, 2.23, 0.360, 269, 261, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
353, d3dk7B_, 0.8414, 1.98, 0.364, 268, 258, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
354, d3ue4B_, 0.8412, 2.17, 0.364, 268, 261, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
355, d3hmiA_, 0.8412, 2.06, 0.358, 268, 260, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
356, d4j97A_, 0.8410, 2.24, 0.383, 282, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
357, d2z8cA1, 0.8409, 2.31, 0.303, 297, 261, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
358, d1opkA3, 0.8409, 2.36, 0.361, 291, 263, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
359, d4j99B_, 0.8408, 2.37, 0.383, 291, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
360, d1xbbA1, 0.8408, 2.05, 0.341, 266, 258, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
361, d4xeyA_, 0.8405, 2.01, 0.359, 269, 259, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
362, d4fl1A_, 0.8405, 2.28, 0.345, 268, 261, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
363, d4dflA1, 0.8404, 1.99, 0.339, 262, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
364, d3dk3B_, 0.8403, 1.98, 0.364, 269, 258, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
365, d2jitB_, 0.8403, 2.41, 0.305, 312, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
366, d5ugxA_, 0.8402, 2.33, 0.380, 297, 263, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
367, d2pwlB_, 0.8402, 2.59, 0.381, 286, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
368, d4fynA1, 0.8401, 1.97, 0.339, 263, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
369, d4cnhB_, 0.8401, 1.97, 0.309, 293, 256, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
370, d3fqsA1, 0.8401, 2.11, 0.341, 264, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
371, d1gjoA_, 0.8400, 2.22, 0.385, 280, 262, THE FGFR2 TYROSINE KINASE DOMAIN
372, d4i0rA1, 0.8399, 1.97, 0.336, 260, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
373, d1oplB2, 0.8398, 2.10, 0.363, 267, 259, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
374, d4lqmA_, 0.8397, 2.35, 0.350, 305, 260, EGFR L858R IN COMPLEX WITH PD168393
375, d4j97B_, 0.8397, 2.16, 0.381, 283, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
376, d2gqgB1, 0.8396, 2.10, 0.369, 270, 260, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
377, d1oplA3, 0.8396, 2.39, 0.361, 291, 263, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
378, d4twpA_, 0.8394, 2.06, 0.368, 266, 258, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
379, d2py3A_, 0.8392, 2.47, 0.374, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
380, d4xliB_, 0.8391, 2.03, 0.360, 264, 258, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
381, d2xynA_, 0.8389, 2.06, 0.357, 264, 258, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
382, d1y57A3, 0.8388, 2.28, 0.313, 285, 262, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
383, d3nsvA_, 0.8386, 2.07, 0.357, 264, 258,  
384, d3dqwA_, 0.8385, 2.25, 0.309, 278, 262, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
385, d2pwlA_, 0.8384, 2.58, 0.383, 284, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
386, d4f4pA1, 0.8381, 2.02, 0.350, 260, 257, SYK IN COMPLEX WITH LIGAND LASW836
387, d2hziB_, 0.8381, 1.98, 0.370, 264, 257, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
388, d2ivsB1, 0.8379, 1.72, 0.368, 272, 253, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
389, d1u4dA_, 0.8379, 1.70, 0.410, 258, 251, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
390, d5tiuA1, 0.8377, 1.91, 0.341, 262, 255, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
391, d2dq7X_, 0.8374, 1.90, 0.336, 262, 256, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
392, d1qpdA_, 0.8374, 2.16, 0.354, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
393, d3ug2A_, 0.8373, 2.14, 0.333, 299, 258, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
394, d2gqgA1, 0.8367, 2.14, 0.365, 271, 260, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
395, d4j97D_, 0.8365, 2.20, 0.382, 285, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
396, d3dqwB_, 0.8365, 2.29, 0.309, 278, 262, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
397, d1u54B_, 0.8364, 1.81, 0.401, 261, 252, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
398, d4fz7A1, 0.8363, 2.03, 0.340, 261, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
399, d4fz6A1, 0.8362, 1.97, 0.336, 262, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
400, d2qu5A_, 0.8361, 2.28, 0.367, 292, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
401, d2hziA_, 0.8359, 2.27, 0.368, 268, 261, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
402, d4j99C_, 0.8358, 2.35, 0.384, 291, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
403, d2pz5B_, 0.8358, 2.44, 0.373, 280, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
404, d4j95C_, 0.8356, 2.28, 0.385, 281, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
405, d3ikaB_, 0.8356, 2.46, 0.302, 310, 265, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
406, d2q0bB_, 0.8356, 2.49, 0.372, 282, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
407, d2ofuA_, 0.8356, 2.20, 0.354, 272, 260, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
408, d3zewA_, 0.8354, 2.25, 0.327, 269, 260, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
409, d2of4A_, 0.8354, 2.28, 0.349, 271, 261, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
410, d2hz0A_, 0.8354, 2.20, 0.362, 265, 257, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
411, d3lctA_, 0.8353, 2.54, 0.306, 308, 265, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
412, d5fedA_, 0.8352, 2.28, 0.337, 288, 258, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
413, d4xliA_, 0.8352, 2.12, 0.360, 264, 258, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
414, d3fqhB_, 0.8352, 1.87, 0.336, 258, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
415, d3kmmA_, 0.8349, 2.22, 0.358, 270, 260, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
416, d1qpcA_, 0.8348, 2.23, 0.358, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
417, d4yjoA_, 0.8347, 2.19, 0.340, 267, 259, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
418, d3kf4A_, 0.8347, 2.15, 0.368, 281, 258, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
419, d3bymA_, 0.8347, 2.22, 0.358, 271, 260, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
420, d3ad6A_, 0.8347, 2.29, 0.356, 272, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
421, d2pzpB_, 0.8346, 2.46, 0.377, 282, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
422, d5t68B_, 0.8344, 2.11, 0.341, 264, 258, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
423, d2psqA_, 0.8344, 2.68, 0.381, 287, 265, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
424, d2itzA_, 0.8344, 2.38, 0.340, 302, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
425, d4hzrA_, 0.8343, 1.86, 0.401, 261, 252, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
426, d5uhnA_, 0.8342, 2.37, 0.380, 282, 263, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
427, d3ac1A_, 0.8342, 2.24, 0.358, 270, 260, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
428, d1k9aB3, 0.8341, 1.77, 0.371, 267, 251, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
429, d1u54A_, 0.8340, 1.85, 0.401, 262, 252, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
430, d3kf4B_, 0.8337, 2.24, 0.367, 270, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
431, d1k9aA3, 0.8337, 1.78, 0.367, 267, 251, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
432, d4mkcA_, 0.8336, 2.31, 0.308, 303, 260, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
433, d5t68A1, 0.8335, 2.11, 0.341, 264, 258, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
434, d3b2tB_, 0.8335, 2.22, 0.375, 287, 259, STRUCTURE OF PHOSPHOTRANSFERASE
435, d4hzrB_, 0.8334, 1.59, 0.402, 258, 249, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
436, d2ittA_, 0.8334, 2.36, 0.344, 302, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
437, d3ac5A_, 0.8333, 2.25, 0.358, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
438, d2pvyA_, 0.8333, 2.20, 0.376, 288, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
439, d2of2A_, 0.8333, 2.32, 0.349, 271, 261, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
440, d2pz5A_, 0.8332, 2.47, 0.373, 280, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
441, d1t46A_, 0.8331, 2.30, 0.346, 297, 257, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
442, d4yjuA_, 0.8330, 2.04, 0.348, 262, 256, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
443, d2itnA_, 0.8329, 2.36, 0.344, 304, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
444, d2hz4A_, 0.8329, 2.12, 0.370, 262, 257, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
445, d4xg8A_, 0.8328, 1.99, 0.341, 258, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
446, d2zm1A_, 0.8328, 2.26, 0.358, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
447, d3ri1A_, 0.8327, 2.70, 0.381, 285, 265, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
448, d3d7uC1, 0.8327, 1.68, 0.368, 255, 250, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
449, d3d7uA1, 0.8327, 1.68, 0.368, 255, 250, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
450, d3fzrA_, 0.8326, 2.00, 0.345, 261, 255, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
451, d3ac2A_, 0.8326, 2.27, 0.358, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
452, d3dk7A_, 0.8325, 2.15, 0.364, 265, 258, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
453, d2zm4A_, 0.8325, 2.27, 0.358, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
454, d3lckA_, 0.8324, 2.27, 0.358, 270, 260, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
455, d3ackA_, 0.8324, 2.27, 0.358, 270, 260, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
456, d3ac3A_, 0.8324, 2.27, 0.358, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
457, d3w2rA_, 0.8323, 2.03, 0.337, 297, 255, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
458, d2ityA1, 0.8323, 2.30, 0.349, 299, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
459, d1qpeA_, 0.8323, 2.25, 0.358, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
460, d2pzpA_, 0.8321, 2.48, 0.377, 280, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
461, d4g5jA_, 0.8320, 2.08, 0.335, 307, 254, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
462, d3acjA_, 0.8320, 2.28, 0.358, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
463, d2zybA_, 0.8320, 2.27, 0.358, 270, 260, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
464, d3ad4A_, 0.8319, 2.28, 0.358, 270, 260, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
465, d4xg9A_, 0.8318, 1.98, 0.350, 259, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
466, d3et7A_, 0.8318, 2.02, 0.345, 261, 255, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
467, d3dk3A_, 0.8318, 2.18, 0.364, 266, 258, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
468, d2q0bA_, 0.8318, 2.49, 0.373, 280, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
469, d2b4sD_, 0.8318, 2.30, 0.308, 294, 260, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
470, d4xeyB2, 0.8317, 1.87, 0.362, 264, 254, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
471, d3ac4A_, 0.8317, 2.28, 0.358, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
472, d2r4bA_, 0.8314, 2.26, 0.366, 292, 257, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
473, d2b4sB_, 0.8313, 2.33, 0.308, 294, 260, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
474, d3ad5A_, 0.8312, 2.30, 0.358, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
475, d3ac8A_, 0.8310, 2.29, 0.358, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
476, d2pzrB_, 0.8309, 2.51, 0.369, 282, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
477, d3bu6A_, 0.8308, 2.24, 0.309, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
478, d2pvyD_, 0.8308, 2.24, 0.380, 283, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
479, d2psqB_, 0.8307, 2.70, 0.385, 286, 265, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
480, d4xg2A1, 0.8305, 2.06, 0.333, 258, 255, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
481, d4u0iA_, 0.8305, 2.25, 0.348, 297, 256, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
482, d2itvA_, 0.8305, 2.40, 0.344, 303, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
483, d4hjoA_, 0.8302, 2.25, 0.341, 278, 258, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
484, d3pxkB_, 0.8301, 1.74, 0.348, 258, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
485, d4yjtA_, 0.8298, 2.34, 0.347, 268, 259, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
486, d3dk6A_, 0.8298, 2.08, 0.367, 262, 256, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
487, d4zseC_, 0.8296, 2.25, 0.350, 301, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
488, d1u46B_, 0.8296, 1.81, 0.402, 257, 249, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
489, d3bu3A_, 0.8295, 2.26, 0.309, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
490, d5d41B_, 0.8292, 2.28, 0.353, 302, 258, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
491, d3zfxA_, 0.8292, 2.09, 0.345, 267, 255, CRYSTAL STRUCTURE OF EPHB1
492, d2xynC_, 0.8292, 2.16, 0.358, 262, 257, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
493, d5gmpA_, 0.8291, 2.34, 0.354, 305, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
494, d4i24B_, 0.8291, 2.38, 0.355, 304, 259, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
495, d3byoA_, 0.8291, 2.33, 0.358, 270, 260, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
496, d2r4bB_, 0.8290, 2.24, 0.367, 291, 256, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
497, d5mjbA_, 0.8289, 2.52, 0.323, 276, 263, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
498, d4zseA_, 0.8288, 2.35, 0.349, 297, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
499, d3ri1B_, 0.8288, 2.73, 0.381, 283, 265, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
500, d3mdyA_, 0.8288, 2.25, 0.276, 320, 257, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
501, d5feeA_, 0.8287, 2.16, 0.341, 287, 255, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
502, d3nsvC_, 0.8287, 2.16, 0.358, 262, 257,  
503, d5gtyH_, 0.8286, 2.18, 0.349, 300, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
504, d4z55A_, 0.8286, 2.37, 0.313, 294, 259, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
505, d3mdyC_, 0.8286, 2.29, 0.275, 320, 258, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
506, d4yjpA_, 0.8285, 2.27, 0.341, 263, 258, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
507, d3zfxD_, 0.8285, 2.14, 0.345, 265, 255, CRYSTAL STRUCTURE OF EPHB1
508, d1pkgB_, 0.8285, 2.04, 0.349, 277, 252, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
509, d5hcyA_, 0.8281, 2.23, 0.353, 302, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
510, d3nsvB_, 0.8280, 2.25, 0.353, 264, 258,  
511, d3zfxH_, 0.8279, 2.12, 0.337, 266, 255, CRYSTAL STRUCTURE OF EPHB1
512, d2xynB_, 0.8279, 2.25, 0.357, 264, 258, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
513, d5uglA_, 0.8278, 2.46, 0.388, 285, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
514, d5cnnB_, 0.8275, 2.41, 0.351, 304, 259, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
515, d1k9aE3, 0.8275, 1.91, 0.369, 268, 252, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
516, d4yc8B_, 0.8274, 2.17, 0.362, 264, 257, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
517, d2pzrA_, 0.8272, 2.50, 0.371, 280, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
518, d3l9pA_, 0.8271, 2.45, 0.307, 303, 261, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
519, d3sxsA1, 0.8266, 2.19, 0.322, 261, 258, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
520, d4zseB_, 0.8265, 2.39, 0.349, 313, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
521, d4j99A_, 0.8263, 2.30, 0.392, 280, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
522, d5xgnB_, 0.8261, 2.40, 0.314, 308, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
523, d5hcxA_, 0.8257, 2.16, 0.352, 298, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
524, d5hicA_, 0.8255, 2.21, 0.346, 302, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
525, d5gtyA_, 0.8253, 2.24, 0.352, 300, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
526, d4u5jA_, 0.8253, 2.06, 0.310, 267, 255, C-SRC IN COMPLEX WITH RUXOLITINIB
527, d4ag8A_, 0.8253, 2.29, 0.373, 296, 255, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
528, d4d4vA_, 0.8251, 1.92, 0.347, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
529, d3zfxI_, 0.8251, 2.06, 0.344, 263, 253, CRYSTAL STRUCTURE OF EPHB1
530, d1u46A_, 0.8251, 1.77, 0.411, 255, 248, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
531, d3kcfE_, 0.8247, 2.59, 0.267, 330, 262, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
532, d5xp7B_, 0.8243, 1.95, 0.313, 267, 252, C-SRC IN COMPLEX WITH ATP-CHCL
533, d3wzeA_, 0.8243, 2.32, 0.366, 298, 254, KDR IN COMPLEX WITH LIGAND SORAFENIB
534, d3kcfA_, 0.8243, 2.75, 0.265, 328, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
535, d2ituA_, 0.8243, 2.32, 0.346, 304, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
536, d4rwkA1, 0.8242, 2.49, 0.396, 307, 260, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
537, d5e8uA1, 0.8241, 2.74, 0.254, 303, 264, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
538, d4zseD_, 0.8241, 2.41, 0.350, 297, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
539, d4wrgA1, 0.8241, 2.05, 0.344, 287, 253, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
540, d5gtyG_, 0.8237, 2.21, 0.354, 299, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
541, d4cd0A_, 0.8237, 2.36, 0.311, 295, 257, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
542, d5ugxB_, 0.8236, 2.03, 0.390, 282, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
543, d4zauA_, 0.8236, 2.29, 0.357, 283, 255, AZD9291 COMPLEX WITH WILD TYPE EGFR
544, d5hczA_, 0.8235, 2.20, 0.348, 300, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
545, d4j95A_, 0.8235, 2.39, 0.392, 279, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
546, d4u5jB_, 0.8233, 2.09, 0.310, 267, 255, C-SRC IN COMPLEX WITH RUXOLITINIB
547, d4d58B_, 0.8233, 2.31, 0.343, 261, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
548, d4d4sB_, 0.8233, 2.31, 0.339, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
549, d3kcfC_, 0.8233, 2.72, 0.261, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
550, d1iasD_, 0.8233, 2.55, 0.267, 330, 262, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
551, d3dk6B_, 0.8232, 1.90, 0.363, 259, 251, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
552, d5cnnA_, 0.8231, 2.13, 0.354, 300, 254, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
553, d4qrcA_, 0.8231, 2.40, 0.364, 297, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
554, d3zosB1, 0.8231, 2.55, 0.355, 301, 259, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
555, d3vntA_, 0.8231, 2.32, 0.373, 301, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
556, d5gtyB_, 0.8230, 2.26, 0.353, 299, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
557, d5grnA_, 0.8230, 2.46, 0.352, 285, 256, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
558, d5d41A_, 0.8230, 2.04, 0.348, 300, 253, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
559, d4d4yA_, 0.8230, 1.91, 0.344, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
560, d2pvyB_, 0.8230, 2.05, 0.375, 286, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
561, d1iasE_, 0.8230, 2.55, 0.267, 330, 262, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
562, d1iasA_, 0.8229, 2.55, 0.267, 330, 262, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
563, d6aywB_, 0.8228, 2.50, 0.222, 293, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
564, d4d5kA_, 0.8227, 1.91, 0.344, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
565, d3kcfB_, 0.8227, 2.59, 0.260, 324, 262, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
566, d5vloB_, 0.8226, 2.52, 0.222, 293, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
567, d1iasC_, 0.8225, 2.55, 0.267, 330, 262, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
568, d5gtyE_, 0.8223, 2.07, 0.344, 297, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
569, d4asdA_, 0.8223, 2.33, 0.373, 305, 255, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
570, d2hz4C_, 0.8223, 2.07, 0.366, 259, 254, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
571, d3c0gB_, 0.8222, 2.47, 0.218, 320, 261, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
572, d2gs7B_, 0.8222, 2.65, 0.332, 288, 262, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
573, d5canA_, 0.8219, 2.26, 0.350, 301, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
574, d2pvyC_, 0.8219, 2.13, 0.378, 285, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
575, d4j95D_, 0.8218, 2.06, 0.391, 271, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
576, d3w32A_, 0.8218, 2.71, 0.346, 317, 263, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
577, d1iasB_, 0.8218, 2.67, 0.266, 324, 263, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
578, d4trlA_, 0.8216, 2.25, 0.339, 268, 257, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
579, d1rqqB_, 0.8216, 2.37, 0.309, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
580, d4d5hA_, 0.8215, 1.78, 0.341, 255, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN
581, d5j7hA_, 0.8214, 2.05, 0.312, 291, 253, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
582, d4d4yB_, 0.8214, 2.33, 0.343, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
583, d3kcfD_, 0.8213, 2.51, 0.268, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
584, d2r2pA1, 0.8213, 2.52, 0.355, 276, 262, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
585, d4rwiA_, 0.8212, 2.56, 0.396, 305, 260, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
586, d5mjbB_, 0.8211, 2.89, 0.323, 278, 266, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
587, d4yjqA_, 0.8211, 2.38, 0.344, 264, 256, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
588, d2gs7A_, 0.8211, 2.69, 0.336, 281, 262, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
589, d5cnoB_, 0.8210, 2.21, 0.350, 302, 254, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
590, d4d5hB_, 0.8210, 2.35, 0.343, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
591, d4aseA_, 0.8210, 2.34, 0.373, 305, 255, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
592, d3bu5A_, 0.8210, 2.25, 0.305, 291, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
593, d4xlvA_, 0.8208, 2.40, 0.309, 307, 259, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
594, d3vo3A_, 0.8208, 2.36, 0.373, 303, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
595, d5gnkA_, 0.8207, 2.60, 0.349, 277, 258, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
596, d4g5pB_, 0.8207, 2.32, 0.310, 303, 258, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
597, d5e8tA1, 0.8205, 2.51, 0.258, 300, 260, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
598, d5e8wA1, 0.8204, 2.72, 0.259, 302, 263, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
599, d2wotA_, 0.8204, 2.67, 0.262, 303, 263, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
600, d5casA_, 0.8203, 2.27, 0.356, 299, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
601, d4yjvA_, 0.8202, 2.35, 0.341, 263, 255, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
602, d5aaaA_, 0.8201, 2.35, 0.309, 294, 256, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
603, d3zfxE_, 0.8201, 2.12, 0.337, 262, 252, CRYSTAL STRUCTURE OF EPHB1
604, d5cnoA_, 0.8200, 2.30, 0.349, 300, 255, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
605, d5gtyD_, 0.8199, 2.21, 0.354, 297, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
606, d2wotA1, 0.8199, 2.64, 0.260, 301, 262, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
607, d3dqxB_, 0.8198, 2.25, 0.309, 268, 256, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
608, d4yc8A_, 0.8196, 1.98, 0.365, 259, 252, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
609, d2x9fA_, 0.8196, 2.25, 0.329, 265, 255, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
610, d5caqA_, 0.8195, 2.21, 0.352, 301, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
611, d4bkjB1, 0.8195, 2.76, 0.362, 296, 260, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
612, d3c0hB_, 0.8194, 2.50, 0.218, 300, 261, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
613, d3bbtB_, 0.8193, 2.48, 0.369, 274, 255, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
614, d5calA_, 0.8192, 2.26, 0.352, 300, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
615, d4x2nA1, 0.8192, 2.64, 0.256, 302, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
616, d3mfsA_, 0.8192, 2.54, 0.226, 303, 261, CASK-4M CAM KINASE DOMAIN AMPPNP
617, d1rqqA_, 0.8192, 2.40, 0.309, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
618, d5capA_, 0.8191, 2.30, 0.346, 303, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
619, d4d55A_, 0.8190, 2.04, 0.340, 260, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN
620, d3emgA_, 0.8190, 2.16, 0.348, 255, 253, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
621, d2i1mA_, 0.8190, 2.39, 0.340, 311, 256, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
622, d2eb3A_, 0.8189, 2.21, 0.344, 294, 253, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
623, d5friA1, 0.8188, 2.50, 0.263, 299, 259, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
624, d5e90A1, 0.8188, 2.60, 0.257, 300, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
625, d4tt7A_, 0.8188, 2.37, 0.306, 291, 255, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
626, d3zbfA_, 0.8188, 1.92, 0.347, 281, 251, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
627, d5kz0A_, 0.8187, 2.29, 0.310, 293, 255, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
628, d5em7A_, 0.8187, 2.29, 0.348, 300, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
629, d4fobA_, 0.8187, 2.54, 0.305, 295, 259, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
630, d3zzeA_, 0.8187, 2.50, 0.320, 286, 256, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
631, d4x2fA1, 0.8186, 2.73, 0.259, 302, 263, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
632, d5em6A_, 0.8185, 2.29, 0.352, 301, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
633, d4focA_, 0.8185, 2.42, 0.307, 296, 257, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
634, d5aa9A_, 0.8184, 2.40, 0.309, 295, 256, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
635, d4x2kA1, 0.8184, 2.73, 0.259, 302, 263, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
636, d4x2jA1, 0.8184, 2.73, 0.259, 302, 263, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
637, d3mfuA_, 0.8184, 2.55, 0.226, 302, 261, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
638, d3c0hA_, 0.8183, 2.52, 0.218, 300, 261, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
639, d1xkkA_, 0.8183, 2.32, 0.350, 289, 254, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
640, d3c0iA_, 0.8182, 2.59, 0.218, 298, 261, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
641, d1py5A_, 0.8182, 2.81, 0.261, 301, 264, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
642, d5aabA_, 0.8181, 2.31, 0.307, 293, 254, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
643, d4zsaA_, 0.8181, 2.67, 0.391, 289, 261, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
644, d4ccuA_, 0.8181, 2.26, 0.304, 292, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
645, d1rw8A_, 0.8181, 2.81, 0.258, 301, 264, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
646, d5e8zA1, 0.8180, 2.61, 0.261, 300, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
647, d4x2gA1, 0.8180, 2.74, 0.259, 302, 263, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
648, d4d58A_, 0.8180, 1.79, 0.343, 255, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
649, d1yi6B_, 0.8180, 2.46, 0.273, 274, 260, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
650, d4x0mA1, 0.8179, 2.74, 0.259, 302, 263, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
651, d4ccbA_, 0.8179, 2.23, 0.312, 287, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
652, d4aoiA_, 0.8178, 2.26, 0.324, 289, 253, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
653, d3ky2A1, 0.8178, 2.40, 0.389, 305, 257, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
654, d3c0gA_, 0.8178, 2.47, 0.215, 309, 260, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
655, d5cauA_, 0.8177, 2.26, 0.353, 297, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
656, d5c8nA_, 0.8177, 2.28, 0.352, 300, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
657, d4gu6A_, 0.8177, 2.58, 0.337, 271, 258, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
658, d4rwjA1, 0.8176, 2.61, 0.392, 306, 260, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
659, d4ap7A_, 0.8176, 2.39, 0.323, 289, 254, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
660, d4agcA_, 0.8176, 2.39, 0.373, 304, 255, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
661, d5ew3A_, 0.8175, 2.11, 0.372, 274, 250, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
662, d3h3cA_, 0.8175, 2.17, 0.352, 263, 253, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
663, d3c4fB_, 0.8174, 2.48, 0.386, 290, 259, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
664, d2p2iA2, 0.8174, 1.99, 0.373, 283, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
665, d3zosA_, 0.8173, 2.76, 0.358, 301, 260, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
666, d1vjyA_, 0.8173, 2.62, 0.258, 299, 260, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
667, d5j9zA_, 0.8172, 2.23, 0.356, 291, 253, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
668, d4d4sA_, 0.8172, 1.85, 0.341, 255, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN
669, d4cliA_, 0.8172, 2.39, 0.309, 294, 256, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
670, d4i22A_, 0.8170, 2.25, 0.352, 297, 253, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
671, d4cmoA_, 0.8170, 2.40, 0.309, 295, 256, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
672, d4asxA1, 0.8170, 2.52, 0.236, 295, 258, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
673, d3zclA_, 0.8170, 2.28, 0.324, 289, 253, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
674, d3w2sA_, 0.8170, 2.59, 0.346, 307, 257, EGFR KINASE DOMAIN WITH COMPOUND4
675, d3c4fA_, 0.8170, 2.48, 0.394, 290, 259, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
676, d5gtyF_, 0.8169, 2.26, 0.350, 297, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
677, d1b6cD_, 0.8169, 2.82, 0.268, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
678, d3mfrA_, 0.8168, 2.58, 0.226, 302, 261, CASK-4M CAM KINASE DOMAIN NATIVE
679, d4qqjA_, 0.8167, 2.42, 0.358, 282, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
680, d1yi6A_, 0.8167, 2.61, 0.299, 274, 261, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
681, d4xg8C_, 0.8166, 1.83, 0.355, 254, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
682, d4cmuA_, 0.8166, 2.40, 0.309, 294, 256, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
683, d4asxB1, 0.8166, 2.60, 0.236, 296, 259, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
684, d3geqB1, 0.8166, 1.96, 0.316, 270, 250, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
685, d3zbxA_, 0.8165, 2.28, 0.324, 282, 253, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
686, d5fm3A_, 0.8164, 2.31, 0.361, 276, 255, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
687, d3js2A_, 0.8164, 2.46, 0.390, 295, 259, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
688, d4ogrI_, 0.8163, 2.63, 0.202, 318, 262, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
689, d3beaA_, 0.8163, 2.45, 0.336, 310, 256, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
690, d2hk5A2, 0.8162, 2.40, 0.366, 268, 257, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
691, d5c8kA_, 0.8161, 2.32, 0.352, 300, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
692, d2etmA_, 0.8161, 2.34, 0.332, 262, 256, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
693, d5mjaA_, 0.8160, 2.46, 0.329, 271, 258, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
694, d5iuiA_, 0.8160, 2.70, 0.287, 303, 261, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
695, d2j0mB_, 0.8160, 1.95, 0.340, 257, 250, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
696, d1mqbB_, 0.8159, 2.20, 0.346, 265, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
697, d4bkjA1, 0.8158, 2.79, 0.363, 294, 259, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
698, d5am7A_, 0.8157, 2.56, 0.395, 294, 258, FGFR1 MUTANT WITH AN INHIBITOR
699, d1b6cH_, 0.8157, 2.76, 0.265, 326, 264, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
700, d5e8sA1, 0.8155, 2.54, 0.259, 299, 259, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
701, d1ir3A_, 0.8155, 2.45, 0.305, 300, 259, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
702, d4rj8A_, 0.8154, 2.29, 0.353, 298, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
703, d3zxzA_, 0.8154, 2.30, 0.324, 289, 253, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
704, d1gagA_, 0.8154, 2.47, 0.305, 300, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
705, d4yjrA_, 0.8153, 2.31, 0.339, 263, 254, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
706, d4rj4A_, 0.8153, 2.34, 0.348, 299, 253, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
707, d4d5kB_, 0.8153, 1.97, 0.345, 256, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN
708, d3mftA_, 0.8153, 2.59, 0.226, 302, 261, CASK-4M CAM KINASE DOMAIN MN2+
709, d3gt8C_, 0.8153, 2.53, 0.346, 296, 257, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
710, d5c8mA_, 0.8152, 2.38, 0.350, 302, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
711, d4rj7A_, 0.8152, 2.22, 0.355, 295, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
712, d3socB1, 0.8152, 2.56, 0.236, 294, 258, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
713, d5ng0B_, 0.8151, 2.55, 0.259, 282, 259, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
714, d5ew8A_, 0.8151, 2.50, 0.390, 291, 259, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
715, d5am6A1, 0.8151, 2.57, 0.391, 294, 258, NATIVE FGFR1 WITH AN INHIBITOR
716, d2wgjA_, 0.8151, 2.43, 0.323, 289, 254, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
717, d4uwcA_, 0.8148, 2.53, 0.386, 300, 259, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
718, d4fodA_, 0.8148, 2.53, 0.306, 308, 258, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
719, d3dqxA_, 0.8148, 2.27, 0.310, 267, 255, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
720, d4wa9B1, 0.8147, 2.18, 0.356, 263, 253, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
721, d2xb7A_, 0.8147, 1.98, 0.316, 286, 250, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
722, d5usqA_, 0.8146, 2.54, 0.255, 299, 259, ALK-5 KINASE INHIBITOR COMPLEX
723, d5a9uA_, 0.8144, 2.30, 0.304, 292, 253, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
724, d4mneB_, 0.8144, 2.31, 0.300, 270, 257, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
725, d4d4vB_, 0.8144, 1.99, 0.345, 255, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN
726, d4cljA_, 0.8144, 2.48, 0.311, 295, 257, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
727, d2rgpA_, 0.8144, 2.34, 0.352, 284, 253, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
728, d1b6cB_, 0.8143, 2.85, 0.268, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
729, d3q4tB1, 0.8142, 2.52, 0.237, 293, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
730, d3en4B_, 0.8142, 2.09, 0.310, 266, 252, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
731, d1fgiA_, 0.8142, 2.52, 0.390, 283, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
732, d3b2wA_, 0.8141, 2.20, 0.352, 261, 253, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
733, d1t45A_, 0.8141, 2.61, 0.339, 331, 257, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
734, d4anqA_, 0.8139, 2.34, 0.303, 293, 254, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
735, d3kexB_, 0.8139, 2.72, 0.330, 283, 261, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
736, d5aa8A_, 0.8138, 2.30, 0.304, 292, 253, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
737, d3gt8A_, 0.8138, 2.39, 0.353, 300, 255, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
738, d2rfeD_, 0.8136, 2.74, 0.339, 278, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
739, d5i9vA_, 0.8135, 2.37, 0.341, 279, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
740, d4yhfB_, 0.8135, 2.19, 0.324, 269, 253, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
741, d3zc5A_, 0.8135, 2.34, 0.324, 289, 253, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
742, d3gt8D_, 0.8135, 2.41, 0.349, 295, 255, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
743, d2xvdA_, 0.8135, 2.49, 0.327, 270, 257, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
744, d5ftoA1, 0.8134, 2.65, 0.304, 297, 260, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
745, d4rj6A_, 0.8134, 2.32, 0.349, 297, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
746, d3js2B_, 0.8134, 2.44, 0.388, 291, 258, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
747, d4qqtA_, 0.8133, 2.34, 0.362, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
748, d3kexA_, 0.8133, 2.72, 0.330, 292, 261, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
749, d4fvrA_, 0.8132, 2.16, 0.250, 274, 252, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
750, d5mjaB_, 0.8131, 2.83, 0.327, 274, 263, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
751, d4r5sA_, 0.8131, 2.57, 0.345, 299, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
752, d3ppzB_, 0.8131, 2.08, 0.319, 264, 251, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
753, d6eixA_, 0.8130, 2.81, 0.278, 312, 263, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
754, d4ctcA_, 0.8130, 2.19, 0.307, 288, 251, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
755, d3ppzA_, 0.8130, 2.19, 0.328, 264, 253, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
756, d3geqA1, 0.8130, 1.97, 0.317, 269, 249, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
757, d4i24A_, 0.8129, 2.20, 0.359, 295, 251, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
758, d6babD_, 0.8128, 2.51, 0.220, 291, 259, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
759, d3b8qA1, 0.8128, 2.02, 0.365, 285, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
760, d3gt8B_, 0.8126, 2.41, 0.349, 292, 255, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
761, d5e8xA_, 0.8125, 2.96, 0.253, 304, 265, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
762, d4uwyA_, 0.8125, 2.26, 0.387, 296, 253, FGFR1 APO STRUCTURE
763, d3tt0A_, 0.8124, 2.52, 0.390, 305, 259, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
764, d2bdjA_, 0.8124, 1.86, 0.319, 254, 248, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
765, d5xdlA_, 0.8123, 2.27, 0.347, 292, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
766, d4uwcB_, 0.8123, 2.58, 0.386, 301, 259, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
767, d4ogrA_, 0.8123, 2.71, 0.202, 314, 263, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
768, d2zvaA1, 0.8123, 2.30, 0.369, 260, 255, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
769, d4mxzA_, 0.8122, 2.14, 0.321, 266, 252, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
770, d4mxyA_, 0.8122, 2.14, 0.321, 266, 252, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
771, d5nkeA_, 0.8121, 2.89, 0.335, 292, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
772, d4yjsA_, 0.8121, 2.13, 0.343, 257, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
773, d4uwbA_, 0.8121, 2.49, 0.391, 299, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
774, d4l7sA1, 0.8121, 1.81, 0.325, 248, 246, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
775, d2xp2A_, 0.8121, 2.23, 0.311, 285, 251, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
776, d1b6cF_, 0.8121, 2.85, 0.268, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
777, d5i4nA1, 0.8120, 2.19, 0.250, 273, 252, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
778, d4fvqA_, 0.8120, 2.18, 0.250, 274, 252, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
779, d3g6hA_, 0.8120, 2.19, 0.312, 266, 253, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
780, d4ansA_, 0.8119, 2.37, 0.307, 293, 254, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
781, d5a46B_, 0.8118, 2.56, 0.386, 297, 259, FGFR1 IN COMPLEX WITH DOVITINIB
782, d3l8pA_, 0.8117, 2.32, 0.339, 292, 251, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
783, d5ut4A_, 0.8116, 2.18, 0.250, 273, 252, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
784, d5gtyC_, 0.8116, 2.21, 0.353, 295, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
785, d3kfaB1, 0.8116, 2.37, 0.379, 283, 253, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
786, d2jkmA_, 0.8116, 2.25, 0.340, 260, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
787, d3plsA_, 0.8115, 2.49, 0.333, 298, 258, RON IN COMPLEX WITH LIGAND AMP-PNP
788, d3kfaA1, 0.8115, 2.37, 0.379, 283, 253, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
789, d4agdA_, 0.8114, 2.47, 0.373, 303, 255, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
790, d3sxrA1, 0.8114, 2.28, 0.315, 257, 254, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
791, d4l7sB1, 0.8113, 1.82, 0.325, 248, 246, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
792, d1ql6A_, 0.8113, 2.54, 0.205, 281, 258, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
793, d3f6xD_, 0.8112, 2.21, 0.316, 267, 253, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
794, d4kabB_, 0.8111, 2.30, 0.344, 258, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
795, d4e26A_, 0.8110, 2.42, 0.295, 270, 258, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
796, d3l8vA_, 0.8109, 2.62, 0.320, 293, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
797, d2wouA_, 0.8109, 2.55, 0.260, 299, 258, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
798, d5e8yA_, 0.8108, 2.65, 0.248, 298, 258, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
799, d3rhxA_, 0.8108, 2.56, 0.390, 289, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
800, d3lzbA_, 0.8108, 2.39, 0.343, 265, 254, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
801, d5aacA_, 0.8107, 2.34, 0.304, 292, 253, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
802, d3socA1, 0.8107, 2.69, 0.232, 296, 259, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
803, d3lzbB_, 0.8107, 2.39, 0.346, 265, 254, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
804, d3d4qB_, 0.8107, 2.12, 0.310, 264, 252, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
805, d3belA_, 0.8107, 2.38, 0.353, 280, 252, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
806, d2etmB_, 0.8107, 2.24, 0.341, 263, 252, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
807, d4y95B1, 0.8106, 2.17, 0.344, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
808, d1qcfA3, 0.8106, 2.40, 0.353, 281, 255, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
809, d1k2pA_, 0.8106, 2.39, 0.332, 258, 256, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
810, d4y95C1, 0.8105, 2.17, 0.344, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
811, d3eflA1, 0.8105, 1.91, 0.370, 279, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
812, d2wouA1, 0.8105, 2.51, 0.257, 297, 257, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
813, d5e92A_, 0.8103, 2.87, 0.246, 298, 260, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
814, d3d4qA_, 0.8103, 2.13, 0.310, 264, 252, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
815, d5nkhA_, 0.8102, 2.92, 0.338, 295, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
816, d4hvsA1, 0.8102, 2.44, 0.346, 323, 254, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
817, d2yfxA_, 0.8102, 2.39, 0.307, 292, 254, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
818, d4qmpA_, 0.8101, 2.43, 0.273, 289, 256, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
819, d3ppkB_, 0.8098, 2.14, 0.302, 264, 252, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
820, d3fzpA_, 0.8098, 2.22, 0.353, 259, 252, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
821, d5vndB_, 0.8097, 2.59, 0.382, 295, 259, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
822, d2bdfB_, 0.8097, 2.26, 0.311, 265, 254, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
823, d4pp9B1, 0.8096, 1.67, 0.324, 246, 244, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
824, d3pxkA_, 0.8096, 1.98, 0.341, 256, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
825, d3bbtD_, 0.8096, 2.35, 0.376, 259, 250, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
826, d4uwbB_, 0.8094, 2.51, 0.389, 299, 257, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
827, d1phkA_, 0.8094, 2.36, 0.208, 277, 255, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
828, d5uhnB_, 0.8093, 2.16, 0.389, 269, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
829, d3tzmA_, 0.8093, 2.47, 0.258, 295, 256, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
830, d2ijmA_, 0.8093, 2.08, 0.343, 260, 251, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
831, d1opjA1, 0.8093, 2.29, 0.377, 282, 252, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
832, d3q4uD_, 0.8091, 2.70, 0.282, 299, 259, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
833, d5nk5A_, 0.8090, 2.75, 0.335, 287, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
834, d4ctbA_, 0.8089, 2.36, 0.308, 292, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
835, d1fpuB1, 0.8089, 2.27, 0.384, 266, 250, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
836, d5ng2B_, 0.8088, 2.24, 0.261, 278, 253, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
837, d5caoA_, 0.8088, 2.29, 0.347, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
838, d4qmmA_, 0.8087, 2.45, 0.273, 288, 256, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
839, d3u6jA1, 0.8087, 2.45, 0.373, 305, 255, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
840, d5edqA_, 0.8085, 2.42, 0.348, 298, 253, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
841, d3lzbC_, 0.8085, 2.18, 0.348, 259, 250, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
842, d4qmoA_, 0.8084, 2.45, 0.273, 288, 256, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
843, d4nw6A1, 0.8084, 2.69, 0.224, 296, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
844, d2oiqB_, 0.8084, 2.19, 0.313, 265, 252, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
845, d5ew8B_, 0.8083, 2.57, 0.388, 290, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
846, d4mxcA_, 0.8083, 2.58, 0.322, 290, 255, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
847, d4fvpA_, 0.8081, 2.24, 0.250, 274, 252, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
848, d3oy3B1, 0.8081, 2.42, 0.379, 283, 253, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
849, d2wd1A_, 0.8081, 2.78, 0.326, 289, 258, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
850, d5e91A_, 0.8080, 2.85, 0.247, 297, 259, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
851, d4nw5A1, 0.8080, 2.69, 0.220, 296, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
852, d3oy3A1, 0.8080, 2.41, 0.379, 283, 253, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
853, d5h0bA3, 0.8079, 2.66, 0.367, 281, 256, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
854, d3lmgB_, 0.8079, 2.80, 0.332, 268, 259, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
855, d2qluA1, 0.8079, 2.61, 0.235, 295, 255, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
856, d6babA_, 0.8078, 2.54, 0.221, 290, 258, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
857, d4qmqA_, 0.8078, 2.47, 0.273, 289, 256, MST3 IN COMPLEX WITH CP-673451
858, d3q4tA1, 0.8078, 2.65, 0.233, 294, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
859, d3hmmA_, 0.8078, 2.62, 0.262, 293, 256, STRUCTURE OF ALK5 + GW855857
860, d3f6xC_, 0.8078, 2.05, 0.309, 265, 249, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
861, d2ijmB_, 0.8078, 2.17, 0.347, 261, 251, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
862, d4r7hA_, 0.8077, 2.31, 0.343, 308, 251, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
863, d4bb4A_, 0.8077, 2.32, 0.332, 265, 253, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
864, d3w33A_, 0.8077, 2.51, 0.348, 297, 253, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
865, d2wkmA_, 0.8077, 2.61, 0.322, 286, 255, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
866, d1fvrB_, 0.8077, 2.45, 0.324, 300, 256, TIE2 KINASE DOMAIN
867, d5imxA_, 0.8076, 1.96, 0.317, 266, 246, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
868, d4v05B_, 0.8076, 2.46, 0.398, 286, 256, FGFR1 IN COMPLEX WITH AZD4547.
869, d5h09A3, 0.8075, 2.60, 0.357, 281, 255, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
870, d3ik3A1, 0.8075, 2.34, 0.377, 279, 252, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
871, d2hckA3, 0.8075, 2.33, 0.361, 271, 252, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
872, d5vndA_, 0.8074, 2.53, 0.388, 302, 258, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
873, d5ut1A_, 0.8074, 2.20, 0.251, 272, 251, JAK2 JH2 IN COMPLEX WITH BI-D1870
874, d5p9fA_, 0.8073, 2.23, 0.340, 266, 253, BTK IN COMPLEX WITH GDC-0834
875, d5ng2A_, 0.8073, 2.12, 0.259, 274, 251, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
876, d4kioC1, 0.8073, 1.95, 0.324, 249, 247, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
877, d3lmgA_, 0.8073, 2.81, 0.332, 268, 259, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
878, d2h8hA3, 0.8073, 2.50, 0.298, 280, 255, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
879, d5ut5A_, 0.8072, 2.19, 0.251, 272, 251, JAK2 JH2 IN COMPLEX WITH GLPG0634
880, d5ut0A_, 0.8072, 2.20, 0.251, 272, 251, JAK2 JH2 IN COMPLEX WITH AT9283
881, d5a46A_, 0.8072, 2.65, 0.391, 289, 258, FGFR1 IN COMPLEX WITH DOVITINIB
882, d4w8dA_, 0.8072, 2.46, 0.273, 289, 256, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
883, d4p2wB_, 0.8072, 1.99, 0.341, 253, 249,  
884, d5ut3A_, 0.8071, 2.20, 0.251, 272, 251, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
885, d5h0hA3, 0.8071, 2.63, 0.357, 281, 255, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
886, d5ftqA1, 0.8071, 2.49, 0.310, 292, 255, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
887, d4y95A1, 0.8070, 2.23, 0.340, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
888, d3g0fA_, 0.8070, 2.57, 0.350, 291, 254, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
889, d4k11A3, 0.8069, 2.49, 0.302, 282, 255, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
890, d4fnyA_, 0.8069, 1.98, 0.305, 273, 246, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
891, d5htiA_, 0.8068, 2.63, 0.325, 290, 255, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
892, d5am7B_, 0.8068, 2.29, 0.395, 287, 253, FGFR1 MUTANT WITH AN INHIBITOR
893, d3f6xB_, 0.8068, 2.15, 0.311, 267, 251, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
894, d3cc6A_, 0.8068, 2.61, 0.353, 269, 258, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
895, d4uxqA_, 0.8067, 2.35, 0.366, 286, 254, FGFR4 IN COMPLEX WITH PONATINIB
896, d3f6xA_, 0.8066, 2.00, 0.315, 264, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
897, d3dtwA1, 0.8066, 2.05, 0.356, 281, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
898, d4y95D_, 0.8065, 2.24, 0.344, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
899, d4u8zA_, 0.8065, 2.48, 0.273, 289, 256, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
900, d5uszA_, 0.8064, 2.20, 0.251, 272, 251, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
901, d5h0eA3, 0.8064, 2.61, 0.357, 281, 255, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
902, d5dg5B_, 0.8064, 2.62, 0.325, 297, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
903, d4otwA_, 0.8064, 2.87, 0.327, 272, 260, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
904, d5ar5A_, 0.8063, 2.23, 0.266, 284, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
905, d3lzbD_, 0.8063, 2.28, 0.347, 261, 251, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
906, d5ut6A_, 0.8062, 2.22, 0.251, 272, 251, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
907, d3vrzB3, 0.8062, 2.21, 0.357, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
908, d3dkcA1, 0.8062, 2.75, 0.309, 310, 259, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
909, d4mxzB_, 0.8061, 2.23, 0.323, 264, 251, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
910, d4mxyB_, 0.8061, 2.23, 0.323, 264, 251, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
911, d3vs3B3, 0.8061, 2.38, 0.365, 271, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
912, d2hckB3, 0.8061, 2.36, 0.361, 271, 252, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
913, d6aywA_, 0.8060, 2.72, 0.222, 293, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
914, d5i9uA_, 0.8060, 2.57, 0.341, 281, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
915, d4z3vA_, 0.8060, 2.24, 0.340, 271, 253, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
916, d4pp9A1, 0.8060, 1.67, 0.325, 245, 243, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
917, d3zfxF_, 0.8060, 1.87, 0.343, 254, 245, CRYSTAL STRUCTURE OF EPHB1
918, d3pozA_, 0.8060, 2.34, 0.351, 293, 251, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
919, d4yznA_, 0.8059, 2.43, 0.277, 269, 256, HUMANIZED ROCO4 BOUND TO COMPOUND 19
920, d3q4uC_, 0.8059, 2.62, 0.280, 296, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
921, d4yhfA_, 0.8058, 2.39, 0.335, 268, 254, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
922, d4ckrA1, 0.8058, 2.82, 0.364, 294, 258, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
923, d4bkiA1, 0.8058, 2.82, 0.364, 294, 258,  
924, d2vx0A_, 0.8058, 2.55, 0.323, 273, 257, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
925, d2hznA2, 0.8058, 2.00, 0.381, 268, 247, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
926, d5ut2A_, 0.8057, 2.22, 0.251, 273, 251, JAK2 JH2 IN COMPLEX WITH PRT062607
927, d4r1vA_, 0.8057, 2.82, 0.322, 289, 258, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
928, d4mxxA_, 0.8057, 2.25, 0.313, 266, 252, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
929, d4k8aB_, 0.8057, 2.29, 0.341, 258, 252, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
930, d5t0pA_, 0.8056, 2.13, 0.316, 264, 250, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
931, d4mxoA_, 0.8055, 2.25, 0.313, 266, 252, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
932, d4bggA_, 0.8054, 2.66, 0.280, 296, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
933, d3ik3B1, 0.8054, 2.36, 0.377, 285, 252, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
934, d5fg8A_, 0.8053, 2.59, 0.222, 269, 257, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
935, d4cmtA_, 0.8053, 2.27, 0.308, 284, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
936, d3mtfB_, 0.8053, 2.72, 0.283, 298, 258, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
937, d3wj6A_, 0.8052, 2.58, 0.388, 282, 255,  
938, d2hz4B1, 0.8052, 1.94, 0.384, 248, 245, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
939, d1opjB1, 0.8052, 2.49, 0.379, 284, 253, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
940, d5h9bA_, 0.8051, 2.58, 0.222, 269, 257, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
941, d5b7vA_, 0.8051, 2.58, 0.388, 282, 255, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
942, d4rwlB_, 0.8051, 2.51, 0.384, 285, 255, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
943, d4qmvA_, 0.8051, 2.50, 0.273, 288, 256, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
944, d3my1A_, 0.8051, 2.88, 0.209, 314, 263, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
945, d3b8rA1, 0.8051, 2.00, 0.370, 282, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
946, d2ckeA_, 0.8051, 2.68, 0.231, 301, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
947, d4rj5A_, 0.8050, 2.36, 0.348, 296, 250, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
948, d3oomA_, 0.8049, 2.68, 0.276, 297, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
949, d1k9aF3, 0.8049, 2.08, 0.336, 264, 247, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
950, d5wr7A_, 0.8048, 2.65, 0.396, 301, 255, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
951, d4v05A_, 0.8048, 2.59, 0.397, 287, 257, FGFR1 IN COMPLEX WITH AZD4547.
952, d4bggB_, 0.8048, 2.66, 0.280, 293, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
953, d3gvuA1, 0.8048, 2.29, 0.369, 261, 249, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
954, d5am6B_, 0.8047, 2.32, 0.401, 280, 252, NATIVE FGFR1 WITH AN INHIBITOR
955, d3orxD_, 0.8047, 2.59, 0.241, 282, 257, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
956, d3orxC_, 0.8047, 2.59, 0.241, 283, 257, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
957, d5oxgC1, 0.8046, 2.74, 0.282, 299, 259, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
958, d5hznE_, 0.8046, 2.49, 0.319, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
959, d3vs4A3, 0.8046, 2.36, 0.367, 270, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
960, d5hznA_, 0.8045, 2.49, 0.319, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
961, d5h0gA3, 0.8045, 2.64, 0.357, 281, 255, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
962, d4bciA_, 0.8045, 2.70, 0.208, 308, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
963, d3orxA_, 0.8045, 2.60, 0.241, 283, 257, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
964, d1kswA3, 0.8045, 2.54, 0.302, 284, 255, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
965, d4bcfA_, 0.8044, 2.62, 0.209, 307, 258, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
966, d4anlA_, 0.8044, 2.47, 0.303, 292, 254, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
967, d2ckeC_, 0.8043, 2.68, 0.231, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
968, d5i9yA_, 0.8042, 2.80, 0.337, 287, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
969, d2srcA3, 0.8042, 2.58, 0.302, 284, 255, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
970, d1fvrA_, 0.8042, 2.45, 0.325, 299, 255, TIE2 KINASE DOMAIN
971, d5edpA_, 0.8041, 2.49, 0.348, 295, 253, EGFR KINASE (T790M/L858R) APO
972, d4tyjA1, 0.8041, 2.23, 0.365, 275, 249, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
973, d4nkaB_, 0.8041, 2.44, 0.386, 287, 254, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
974, d3vs1A3, 0.8041, 2.30, 0.369, 268, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
975, d2yhvA_, 0.8041, 2.43, 0.308, 291, 253, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
976, d2zv8A1, 0.8040, 2.21, 0.375, 256, 251, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
977, d4nk9B_, 0.8039, 2.52, 0.386, 282, 254, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
978, d3thbA_, 0.8039, 2.82, 0.263, 287, 259, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
979, d2xuuA_, 0.8039, 2.69, 0.242, 301, 260, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
980, d2biyA_, 0.8039, 2.71, 0.239, 287, 259, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
981, d5iugA_, 0.8038, 2.20, 0.310, 285, 248, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
982, d4xcuA1, 0.8038, 2.47, 0.357, 287, 255, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
983, d2a2aA_, 0.8038, 2.70, 0.223, 304, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
984, d5nkgA_, 0.8037, 3.01, 0.331, 292, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
985, d5hznC_, 0.8037, 2.49, 0.319, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
986, d5e8vA_, 0.8037, 2.87, 0.248, 296, 258, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
987, d4nk9A_, 0.8037, 2.48, 0.390, 281, 254, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
988, d3zfxB_, 0.8037, 1.93, 0.339, 254, 245, CRYSTAL STRUCTURE OF EPHB1
989, d2vwyA_, 0.8037, 2.74, 0.328, 274, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
990, d5hznG_, 0.8036, 2.49, 0.319, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
991, d4mxoB_, 0.8036, 2.18, 0.312, 264, 250, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
992, d3ppkA_, 0.8036, 2.14, 0.304, 262, 250, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
993, d5hznF_, 0.8035, 2.50, 0.319, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
994, d5hznB_, 0.8035, 2.50, 0.319, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
995, d4bcgA_, 0.8035, 2.86, 0.209, 312, 263, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
996, d4h1jA_, 0.8034, 2.68, 0.345, 263, 258, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
997, d3vryA3, 0.8034, 2.33, 0.368, 269, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
998, d3sxrB1, 0.8034, 2.28, 0.313, 255, 252, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
999, d3q4uA_, 0.8034, 2.76, 0.283, 298, 258, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1000, d2yabB_, 0.8034, 2.72, 0.230, 299, 261, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1001, d5xy1A1, 0.8033, 1.99, 0.381, 252, 247, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
1002, d4gu9B_, 0.8033, 2.40, 0.345, 255, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
1003, d2ckeB_, 0.8033, 2.67, 0.231, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1004, d4fnwA_, 0.8032, 2.46, 0.308, 304, 253, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1005, d5p9gA_, 0.8031, 2.27, 0.333, 265, 252, STRUCTURE OF BTK WITH RN486
1006, d5ia2A_, 0.8031, 2.73, 0.336, 287, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
1007, d4v01B_, 0.8031, 2.38, 0.378, 275, 251, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
1008, d3zfxG_, 0.8031, 1.86, 0.344, 253, 244, CRYSTAL STRUCTURE OF EPHB1
1009, d3lq5A_, 0.8031, 2.65, 0.209, 307, 258, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
1010, d3g0fB_, 0.8031, 2.48, 0.344, 293, 253, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
1011, d4ymjB1, 0.8030, 2.28, 0.385, 272, 252, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1012, d4ot6A_, 0.8030, 2.29, 0.329, 265, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1013, d3tn8A_, 0.8030, 2.69, 0.208, 304, 259, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1014, d4bcjA_, 0.8029, 2.93, 0.205, 309, 263, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1015, d5p9iA_, 0.8028, 2.36, 0.304, 271, 253, BTK1 SOAKED WITH IBRUTINIB-REV
1016, d5bvkA_, 0.8028, 2.53, 0.361, 278, 255, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
1017, d4bchA_, 0.8028, 2.64, 0.209, 308, 258, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1018, d4b4lA_, 0.8028, 2.70, 0.246, 299, 260, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
1019, d2i0yA_, 0.8028, 2.49, 0.345, 289, 252, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
1020, d2ckeD_, 0.8028, 2.71, 0.231, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1021, d5dg5A_, 0.8027, 2.71, 0.322, 297, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1022, d2yabA_, 0.8027, 2.70, 0.231, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1023, d2jkqA_, 0.8027, 2.27, 0.343, 258, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1024, d4otqA_, 0.8026, 2.29, 0.329, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
1025, d3vs4B3, 0.8026, 2.33, 0.368, 269, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1026, d3my0M1, 0.8026, 2.88, 0.264, 297, 261, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1027, d2vx1A_, 0.8026, 2.76, 0.328, 274, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1028, d1ad5B3, 0.8026, 2.41, 0.361, 271, 252, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
1029, d1ad5A3, 0.8026, 2.40, 0.361, 271, 252, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
1030, d3vryB3, 0.8025, 2.31, 0.368, 269, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
1031, d5p9jA_, 0.8024, 2.30, 0.336, 263, 253, BTK1 COCRYSTALLIZED WITH IBRUTINIB
1032, d4l00A_, 0.8024, 2.24, 0.254, 277, 252, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
1033, d4h58A_, 0.8024, 2.15, 0.304, 263, 250, BRAF IN COMPLEX WITH COMPOUND 3
1034, d2c0tA3, 0.8024, 2.23, 0.359, 268, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
1035, d2bdfA_, 0.8024, 2.27, 0.313, 261, 252, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
1036, d5nk7A_, 0.8023, 2.70, 0.340, 284, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
1037, d4zlzA_, 0.8023, 2.25, 0.341, 270, 252, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
1038, d4rfyA_, 0.8023, 2.29, 0.329, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
1039, d4gg5A_, 0.8023, 2.39, 0.315, 274, 251, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1040, d5ng0A_, 0.8022, 2.25, 0.263, 274, 251, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1041, d4c02A_, 0.8022, 2.63, 0.288, 313, 257, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
1042, d3vs6A3, 0.8022, 2.35, 0.368, 269, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
1043, d3prfB_, 0.8022, 2.15, 0.296, 262, 250, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1044, d3orxB_, 0.8022, 2.53, 0.243, 280, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1045, d3mtfA_, 0.8022, 2.68, 0.281, 296, 256, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
1046, d2c0oA3, 0.8022, 2.22, 0.359, 268, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
1047, d5p9kA_, 0.8021, 2.39, 0.327, 271, 254, CRYSTAL STRUCTURE OF BTK WITH CNX 774
1048, d5nkfA_, 0.8021, 2.98, 0.332, 291, 259, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
1049, d5k9iB_, 0.8021, 2.17, 0.316, 262, 250, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1050, d5ig1A_, 0.8021, 2.76, 0.257, 300, 261, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1051, d4ogrE_, 0.8021, 2.70, 0.197, 310, 259, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1052, d3k5vA1, 0.8021, 2.37, 0.375, 281, 251, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
1053, d2vwzA_, 0.8021, 2.76, 0.328, 274, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1054, d3prfA_, 0.8020, 2.17, 0.296, 262, 250, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1055, d2hiwA1, 0.8020, 2.32, 0.384, 270, 250, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
1056, d3vs6B3, 0.8019, 2.35, 0.368, 269, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
1057, d3cp9A1, 0.8019, 2.09, 0.359, 281, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1058, d2c0iA3, 0.8019, 2.23, 0.359, 268, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
1059, d3gqlA_, 0.8018, 2.71, 0.401, 287, 257, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1060, d2yaaA_, 0.8018, 2.70, 0.231, 300, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1061, d2a2aD_, 0.8018, 2.69, 0.231, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1062, d3qgyB1, 0.8017, 1.62, 0.336, 244, 241, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1063, d3q4uB1, 0.8017, 2.85, 0.291, 298, 258, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1064, d5iuhA_, 0.8016, 2.14, 0.308, 285, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
1065, d4o2pB_, 0.8016, 2.18, 0.316, 265, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1066, d4c7tA_, 0.8016, 2.45, 0.336, 259, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1067, d2xikA_, 0.8016, 2.56, 0.266, 288, 256, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1068, d1k3aA_, 0.8016, 2.63, 0.304, 288, 257, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
1069, d1fpuA1, 0.8016, 2.39, 0.384, 271, 250, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1070, d5xp7A_, 0.8015, 2.28, 0.315, 265, 251, C-SRC IN COMPLEX WITH ATP-CHCL
1071, d5a4cB1, 0.8015, 2.62, 0.391, 284, 256, FGFR1 LIGAND COMPLEX
1072, d4v04B_, 0.8015, 2.48, 0.383, 287, 253, FGFR1 IN COMPLEX WITH PONATINIB.
1073, d3cpbA1, 0.8015, 2.05, 0.352, 278, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
1074, d5b7vB_, 0.8014, 2.50, 0.395, 277, 253, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1075, d4zsaB_, 0.8014, 2.41, 0.399, 282, 253, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
1076, d2zv9A1, 0.8014, 2.17, 0.376, 255, 250, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
1077, d2e2bA1, 0.8014, 2.16, 0.379, 266, 248, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
1078, d3uqgA_, 0.8013, 2.21, 0.316, 263, 250, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1079, d2yaaB_, 0.8013, 2.70, 0.231, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1080, d5oxgB_, 0.8012, 2.70, 0.280, 296, 257, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1081, d5oxgA_, 0.8012, 2.69, 0.281, 293, 256, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1082, d5ar2B_, 0.8012, 2.32, 0.270, 285, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1083, d4ebvA1, 0.8012, 2.51, 0.339, 261, 251, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
1084, d3my0L1, 0.8012, 2.92, 0.268, 295, 261, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1085, d4brxA_, 0.8011, 2.58, 0.339, 259, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1086, d3wj6B_, 0.8011, 2.49, 0.395, 277, 253,  
1087, d3vs1B3, 0.8011, 2.35, 0.369, 268, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
1088, d3vrzA3, 0.8011, 2.35, 0.369, 268, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
1089, d3my0B_, 0.8011, 2.87, 0.264, 295, 261, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1090, d2c0tB3, 0.8011, 2.28, 0.359, 268, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
1091, d5t0pB_, 0.8010, 2.15, 0.313, 263, 249, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1092, d4r7iA_, 0.8010, 2.35, 0.344, 290, 250, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
1093, d4otrA_, 0.8010, 2.31, 0.329, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
1094, d3vs0B3, 0.8010, 2.33, 0.369, 268, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
1095, d3rwqA_, 0.8010, 2.55, 0.243, 283, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1096, d2a2aC_, 0.8010, 2.73, 0.231, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1097, d5fbnC_, 0.8009, 2.39, 0.336, 256, 253, BTK KINASE DOMAIN WITH INHIBITOR 1
1098, d5edrA_, 0.8009, 2.50, 0.349, 299, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
1099, d3lvpC_, 0.8009, 2.63, 0.302, 293, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1100, d2a2aB_, 0.8009, 2.72, 0.227, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1101, d5uglB_, 0.8008, 2.31, 0.397, 271, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
1102, d5i9xA_, 0.8008, 2.72, 0.340, 284, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
1103, d5eobA_, 0.8008, 2.81, 0.319, 288, 257, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1104, d5dh3B_, 0.8008, 2.70, 0.272, 283, 257, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1105, d3vs3A3, 0.8008, 2.36, 0.368, 269, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
1106, d3aoxA_, 0.8008, 2.50, 0.304, 298, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
1107, d4hw7A_, 0.8007, 2.37, 0.344, 289, 250, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
1108, d4a4lA_, 0.8007, 2.75, 0.260, 290, 258, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1109, d1fgkA_, 0.8007, 2.37, 0.391, 278, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1110, d1agwA_, 0.8007, 2.38, 0.387, 278, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1111, d3vs0A3, 0.8006, 2.35, 0.369, 268, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
1112, d2vwxA_, 0.8006, 2.78, 0.328, 274, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1113, d2qu6A1, 0.8006, 1.84, 0.368, 276, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1114, d4ks8A_, 0.8005, 2.57, 0.207, 286, 256, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1115, d4f64A_, 0.8005, 2.38, 0.383, 278, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1116, d3lvpB_, 0.8005, 2.63, 0.300, 295, 257, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1117, d3kb7A_, 0.8005, 2.76, 0.260, 289, 258, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1118, d5hu9A1, 0.8004, 2.43, 0.376, 262, 250, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
1119, d3blrA_, 0.8004, 2.63, 0.213, 300, 258, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
1120, d2c0oB3, 0.8004, 2.35, 0.369, 268, 249, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
1121, d5u6bC_, 0.8003, 2.45, 0.317, 270, 252, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1122, d5nkcA_, 0.8003, 2.72, 0.340, 286, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
1123, d3my0N1, 0.8003, 2.83, 0.270, 299, 259, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1124, d2jkkA_, 0.8003, 2.56, 0.340, 258, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1125, d4imyE_, 0.8002, 2.78, 0.208, 313, 260, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1126, d4f63A_, 0.8002, 2.39, 0.383, 278, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1127, d4aojA_, 0.8002, 2.01, 0.399, 260, 248, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1128, d3vw8A_, 0.8002, 2.52, 0.328, 303, 250, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
1129, d2phkA_, 0.8002, 2.51, 0.208, 277, 255, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
1130, d1lufA_, 0.8002, 2.34, 0.341, 275, 249, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
1131, d5oy6B_, 0.8001, 2.76, 0.284, 292, 257, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1132, d4hctA_, 0.8001, 2.47, 0.324, 265, 253, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
1133, d4rwlA_, 0.8000, 2.44, 0.387, 282, 253, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1134, d4l00B_, 0.8000, 2.33, 0.249, 278, 253, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
1135, d4a4oA_, 0.8000, 2.77, 0.260, 290, 258, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1136, d5j87A_, 0.7999, 2.30, 0.341, 263, 252, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1137, d4f65A_, 0.7999, 2.52, 0.385, 279, 252, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
1138, d3k5vB1, 0.7999, 2.29, 0.378, 279, 249, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
1139, d2vn9B_, 0.7999, 2.75, 0.204, 301, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1140, d2fgiA_, 0.7999, 2.33, 0.381, 274, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1141, d1k2pB_, 0.7999, 2.52, 0.325, 258, 255, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1142, d4p2wA_, 0.7998, 2.04, 0.344, 250, 247,  
1143, d3vs2A3, 0.7998, 2.25, 0.359, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1144, d3gxlA_, 0.7998, 2.50, 0.249, 285, 253, ALK-5 KINASE COMPLEX WITH GW857175
1145, d1unlB_, 0.7998, 2.72, 0.230, 292, 256, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
1146, d5u6bA_, 0.7997, 2.47, 0.317, 270, 252, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1147, d4or5F_, 0.7996, 2.83, 0.205, 324, 259, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1148, d3v5lD1, 0.7996, 1.77, 0.326, 244, 242, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1149, d2vn9A_, 0.7996, 2.75, 0.204, 301, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1150, d2oiqA_, 0.7996, 2.31, 0.312, 265, 250, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
1151, d1iepB1, 0.7996, 2.19, 0.383, 270, 248, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
1152, d5u9dA_, 0.7995, 2.41, 0.335, 271, 254, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
1153, d5nkbA_, 0.7995, 2.74, 0.340, 285, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
1154, d5hznH_, 0.7995, 2.57, 0.319, 303, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1155, d5hznD_, 0.7995, 2.57, 0.319, 304, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1156, d3my0G1, 0.7995, 2.96, 0.261, 293, 261, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1157, d3my0F1, 0.7995, 2.87, 0.269, 293, 260, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1158, d3my0A1, 0.7995, 2.85, 0.269, 295, 260, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1159, d5p9hA_, 0.7994, 2.32, 0.333, 264, 252, BTK1 COCRYSTALLIZED WITH RN983
1160, d4mneG_, 0.7994, 2.07, 0.298, 259, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1161, d4fnxA_, 0.7994, 2.37, 0.299, 292, 251, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1162, d3vs5A3, 0.7993, 2.34, 0.369, 268, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1163, d3my0R1, 0.7993, 2.95, 0.264, 293, 261, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1164, d4or5A_, 0.7992, 2.95, 0.202, 319, 262, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1165, d5p9mA_, 0.7991, 2.43, 0.320, 271, 253, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
1166, d5nk1A_, 0.7991, 2.74, 0.337, 284, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
1167, d5eydA_, 0.7991, 2.76, 0.331, 289, 254, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
1168, d4hcvA_, 0.7991, 2.40, 0.317, 263, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
1169, d4gk3A_, 0.7991, 2.43, 0.364, 275, 253, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
1170, d4degA_, 0.7991, 2.75, 0.331, 286, 254, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
1171, d4b6lA_, 0.7991, 2.84, 0.232, 281, 259, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1172, d3my0U1, 0.7991, 2.88, 0.269, 284, 260, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1173, d5osdA_, 0.7990, 2.53, 0.251, 266, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1174, d4rx5A1, 0.7990, 2.30, 0.331, 264, 251, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
1175, d3vs7A3, 0.7990, 2.31, 0.367, 267, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1176, d2c0iB3, 0.7990, 2.39, 0.369, 268, 249, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
1177, d4h58B_, 0.7989, 2.22, 0.300, 262, 250, BRAF IN COMPLEX WITH COMPOUND 3
1178, d2qu6B_, 0.7989, 1.97, 0.360, 260, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1179, d5oryA_, 0.7988, 2.53, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1180, d5hu3A_, 0.7988, 2.56, 0.213, 266, 254, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1181, d5bpyA1, 0.7988, 2.30, 0.335, 262, 251, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1182, d3krjA_, 0.7988, 2.43, 0.336, 304, 250, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
1183, d3b8qB_, 0.7988, 1.90, 0.369, 271, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1184, d2qocA_, 0.7988, 2.55, 0.335, 283, 254, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
1185, d3my0E1, 0.7987, 2.90, 0.265, 293, 260, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1186, d2yjsA_, 0.7987, 2.30, 0.305, 286, 249, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
1187, d2w4kA_, 0.7987, 2.76, 0.242, 301, 260, X-RAY STRUCTURE OF A DAP-KINASE 2-302
1188, d5orpA_, 0.7986, 2.54, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1189, d2q0nA_, 0.7986, 2.64, 0.195, 293, 257, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1190, d5osfA_, 0.7985, 2.54, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1191, d5orzA_, 0.7985, 2.54, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1192, d5nk2A_, 0.7985, 2.73, 0.337, 290, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
1193, d4xyfA_, 0.7985, 2.80, 0.329, 290, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
1194, d4o0yA1, 0.7985, 2.57, 0.195, 289, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1195, p4ib5A_, 0.7985, 2.75, 0.190, 331, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1196, d3vs5B3, 0.7985, 2.34, 0.369, 268, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1197, d3up2A_, 0.7985, 2.64, 0.237, 266, 257, AURORA A IN COMPLEX WITH RPM1686
1198, d2i0vA_, 0.7985, 2.46, 0.339, 303, 251, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
1199, d2hyyA_, 0.7985, 2.15, 0.385, 263, 247, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
1200, d5eycA_, 0.7984, 2.62, 0.328, 288, 253, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
1201, d5orvA_, 0.7983, 2.54, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1202, d5ornA_, 0.7983, 2.54, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1203, d5nk6A_, 0.7983, 2.79, 0.337, 284, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
1204, d5j87B_, 0.7983, 2.52, 0.335, 274, 254, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1205, d4dceB_, 0.7983, 2.06, 0.301, 284, 246, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
1206, d3uodA_, 0.7983, 2.68, 0.253, 266, 257, AURORA A IN COMPLEX WITH RPM1693
1207, d3el8A_, 0.7983, 2.27, 0.316, 263, 250, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1208, d2zv7A1, 0.7983, 2.28, 0.375, 256, 251, LYN TYROSINE KINASE DOMAIN APO FORM
1209, d5oy6A_, 0.7982, 2.63, 0.286, 291, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1210, d5oxgD_, 0.7982, 2.75, 0.280, 293, 257, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1211, d5oseA_, 0.7982, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1212, d5os5A_, 0.7982, 2.55, 0.251, 267, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1213, d5a4cA_, 0.7982, 2.51, 0.391, 294, 253, FGFR1 LIGAND COMPLEX
1214, d4o0xA1, 0.7982, 2.56, 0.195, 289, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1215, d4hcuA_, 0.7982, 2.49, 0.324, 263, 253, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
1216, d3cp9B_, 0.7982, 2.01, 0.374, 269, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1217, d2ogvA_, 0.7982, 2.60, 0.335, 317, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
1218, d4gk4A_, 0.7981, 2.49, 0.362, 275, 254, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
1219, d3u4wA_, 0.7981, 2.56, 0.314, 275, 255, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
1220, d3svvA_, 0.7981, 2.10, 0.312, 261, 247, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1221, d2ya9A_, 0.7981, 2.75, 0.235, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1222, d2vz6A1, 0.7981, 2.45, 0.217, 285, 253, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1223, d5os4A_, 0.7980, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1224, d5orrA_, 0.7980, 2.54, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1225, d5ig1B_, 0.7980, 2.80, 0.257, 304, 261, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1226, d4zlyA_, 0.7980, 2.41, 0.320, 270, 253, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
1227, d4yhtB_, 0.7980, 2.16, 0.309, 258, 249, BRAF COMPLEXED WITH AN INHIBITOR
1228, d4rwkB_, 0.7980, 2.65, 0.396, 282, 255, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
1229, d4jdiA_, 0.7980, 2.57, 0.195, 289, 256, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1230, d2yjrA_, 0.7980, 2.16, 0.323, 278, 248, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
1231, d5vloA_, 0.7979, 2.71, 0.213, 290, 258, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1232, d4ot5A_, 0.7979, 2.36, 0.329, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1233, d4f0iB_, 0.7979, 2.78, 0.395, 294, 256, CRYSTAL STRUCTURE OF APO TRKA
1234, d5os1A_, 0.7978, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1235, d5os0A_, 0.7978, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1236, d5orwA_, 0.7978, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1237, d3vs2B3, 0.7978, 2.35, 0.369, 268, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1238, d3my0Q1, 0.7978, 2.92, 0.265, 293, 260, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1239, d3f82A_, 0.7978, 1.99, 0.332, 278, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1240, d3b8rB_, 0.7978, 1.94, 0.374, 267, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1241, d5os3A_, 0.7977, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1242, d5d7vB1, 0.7977, 2.40, 0.315, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1243, d4mcvA_, 0.7977, 2.30, 0.283, 267, 251, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1244, d4ludB3, 0.7977, 2.26, 0.372, 264, 247, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1245, d4imyA_, 0.7977, 2.85, 0.208, 314, 259, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1246, d4deaA_, 0.7977, 2.65, 0.237, 266, 257, AURORA A IN COMPLEX WITH YL1-038-18
1247, d3v8tB1, 0.7977, 1.65, 0.329, 242, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
1248, d1h1wA_, 0.7977, 2.59, 0.243, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1249, d5os6A_, 0.7976, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1250, d3uo5A_, 0.7976, 2.68, 0.253, 267, 257, AURORA A IN COMPLEX WITH YL1-038-31
1251, d1iepA1, 0.7976, 2.23, 0.383, 270, 248, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
1252, d5tobA_, 0.7975, 1.93, 0.366, 245, 243, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
1253, d5orxA_, 0.7975, 2.56, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1254, d5nk9A_, 0.7975, 2.79, 0.337, 285, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
1255, d4nksB_, 0.7975, 2.48, 0.393, 271, 252, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
1256, d4kabA_, 0.7975, 2.18, 0.339, 255, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
1257, d2auhA1, 0.7975, 2.75, 0.309, 294, 259, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
1258, p5x02A_, 0.7974, 2.45, 0.351, 305, 251, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
1259, d5orsA_, 0.7974, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1260, d5oroA_, 0.7974, 2.53, 0.259, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1261, d5j87D_, 0.7974, 2.35, 0.333, 263, 252, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1262, d3nrmA_, 0.7974, 2.68, 0.249, 263, 257, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
1263, d2helA_, 0.7974, 2.30, 0.332, 256, 250, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
1264, d1fgiB_, 0.7974, 2.52, 0.395, 272, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
1265, d4ymjA1, 0.7973, 2.29, 0.388, 267, 250, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1266, d4bggD_, 0.7973, 2.72, 0.277, 286, 256, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1267, d4rfzA_, 0.7972, 2.37, 0.329, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
1268, d4gu9A_, 0.7972, 2.19, 0.343, 252, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
1269, d3u51A_, 0.7972, 2.02, 0.309, 256, 246, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1270, d1xo2B_, 0.7972, 2.67, 0.239, 289, 255, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1271, d4tl0A_, 0.7971, 2.78, 0.242, 300, 260, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
1272, d4cegA_, 0.7971, 2.54, 0.259, 264, 255, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
1273, d3u6iA_, 0.7971, 2.42, 0.317, 281, 249, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
1274, d3q6uA1, 0.7971, 2.49, 0.324, 281, 250, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
1275, d3cpcA1, 0.7971, 2.12, 0.357, 277, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1276, d2zm3D2, 0.7971, 2.74, 0.314, 292, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1277, d2hiwB1, 0.7971, 2.40, 0.384, 270, 250, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
1278, d1agwB_, 0.7971, 2.56, 0.395, 272, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1279, d3rhxB_, 0.7970, 2.55, 0.395, 275, 253, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1280, d3my0H1, 0.7970, 2.83, 0.271, 293, 258, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1281, d2zm3C2, 0.7970, 2.76, 0.313, 295, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1282, d2zm3B2, 0.7970, 2.79, 0.313, 295, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1283, d2yacA_, 0.7970, 2.80, 0.260, 290, 258, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1284, d5orlA_, 0.7969, 2.55, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1285, d4l01A_, 0.7969, 2.26, 0.251, 274, 251, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
1286, d4f64B_, 0.7969, 2.54, 0.399, 272, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1287, d4a06A_, 0.7969, 2.64, 0.246, 282, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
1288, d3oxzA1, 0.7969, 1.98, 0.385, 267, 244, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
1289, d3my0S1, 0.7969, 2.95, 0.265, 293, 260, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1290, d4rg0A_, 0.7968, 2.34, 0.337, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
1291, d4mcvB_, 0.7968, 2.24, 0.300, 265, 250, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1292, d4dehA_, 0.7968, 2.66, 0.332, 286, 253, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
1293, d3miaA_, 0.7968, 2.87, 0.205, 324, 259, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
1294, d5lvlA_, 0.7967, 2.64, 0.246, 285, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1295, d4xi2A2, 0.7967, 2.46, 0.336, 274, 253, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
1296, d3a4pA_, 0.7967, 2.67, 0.328, 285, 253, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
1297, d2g15A_, 0.7967, 2.94, 0.323, 301, 257, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
1298, d5dt3A_, 0.7966, 2.60, 0.258, 263, 256, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
1299, d5d7vC1, 0.7966, 2.37, 0.311, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1300, d4deeA_, 0.7966, 2.61, 0.250, 271, 256, AURORA A IN COMPLEX WITH ADP
1301, d3my0I1, 0.7966, 2.89, 0.266, 292, 259, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1302, d3g6gB_, 0.7966, 2.18, 0.306, 263, 248, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1303, d3cs9A_, 0.7966, 2.15, 0.382, 264, 246, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
1304, d2x4fB_, 0.7966, 2.67, 0.205, 288, 259, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
1305, d1sm2A_, 0.7966, 1.79, 0.326, 245, 242, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1306, d5dn3A_, 0.7965, 2.62, 0.250, 264, 256, AURORA A IN COMPLEX WITH ATP AND AA35.
1307, d4aojC_, 0.7965, 2.12, 0.402, 261, 249, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1308, d2zm3A2, 0.7965, 2.76, 0.313, 299, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1309, d2eufB_, 0.7965, 2.74, 0.238, 282, 256, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1310, d5fbnD_, 0.7964, 2.31, 0.339, 255, 251, BTK KINASE DOMAIN WITH INHIBITOR 1
1311, d4deiA_, 0.7964, 2.81, 0.335, 287, 254, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
1312, d3qhwC1, 0.7964, 2.60, 0.260, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1313, d3gxjA_, 0.7964, 2.67, 0.260, 288, 254,  
1314, d1bkxA_, 0.7964, 2.54, 0.217, 337, 254, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1315, d5vefA_, 0.7963, 2.58, 0.195, 289, 256, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1316, d3t9tA_, 0.7963, 2.43, 0.295, 263, 251, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
1317, d2p2iB_, 0.7963, 1.68, 0.367, 263, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
1318, d5dnrA_, 0.7962, 2.63, 0.250, 264, 256, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
1319, d4jajA_, 0.7962, 2.67, 0.249, 265, 257, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
1320, d4gu6B_, 0.7962, 2.48, 0.337, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
1321, d1uvrA_, 0.7962, 2.63, 0.243, 284, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1322, d5vedA_, 0.7961, 2.57, 0.195, 289, 256, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1323, d5ia3A_, 0.7961, 2.52, 0.339, 275, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
1324, d3vs7B3, 0.7961, 2.27, 0.368, 266, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1325, d1smhA_, 0.7961, 2.55, 0.224, 348, 254, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1326, d5i9zA_, 0.7960, 2.42, 0.335, 273, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
1327, d5bmsA1, 0.7960, 2.59, 0.195, 289, 256, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1328, p4md8G_, 0.7960, 2.70, 0.180, 332, 255, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1329, d4f63B_, 0.7960, 2.51, 0.393, 271, 252, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1330, d2gcdB_, 0.7960, 2.64, 0.273, 308, 256, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1331, d1bx6A_, 0.7960, 2.54, 0.217, 337, 254, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1332, d5ortA_, 0.7959, 2.57, 0.255, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1333, d4md7H_, 0.7959, 2.80, 0.190, 330, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1334, d4md7F_, 0.7959, 2.80, 0.190, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1335, d4fijA_, 0.7959, 2.57, 0.195, 291, 256, CATALYTIC DOMAIN OF HUMAN PAK4
1336, d3v8wA1, 0.7959, 1.60, 0.326, 241, 239, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1337, d3qhwA1, 0.7959, 2.60, 0.260, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1338, d2gnjA_, 0.7959, 2.55, 0.224, 335, 254, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1339, d5nkdA_, 0.7958, 2.72, 0.339, 287, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
1340, d4xmoA_, 0.7958, 2.73, 0.316, 289, 253, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
1341, d4md7G_, 0.7958, 2.80, 0.190, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1342, d3my0C1, 0.7958, 2.85, 0.271, 298, 258, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1343, d3lq8A_, 0.7958, 2.60, 0.327, 278, 251, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
1344, d3iw4A_, 0.7958, 2.62, 0.230, 330, 256, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1345, d1okyA_, 0.7958, 2.54, 0.245, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1346, d1fgkB_, 0.7958, 2.58, 0.395, 272, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1347, d5dr2A1, 0.7957, 2.64, 0.254, 263, 256, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
1348, d4wunA_, 0.7957, 2.26, 0.406, 282, 249, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
1349, d4rqvA_, 0.7957, 2.65, 0.246, 288, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1350, d4e26B_, 0.7957, 2.35, 0.302, 264, 252, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1351, d1h1pC1, 0.7957, 2.80, 0.268, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1352, p4md9K_, 0.7956, 2.62, 0.185, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1353, d3q9zB_, 0.7956, 2.79, 0.186, 332, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1354, d3eflB_, 0.7956, 2.08, 0.370, 263, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
1355, d4jdhA_, 0.7955, 2.60, 0.195, 289, 256, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1356, d3lvpA_, 0.7954, 2.54, 0.311, 289, 254, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1357, d3cthA_, 0.7954, 2.65, 0.312, 295, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
1358, d2a27C_, 0.7954, 2.78, 0.235, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1359, d5bvwA_, 0.7953, 2.42, 0.364, 274, 253, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
1360, d2y7jB_, 0.7953, 2.60, 0.196, 281, 255, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1361, d2vz6B1, 0.7953, 2.57, 0.220, 288, 255, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1362, d2a27E_, 0.7953, 2.78, 0.231, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1363, d1rejA_, 0.7953, 2.53, 0.217, 333, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1364, d5nk4A_, 0.7952, 2.76, 0.339, 290, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
1365, d5njzA_, 0.7952, 2.47, 0.339, 273, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
1366, d4rwiB_, 0.7952, 2.55, 0.395, 280, 253, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
1367, d4rqkA_, 0.7952, 2.66, 0.246, 285, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1368, d4debA_, 0.7952, 2.68, 0.237, 264, 257, AURORA A IN COMPLEX WITH RK2-17-01
1369, d3cjgA_, 0.7952, 2.19, 0.363, 280, 248, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
1370, d2gfcA_, 0.7952, 2.56, 0.224, 335, 254, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1371, d2a27A_, 0.7952, 2.81, 0.231, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1372, d5vgoA1, 0.7951, 2.34, 0.335, 264, 251, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
1373, d5jfxA_, 0.7951, 2.31, 0.402, 277, 249, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
1374, d5d7vD1, 0.7951, 2.45, 0.319, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1375, d4utdA_, 0.7951, 2.60, 0.255, 266, 255, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
1376, d4riyC_, 0.7951, 2.70, 0.341, 275, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1377, d4pmmA1, 0.7951, 2.40, 0.402, 281, 249, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
1378, d4g2fA_, 0.7951, 2.44, 0.361, 275, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
1379, d4dglD_, 0.7951, 2.74, 0.187, 328, 257, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1380, d4dceA_, 0.7951, 2.32, 0.301, 288, 249, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
1381, d3iw4B_, 0.7951, 2.65, 0.230, 325, 256, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1382, d3bhhB1, 0.7951, 2.59, 0.208, 288, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1383, d2y7jC_, 0.7951, 2.63, 0.195, 284, 256, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1384, d1re8A_, 0.7951, 2.54, 0.217, 337, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1385, d5oy6C_, 0.7950, 2.83, 0.285, 291, 256, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1386, d5d7vA1, 0.7950, 2.38, 0.311, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1387, d4xx9A_, 0.7950, 2.66, 0.246, 288, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1388, d4mf1B1, 0.7950, 1.81, 0.326, 244, 242, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1389, d3zewB_, 0.7950, 2.16, 0.333, 252, 246, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
1390, d3bz3A_, 0.7950, 2.44, 0.339, 259, 251, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
1391, d1xjdA_, 0.7950, 2.49, 0.250, 280, 252, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
1392, d5kupA1, 0.7949, 2.35, 0.335, 264, 251, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
1393, d5em5A_, 0.7949, 2.52, 0.348, 298, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
1394, d2uztA_, 0.7949, 2.63, 0.224, 336, 255, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1395, d2fb8A_, 0.7949, 2.15, 0.306, 259, 248, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1396, d4v01A_, 0.7948, 2.39, 0.382, 273, 249, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
1397, p4md9H_, 0.7948, 2.77, 0.187, 328, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1398, d4l01B_, 0.7948, 2.23, 0.252, 274, 250, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
1399, d4fihA_, 0.7948, 2.65, 0.206, 291, 257, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1400, d1snuA_, 0.7948, 1.82, 0.326, 245, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1401, d1jbpE_, 0.7948, 2.56, 0.217, 339, 254, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1402, d5h2uB1, 0.7947, 2.46, 0.315, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1403, d4md7E_, 0.7947, 2.82, 0.190, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1404, d4bn1A_, 0.7947, 2.62, 0.255, 261, 255, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
1405, d3qhrA1, 0.7947, 2.63, 0.260, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1406, d3fhiA_, 0.7947, 2.55, 0.217, 336, 254, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1407, d3ewhA1, 0.7947, 2.68, 0.366, 295, 254, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
1408, d2gniA_, 0.7947, 2.56, 0.224, 338, 254, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1409, d1q61A_, 0.7947, 2.57, 0.224, 335, 254, PKA TRIPLE MUTANT MODEL OF PKB
1410, d5nk3A_, 0.7946, 2.72, 0.336, 281, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
1411, d5jfsA_, 0.7946, 2.20, 0.403, 277, 248, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
1412, d4nwmB_, 0.7946, 2.33, 0.328, 261, 250, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1413, d4eonA1, 0.7946, 2.64, 0.264, 297, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1414, d3qhrC1, 0.7946, 2.63, 0.260, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1415, d1u7eA_, 0.7946, 2.55, 0.217, 338, 254,  
1416, d5h2uC1, 0.7945, 2.48, 0.319, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1417, d5h2uA1, 0.7945, 2.51, 0.321, 261, 252, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1418, d4o0vA1, 0.7945, 2.64, 0.206, 289, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1419, d4f1oA1, 0.7945, 2.59, 0.259, 274, 255, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
1420, d2a27H_, 0.7945, 2.79, 0.235, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1421, d1rdqE_, 0.7945, 2.57, 0.217, 340, 254, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1422, d4eolC1, 0.7944, 2.63, 0.272, 296, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1423, d2ya9B_, 0.7944, 2.81, 0.231, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1424, d2a27G_, 0.7944, 2.81, 0.235, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1425, d2a27B_, 0.7944, 2.79, 0.235, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1426, d1uu7A_, 0.7944, 2.66, 0.244, 280, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1427, d1snxA_, 0.7944, 1.83, 0.326, 245, 242, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1428, d5dh3A_, 0.7943, 2.80, 0.265, 287, 257, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1429, d4rixC_, 0.7943, 2.70, 0.337, 275, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1430, d4o0sA_, 0.7943, 2.62, 0.251, 265, 255, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
1431, d4f1mA1, 0.7943, 2.62, 0.247, 274, 255, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
1432, d1xh8A_, 0.7943, 2.57, 0.224, 337, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1433, p4md9E_, 0.7942, 2.64, 0.181, 329, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1434, d4jboA_, 0.7942, 2.63, 0.254, 266, 256, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
1435, d3my0P_, 0.7942, 2.89, 0.266, 290, 259, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1436, d2a27F_, 0.7942, 2.86, 0.230, 303, 261, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1437, d1xhaA_, 0.7942, 2.58, 0.224, 348, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1438, d5h2uD1, 0.7941, 2.47, 0.315, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1439, d4mf1A1, 0.7941, 1.63, 0.326, 241, 239, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1440, p4md8F_, 0.7941, 2.83, 0.190, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1441, d4j52A_, 0.7941, 2.84, 0.264, 293, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1442, d3ocsA1, 0.7941, 2.32, 0.332, 262, 250, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
1443, d3genA_, 0.7941, 2.33, 0.328, 264, 250, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
1444, d3g0eA1, 0.7941, 2.82, 0.345, 330, 255, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1445, d3byuA_, 0.7941, 2.13, 0.366, 256, 246, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
1446, d1u5qB_, 0.7941, 2.68, 0.273, 308, 256, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1447, d1snxB_, 0.7941, 1.85, 0.326, 245, 242, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1448, d3u51B_, 0.7940, 2.02, 0.310, 255, 245, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1449, d2a27D_, 0.7940, 2.82, 0.235, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1450, d5d12A_, 0.7939, 2.09, 0.313, 260, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1451, d5ackA_, 0.7939, 2.68, 0.246, 286, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1452, d3tnpF_, 0.7939, 2.50, 0.217, 334, 253, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1453, d3tnpC_, 0.7939, 2.50, 0.217, 334, 253, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1454, d3rhkA_, 0.7939, 2.69, 0.311, 298, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
1455, d3mj2A_, 0.7939, 2.26, 0.333, 259, 249, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
1456, d5uq0A_, 0.7938, 2.19, 0.405, 266, 247, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
1457, d4w8eA_, 0.7938, 2.66, 0.270, 290, 256, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1458, d4mneC_, 0.7938, 2.22, 0.289, 260, 249, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1459, d4k8aA_, 0.7938, 2.16, 0.348, 251, 247, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
1460, d4aw1A_, 0.7938, 2.57, 0.249, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1461, d3qlgB_, 0.7938, 2.04, 0.310, 260, 245, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1462, d3oxtA_, 0.7938, 2.48, 0.225, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1463, d3my0V1, 0.7938, 2.65, 0.272, 281, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1464, d2owbA_, 0.7938, 2.85, 0.264, 294, 258, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1465, d1ol7A_, 0.7938, 2.62, 0.255, 261, 255, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
1466, d3zfxC_, 0.7937, 1.89, 0.349, 248, 241, CRYSTAL STRUCTURE OF EPHB1
1467, d3qgwB_, 0.7937, 1.52, 0.333, 240, 237, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1468, d3mi9A_, 0.7937, 3.03, 0.202, 328, 262, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
1469, d2cdzA_, 0.7937, 2.55, 0.197, 289, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1470, d3q9xB_, 0.7936, 2.73, 0.187, 330, 257, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1471, d3f3tB_, 0.7936, 1.99, 0.307, 259, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
1472, d3dtwB_, 0.7936, 1.98, 0.370, 269, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
1473, d5tehB_, 0.7935, 2.25, 0.308, 262, 247, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
1474, d5ek7B_, 0.7935, 2.51, 0.353, 286, 252, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
1475, d4yhtA_, 0.7935, 2.13, 0.312, 256, 247, BRAF COMPLEXED WITH AN INHIBITOR
1476, p4md9M_, 0.7935, 2.83, 0.190, 331, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1477, d4m0yA_, 0.7935, 2.61, 0.294, 263, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
1478, d3my0D1, 0.7935, 2.87, 0.267, 297, 258, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1479, d3hrfA_, 0.7935, 2.68, 0.246, 284, 256, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1480, d3fjqE_, 0.7935, 2.59, 0.213, 334, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1481, d3eknA_, 0.7935, 2.53, 0.315, 297, 254, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
1482, d3aglB_, 0.7935, 2.57, 0.224, 335, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1483, d4rixA_, 0.7934, 2.76, 0.337, 269, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1484, d4o2pA_, 0.7934, 2.44, 0.316, 265, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1485, d4kaoB_, 0.7934, 2.30, 0.329, 254, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
1486, d4eolA1, 0.7934, 2.65, 0.272, 293, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1487, d3uqfA_, 0.7934, 2.18, 0.320, 260, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1488, d3uo4A_, 0.7934, 2.71, 0.237, 266, 257, AURORA A IN COMPLEX WITH RPM1680
1489, d3qamE_, 0.7934, 2.58, 0.213, 348, 254, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1490, d2y7jD_, 0.7934, 2.64, 0.196, 281, 255, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1491, d5oy6D_, 0.7933, 2.84, 0.284, 292, 257, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1492, d4riyA_, 0.7933, 2.75, 0.341, 269, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1493, p4md9P_, 0.7933, 2.61, 0.181, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1494, d3v8wB1, 0.7933, 1.59, 0.328, 240, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1495, d3qalE_, 0.7933, 2.60, 0.213, 339, 254, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1496, d3my0T1, 0.7933, 2.87, 0.267, 291, 258, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1497, d5jfwA_, 0.7932, 2.34, 0.402, 277, 249, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
1498, p4md8H_, 0.7932, 2.84, 0.190, 331, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1499, d2y7jA_, 0.7932, 2.66, 0.195, 284, 256, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1500, d4x6qC_, 0.7931, 2.51, 0.217, 334, 253, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1501, d4j8nD_, 0.7931, 2.75, 0.237, 265, 257, AURORA A KINASE APO
1502, d4i4fA_, 0.7931, 2.41, 0.341, 255, 249, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
1503, d3fzoA_, 0.7931, 2.75, 0.355, 262, 256, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
1504, d3a7fA_, 0.7931, 2.44, 0.279, 283, 251, HUMAN MST3 KINASE
1505, d1stcE_, 0.7931, 2.60, 0.224, 334, 254, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1506, d5ta8A_, 0.7930, 2.85, 0.264, 294, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1507, d5ta6A_, 0.7930, 2.85, 0.264, 294, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1508, d4mnfB_, 0.7930, 2.10, 0.305, 257, 246, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
1509, p4md8E_, 0.7930, 2.94, 0.189, 332, 259, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1510, d4jdkA_, 0.7930, 2.59, 0.196, 288, 255, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1511, d4j8nC_, 0.7930, 2.75, 0.237, 266, 257, AURORA A KINASE APO
1512, d4imyC_, 0.7930, 2.64, 0.204, 310, 255, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1513, d2fgiB_, 0.7930, 2.60, 0.399, 272, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1514, d1vebA_, 0.7930, 2.59, 0.224, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1515, d1u5rB_, 0.7930, 2.69, 0.273, 308, 256, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1516, d1q24A_, 0.7930, 2.60, 0.220, 335, 254, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1517, d6babB_, 0.7929, 2.48, 0.214, 285, 252, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1518, d4ubaA_, 0.7929, 2.94, 0.185, 333, 259, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1519, d4otfA1, 0.7929, 2.33, 0.336, 261, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
1520, d4j8nB_, 0.7929, 2.75, 0.237, 266, 257, AURORA A KINASE APO
1521, d3v5lC1, 0.7929, 1.75, 0.325, 242, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1522, p3u9cB_, 0.7929, 2.83, 0.194, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1523, d3mvjE_, 0.7929, 2.59, 0.224, 334, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1524, d3iw4C_, 0.7929, 2.68, 0.230, 332, 256, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1525, d5lvnA_, 0.7928, 2.69, 0.246, 283, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1526, d5ar5B_, 0.7928, 2.18, 0.271, 279, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1527, d4mxxB_, 0.7928, 2.23, 0.316, 260, 247, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1528, d4j8nA_, 0.7928, 2.75, 0.237, 266, 257, AURORA A KINASE APO
1529, d2bdwB_, 0.7928, 2.82, 0.208, 309, 259, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1530, d1q62A_, 0.7928, 2.60, 0.220, 336, 254, PKA DOUBLE MUTANT MODEL OF PKB
1531, d1mq4A_, 0.7928, 2.64, 0.251, 261, 255, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
1532, d1fmoE_, 0.7928, 2.58, 0.217, 336, 254, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1533, d4wsqA_, 0.7927, 2.82, 0.198, 317, 253, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1534, d4jdjA_, 0.7927, 2.63, 0.207, 288, 256, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1535, d3qa0B_, 0.7927, 2.75, 0.191, 330, 257, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1536, d3nx8A_, 0.7927, 2.61, 0.220, 333, 254, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1537, d2f7zE_, 0.7927, 2.64, 0.224, 336, 255, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1538, d1svhA_, 0.7927, 2.60, 0.224, 335, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1539, d1svgA_, 0.7927, 2.59, 0.224, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1540, d1apmE_, 0.7927, 2.59, 0.217, 338, 254, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1541, d5ia0C_, 0.7926, 2.33, 0.345, 269, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
1542, d5f9eA1, 0.7926, 2.64, 0.235, 331, 255, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1543, d4riwC_, 0.7926, 2.77, 0.336, 275, 256, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1544, p4md9G_, 0.7926, 2.80, 0.191, 329, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1545, d4eonC1, 0.7926, 2.67, 0.268, 296, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1546, d3fc2A_, 0.7926, 2.86, 0.264, 293, 258, PLK1 IN COMPLEX WITH BI6727
1547, d4yneA1, 0.7925, 2.31, 0.399, 276, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1548, d4j53A_, 0.7925, 2.86, 0.264, 293, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1549, d3u6hA_, 0.7925, 2.44, 0.319, 280, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
1550, d1sveA_, 0.7925, 2.60, 0.224, 341, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1551, p5owlB_, 0.7924, 2.94, 0.189, 332, 259, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1552, d5ci7A_, 0.7924, 2.71, 0.261, 276, 257, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
1553, p4md9F_, 0.7924, 2.71, 0.187, 327, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1554, d4bggC_, 0.7924, 2.77, 0.287, 279, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1555, d3oogA_, 0.7924, 2.60, 0.224, 333, 254, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1556, d3l9nA_, 0.7924, 2.50, 0.225, 332, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1557, d1jluE_, 0.7924, 2.59, 0.217, 337, 254, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1558, d1atpE_, 0.7924, 2.58, 0.217, 334, 254, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1559, d5l2wA1, 0.7923, 2.75, 0.267, 296, 255, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
1560, d4ybkA_, 0.7923, 2.44, 0.311, 266, 251, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1561, d4u45A_, 0.7923, 2.64, 0.245, 289, 253, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1562, d4eokC1, 0.7923, 2.65, 0.272, 296, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1563, d2uzvA_, 0.7923, 2.64, 0.224, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1564, d1h1pA1, 0.7923, 2.83, 0.268, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1565, d5ew3B_, 0.7922, 1.89, 0.365, 266, 241, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
1566, d4f0fA1, 0.7922, 2.66, 0.247, 274, 255, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
1567, d4dgnA_, 0.7922, 2.88, 0.190, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1568, d3g5dB_, 0.7922, 1.99, 0.307, 257, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1569, d2ou7A_, 0.7922, 2.83, 0.249, 292, 257, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1570, d2ojfE_, 0.7922, 2.65, 0.224, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1571, d2f7eE_, 0.7922, 2.65, 0.224, 336, 255, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1572, d5xgmA_, 0.7921, 2.41, 0.355, 288, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
1573, d4dgoA_, 0.7921, 2.77, 0.191, 325, 257, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
1574, d3cquA_, 0.7921, 2.61, 0.235, 318, 255, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1575, d5h8eA_, 0.7920, 2.86, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1576, p3u9cA_, 0.7920, 2.85, 0.194, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1577, d2gnfA_, 0.7920, 2.60, 0.224, 339, 254, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1578, d1wvxA_, 0.7920, 2.54, 0.248, 275, 254, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1579, d5li1A1, 0.7919, 2.50, 0.202, 329, 253, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1580, d4yo4A1, 0.7919, 2.58, 0.240, 276, 254, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
1581, d4uv0A_, 0.7919, 2.82, 0.242, 300, 260, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
1582, d4krcA_, 0.7919, 2.83, 0.238, 297, 256, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
1583, d3en4A_, 0.7919, 2.02, 0.316, 257, 244, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
1584, d2qcsA_, 0.7919, 2.54, 0.217, 335, 253, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
1585, d5j79A_, 0.7918, 2.28, 0.270, 283, 248, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1586, d4x6rA_, 0.7918, 2.54, 0.217, 347, 253, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1587, d4riwA_, 0.7918, 2.78, 0.337, 269, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1588, d4dgmA_, 0.7918, 2.88, 0.190, 326, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1589, d3sc1A_, 0.7918, 2.50, 0.247, 278, 251, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
1590, d3el8B_, 0.7918, 2.02, 0.320, 259, 244, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1591, d5ia0B_, 0.7917, 2.62, 0.335, 266, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
1592, d4yxrA_, 0.7917, 2.60, 0.224, 334, 254, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1593, d4w9xA_, 0.7917, 2.81, 0.218, 300, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
1594, d4o21A_, 0.7917, 2.56, 0.217, 333, 253, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1595, d4ct1A_, 0.7917, 2.70, 0.246, 283, 256, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
1596, d2rkuA_, 0.7917, 2.87, 0.264, 294, 258, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1597, d1xh9A_, 0.7917, 2.61, 0.228, 336, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1598, d1cdkB_, 0.7917, 2.62, 0.224, 342, 254, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1599, d4mneF_, 0.7916, 2.14, 0.300, 258, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1600, d3my0W1, 0.7916, 2.70, 0.272, 280, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1601, d3mvjA_, 0.7916, 2.60, 0.224, 334, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1602, d3idcA_, 0.7916, 2.62, 0.213, 341, 254, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1603, d3e5aA_, 0.7916, 2.70, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
1604, d3aglA_, 0.7916, 2.58, 0.220, 338, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1605, d2uvxA_, 0.7916, 2.61, 0.220, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1606, d1cdkA_, 0.7916, 2.62, 0.220, 342, 254, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1607, d3u87B_, 0.7915, 2.75, 0.195, 329, 257, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1608, d3rcjA_, 0.7915, 2.68, 0.243, 281, 255, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1609, d3gu8A1, 0.7915, 2.58, 0.240, 276, 254, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
1610, d1snuB_, 0.7915, 1.71, 0.331, 241, 239, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1611, d1rekA_, 0.7915, 2.59, 0.217, 336, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1612, d4uwyB_, 0.7914, 2.34, 0.402, 273, 249, FGFR1 APO STRUCTURE
1613, d4txcA_, 0.7914, 2.55, 0.247, 276, 255, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1614, d4fnzA_, 0.7914, 2.28, 0.302, 287, 248, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
1615, d3l9mB_, 0.7914, 2.62, 0.224, 336, 254, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1616, d3dgkA1, 0.7914, 2.58, 0.240, 276, 254, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
1617, d2qo9A_, 0.7914, 2.55, 0.340, 277, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
1618, d2fb8B_, 0.7914, 2.23, 0.306, 259, 248, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1619, d2f7xE_, 0.7914, 2.65, 0.224, 336, 255, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1620, d5lvoA_, 0.7913, 2.70, 0.238, 285, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1621, d5kmnA1, 0.7913, 2.58, 0.395, 290, 253, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
1622, d5hngA_, 0.7913, 2.51, 0.247, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1623, d4ypdA1, 0.7913, 2.59, 0.240, 276, 254, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
1624, d4v04A_, 0.7913, 2.46, 0.384, 290, 250, FGFR1 IN COMPLEX WITH PONATINIB.
1625, d4tygA1, 0.7913, 2.71, 0.353, 290, 255, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
1626, d4eopC1, 0.7913, 2.70, 0.268, 295, 254, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1627, d3up7A_, 0.7913, 2.70, 0.250, 264, 256, AURORA A IN COMPLEX WITH YL1-038-09
1628, d3ky2B_, 0.7913, 2.63, 0.389, 280, 252, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
1629, d4nkaA_, 0.7912, 2.47, 0.384, 279, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
1630, d4l67A_, 0.7912, 2.66, 0.195, 289, 256, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1631, d4f1tA1, 0.7912, 2.75, 0.251, 267, 255, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
1632, d3my0O1, 0.7912, 2.93, 0.267, 296, 258, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1633, d2v7oA1, 0.7912, 2.88, 0.208, 297, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1634, d1dawA_, 0.7912, 2.97, 0.185, 327, 259, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1635, d5i0bA_, 0.7911, 2.70, 0.206, 288, 257, STRUCTURE OF PAK4
1636, d4at3A1, 0.7911, 2.71, 0.372, 286, 253, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
1637, d3l9lB_, 0.7911, 2.62, 0.224, 337, 254, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1638, d2rl5A1, 0.7911, 2.50, 0.368, 290, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
1639, d2gnhA_, 0.7911, 2.60, 0.224, 338, 254, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1640, d1sm2B_, 0.7911, 1.72, 0.331, 241, 239, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1641, d1ol5A_, 0.7911, 2.59, 0.260, 263, 254, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
1642, d4f65B_, 0.7910, 2.71, 0.382, 279, 254, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
1643, d3rp0A_, 0.7910, 2.89, 0.190, 329, 258,  
1644, d3gu5A1, 0.7910, 2.59, 0.244, 276, 254, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
1645, d2uzwE_, 0.7910, 2.66, 0.224, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1646, d2uzdA_, 0.7910, 2.84, 0.268, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1647, d2gcdA_, 0.7910, 2.72, 0.270, 308, 256, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1648, d5m56A_, 0.7909, 2.77, 0.187, 331, 257, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1649, d4at5A1, 0.7909, 2.90, 0.369, 291, 255, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
1650, d3pooA_, 0.7909, 2.61, 0.224, 331, 254, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1651, d3fztA_, 0.7909, 2.59, 0.352, 259, 253, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
1652, d2w4jA_, 0.7909, 2.64, 0.243, 276, 255, X-RAY STRUCTURE OF A DAP-KINASE 2-277
1653, d2rfsA_, 0.7909, 2.53, 0.333, 264, 249, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
1654, d2jdrA_, 0.7909, 2.65, 0.235, 316, 255, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1655, d2gngA_, 0.7909, 2.61, 0.224, 338, 254, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1656, d5i9wA_, 0.7908, 2.23, 0.340, 267, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
1657, d4wsqB_, 0.7908, 2.84, 0.198, 310, 253, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1658, d2vo7A_, 0.7908, 2.62, 0.224, 335, 254, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1659, d2erzE_, 0.7908, 2.61, 0.217, 334, 254, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1660, d1eh4A_, 0.7908, 3.17, 0.169, 293, 266, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
1661, d4ubaB_, 0.7907, 2.96, 0.189, 333, 259, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1662, d3rp0D_, 0.7907, 2.90, 0.190, 329, 258,  
1663, d2uw4A_, 0.7907, 2.58, 0.217, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1664, d1lp4A_, 0.7907, 2.91, 0.190, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
1665, d5ur1A_, 0.7906, 2.27, 0.407, 278, 248, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
1666, d5os2A_, 0.7906, 2.52, 0.258, 261, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1667, d4ebwA_, 0.7906, 2.46, 0.337, 259, 249, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
1668, d4dedA_, 0.7906, 2.75, 0.237, 265, 257, AURORA A IN COMPLEX WITH YL1-038-21
1669, d3u87A_, 0.7906, 2.78, 0.191, 329, 257, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1670, d3q9zA_, 0.7906, 2.88, 0.186, 332, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1671, d3kxmA_, 0.7906, 2.88, 0.186, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1672, d2reiA1, 0.7906, 2.42, 0.341, 274, 249, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
1673, d2oxdA_, 0.7906, 2.77, 0.191, 325, 257, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
1674, d2oh0E_, 0.7906, 2.66, 0.224, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1675, d5v24B_, 0.7905, 2.52, 0.260, 263, 250, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
1676, p4md9L_, 0.7905, 2.66, 0.181, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1677, d4gg7A_, 0.7905, 2.66, 0.321, 278, 252, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1678, d4fx3C_, 0.7905, 2.73, 0.259, 298, 255, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1679, d3ow3A_, 0.7905, 2.62, 0.217, 334, 254, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1680, d3gubA1, 0.7905, 2.60, 0.240, 276, 254, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
1681, d3gqlB_, 0.7905, 2.45, 0.402, 276, 251, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1682, d3amaA_, 0.7905, 2.62, 0.220, 342, 254, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1683, p2pvnA_, 0.7905, 2.88, 0.182, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1684, d5jfvA_, 0.7904, 2.26, 0.403, 277, 248, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
1685, d5ikwA_, 0.7904, 2.85, 0.217, 297, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
1686, d6babC_, 0.7903, 2.52, 0.222, 284, 252, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1687, d5i3oA_, 0.7903, 2.90, 0.217, 302, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
1688, d5fboA_, 0.7903, 2.23, 0.319, 255, 248, BTK-INHIBITOR CO-STRUCTURE
1689, d4mnfA_, 0.7903, 2.14, 0.305, 257, 246, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
1690, d4fzaB1, 0.7903, 2.73, 0.263, 280, 255, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1691, d3mpmA_, 0.7903, 2.50, 0.345, 257, 249, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
1692, d3idbA_, 0.7903, 2.63, 0.217, 341, 254, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1693, d3gu4A1, 0.7903, 2.60, 0.244, 276, 254, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
1694, d2x39A_, 0.7903, 2.66, 0.235, 316, 255, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1695, d1u5qA_, 0.7903, 2.73, 0.270, 308, 256, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1696, d5cu3B_, 0.7902, 2.55, 0.183, 324, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1697, d4rlkA_, 0.7902, 2.91, 0.186, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1698, d3dneA_, 0.7902, 2.63, 0.224, 336, 254, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1699, d3d94A_, 0.7902, 2.42, 0.325, 288, 249, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
1700, d3d7tB_, 0.7902, 2.38, 0.283, 265, 251, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1701, d2uw8A_, 0.7902, 2.59, 0.221, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1702, d2qc6A_, 0.7902, 2.92, 0.186, 326, 258, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
1703, d1l3rE_, 0.7902, 2.59, 0.217, 338, 253, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1704, d1jamA_, 0.7902, 2.91, 0.186, 327, 258, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1705, d5uoxA_, 0.7901, 2.53, 0.260, 263, 250, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
1706, d4eokA1, 0.7901, 2.57, 0.266, 292, 252, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1707, d3ms9B1, 0.7901, 2.22, 0.384, 267, 245, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
1708, d2uzuE_, 0.7901, 2.67, 0.224, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1709, d2uw3A_, 0.7901, 2.58, 0.221, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1710, d2jdtA_, 0.7901, 2.63, 0.220, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1711, d1q8tA_, 0.7901, 2.62, 0.224, 338, 254, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1712, d1o6kA_, 0.7901, 2.67, 0.235, 317, 255, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1713, d1ds5C_, 0.7901, 2.98, 0.185, 328, 259, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1714, d5ek7A_, 0.7900, 2.55, 0.353, 286, 252, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
1715, d4m13A_, 0.7900, 2.51, 0.295, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1716, p4lfiB_, 0.7900, 2.89, 0.182, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1717, d4eoiC1, 0.7900, 2.72, 0.268, 295, 254, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1718, d2c1bA_, 0.7900, 2.63, 0.224, 335, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1719, d1xh5A_, 0.7900, 2.65, 0.220, 335, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1720, d1m2qA_, 0.7900, 2.89, 0.190, 327, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1721, d1jwhB_, 0.7900, 2.89, 0.190, 335, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1722, p6ehuB_, 0.7899, 2.78, 0.195, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1723, p5ooiA_, 0.7899, 2.88, 0.182, 329, 258, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1724, d5k9iA_, 0.7899, 2.22, 0.317, 258, 246, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1725, d5ho8A_, 0.7899, 2.48, 0.248, 278, 250, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1726, d5cqwB_, 0.7899, 2.89, 0.194, 331, 258, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1727, d4otdA_, 0.7899, 2.62, 0.260, 334, 254, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1728, d4nwmA_, 0.7899, 2.33, 0.329, 261, 249, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1729, d4m0zA_, 0.7899, 2.52, 0.295, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
1730, d4dggA_, 0.7899, 2.17, 0.313, 261, 246, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1731, d3gu6A1, 0.7899, 2.61, 0.240, 276, 254, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
1732, d2uw7A_, 0.7899, 2.63, 0.220, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1733, d1ydrE_, 0.7899, 2.61, 0.220, 334, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1734, d1ds5A_, 0.7899, 2.99, 0.185, 328, 259, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1735, d3bhhA1, 0.7898, 2.62, 0.205, 287, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1736, d2jedA_, 0.7898, 2.69, 0.247, 324, 255, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1737, p4lfiA_, 0.7897, 2.90, 0.182, 370, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1738, d2j0iA_, 0.7897, 2.85, 0.205, 289, 258, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1739, d2c6tA_, 0.7897, 2.71, 0.264, 295, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1740, d2c1aA_, 0.7897, 2.63, 0.224, 335, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1741, d1ydsE_, 0.7897, 2.62, 0.220, 334, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1742, d1xh7A_, 0.7897, 2.61, 0.225, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1743, p6ehuA_, 0.7896, 2.77, 0.195, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1744, d5kwhB_, 0.7896, 2.90, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2
1745, d5kmlA1, 0.7896, 2.59, 0.395, 290, 253, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
1746, d4rwjB_, 0.7896, 2.79, 0.394, 282, 254, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
1747, d4bxaB_, 0.7896, 2.89, 0.194, 331, 258,  
1748, d3kxgA_, 0.7896, 2.90, 0.190, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
1749, d3e8eA_, 0.7896, 2.63, 0.224, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1750, d5h8bA_, 0.7895, 2.89, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1751, d4q9zA1, 0.7895, 2.63, 0.236, 330, 254, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1752, d4o22A1, 0.7895, 2.60, 0.217, 333, 253, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1753, d4nifB_, 0.7895, 2.74, 0.196, 349, 255, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
1754, d4ii5A_, 0.7895, 2.71, 0.264, 295, 254, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
1755, d4fx3A_, 0.7895, 2.75, 0.259, 298, 255, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1756, d3wzdA_, 0.7895, 2.11, 0.371, 278, 245, KDR IN COMPLEX WITH LIGAND LENVATINIB
1757, d3pwdA_, 0.7895, 2.91, 0.190, 327, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
1758, d3g5dA_, 0.7895, 1.94, 0.310, 256, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1759, d2hy81_, 0.7895, 2.73, 0.214, 293, 257, PAK1 COMPLEX WITH ST2001
1760, d1ydtE_, 0.7895, 2.63, 0.220, 334, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1761, d5jrsA1, 0.7894, 2.26, 0.332, 257, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1762, d4wbbB_, 0.7894, 2.57, 0.217, 334, 253, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1763, d4ii5C_, 0.7894, 2.71, 0.264, 295, 254, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
1764, d3ngaB_, 0.7894, 2.89, 0.186, 331, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1765, d2uvyA_, 0.7894, 2.59, 0.221, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1766, d1xh4A_, 0.7894, 2.59, 0.225, 334, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1767, d1o6lA_, 0.7894, 2.68, 0.235, 316, 255, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1768, d1ds5D_, 0.7894, 3.00, 0.185, 328, 259, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1769, d5h8eB_, 0.7893, 2.91, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1770, d5cqwA_, 0.7893, 2.90, 0.194, 331, 258, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1771, d2uw5A_, 0.7893, 2.60, 0.221, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1772, d2gu8A_, 0.7893, 2.63, 0.217, 335, 254, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1773, p4nh1B_, 0.7892, 2.90, 0.182, 332, 258, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1774, d4eosC1, 0.7892, 2.73, 0.264, 295, 254, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1775, d3v5lB1, 0.7892, 1.61, 0.325, 239, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1776, d3v5jA1, 0.7892, 1.61, 0.329, 239, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
1777, d3pzhA_, 0.7892, 2.92, 0.186, 327, 258, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
1778, d3l9lA_, 0.7892, 2.54, 0.225, 338, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1779, d3cpcB_, 0.7892, 1.73, 0.370, 262, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1780, p2pvhA_, 0.7892, 2.92, 0.186, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1781, d1ds5B_, 0.7892, 3.02, 0.189, 328, 259, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1782, d5da3A1, 0.7891, 2.52, 0.319, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
1783, d4bxaA_, 0.7891, 2.90, 0.194, 331, 258,  
1784, d2cpkE_, 0.7891, 2.59, 0.217, 333, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
1785, d1lr4A_, 0.7891, 2.93, 0.186, 327, 258, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1786, d5w5oO_, 0.7890, 2.15, 0.273, 276, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1787, d5ia1A_, 0.7890, 2.26, 0.343, 261, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
1788, d4wnoA_, 0.7890, 2.81, 0.256, 272, 258, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
1789, d4njdA1, 0.7890, 2.84, 0.205, 289, 258, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1790, d4nifE_, 0.7890, 2.74, 0.196, 348, 255, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
1791, d4m12A_, 0.7890, 2.54, 0.295, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1792, d4gt5A_, 0.7890, 2.65, 0.391, 290, 253, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
1793, d3e8eP_, 0.7890, 2.63, 0.224, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1794, d3dfcB1, 0.7890, 2.61, 0.240, 276, 254, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
1795, d2gnlA_, 0.7890, 2.64, 0.224, 338, 254, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1796, d2cchC2, 0.7890, 2.71, 0.264, 295, 254, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
1797, d1zogA_, 0.7890, 2.78, 0.187, 325, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1798, d5kwhA_, 0.7889, 2.89, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2
1799, d5ku8A_, 0.7889, 2.90, 0.194, 328, 258, CRYSTAL STRUCTURE OF CK2
1800, d5i3oB_, 0.7889, 2.97, 0.217, 302, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
1801, p4mwhA_, 0.7889, 2.90, 0.182, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1802, p4fi1A_, 0.7889, 2.90, 0.182, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1803, d4dymA_, 0.7889, 2.72, 0.281, 293, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
1804, d3mv5A_, 0.7889, 2.70, 0.235, 315, 255, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1805, d3l9mA_, 0.7889, 2.54, 0.225, 338, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1806, d3h9rA_, 0.7889, 2.47, 0.292, 312, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
1807, d2oxxA_, 0.7889, 2.81, 0.191, 325, 257, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1808, d2oh4A1, 0.7889, 2.55, 0.371, 296, 251, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
1809, d1ckjA_, 0.7889, 3.10, 0.197, 296, 264, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
1810, d5veeA_, 0.7888, 2.69, 0.199, 289, 256, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1811, d5mo8A_, 0.7888, 2.79, 0.191, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1812, d5h8bB_, 0.7888, 2.92, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1813, p4nh1A_, 0.7888, 2.91, 0.186, 330, 258, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1814, d4i3zC_, 0.7888, 2.72, 0.264, 295, 254, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
1815, d4i3zA_, 0.7888, 2.72, 0.264, 295, 254, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
1816, p4fmqA_, 0.7888, 2.82, 0.199, 350, 256, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1817, d3tudA1, 0.7888, 2.47, 0.336, 255, 250, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
1818, p3nieA_, 0.7888, 3.09, 0.185, 369, 260, CRYSTAL STRUCTURE OF PF11_0147
1819, d3e8eB_, 0.7888, 2.64, 0.224, 337, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1820, d2xbaA_, 0.7888, 2.33, 0.304, 283, 247, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
1821, d2uzlA_, 0.7888, 2.70, 0.268, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1822, d2jkoA_, 0.7888, 2.41, 0.344, 256, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1823, d1xh6A_, 0.7888, 2.66, 0.224, 331, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1824, d1m2rA_, 0.7888, 2.91, 0.190, 327, 258, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1825, d5lvmA_, 0.7887, 2.75, 0.246, 283, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
1826, d4ks7A_, 0.7887, 2.83, 0.198, 286, 257, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1827, d4figB_, 0.7887, 2.69, 0.195, 292, 256, CATALYTIC DOMAIN OF HUMAN PAK4
1828, d4cnhA_, 0.7887, 2.43, 0.302, 285, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
1829, d3qlgA_, 0.7887, 2.20, 0.313, 259, 246, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1830, d3qlfB_, 0.7887, 2.13, 0.306, 258, 245, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
1831, d3e8cA_, 0.7887, 2.63, 0.224, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1832, d2xchA_, 0.7887, 2.55, 0.247, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1833, d2uw9A_, 0.7887, 2.67, 0.235, 316, 255, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1834, d1lpuA_, 0.7887, 2.93, 0.186, 327, 258, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1835, d1dayA_, 0.7887, 2.93, 0.182, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
1836, d5w5oM_, 0.7886, 2.16, 0.273, 276, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1837, d5nkaA_, 0.7886, 2.62, 0.336, 271, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
1838, d5mmrA_, 0.7886, 2.80, 0.191, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1839, d5cyiC1, 0.7886, 2.72, 0.264, 295, 254, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
1840, d4eklA_, 0.7886, 2.67, 0.235, 329, 255, AKT1 WITH GDC0068
1841, d4c3fA_, 0.7886, 2.41, 0.347, 257, 248, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
1842, d3warA_, 0.7886, 2.94, 0.186, 334, 258, CRYSTAL STRUCTURE OF HUMAN CK2A
1843, d3qcsA_, 0.7886, 2.50, 0.248, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
1844, d3qcqA_, 0.7886, 2.50, 0.248, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
1845, d3o2mB_, 0.7886, 2.73, 0.224, 358, 255, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1846, d3efkA_, 0.7886, 2.34, 0.314, 276, 245, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
1847, d3e8cC_, 0.7886, 2.63, 0.224, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1848, d2vnyA_, 0.7886, 2.60, 0.221, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1849, d1ymiA_, 0.7886, 2.78, 0.192, 334, 255,  
1850, d5i3rA_, 0.7885, 2.92, 0.217, 302, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
1851, d5ho7A_, 0.7885, 2.54, 0.247, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1852, d3uqgB_, 0.7885, 1.95, 0.306, 257, 242, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1853, d3ngaA_, 0.7885, 2.91, 0.190, 331, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1854, d3h9oA_, 0.7885, 2.51, 0.248, 275, 250, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
1855, d3e8cF_, 0.7885, 2.63, 0.224, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1856, d3bysA_, 0.7885, 2.13, 0.361, 255, 244, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
1857, d3bw5A_, 0.7885, 2.78, 0.192, 334, 255,  
1858, d2y0aA_, 0.7885, 2.89, 0.246, 300, 260, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
1859, d2uvzA_, 0.7885, 2.61, 0.221, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1860, d1fq1B_, 0.7885, 2.70, 0.260, 295, 254, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
1861, d3qgwA_, 0.7884, 1.95, 0.326, 244, 242, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1862, d3nunA_, 0.7884, 2.51, 0.248, 278, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
1863, d3gu7A1, 0.7884, 2.64, 0.244, 276, 254, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
1864, d3e8cE_, 0.7884, 2.63, 0.224, 336, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1865, d1jklA_, 0.7884, 2.68, 0.239, 280, 255, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
1866, d4otgA_, 0.7883, 2.63, 0.260, 322, 254, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1867, d4knbC_, 0.7883, 2.66, 0.333, 271, 249, C-MET IN COMPLEX WITH OSI LIGAND
1868, d4figA_, 0.7883, 2.70, 0.195, 292, 256, CATALYTIC DOMAIN OF HUMAN PAK4
1869, d3tt0B_, 0.7883, 2.41, 0.402, 272, 249, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
1870, d2jdoA_, 0.7883, 2.69, 0.235, 314, 255, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1871, d1yrpA_, 0.7883, 2.56, 0.241, 275, 253, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1872, d1ig1A_, 0.7883, 2.62, 0.240, 280, 254, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
1873, d5w5oD_, 0.7882, 2.12, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1874, d3rhkB_, 0.7882, 2.54, 0.304, 299, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
1875, d3q9xA_, 0.7882, 2.82, 0.187, 330, 257, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1876, d3nayA_, 0.7882, 2.56, 0.251, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
1877, d3kxnA_, 0.7882, 2.93, 0.190, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
1878, d3e8cD_, 0.7882, 2.64, 0.224, 344, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1879, d3e8cB_, 0.7882, 2.64, 0.224, 344, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1880, d3bwjA_, 0.7882, 2.62, 0.221, 338, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
1881, d1yrpB_, 0.7882, 2.56, 0.241, 275, 253, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1882, d1qmzC1, 0.7882, 2.73, 0.264, 295, 254, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1883, d5w5oJ_, 0.7881, 2.11, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1884, d5mo7A_, 0.7881, 2.80, 0.191, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1885, d5ku8B_, 0.7881, 2.92, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2
1886, d4w9wA_, 0.7881, 2.87, 0.218, 306, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
1887, d3rp0B_, 0.7881, 2.81, 0.191, 329, 257,  
1888, d3nayB_, 0.7881, 2.55, 0.251, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
1889, d2uzlC_, 0.7881, 2.72, 0.264, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1890, d2pe0A_, 0.7881, 2.46, 0.249, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
1891, d2g9xC2, 0.7881, 2.77, 0.268, 273, 254, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
1892, d1uu8A_, 0.7881, 2.56, 0.247, 277, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
1893, d5w5oK_, 0.7880, 2.12, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1894, d5mo8B_, 0.7880, 2.73, 0.192, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1895, d5cx9A_, 0.7880, 2.80, 0.191, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1896, d4qmzA_, 0.7880, 2.72, 0.259, 286, 255, MST3 IN COMPLEX WITH SUNITINIB
1897, d4qmyA_, 0.7880, 2.75, 0.270, 287, 256, MST3 IN COMPLEX WITH STAUROSPORINE
1898, d4p2kA_, 0.7880, 2.31, 0.335, 259, 248, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1899, d4a07A_, 0.7880, 2.72, 0.247, 282, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
1900, d3tz8B_, 0.7880, 2.29, 0.312, 263, 247, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
1901, d3pvgA_, 0.7880, 2.93, 0.186, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
1902, d3p0mA_, 0.7880, 2.66, 0.224, 335, 254, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1903, d3ddpC1, 0.7880, 2.72, 0.264, 297, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
1904, d2vo6A_, 0.7880, 2.61, 0.221, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1905, d2uw6A_, 0.7880, 2.63, 0.221, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1906, d2jedB1, 0.7880, 2.74, 0.247, 315, 255, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1907, d1oiyC1, 0.7880, 2.72, 0.268, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1908, d1m2pA_, 0.7880, 2.82, 0.191, 325, 257, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
1909, d5i3rB_, 0.7879, 2.99, 0.217, 302, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
1910, d4wnpD_, 0.7879, 2.82, 0.256, 272, 258, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1911, d3blhA1, 0.7879, 2.85, 0.210, 291, 257, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
1912, d1h1sC1, 0.7879, 2.71, 0.264, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
1913, d5mrdA_, 0.7878, 2.77, 0.246, 283, 256, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
1914, d4eopA1, 0.7878, 2.70, 0.268, 294, 254, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1915, d4anmA1, 0.7878, 2.94, 0.186, 327, 258, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
1916, d3rp0C_, 0.7878, 2.79, 0.191, 329, 257,  
1917, d3kxjA_, 0.7878, 2.93, 0.186, 326, 258,  
1918, d3efjA_, 0.7878, 2.36, 0.302, 276, 245, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
1919, d1tkiB_, 0.7878, 2.97, 0.165, 321, 260, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
1920, d1tkiA_, 0.7878, 2.97, 0.165, 321, 260, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
1921, d5mo7B_, 0.7877, 2.73, 0.192, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1922, d5j87C_, 0.7877, 2.41, 0.336, 261, 250, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1923, d5cu4A_, 0.7877, 2.66, 0.186, 327, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1924, p4jqeA_, 0.7877, 2.91, 0.182, 369, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
1925, d3qa0A_, 0.7877, 2.82, 0.187, 330, 257, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1926, d3lm0A1, 0.7877, 2.76, 0.209, 271, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
1927, d3juhA_, 0.7877, 2.79, 0.192, 334, 255, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1928, d3fl5A_, 0.7877, 2.82, 0.191, 324, 257, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
1929, d3e8eL_, 0.7877, 2.65, 0.224, 336, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1930, d3bhuC1, 0.7877, 2.75, 0.268, 269, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
1931, d3agmA_, 0.7877, 2.64, 0.224, 337, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1932, d2yakA_, 0.7877, 2.63, 0.247, 277, 255, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
1933, d2vo0A_, 0.7877, 2.67, 0.220, 340, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1934, d2uzeA_, 0.7877, 2.72, 0.264, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1935, d1qmzA1, 0.7877, 2.74, 0.264, 295, 254, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1936, d1jksA_, 0.7877, 2.66, 0.244, 280, 254, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1937, d1eh4B_, 0.7877, 3.28, 0.169, 293, 267, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
1938, d5modA_, 0.7876, 2.80, 0.184, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1939, d4wnpA_, 0.7876, 2.81, 0.260, 273, 258, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1940, d3oezA_, 0.7876, 2.35, 0.316, 261, 247, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
1941, p3o17B_, 0.7876, 2.80, 0.227, 357, 256, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1942, d3ha6A1, 0.7876, 2.72, 0.243, 262, 255, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
1943, d3ckxA_, 0.7876, 2.61, 0.273, 276, 253, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
1944, d1q8wA_, 0.7876, 2.64, 0.225, 334, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1945, d1om1A_, 0.7876, 2.83, 0.195, 325, 257, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
1946, d5mo5A_, 0.7875, 2.73, 0.188, 326, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1947, d5ct0A_, 0.7875, 2.80, 0.187, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1948, d4qmuA_, 0.7875, 2.73, 0.263, 286, 255, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
1949, d4kioD1, 0.7875, 1.72, 0.336, 240, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1950, d4aw0A_, 0.7875, 2.71, 0.239, 283, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
1951, d3nusA_, 0.7875, 2.52, 0.248, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
1952, p3be9A_, 0.7875, 2.94, 0.186, 327, 258, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1953, d1z5mA_, 0.7875, 2.47, 0.249, 275, 249, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
1954, d3qcxA_, 0.7874, 2.51, 0.248, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
1955, d3d5uA_, 0.7874, 2.72, 0.247, 288, 255, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
1956, d3ambA_, 0.7874, 2.66, 0.220, 340, 254, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1957, d2uzeC_, 0.7874, 2.73, 0.264, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1958, d2ptkA3, 0.7874, 2.14, 0.305, 259, 243, CHICKEN SRC TYROSINE KINASE
1959, d2dwbA_, 0.7874, 2.57, 0.258, 259, 252, AURORA-A KINASE COMPLEXED WITH AMPPNP
1960, d5w5oG_, 0.7873, 2.13, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1961, d5moeA_, 0.7873, 2.73, 0.192, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1962, d4m15A_, 0.7873, 2.52, 0.296, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
1963, d3v5jB1, 0.7873, 1.74, 0.329, 239, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
1964, d3juhB_, 0.7873, 2.80, 0.192, 334, 255, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1965, d2vo3A_, 0.7873, 2.63, 0.221, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1966, d5to8A_, 0.7872, 2.27, 0.354, 250, 246, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
1967, d5swhB_, 0.7872, 2.19, 0.314, 261, 245, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1968, p5omyA_, 0.7872, 2.89, 0.194, 332, 258, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1969, d5objA_, 0.7872, 2.63, 0.257, 260, 253, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
1970, d5kmoA1, 0.7872, 2.44, 0.396, 290, 250, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
1971, d5cu2A_, 0.7872, 2.81, 0.191, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1972, d4qmxA_, 0.7872, 2.74, 0.263, 287, 255, MST3 IN COMPLEX WITH SARACATINIB
1973, d4qmtA_, 0.7872, 2.72, 0.259, 284, 255, MST3 IN COMPLEX WITH HESPERADIN
1974, d4aw5A_, 0.7872, 2.43, 0.333, 261, 249, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
1975, d3o2mA_, 0.7872, 2.73, 0.224, 358, 255, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1976, d3hrcA_, 0.7872, 2.72, 0.247, 279, 255, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
1977, d3blqA_, 0.7872, 2.88, 0.210, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
1978, d2vnwA_, 0.7872, 2.62, 0.221, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1979, d1jkkA_, 0.7872, 2.65, 0.240, 277, 254, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
1980, d1h1qC1, 0.7872, 2.72, 0.264, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
1981, d5av1A_, 0.7871, 2.61, 0.249, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
1982, d4pf4A1, 0.7871, 2.68, 0.243, 277, 255, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
1983, d3svvB_, 0.7871, 1.99, 0.302, 257, 242, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1984, d3ehaA1, 0.7871, 2.61, 0.245, 275, 253, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
1985, d3e8eE_, 0.7871, 2.66, 0.224, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1986, d3d0eB_, 0.7871, 2.71, 0.235, 322, 255, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1987, d3d0eA_, 0.7871, 2.71, 0.235, 322, 255, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1988, d2zjwA_, 0.7871, 2.69, 0.182, 332, 253, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
1989, d1oguC1, 0.7871, 2.77, 0.268, 269, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1990, d5w5oL_, 0.7870, 2.13, 0.275, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1991, d5mmfA_, 0.7870, 2.82, 0.191, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1992, d5cu3A_, 0.7870, 2.74, 0.188, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1993, d4u44A_, 0.7870, 2.66, 0.246, 286, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1994, d3v5qB1, 0.7870, 2.29, 0.381, 262, 247, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
1995, d3at4A_, 0.7870, 2.81, 0.187, 331, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1996, d2wevA_, 0.7870, 2.81, 0.258, 296, 256, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1997, d1uwhA_, 0.7870, 2.55, 0.307, 264, 251, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
1998, d1f0qA_, 0.7870, 2.89, 0.187, 329, 257, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1999, d5nk0A_, 0.7869, 2.58, 0.345, 273, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
2000, d5cu0A_, 0.7869, 2.81, 0.187, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2001, d4r1yA_, 0.7869, 2.40, 0.318, 265, 245, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
2002, p4ib5C_, 0.7869, 2.93, 0.186, 332, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2003, d3nuuA_, 0.7869, 2.52, 0.248, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2004, d3gqlC_, 0.7869, 2.55, 0.401, 275, 252, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2005, d3dndA_, 0.7869, 2.66, 0.224, 334, 254, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2006, d2zoqB_, 0.7869, 3.06, 0.198, 351, 258, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
2007, d1zwsC_, 0.7869, 2.73, 0.237, 278, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2008, d5w5oE_, 0.7868, 2.13, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2009, d4twoA_, 0.7868, 2.57, 0.365, 278, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
2010, d4gv1A1, 0.7868, 2.72, 0.235, 328, 255, PKB ALPHA IN COMPLEX WITH AZD5363
2011, d3tnqB_, 0.7868, 2.61, 0.217, 331, 253, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2012, d3e87A_, 0.7868, 2.83, 0.234, 321, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2013, d2jdvA_, 0.7868, 2.68, 0.220, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
2014, p2h96B_, 0.7868, 2.73, 0.224, 357, 255, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2015, d1u5rA_, 0.7868, 2.78, 0.270, 308, 256, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2016, d1fvvA_, 0.7868, 2.76, 0.255, 298, 255, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2017, d5w5oH_, 0.7867, 2.14, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2018, d4fbxA_, 0.7867, 2.89, 0.190, 333, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
2019, d3uzpA_, 0.7867, 3.24, 0.182, 292, 264, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2020, d3rwpA_, 0.7867, 2.53, 0.248, 277, 250, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2021, d3f5gA1, 0.7867, 2.60, 0.245, 275, 253, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2022, d3e88B_, 0.7867, 2.72, 0.239, 319, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2023, d3e88A_, 0.7867, 2.72, 0.239, 319, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2024, d3e87B_, 0.7867, 2.83, 0.234, 321, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2025, d3be2A1, 0.7867, 2.35, 0.359, 285, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
2026, d3at2A_, 0.7867, 2.96, 0.186, 334, 258, CRYSTAL STRUCTURE OF CK2ALPHA
2027, d2x4fA_, 0.7867, 2.69, 0.199, 289, 256, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2028, d2uw0A_, 0.7867, 2.64, 0.221, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
2029, d1oi9C1, 0.7867, 2.76, 0.264, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2030, d5w5oI_, 0.7866, 2.15, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2031, d5uorB_, 0.7866, 2.52, 0.261, 262, 249, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2032, d5m4cA_, 0.7866, 2.73, 0.185, 329, 254, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2033, d4wnpC_, 0.7866, 2.79, 0.261, 271, 257, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2034, d4pmpA1, 0.7866, 2.59, 0.403, 276, 248, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
2035, d3kxhA_, 0.7866, 2.96, 0.190, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
2036, d3f66A_, 0.7866, 2.87, 0.332, 288, 253, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
2037, d2pe1A_, 0.7866, 2.47, 0.249, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2038, d1okzA_, 0.7866, 2.53, 0.248, 276, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2039, d5clpB_, 0.7865, 2.83, 0.191, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2040, d5av0A_, 0.7865, 2.61, 0.245, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2041, d4ra5A1, 0.7865, 2.74, 0.235, 331, 255, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2042, d4qmsA_, 0.7865, 2.76, 0.263, 283, 255, MST3 IN COMPLEX WITH DASATINIB
2043, d3qgyA1, 0.7865, 1.93, 0.328, 244, 241, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
2044, d3cd8A_, 0.7865, 2.74, 0.340, 278, 250, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
2045, d3bhtC1, 0.7865, 2.76, 0.268, 269, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2046, d5ctpB_, 0.7864, 2.82, 0.187, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2047, d3qd3A_, 0.7864, 2.55, 0.248, 278, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2048, d3nuyA_, 0.7864, 2.54, 0.248, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2049, d3d5wA_, 0.7864, 2.72, 0.235, 284, 255, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2050, d1zwsD_, 0.7864, 2.69, 0.238, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2051, d5v60A_, 0.7863, 2.86, 0.199, 347, 256, PHOSPHO-ERK2 BOUND TO AMP-PCP
2052, d5mpjA_, 0.7863, 2.82, 0.191, 326, 256, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2053, d5ax9C_, 0.7863, 2.53, 0.241, 282, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2054, d4ct2A_, 0.7863, 2.65, 0.245, 277, 253, HUMAN PDK1-PKCZETA KINASE CHIMERA
2055, d3rpsA_, 0.7863, 2.79, 0.184, 334, 255, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2056, d3miyA1, 0.7863, 1.51, 0.332, 237, 235, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
2057, d3eh9A1, 0.7863, 2.65, 0.240, 274, 254, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2058, d2qobA_, 0.7863, 2.65, 0.335, 279, 251, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
2059, d1urcC_, 0.7863, 2.80, 0.259, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2060, d1q8uA_, 0.7863, 2.66, 0.224, 341, 254, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
2061, d1bygA_, 0.7863, 1.97, 0.376, 246, 242, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
2062, d5uyjA1, 0.7862, 2.87, 0.244, 279, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2063, d5kmjA_, 0.7862, 2.65, 0.397, 300, 252, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
2064, d5dt4A_, 0.7862, 2.60, 0.258, 259, 252, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2065, d5drdA_, 0.7862, 2.62, 0.258, 259, 252, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2066, p3n9xB_, 0.7862, 3.03, 0.189, 362, 259, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
2067, d3iopA_, 0.7862, 2.55, 0.248, 275, 250, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2068, d3en5B_, 0.7862, 2.24, 0.317, 261, 246, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
2069, p2pvlA_, 0.7862, 2.94, 0.182, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2070, d2oxyA_, 0.7862, 2.84, 0.184, 327, 255, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2071, d2jdsA_, 0.7862, 2.63, 0.225, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
2072, d1zohA_, 0.7862, 2.84, 0.191, 326, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2073, d5n1vA_, 0.7861, 2.82, 0.184, 331, 255, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2074, p4ib5B_, 0.7861, 2.86, 0.191, 329, 257, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2075, d4bcoC1, 0.7861, 2.80, 0.268, 268, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2076, d3orzB_, 0.7861, 2.65, 0.250, 278, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2077, d5w5oC_, 0.7860, 2.15, 0.270, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2078, d5w5oA_, 0.7860, 2.15, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2079, d5t1hA_, 0.7860, 2.94, 0.194, 331, 258, CRYSTAL STRUCTURE OF CK2
2080, d5ar2A_, 0.7860, 2.19, 0.265, 277, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2081, d3wowA_, 0.7860, 2.96, 0.182, 334, 258, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
2082, d3orzD_, 0.7860, 2.66, 0.250, 278, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2083, d3f3uA_, 0.7860, 2.32, 0.316, 261, 247, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
2084, d3at3A_, 0.7860, 2.82, 0.187, 332, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
2085, d1h1rC1, 0.7860, 2.76, 0.264, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2086, d4q9zB_, 0.7859, 2.74, 0.220, 308, 255, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2087, d3zh8A_, 0.7859, 2.83, 0.195, 318, 257, A NOVEL SMALL MOLECULE APKC INHIBITOR
2088, p3nieB_, 0.7859, 3.01, 0.190, 367, 258, CRYSTAL STRUCTURE OF PF11_0147
2089, d1okuC_, 0.7859, 2.78, 0.263, 296, 255,  
2090, d5w5oF_, 0.7858, 2.16, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2091, d5ia5A_, 0.7858, 2.95, 0.340, 273, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
2092, d5hq0A1, 0.7858, 2.88, 0.260, 289, 254, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
2093, d5cvhA_, 0.7858, 2.82, 0.184, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA
2094, d5av3A_, 0.7858, 2.64, 0.244, 275, 254, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2095, d4zs0A_, 0.7858, 2.54, 0.259, 257, 251, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2096, d4y72A1, 0.7858, 2.88, 0.260, 289, 254, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
2097, d3zh8C_, 0.7858, 2.83, 0.195, 312, 257, A NOVEL SMALL MOLECULE APKC INHIBITOR
2098, d3f66B_, 0.7858, 2.63, 0.333, 269, 249, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
2099, d2uzbA_, 0.7858, 2.76, 0.268, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2100, d3bhyA1, 0.7857, 2.49, 0.235, 267, 251, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2101, d2xckA_, 0.7857, 2.62, 0.243, 275, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2102, d1zwsB_, 0.7857, 2.74, 0.233, 278, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2103, p5otyA_, 0.7856, 2.82, 0.195, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
2104, d5j5sA_, 0.7856, 2.16, 0.314, 258, 245, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
2105, d5auvA_, 0.7856, 2.63, 0.245, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2106, d4p5qA_, 0.7856, 2.54, 0.359, 275, 251, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
2107, d4appA1, 0.7856, 2.70, 0.188, 290, 255, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
2108, d3ionA_, 0.7856, 2.51, 0.249, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
2109, d2x0gA_, 0.7856, 2.94, 0.220, 318, 259, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2110, d2wmbC1, 0.7856, 2.65, 0.270, 265, 252, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2111, d5w5oB_, 0.7855, 2.16, 0.266, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2112, d5t3qA1, 0.7855, 2.44, 0.321, 277, 246, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
2113, d5t18A1, 0.7855, 2.36, 0.335, 259, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
2114, d4f0iA_, 0.7855, 2.75, 0.398, 284, 251, CRYSTAL STRUCTURE OF APO TRKA
2115, d3a7iA_, 0.7855, 2.77, 0.285, 286, 256, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2116, d2c5vC_, 0.7855, 2.78, 0.263, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2117, d2c5pA_, 0.7855, 2.78, 0.263, 296, 255,  
2118, d1zwsH_, 0.7855, 2.71, 0.238, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2119, d1ol1C_, 0.7855, 2.78, 0.263, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2120, d4ypsA1, 0.7854, 2.38, 0.390, 275, 246, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
2121, d3zh8B_, 0.7854, 2.84, 0.195, 317, 257, A NOVEL SMALL MOLECULE APKC INHIBITOR
2122, d3of0A_, 0.7854, 2.25, 0.313, 260, 246, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
2123, d3e8dB_, 0.7854, 2.73, 0.239, 317, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2124, d3cqwA_, 0.7854, 2.75, 0.235, 318, 255, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2125, p2pvmA_, 0.7854, 2.95, 0.186, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2126, d2clqA_, 0.7854, 2.56, 0.260, 263, 250, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2127, d2c5vA_, 0.7854, 2.78, 0.263, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2128, d5hkmA_, 0.7853, 2.51, 0.249, 272, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2129, d4m14A_, 0.7853, 2.55, 0.296, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
2130, d4cfnC1, 0.7853, 2.74, 0.268, 293, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2131, d3wikA_, 0.7853, 2.96, 0.182, 334, 258, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
2132, d3q9wA_, 0.7853, 2.83, 0.187, 328, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
2133, d3oezB_, 0.7853, 2.30, 0.313, 261, 246, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
2134, d3ocbB_, 0.7853, 2.74, 0.235, 319, 255, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2135, d3lm5A1, 0.7853, 2.84, 0.209, 267, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2136, d3e8dA_, 0.7853, 2.73, 0.239, 315, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2137, d2uzbC_, 0.7853, 2.71, 0.269, 292, 253, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2138, d5mpjB_, 0.7852, 2.76, 0.192, 324, 255, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2139, d5j79B_, 0.7852, 2.32, 0.268, 277, 246, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2140, d3wilA_, 0.7852, 2.83, 0.184, 331, 256, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
2141, d3mb6A_, 0.7852, 2.84, 0.191, 329, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
2142, d1zoeA_, 0.7852, 2.86, 0.191, 325, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2143, d5cu0B_, 0.7851, 2.84, 0.191, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2144, d4twcA_, 0.7851, 3.28, 0.200, 293, 265, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2145, d4qnaA_, 0.7851, 2.79, 0.270, 284, 256, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2146, d4i4eA_, 0.7851, 2.37, 0.339, 254, 248, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
2147, d3f3uB_, 0.7851, 2.26, 0.314, 259, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
2148, d3ddpA1, 0.7851, 2.74, 0.264, 296, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2149, d2xzsA_, 0.7851, 2.91, 0.242, 301, 260, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2150, d2iw8A1, 0.7851, 2.77, 0.260, 296, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2151, d5t1hB_, 0.7850, 2.96, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2
2152, d5mohA_, 0.7850, 2.80, 0.187, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
2153, d5av2A_, 0.7850, 2.68, 0.248, 275, 254, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2154, d4krdA_, 0.7850, 2.91, 0.238, 294, 256, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
2155, d3w8lB_, 0.7850, 2.83, 0.187, 326, 256, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
2156, d3qkmA_, 0.7850, 2.73, 0.235, 329, 255, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
2157, d3f5pT1, 0.7850, 2.98, 0.291, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2158, d3e8eI_, 0.7850, 2.69, 0.224, 345, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2159, d2c5nA_, 0.7850, 2.77, 0.263, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2160, p5v62A_, 0.7849, 2.90, 0.199, 349, 256, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
2161, d5sysA_, 0.7849, 2.25, 0.306, 258, 245, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2162, d5nqcA_, 0.7849, 2.82, 0.184, 331, 255, CK2ALPHA IN COMPLEX WITH NMR154
2163, p5n9nA_, 0.7849, 2.82, 0.176, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
2164, p5n9lA_, 0.7849, 2.84, 0.184, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
2165, d5moeB_, 0.7849, 2.71, 0.193, 323, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2166, d5m56B_, 0.7849, 2.96, 0.186, 328, 258, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2167, d5auxA_, 0.7849, 2.68, 0.244, 275, 254, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2168, d4ra4A_, 0.7849, 2.65, 0.197, 317, 254, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2169, d3g6gA_, 0.7849, 2.40, 0.310, 264, 248, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
2170, d3efjB_, 0.7849, 2.34, 0.320, 275, 244, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
2171, d3ce3A_, 0.7849, 2.99, 0.315, 293, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
2172, d4rllA_, 0.7848, 2.85, 0.187, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
2173, d3bqcA_, 0.7848, 2.84, 0.187, 328, 256, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2174, d2fysA_, 0.7848, 2.91, 0.202, 348, 258, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
2175, d2c5oC_, 0.7848, 2.80, 0.259, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2176, d2c5oA_, 0.7848, 2.80, 0.259, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2177, d1okuA_, 0.7848, 2.87, 0.258, 296, 256,  
2178, d5x17A_, 0.7847, 3.24, 0.201, 290, 264, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2179, p5n9kA_, 0.7847, 2.85, 0.184, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
2180, d4qmnA_, 0.7847, 2.80, 0.263, 283, 255, MST3 IN COMPLEX WITH BOSUTINIB
2181, d4h1mA_, 0.7847, 2.62, 0.347, 256, 251, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
2182, d5dosA_, 0.7846, 2.62, 0.258, 259, 252, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2183, d5cx9B_, 0.7846, 2.77, 0.192, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
2184, d5cu2B_, 0.7846, 2.77, 0.188, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
2185, d5auwA_, 0.7846, 2.57, 0.246, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2186, d4qnyA_, 0.7846, 2.76, 0.213, 333, 254, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2187, d4qmwA_, 0.7846, 2.80, 0.255, 286, 255, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2188, d4crsA1, 0.7846, 2.60, 0.251, 329, 251, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
2189, d3rpsB_, 0.7846, 2.91, 0.187, 334, 256, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2190, d3qklA_, 0.7846, 2.75, 0.235, 317, 255, SPIROCHROMANE AKT INHIBITORS
2191, d3f5uA1, 0.7846, 2.69, 0.240, 275, 254, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2192, d2c5pC_, 0.7846, 2.83, 0.263, 296, 255,  
2193, d5ia4A_, 0.7845, 2.72, 0.341, 269, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
2194, d5auyA_, 0.7845, 2.62, 0.245, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2195, d3ofmA_, 0.7845, 2.85, 0.187, 325, 257, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
2196, d2rkpA_, 0.7845, 2.82, 0.184, 334, 255,  
2197, d5mo6A_, 0.7844, 2.77, 0.188, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2198, d3mvhA_, 0.7844, 2.72, 0.236, 311, 254, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2199, d1yomA_, 0.7844, 2.13, 0.311, 260, 244, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2200, d1mruB_, 0.7844, 2.38, 0.219, 271, 247, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2201, d5swhA_, 0.7843, 2.23, 0.314, 258, 245, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
2202, d5mp8A_, 0.7843, 2.78, 0.184, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2203, d4nusA_, 0.7843, 2.94, 0.230, 301, 257, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2204, p4h3qA_, 0.7843, 2.88, 0.198, 352, 257, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2205, d4eosA1, 0.7843, 2.70, 0.265, 293, 253, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2206, d3q9yA_, 0.7843, 2.85, 0.187, 327, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
2207, d2pe2A_, 0.7843, 2.52, 0.249, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2208, d1uu9A_, 0.7843, 2.58, 0.248, 276, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2209, d1jktA_, 0.7843, 2.75, 0.239, 276, 255, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2210, d5ia0A_, 0.7842, 2.39, 0.339, 263, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2211, d5cvhB_, 0.7842, 2.77, 0.188, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA
2212, d5av4A_, 0.7842, 2.59, 0.246, 274, 252, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2213, d4hnfB_, 0.7842, 3.18, 0.205, 290, 264, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2214, d2yn8B_, 0.7842, 2.37, 0.328, 260, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2215, d2whaC_, 0.7842, 2.82, 0.263, 296, 255,  
2216, d2e2bB1, 0.7842, 2.14, 0.388, 258, 242, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
2217, d2b9iA_, 0.7842, 2.60, 0.232, 338, 250, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
2218, d1h1rA1, 0.7842, 2.77, 0.264, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2219, d3cpbB_, 0.7841, 1.82, 0.366, 263, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
2220, d3axwA_, 0.7841, 2.87, 0.183, 329, 257, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
2221, d3a7jA_, 0.7841, 2.78, 0.251, 286, 255, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2222, p2pvkA_, 0.7841, 2.98, 0.186, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2223, d5mmrB_, 0.7840, 2.78, 0.192, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
2224, d4ybjA_, 0.7840, 2.11, 0.313, 255, 243, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2225, d4kbkB_, 0.7840, 3.16, 0.183, 289, 263, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2226, p4gubA_, 0.7840, 2.73, 0.176, 329, 255, CASEIN KINASE II BOUND TO INHIBITOR
2227, d2iw9C2, 0.7840, 2.69, 0.266, 267, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2228, d5motA_, 0.7839, 2.82, 0.184, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
2229, d5cs6A_, 0.7839, 2.86, 0.191, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
2230, d4knbA_, 0.7839, 2.76, 0.328, 273, 250, C-MET IN COMPLEX WITH OSI LIGAND
2231, d4kioA1, 0.7839, 1.68, 0.331, 238, 236, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2232, d3qcyA_, 0.7839, 2.52, 0.249, 275, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2233, d3o7lB_, 0.7839, 2.65, 0.203, 326, 251, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2234, d3h30A_, 0.7839, 2.83, 0.184, 333, 255, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2235, d3g6hB_, 0.7839, 2.29, 0.321, 259, 246, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
2236, d2x1nC_, 0.7839, 2.83, 0.263, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2237, d2cciC2, 0.7839, 2.81, 0.264, 295, 254, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2238, d1unlA_, 0.7839, 2.86, 0.227, 292, 255, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
2239, d1ckjB_, 0.7839, 3.22, 0.186, 293, 264, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2240, d6bleA1, 0.7838, 2.84, 0.245, 263, 253, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2241, d5nhjA_, 0.7838, 3.10, 0.205, 345, 259, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2242, d5mmfB_, 0.7838, 2.78, 0.192, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
2243, d5cyiA1, 0.7838, 2.77, 0.260, 297, 254, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2244, d5ct0B_, 0.7838, 2.78, 0.192, 326, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
2245, d4i6fA_, 0.7838, 3.18, 0.201, 285, 259, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2246, d3v5lA1, 0.7838, 1.66, 0.335, 238, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2247, d2wevC_, 0.7838, 2.83, 0.263, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2248, p2pvjA_, 0.7838, 2.99, 0.186, 326, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2249, d1urcA_, 0.7838, 2.82, 0.259, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2250, d1k9aD3, 0.7838, 2.67, 0.333, 268, 249, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
2251, d6bqpA1, 0.7837, 2.82, 0.241, 262, 253, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2252, d4eevA_, 0.7837, 2.65, 0.328, 283, 250, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
2253, d3pe2A_, 0.7837, 2.82, 0.187, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
2254, d3pe1A_, 0.7837, 2.82, 0.187, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
2255, d2qokA_, 0.7837, 2.65, 0.347, 281, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
2256, d2cchA2, 0.7837, 2.81, 0.264, 295, 254, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2257, d4uy9A_, 0.7836, 2.86, 0.335, 313, 254, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2258, d4qmlA_, 0.7836, 2.79, 0.270, 280, 256, MST3 IN COMPLEX WITH AMP-PNP
2259, d3lvpD_, 0.7836, 2.47, 0.294, 282, 248, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2260, p3e3bX_, 0.7836, 2.76, 0.184, 334, 255, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
2261, d2iw6C2, 0.7836, 2.80, 0.268, 294, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2262, d5d7aA_, 0.7835, 2.66, 0.243, 289, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2263, d5bpyB1, 0.7835, 2.28, 0.354, 246, 246, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
2264, d4o0tA_, 0.7835, 2.85, 0.214, 292, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2265, d4eoiA1, 0.7835, 2.64, 0.266, 293, 252, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2266, d3qkkA_, 0.7835, 2.76, 0.235, 326, 255, SPIROCHROMANE AKT INHIBITORS
2267, p3o17A_, 0.7835, 2.85, 0.227, 357, 256, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2268, d3c13A_, 0.7835, 2.83, 0.176, 328, 256, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2269, p5v61A_, 0.7834, 2.90, 0.199, 348, 256, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
2270, d3h30B_, 0.7834, 2.83, 0.184, 333, 255, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2271, p5otzA_, 0.7833, 2.71, 0.182, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
2272, d5n1vB_, 0.7833, 2.98, 0.182, 331, 258, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2273, d5jkgA_, 0.7833, 2.25, 0.370, 266, 246, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
2274, d4bcoA1, 0.7833, 2.78, 0.264, 297, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2275, d3uytB_, 0.7833, 3.24, 0.195, 286, 262, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2276, d3dpkA_, 0.7833, 2.33, 0.348, 279, 244, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
2277, d2qurA_, 0.7833, 2.72, 0.217, 338, 254, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2278, d2oxyB_, 0.7833, 3.00, 0.190, 327, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2279, d1zwsG_, 0.7833, 2.78, 0.233, 278, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2280, d1oiuC1, 0.7833, 2.68, 0.271, 264, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2281, d5uy6A1, 0.7832, 2.88, 0.245, 280, 253, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2282, d5mo6B_, 0.7832, 2.79, 0.192, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2283, d5b0xA_, 0.7832, 2.90, 0.187, 329, 257, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
2284, d4nksA_, 0.7832, 2.42, 0.387, 265, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2285, d3orzA_, 0.7832, 2.66, 0.251, 276, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2286, d2whbC_, 0.7832, 2.83, 0.259, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2287, d2whbA_, 0.7832, 2.90, 0.254, 296, 256, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2288, d1h1sA1, 0.7832, 2.78, 0.268, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2289, d5w5oP_, 0.7831, 2.22, 0.270, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2290, d4i5pA_, 0.7831, 2.96, 0.203, 284, 256, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2291, d4bcnC1, 0.7831, 2.79, 0.264, 293, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2292, d3orzC_, 0.7831, 2.66, 0.251, 276, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2293, d3o0gA_, 0.7831, 2.87, 0.231, 289, 255, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
2294, d2pl0A_, 0.7831, 2.53, 0.364, 268, 247, LCK BOUND TO IMATINIB
2295, d2henB1, 0.7831, 2.44, 0.328, 258, 247, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
2296, p2gmxB_, 0.7831, 2.87, 0.227, 357, 256, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2297, d2c5xC_, 0.7831, 2.82, 0.259, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2298, d5xvuA_, 0.7830, 2.72, 0.190, 321, 252, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2299, d5mowA1, 0.7830, 2.78, 0.184, 326, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2300, d4lueA3, 0.7830, 2.20, 0.364, 261, 242, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
2301, d3ms9A1, 0.7830, 2.14, 0.388, 261, 242, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
2302, d3f3vB_, 0.7830, 2.33, 0.309, 262, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2303, d1yomB_, 0.7830, 2.21, 0.314, 261, 245, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2304, d1h1qA1, 0.7830, 2.78, 0.264, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2305, d5xvuB_, 0.7829, 2.83, 0.186, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2306, d4ra5B_, 0.7829, 2.89, 0.219, 310, 256, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2307, d4dhfA_, 0.7829, 2.56, 0.255, 258, 251, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2308, d3dogA1, 0.7829, 2.81, 0.264, 296, 254, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2309, d3db6A_, 0.7829, 2.78, 0.247, 287, 255, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2310, d2wxvA1, 0.7829, 2.83, 0.255, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2311, d1h26C1, 0.7829, 2.72, 0.266, 266, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2312, d5cspA_, 0.7828, 2.83, 0.184, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2313, d5auuA_, 0.7828, 2.61, 0.242, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2314, d4dhfB_, 0.7828, 2.56, 0.255, 258, 251, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2315, d3r0tA_, 0.7828, 2.84, 0.187, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
2316, d3bhvC1, 0.7828, 2.80, 0.268, 269, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2317, d2v22C_, 0.7828, 2.85, 0.263, 296, 255, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2318, d2r7bA_, 0.7828, 2.54, 0.249, 274, 249, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2319, d1zwsF_, 0.7828, 2.79, 0.233, 278, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2320, d5u6iA_, 0.7827, 3.08, 0.202, 339, 258, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
2321, d4qteA_, 0.7827, 3.13, 0.205, 348, 259, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
2322, d4ludA3, 0.7827, 2.28, 0.376, 261, 242, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2323, d4i6hA_, 0.7827, 3.12, 0.198, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2324, d1jstC_, 0.7827, 2.80, 0.268, 297, 254, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2325, d1gy3C_, 0.7827, 2.80, 0.264, 295, 254, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2326, d5kmkA1, 0.7826, 2.65, 0.394, 302, 251, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
2327, d4iz5D_, 0.7826, 2.91, 0.199, 347, 256, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2328, d4iz5C_, 0.7826, 2.91, 0.199, 347, 256, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2329, d4i6bA_, 0.7826, 3.14, 0.202, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2330, d2c5xA_, 0.7826, 2.90, 0.250, 296, 256, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2331, d5w4wC_, 0.7825, 3.21, 0.190, 284, 263, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2332, d5kmiA_, 0.7825, 2.64, 0.394, 300, 251, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
2333, d5cquA_, 0.7825, 2.87, 0.187, 328, 256, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2334, d4wunB_, 0.7825, 2.31, 0.397, 268, 247, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
2335, d4iz5B_, 0.7825, 2.91, 0.199, 347, 256, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2336, d4iz5A_, 0.7825, 2.92, 0.199, 347, 256, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2337, d2iw8C2, 0.7825, 2.68, 0.267, 264, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2338, d1oi9A1, 0.7825, 2.81, 0.264, 294, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2339, d1j91B_, 0.7825, 3.06, 0.186, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2340, d5u94A_, 0.7824, 2.39, 0.219, 263, 247, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2341, d5csvA_, 0.7824, 2.83, 0.184, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
2342, d4bcpA1, 0.7824, 2.88, 0.259, 297, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2343, d3ow4A_, 0.7824, 2.89, 0.234, 317, 256, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2344, d3mssA1, 0.7824, 2.15, 0.388, 260, 242, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2345, d3f5pI1, 0.7824, 3.02, 0.291, 293, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2346, d3f5pA1, 0.7824, 3.03, 0.291, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2347, d3dogC1, 0.7824, 2.67, 0.267, 266, 251, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2348, d2g9xA2, 0.7824, 2.81, 0.264, 297, 254, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2349, p2g01B_, 0.7824, 2.87, 0.230, 356, 256, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
2350, d5modB_, 0.7823, 2.80, 0.192, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2351, d5bvnA_, 0.7823, 2.81, 0.323, 278, 254, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2352, d5auzA_, 0.7823, 2.61, 0.242, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2353, d4eojC1, 0.7823, 2.85, 0.268, 278, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2354, d4cfwC1, 0.7823, 2.81, 0.264, 295, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2355, d4bxbA_, 0.7823, 2.87, 0.187, 328, 256,  
2356, d3f3wA_, 0.7823, 2.34, 0.313, 261, 246, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2357, d2whaA_, 0.7823, 2.86, 0.263, 296, 255,  
2358, d1rjbA_, 0.7823, 2.42, 0.359, 298, 245, CRYSTAL STRUCTURE OF FLT3
2359, d1ol2C_, 0.7823, 2.84, 0.263, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2360, d5l6oA_, 0.7822, 2.52, 0.329, 267, 246, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
2361, d3ocbA_, 0.7822, 2.78, 0.235, 315, 255, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2362, d3f5pD1, 0.7822, 3.04, 0.291, 296, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2363, d3bhuA1, 0.7822, 2.79, 0.264, 295, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2364, d2jgzA_, 0.7822, 2.77, 0.264, 288, 254, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2365, d2henD1, 0.7822, 2.40, 0.321, 258, 246, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
2366, d2c5nC_, 0.7822, 2.85, 0.263, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2367, d1j91A_, 0.7822, 3.04, 0.186, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2368, p5owlA_, 0.7821, 2.99, 0.191, 331, 257, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2369, d5if1A_, 0.7821, 2.83, 0.255, 298, 255, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2370, d4ybjB_, 0.7821, 2.02, 0.315, 253, 241, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2371, d3tl8D_, 0.7821, 2.69, 0.265, 306, 253, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2372, d3ddqC1, 0.7821, 2.69, 0.271, 265, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2373, d3d7tA_, 0.7821, 2.14, 0.362, 249, 243, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
2374, d2r7iD_, 0.7821, 2.77, 0.185, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2375, d5lmkC1, 0.7820, 2.60, 0.272, 264, 250, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2376, d4dggB_, 0.7820, 2.28, 0.320, 259, 244, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
2377, d4c2vA_, 0.7820, 2.74, 0.216, 270, 255, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2378, d3qd4A_, 0.7820, 2.51, 0.250, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2379, d3miyB1, 0.7820, 1.65, 0.331, 238, 236, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
2380, d3fwqB_, 0.7820, 2.87, 0.184, 334, 255, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2381, d2x1nA_, 0.7820, 2.88, 0.259, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2382, d2iw6A1, 0.7820, 2.74, 0.265, 291, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2383, d5nhoA_, 0.7819, 3.08, 0.202, 343, 258, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2384, d5nhhA_, 0.7819, 3.16, 0.205, 348, 259, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2385, d5f9eB_, 0.7819, 2.86, 0.207, 293, 256, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2386, d2x4zA1, 0.7819, 2.84, 0.180, 289, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2387, d1wvyA_, 0.7819, 2.65, 0.249, 273, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2388, d1oiuA1, 0.7819, 2.73, 0.265, 293, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2389, d5xvuC_, 0.7818, 2.74, 0.190, 321, 252, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2390, d3f5pM1, 0.7818, 3.03, 0.291, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2391, d3f5pB1, 0.7818, 3.04, 0.291, 297, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2392, d2c6tC_, 0.7818, 2.81, 0.264, 295, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2393, d2c5tC_, 0.7818, 2.86, 0.263, 296, 255,  
2394, d1gy3A_, 0.7818, 2.82, 0.268, 295, 254, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2395, d5lpvA_, 0.7817, 2.67, 0.248, 282, 250, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
2396, d4qnyB_, 0.7817, 2.97, 0.205, 339, 258, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2397, d4pdoB_, 0.7817, 2.01, 0.344, 261, 241, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2398, d4pdoA_, 0.7817, 2.01, 0.344, 261, 241, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2399, d4eorC1, 0.7817, 2.80, 0.265, 269, 253, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2400, d3mssC1, 0.7817, 2.16, 0.388, 260, 242, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2401, d3i5nA_, 0.7817, 2.96, 0.331, 280, 251, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
2402, d3f5pK1, 0.7817, 2.99, 0.292, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2403, d3f3vA_, 0.7817, 2.36, 0.313, 261, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2404, d5nkiA_, 0.7816, 2.40, 0.341, 268, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
2405, d5cshA_, 0.7816, 2.81, 0.192, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
2406, d3f5pG1, 0.7816, 3.05, 0.291, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2407, d3f5pC1, 0.7816, 3.04, 0.291, 300, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2408, d3el7A_, 0.7816, 2.03, 0.311, 254, 241, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
2409, d3d14A1, 0.7816, 2.58, 0.243, 257, 251, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
2410, d3cjfA_, 0.7816, 2.46, 0.359, 276, 248, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
2411, d1wvwA_, 0.7816, 2.65, 0.248, 275, 254, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2412, d5te0A_, 0.7815, 3.02, 0.198, 316, 253, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2413, d5mo5B_, 0.7815, 2.81, 0.192, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2414, d5kmmA1, 0.7815, 2.66, 0.394, 300, 251, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
2415, d3ow4B_, 0.7815, 2.80, 0.235, 317, 255, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2416, d2uueC_, 0.7815, 2.87, 0.263, 296, 255, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2417, d2r7iB_, 0.7815, 2.78, 0.185, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2418, p2g01A_, 0.7815, 3.01, 0.226, 355, 257, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
2419, d5nevA1, 0.7814, 2.81, 0.264, 294, 254, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2420, d5lmkA1, 0.7814, 2.82, 0.268, 295, 254, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2421, d5autA_, 0.7814, 2.60, 0.242, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2422, d4bcmC1, 0.7814, 2.82, 0.272, 293, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2423, d3mssB1, 0.7814, 2.20, 0.388, 260, 242, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2424, p2no3B_, 0.7814, 2.90, 0.227, 357, 256, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
2425, p2h96A_, 0.7814, 2.89, 0.223, 358, 256, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2426, d2c4gA2, 0.7814, 2.87, 0.255, 297, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2427, d1zwsA_, 0.7814, 2.81, 0.233, 278, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2428, d4eooC1, 0.7813, 2.85, 0.268, 295, 254, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2429, d4eomC1, 0.7813, 2.87, 0.264, 271, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2430, d3otuA_, 0.7813, 2.68, 0.246, 276, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2431, d3f5pH1, 0.7813, 3.06, 0.291, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2432, d3efkB_, 0.7813, 2.28, 0.322, 272, 242, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
2433, d3dj7A_, 0.7813, 2.60, 0.239, 257, 251, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
2434, d2nruA_, 0.7813, 2.96, 0.274, 293, 252, CRYSTAL STRUCTURE OF IRAK-4
2435, d1oiyA1, 0.7813, 2.73, 0.265, 292, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2436, d5x17B_, 0.7812, 3.18, 0.187, 289, 262, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2437, d3q53A_, 0.7812, 2.82, 0.215, 291, 256, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
2438, d3f5pS1, 0.7812, 3.04, 0.291, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2439, d2welA_, 0.7812, 2.98, 0.198, 304, 258, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
2440, d1vywA1, 0.7812, 2.85, 0.255, 298, 255, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2441, d1szmA_, 0.7812, 2.69, 0.225, 317, 253, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2442, p5os8A_, 0.7811, 2.88, 0.195, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
2443, d5mowB_, 0.7811, 2.81, 0.188, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2444, d3q04A_, 0.7811, 2.88, 0.187, 328, 256, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
2445, d3mssD1, 0.7811, 2.21, 0.388, 260, 242, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2446, d2gphA_, 0.7811, 2.81, 0.200, 345, 255, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
2447, d1oguA1, 0.7811, 2.74, 0.265, 293, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2448, d1koaA2, 0.7811, 3.09, 0.199, 350, 261, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2449, d4oa2A_, 0.7810, 2.70, 0.244, 280, 250,  
2450, d4cfuC1, 0.7810, 2.85, 0.264, 269, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2451, d4aojB_, 0.7810, 2.15, 0.404, 258, 245, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
2452, d3u4uA_, 0.7810, 2.87, 0.187, 327, 256, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
2453, d3fzsA_, 0.7810, 2.56, 0.345, 254, 249, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
2454, d3ccnA_, 0.7810, 2.63, 0.340, 275, 247, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
2455, d2gsfA_, 0.7810, 2.62, 0.337, 281, 249, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
2456, d1yolB_, 0.7810, 2.04, 0.311, 253, 241, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2457, d1na7A_, 0.7810, 2.92, 0.191, 326, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
2458, d5nevC1, 0.7809, 2.82, 0.264, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2459, d5m4fA_, 0.7809, 2.83, 0.185, 330, 254, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2460, d4wnpB_, 0.7809, 2.91, 0.256, 272, 258, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2461, d3bhtA2, 0.7809, 2.81, 0.264, 295, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2462, d2x6dA_, 0.7809, 2.71, 0.258, 255, 252, AURORA-A BOUND TO AN INHIBITOR
2463, p2no3A_, 0.7809, 2.90, 0.227, 357, 256, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
2464, d4cfmA1, 0.7808, 2.82, 0.264, 295, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2465, d3uysC_, 0.7808, 3.24, 0.186, 286, 263, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2466, d3f5pL1, 0.7808, 3.00, 0.292, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2467, d2v22A_, 0.7808, 2.92, 0.254, 296, 256, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2468, d5dt0A_, 0.7807, 2.72, 0.258, 259, 252, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
2469, d4oa9A_, 0.7807, 2.79, 0.247, 280, 251,  
2470, d4kwpA_, 0.7807, 2.87, 0.180, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
2471, d3ddqA1, 0.7807, 2.83, 0.268, 295, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2472, d3c1xA_, 0.7807, 2.71, 0.325, 290, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
2473, d2pvrA_, 0.7807, 2.87, 0.184, 328, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
2474, d3owkA_, 0.7806, 2.80, 0.188, 330, 255, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2475, d3f3zA_, 0.7806, 2.86, 0.183, 271, 257, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
2476, d2iw9A2, 0.7806, 2.69, 0.258, 292, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2477, d1csnA_, 0.7806, 3.32, 0.169, 293, 266, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
2478, d5ctpA_, 0.7805, 2.83, 0.192, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2479, d3tz9A_, 0.7805, 2.37, 0.313, 261, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2480, d3owlA_, 0.7805, 2.83, 0.188, 330, 255, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2481, d2xzsB_, 0.7805, 2.97, 0.224, 293, 259, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2482, d2rfnA_, 0.7805, 2.21, 0.315, 268, 241, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
2483, d2zoqA_, 0.7804, 3.08, 0.202, 351, 257, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
2484, d1okwC_, 0.7804, 2.88, 0.263, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
2485, d5movA_, 0.7803, 2.81, 0.184, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
2486, d5j7bA_, 0.7803, 2.35, 0.264, 277, 246, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2487, d5bvoA_, 0.7803, 2.72, 0.368, 276, 253, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2488, d4qtbB_, 0.7803, 2.98, 0.196, 348, 255, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
2489, d4q9sA_, 0.7803, 2.34, 0.336, 252, 247, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
2490, d4dawA_, 0.7803, 2.83, 0.215, 293, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2491, d4bicA_, 0.7803, 2.53, 0.263, 260, 247, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2492, d3tz8A_, 0.7803, 2.39, 0.313, 261, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
2493, p2gmxA_, 0.7803, 2.92, 0.227, 357, 256, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2494, p6gihA_, 0.7802, 2.76, 0.190, 324, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
2495, d5v19B_, 0.7802, 2.52, 0.259, 260, 247, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2496, d5j5sB_, 0.7802, 2.15, 0.313, 258, 243, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
2497, d4kioB1, 0.7802, 1.67, 0.332, 237, 235, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2498, d2fumB_, 0.7802, 2.38, 0.215, 262, 246, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2499, d2cciA2, 0.7802, 2.89, 0.263, 295, 255, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2500, d2b9jA_, 0.7802, 2.62, 0.233, 337, 249, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
2501, d4oacA_, 0.7801, 2.81, 0.247, 280, 251,  
2502, d3f5pF1, 0.7801, 3.06, 0.291, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2503, d2wihA1, 0.7801, 2.85, 0.255, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2504, d2bujA1, 0.7801, 3.17, 0.216, 283, 259, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2505, d2b9hA_, 0.7801, 2.63, 0.233, 337, 249, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
2506, d1mqbA_, 0.7801, 2.60, 0.339, 263, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
2507, d6bkuA1, 0.7800, 2.87, 0.246, 264, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2508, p3n9xA_, 0.7800, 3.01, 0.195, 374, 257, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
2509, d1e9hC1, 0.7800, 2.85, 0.268, 295, 254, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2510, d5cvgA_, 0.7799, 2.69, 0.183, 326, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
2511, d4u43A_, 0.7799, 2.76, 0.243, 287, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2512, d4cxaA_, 0.7799, 2.96, 0.249, 329, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
2513, d3v8tA1, 0.7799, 1.63, 0.333, 236, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
2514, d3my5C1, 0.7799, 2.76, 0.266, 265, 252, CDK2/CYCLINA IN COMPLEX WITH DRB
2515, d3mb7A_, 0.7799, 2.83, 0.188, 330, 255, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
2516, d3tnwC_, 0.7798, 2.75, 0.262, 291, 252, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2517, d3qriA1, 0.7798, 2.67, 0.391, 270, 248, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
2518, d2rfnB_, 0.7798, 2.22, 0.315, 269, 241, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
2519, d2fumA_, 0.7798, 2.46, 0.215, 263, 247, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2520, d3a8xA1, 0.7797, 2.78, 0.199, 331, 256, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2521, d2wfyC_, 0.7797, 2.89, 0.259, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2522, d2uueA_, 0.7797, 2.93, 0.254, 296, 256, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2523, d2i0eA_, 0.7797, 2.71, 0.242, 326, 252, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2524, d5p9lA_, 0.7796, 2.35, 0.333, 252, 246, BTK1 IN COMPLEX WITH CC 292
2525, d5fd2A_, 0.7796, 2.74, 0.310, 264, 252, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
2526, d4pmsA1, 0.7796, 2.43, 0.401, 279, 247, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
2527, d4eorA1, 0.7796, 2.73, 0.262, 292, 252, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2528, d3ztxA_, 0.7796, 2.76, 0.201, 269, 254, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2529, d3uytC_, 0.7796, 3.30, 0.204, 286, 265, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2530, d3lw0B_, 0.7796, 2.74, 0.320, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2531, d3f5pJ1, 0.7796, 3.02, 0.292, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2532, d3f3tA_, 0.7796, 2.41, 0.312, 261, 247, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
2533, d5j7bB_, 0.7795, 2.34, 0.264, 281, 246, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2534, d5fqdF_, 0.7795, 3.22, 0.194, 294, 263, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2535, d5cu6A_, 0.7795, 2.90, 0.187, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA
2536, d4obpA_, 0.7795, 2.86, 0.241, 285, 253, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2537, d3qd0A_, 0.7795, 2.53, 0.250, 274, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2538, d2xh5A_, 0.7795, 2.84, 0.235, 316, 255, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
2539, d1ol1A_, 0.7795, 2.93, 0.258, 296, 256, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2540, d5ke0A_, 0.7794, 3.11, 0.202, 340, 258, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
2541, d5ax9A_, 0.7794, 2.62, 0.242, 282, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2542, d4y73C_, 0.7794, 2.61, 0.282, 290, 248, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
2543, d4tw9A_, 0.7794, 3.25, 0.202, 290, 262, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2544, d4grbA_, 0.7794, 2.91, 0.187, 327, 256, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
2545, d3lw0A_, 0.7794, 2.74, 0.320, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2546, d3f5pE1, 0.7794, 3.08, 0.291, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2547, d2qonA_, 0.7794, 2.62, 0.337, 281, 249, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
2548, d2f2cB_, 0.7794, 2.92, 0.237, 280, 253, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
2549, d5tehA_, 0.7793, 2.30, 0.306, 261, 245, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
2550, p5oulA_, 0.7793, 2.90, 0.187, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
2551, d5kx8C_, 0.7793, 2.61, 0.282, 287, 248, IRAK4-INHIBITOR CO-STRUCTURE
2552, d3lw0C_, 0.7793, 2.75, 0.320, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2553, d2uzdC_, 0.7793, 2.85, 0.268, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2554, d1uwhB_, 0.7793, 2.66, 0.299, 264, 251, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2555, d1uu3A_, 0.7793, 2.60, 0.249, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2556, d1fmkA3, 0.7793, 2.52, 0.310, 270, 248, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
2557, d5uq2A_, 0.7792, 2.89, 0.255, 296, 255, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
2558, d5mp8B_, 0.7792, 2.77, 0.190, 323, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2559, d5m4uA_, 0.7792, 2.95, 0.187, 332, 256, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2560, d4gk2A_, 0.7792, 2.39, 0.362, 265, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
2561, d3lw0D_, 0.7792, 2.75, 0.320, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2562, d2c4gC2, 0.7792, 2.91, 0.259, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2563, d3f5pR1, 0.7791, 3.07, 0.291, 293, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2564, d1h28C1, 0.7791, 2.87, 0.264, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2565, d4ztmA_, 0.7790, 2.60, 0.283, 287, 247, IRAK4-INHIBITOR CO-STRUCTURE
2566, d2c5tA_, 0.7790, 2.94, 0.254, 296, 256,  
2567, d1yolA_, 0.7790, 2.06, 0.307, 256, 241, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2568, d4zk5A_, 0.7789, 2.86, 0.241, 286, 253, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2569, d4eoqC1, 0.7789, 2.87, 0.264, 271, 254, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2570, d2bkzA2, 0.7789, 2.89, 0.255, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2571, d1w98A2, 0.7789, 2.84, 0.264, 296, 254, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
2572, d4o0rA_, 0.7788, 2.90, 0.215, 293, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2573, d1pjkA_, 0.7788, 2.86, 0.188, 331, 255, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2574, d5sysB_, 0.7787, 2.27, 0.303, 258, 244, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2575, d1fvvC_, 0.7787, 2.91, 0.263, 298, 255, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2576, d1p5eC1, 0.7786, 2.90, 0.264, 295, 254, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2577, d1kobB_, 0.7786, 3.06, 0.204, 352, 260, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2578, d5nk8A_, 0.7785, 2.38, 0.340, 266, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
2579, d4fv7A_, 0.7785, 3.16, 0.194, 342, 258, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
2580, d3owjA_, 0.7785, 2.83, 0.184, 328, 255, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
2581, d2wpaA1, 0.7785, 2.95, 0.250, 298, 256, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2582, d1h27C1, 0.7785, 2.87, 0.264, 290, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2583, d5w4wB_, 0.7784, 3.25, 0.186, 291, 263, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2584, d5nhlA_, 0.7784, 3.02, 0.200, 345, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2585, d5l8lA_, 0.7784, 2.81, 0.224, 263, 255, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2586, d5dpvA_, 0.7784, 2.57, 0.260, 257, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2587, d3tl8G_, 0.7784, 2.74, 0.261, 301, 253, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2588, d2csnA_, 0.7784, 3.34, 0.169, 293, 266, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
2589, d1jktB_, 0.7784, 2.81, 0.247, 276, 255, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2590, d4au8B_, 0.7783, 2.51, 0.239, 277, 247, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
2591, d2yn8A_, 0.7783, 2.30, 0.332, 253, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2592, d2wmbA1, 0.7783, 2.86, 0.268, 295, 254, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2593, d2og8A_, 0.7783, 2.24, 0.364, 246, 242, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
2594, d1uv5A_, 0.7783, 3.18, 0.222, 348, 257, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
2595, d5dr9A_, 0.7782, 2.67, 0.260, 257, 250, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
2596, d3nszA_, 0.7782, 2.91, 0.191, 327, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
2597, d3dkfA1, 0.7782, 2.89, 0.331, 293, 251, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
2598, d3d15A_, 0.7782, 2.60, 0.244, 256, 250, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
2599, d5d7aB_, 0.7781, 2.78, 0.243, 286, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2600, d1pkdC1, 0.7781, 2.88, 0.268, 295, 254, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
2601, p6g97A_, 0.7780, 3.16, 0.205, 344, 258, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2602, d5w4wA_, 0.7779, 3.23, 0.187, 291, 262, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2603, d1okvC_, 0.7779, 2.90, 0.263, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
2604, d3d2iA_, 0.7778, 2.61, 0.244, 255, 250, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
2605, d2p2hA1, 0.7778, 2.48, 0.367, 289, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
2606, d1h28A1, 0.7778, 2.87, 0.268, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2607, d4qo9B_, 0.7777, 2.81, 0.248, 285, 254, MST3 IN COMPLEX WITH DANUSERTIB
2608, d4pqnA_, 0.7777, 1.89, 0.336, 240, 238, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
2609, d3f3wB_, 0.7777, 2.42, 0.317, 260, 246, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2610, d2wfyA_, 0.7777, 2.92, 0.259, 295, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2611, d1mp8A_, 0.7777, 2.38, 0.321, 252, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
2612, d5if1C_, 0.7776, 2.91, 0.263, 296, 255, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2613, d3e8nA1, 0.7776, 3.19, 0.239, 290, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
2614, d2qi8A_, 0.7776, 2.17, 0.322, 255, 242, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
2615, d2f57B1, 0.7776, 2.95, 0.187, 293, 257, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2616, d1kobA_, 0.7776, 3.05, 0.200, 352, 260, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2617, d5nhpA_, 0.7775, 3.21, 0.205, 338, 259, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2618, d5lpzA_, 0.7775, 2.72, 0.249, 283, 249, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
2619, p4jr7A_, 0.7775, 2.84, 0.178, 367, 253, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
2620, d4bcnA1, 0.7775, 2.86, 0.268, 295, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2621, d2bfyA_, 0.7775, 2.81, 0.201, 270, 254, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2622, d5uafA_, 0.7774, 2.67, 0.346, 291, 246, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
2623, d5uadA_, 0.7774, 2.67, 0.346, 291, 246, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
2624, d4bicB_, 0.7774, 2.47, 0.272, 259, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2625, d2erkA_, 0.7774, 2.74, 0.190, 351, 252, PHOSPHORYLATED MAP KINASE ERK2
2626, d1h26A1, 0.7774, 2.95, 0.259, 295, 255, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2627, d5up3A_, 0.7773, 2.44, 0.265, 258, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2628, d5fqdC_, 0.7773, 3.25, 0.194, 294, 263, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2629, d5dr6A_, 0.7773, 2.67, 0.260, 257, 250, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
2630, d4twcB_, 0.7773, 3.20, 0.188, 292, 261, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2631, d4b8mA_, 0.7773, 2.80, 0.201, 270, 254, AURORA B KINASE IN COMPLEX WITH VX-680
2632, d3w8lA_, 0.7773, 2.89, 0.181, 326, 254, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
2633, d3ag9B_, 0.7773, 2.80, 0.224, 317, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2634, d2vrxA_, 0.7773, 2.80, 0.197, 268, 254, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2635, d6brcA1, 0.7772, 2.90, 0.242, 263, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2636, d4ztlD_, 0.7772, 2.63, 0.283, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
2637, d4rfmA1, 0.7772, 2.41, 0.306, 248, 245, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
2638, d3iecC_, 0.7772, 2.68, 0.263, 311, 251, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2639, d1finA_, 0.7772, 2.93, 0.263, 298, 255, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2640, d5mo4A3, 0.7771, 2.27, 0.370, 271, 243, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
2641, d4eomA1, 0.7771, 2.90, 0.268, 294, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2642, d4bidB_, 0.7771, 2.44, 0.269, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2643, d4agwA_, 0.7771, 2.25, 0.307, 258, 244, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
2644, d3iecD_, 0.7771, 2.67, 0.263, 311, 251, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2645, d2bkzC2, 0.7771, 2.93, 0.259, 297, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2646, d3tz9B_, 0.7770, 2.31, 0.303, 259, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2647, d3eidA_, 0.7770, 2.76, 0.258, 292, 252, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2648, d2yexA_, 0.7770, 3.20, 0.234, 269, 256, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2649, d2xyuA_, 0.7770, 2.54, 0.343, 260, 248, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
2650, d2wmaA1, 0.7770, 2.86, 0.264, 295, 254, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2651, d1zwsE_, 0.7770, 2.86, 0.233, 278, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2652, d5mqvC_, 0.7769, 3.20, 0.187, 288, 262, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2653, d4oa6A_, 0.7769, 2.80, 0.248, 279, 250,  
2654, d4bcmA1, 0.7769, 2.80, 0.269, 292, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2655, d2vwvA_, 0.7769, 2.45, 0.333, 255, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2656, d2bfxA_, 0.7769, 2.81, 0.197, 269, 254, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2657, d4u7zA1, 0.7768, 3.35, 0.238, 290, 261, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
2658, d4eqcA1, 0.7768, 2.90, 0.219, 292, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2659, d4bhnB_, 0.7768, 2.39, 0.275, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2660, d3bhvA1, 0.7768, 2.87, 0.264, 295, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2661, d5op2A_, 0.7767, 3.00, 0.238, 263, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2662, d5c03B_, 0.7767, 2.29, 0.249, 260, 245, CRYSTAL STRUCTURE OF KINASE
2663, d4ztnD_, 0.7767, 2.62, 0.283, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
2664, d4qp8B_, 0.7767, 2.74, 0.198, 337, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
2665, d3v5qA1, 0.7767, 2.24, 0.383, 260, 243, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
2666, d5ng3A_, 0.7766, 2.73, 0.265, 283, 253, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2667, d1mruA_, 0.7766, 2.48, 0.219, 269, 247, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2668, d5kx7B_, 0.7765, 2.62, 0.283, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
2669, d4tyeA_, 0.7765, 2.91, 0.357, 292, 255, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2670, d3iecB_, 0.7765, 2.78, 0.257, 313, 253, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2671, d3etaB_, 0.7765, 2.75, 0.312, 292, 250, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
2672, d2np8A_, 0.7765, 2.57, 0.268, 256, 250, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
2673, d1vr2A_, 0.7765, 2.53, 0.371, 275, 248, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
2674, d1ol2A_, 0.7765, 2.92, 0.259, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2675, d5opbA_, 0.7764, 2.93, 0.239, 262, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2676, d4xs2A_, 0.7764, 2.72, 0.283, 283, 247, IRAK4-INHIBITOR CO-STRUCTURE
2677, d4eojA1, 0.7764, 2.78, 0.266, 293, 252, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2678, d5cshB_, 0.7763, 2.78, 0.187, 323, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
2679, d4yo6A_, 0.7763, 2.64, 0.283, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
2680, d3cs9B_, 0.7763, 2.07, 0.383, 247, 240, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2681, d2nruB_, 0.7763, 3.06, 0.274, 294, 252, CRYSTAL STRUCTURE OF IRAK-4
2682, d2bpmA2, 0.7763, 2.92, 0.255, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2683, d2b9fA_, 0.7763, 2.67, 0.229, 337, 249, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
2684, d5l8kA_, 0.7762, 2.96, 0.212, 266, 255, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2685, d4oabA_, 0.7762, 2.82, 0.248, 279, 250,  
2686, d3krlA_, 0.7762, 2.61, 0.340, 281, 247, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
2687, d3a7gB_, 0.7762, 2.89, 0.271, 290, 255, HUMAN MST3 KINASE
2688, d4uy9B_, 0.7761, 2.91, 0.332, 315, 253, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2689, d3a7gA_, 0.7761, 2.88, 0.263, 289, 255, HUMAN MST3 KINASE
2690, d1k9aC3, 0.7761, 2.62, 0.337, 266, 246, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
2691, p3zuvA_, 0.7760, 2.77, 0.190, 357, 252, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
2692, d3qyiA_, 0.7760, 3.01, 0.203, 346, 256,  
2693, d2r7iA_, 0.7760, 2.77, 0.183, 322, 252, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2694, d5hhwA_, 0.7759, 2.73, 0.311, 306, 251, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
2695, d5ar4B_, 0.7759, 2.39, 0.264, 279, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2696, d4cfnA1, 0.7759, 2.80, 0.265, 293, 253, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2697, d2oibD_, 0.7759, 2.74, 0.281, 288, 249, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
2698, d5lqfA1, 0.7758, 2.73, 0.258, 284, 248, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2699, d4bibB_, 0.7758, 2.46, 0.273, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2700, d2yerA_, 0.7758, 3.07, 0.240, 268, 254, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2701, d2wqbA_, 0.7758, 2.63, 0.325, 289, 249, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
2702, d2vgoB_, 0.7758, 2.77, 0.198, 277, 253, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2703, d3pp1A1, 0.7757, 3.24, 0.243, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
2704, d3my5A1, 0.7757, 2.84, 0.265, 294, 253, CDK2/CYCLINA IN COMPLEX WITH DRB
2705, d3fwqA_, 0.7757, 2.98, 0.184, 334, 255, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2706, d4ztnA_, 0.7756, 2.66, 0.283, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
2707, d4ub7A_, 0.7756, 3.19, 0.190, 334, 258, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
2708, d1jwhA_, 0.7756, 3.12, 0.190, 336, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2709, d1h25C1, 0.7756, 2.82, 0.266, 277, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2710, d4k9yA_, 0.7755, 3.26, 0.304, 271, 257, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
2711, d4cfvA1, 0.7755, 2.97, 0.255, 297, 255, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2712, d4bcpC1, 0.7755, 2.81, 0.267, 266, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2713, d2wxvC1, 0.7755, 2.97, 0.259, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2714, d5t1tC_, 0.7754, 2.69, 0.282, 286, 248, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2715, d5kbqA_, 0.7754, 2.91, 0.215, 289, 256, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2716, d5efqA_, 0.7754, 3.08, 0.248, 321, 258, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2717, d2vgoA_, 0.7754, 2.85, 0.189, 268, 254, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2718, d2clqB_, 0.7754, 2.49, 0.268, 259, 246, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2719, d1yhwA_, 0.7754, 2.96, 0.207, 293, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2720, d5dfpA_, 0.7753, 2.97, 0.222, 292, 257, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2721, d4cfmC1, 0.7753, 2.72, 0.268, 265, 250, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2722, d3orxE_, 0.7753, 2.70, 0.248, 274, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2723, d3dlsD_, 0.7753, 2.88, 0.223, 284, 251, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2724, d5nhvA_, 0.7752, 3.26, 0.197, 345, 259, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2725, d4qtbA_, 0.7752, 3.23, 0.201, 351, 259, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
2726, d3pixA_, 0.7752, 2.79, 0.307, 268, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
2727, d1zrzA_, 0.7752, 2.92, 0.192, 310, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
2728, d1p5eA1, 0.7752, 3.00, 0.259, 295, 255, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2729, d1o6yA_, 0.7752, 2.35, 0.217, 260, 244, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2730, d5efqC_, 0.7751, 3.10, 0.248, 325, 258, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2731, d5d11B_, 0.7751, 2.15, 0.324, 255, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2732, d4yo6D_, 0.7751, 2.68, 0.283, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
2733, d4cfuA1, 0.7751, 2.98, 0.263, 295, 255, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2734, p3zuvC_, 0.7751, 2.78, 0.190, 357, 252, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
2735, d5t1sA_, 0.7750, 2.61, 0.285, 280, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2736, d4yp8C_, 0.7750, 2.65, 0.282, 287, 248, IRAK4-INHIBITOR CO-STRUCTURE
2737, d2y6oA_, 0.7750, 2.54, 0.347, 263, 248, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
2738, d1ckiA_, 0.7750, 3.01, 0.202, 292, 257, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2739, d5w5oN_, 0.7749, 2.19, 0.266, 272, 241, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2740, d5aagA_, 0.7749, 2.60, 0.262, 253, 248, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
2741, d3a7hA_, 0.7749, 2.84, 0.260, 289, 254, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2742, d2nruC_, 0.7749, 3.01, 0.275, 293, 251, CRYSTAL STRUCTURE OF IRAK-4
2743, d4izaA_, 0.7748, 2.98, 0.200, 346, 255, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
2744, d3tl8A_, 0.7748, 2.75, 0.258, 300, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2745, d3mblA_, 0.7748, 3.34, 0.238, 290, 260, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
2746, d1okwA_, 0.7748, 2.97, 0.259, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
2747, d1yhvA_, 0.7747, 2.97, 0.207, 293, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2748, d1jpaB_, 0.7747, 2.35, 0.348, 269, 244, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
2749, d5h8gA_, 0.7746, 2.86, 0.177, 324, 254, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
2750, d4ztlC_, 0.7746, 2.95, 0.273, 282, 249, IRAK4-INHIBITOR CO-STRUCTURE
2751, d5hieC_, 0.7745, 2.25, 0.313, 253, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2752, d5cenA_, 0.7745, 2.47, 0.344, 281, 247, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
2753, d4ic7A_, 0.7745, 3.20, 0.215, 355, 260, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
2754, d2cjmC_, 0.7745, 2.86, 0.269, 294, 253, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2755, d1jpaA_, 0.7745, 2.45, 0.341, 273, 246, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
2756, d5uiqC_, 0.7744, 2.72, 0.279, 280, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
2757, d5jsmA1, 0.7744, 2.68, 0.301, 262, 249, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2758, d3f69B_, 0.7744, 2.92, 0.214, 282, 257, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2759, d3eqgA_, 0.7744, 3.21, 0.239, 314, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
2760, d5d7aC_, 0.7743, 2.76, 0.248, 286, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2761, d4nstA_, 0.7743, 3.06, 0.245, 322, 257, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2762, d3a7hB_, 0.7743, 2.92, 0.271, 290, 255, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2763, d2vwwA_, 0.7743, 2.43, 0.327, 253, 245, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2764, d5k3yB_, 0.7742, 2.91, 0.185, 277, 254, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2765, d3q52A_, 0.7742, 2.96, 0.219, 292, 256, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2766, d3orxG_, 0.7742, 2.67, 0.249, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2767, d3c7qA_, 0.7742, 2.52, 0.360, 286, 247, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
2768, d2nryB_, 0.7742, 3.00, 0.277, 286, 249, CRYSTAL STRUCTURE OF IRAK-4
2769, d2nruD_, 0.7742, 3.06, 0.274, 293, 252, CRYSTAL STRUCTURE OF IRAK-4
2770, d6bqqA1, 0.7741, 2.92, 0.246, 269, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2771, d1pkdA1, 0.7741, 2.91, 0.268, 295, 254, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
2772, d5cvfA_, 0.7740, 2.90, 0.189, 325, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2773, d5c01B_, 0.7740, 2.27, 0.258, 260, 244, CRYSTAL STRUCTURE OF KINASE
2774, d4eoqA1, 0.7740, 2.86, 0.269, 293, 253, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2775, d3f5xC_, 0.7740, 2.96, 0.263, 298, 255, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2776, d1h24C1, 0.7740, 3.02, 0.263, 292, 255, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2777, d5deyA_, 0.7739, 3.02, 0.214, 295, 257, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2778, d4mwiA_, 0.7739, 2.34, 0.224, 266, 245, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
2779, d4eooA1, 0.7739, 2.80, 0.262, 292, 252, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2780, p3vugA_, 0.7739, 2.85, 0.217, 356, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
2781, d3dlsA_, 0.7739, 2.89, 0.223, 285, 251, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2782, d1q8zB_, 0.7739, 3.25, 0.192, 364, 260, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
2783, d5lpbA_, 0.7738, 2.71, 0.250, 280, 248, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
2784, d5hieB_, 0.7738, 2.70, 0.297, 259, 249, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2785, d5hd4A_, 0.7738, 3.08, 0.200, 347, 255, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
2786, d4agwB_, 0.7738, 2.34, 0.307, 257, 244, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
2787, d3bhhD1, 0.7738, 2.81, 0.202, 285, 252, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2788, d1p4fA_, 0.7737, 2.55, 0.242, 269, 248, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
2789, d1e9hA_, 0.7737, 2.98, 0.259, 295, 255, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2790, d4qp7A_, 0.7736, 2.78, 0.198, 337, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
2791, d3iecA_, 0.7736, 2.78, 0.255, 311, 251, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2792, d2r7iC_, 0.7736, 2.76, 0.187, 321, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2793, d5ih6A_, 0.7735, 3.26, 0.185, 286, 259, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
2794, d5c03A_, 0.7735, 2.30, 0.250, 260, 244, CRYSTAL STRUCTURE OF KINASE
2795, d4qp9A_, 0.7735, 2.73, 0.200, 335, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
2796, d4b8mB_, 0.7735, 2.89, 0.197, 279, 254, AURORA B KINASE IN COMPLEX WITH VX-680
2797, d1pyxA_, 0.7735, 3.26, 0.222, 343, 257, GSK-3 BETA COMPLEXED WITH AMP-PNP
2798, p6gdqA_, 0.7734, 3.07, 0.201, 339, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2799, d5clpA_, 0.7734, 2.81, 0.191, 322, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2800, d4y73A_, 0.7734, 2.62, 0.285, 289, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
2801, d4nstC_, 0.7734, 3.08, 0.249, 317, 257, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2802, d4kspA_, 0.7734, 2.42, 0.302, 257, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
2803, d4cfwA1, 0.7734, 2.91, 0.264, 297, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2804, d4c2wA_, 0.7734, 2.87, 0.197, 268, 254, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2805, d4c2vB_, 0.7734, 2.89, 0.197, 280, 254, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2806, d2jd5A_, 0.7734, 2.95, 0.198, 353, 252, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2807, d4yo6C_, 0.7733, 2.63, 0.283, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
2808, d4ixpA_, 0.7733, 3.10, 0.234, 334, 256, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
2809, d4byiA_, 0.7733, 2.53, 0.259, 254, 247, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
2810, d2bfyB_, 0.7733, 2.87, 0.185, 278, 254, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2811, d5kx8A_, 0.7732, 2.64, 0.285, 285, 246, IRAK4-INHIBITOR CO-STRUCTURE
2812, d5aadA_, 0.7732, 2.43, 0.268, 252, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
2813, d3orxH_, 0.7732, 2.69, 0.249, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2814, d3orxF_, 0.7732, 2.69, 0.249, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2815, d2wpaC1, 0.7732, 3.00, 0.263, 298, 255, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2816, d1h25A1, 0.7732, 3.01, 0.259, 292, 255, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2817, p4f9bA_, 0.7731, 3.15, 0.202, 318, 257, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
2818, d4bieA_, 0.7731, 2.49, 0.266, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2819, d3qc4A_, 0.7731, 2.87, 0.246, 276, 252, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2820, d1vywC1, 0.7731, 3.00, 0.259, 298, 255, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2821, d5kziA_, 0.7730, 2.66, 0.194, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2822, d4p5zA_, 0.7730, 2.50, 0.346, 267, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
2823, d3r22A_, 0.7730, 2.63, 0.254, 255, 248, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2824, d2i40C_, 0.7730, 3.02, 0.259, 296, 255, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2825, d5vamB_, 0.7729, 2.59, 0.294, 260, 248, BRAF IN COMPLEX WITH RAF709
2826, d5k3yA_, 0.7729, 2.83, 0.178, 267, 253, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2827, d5ih5A_, 0.7729, 3.30, 0.200, 286, 260, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
2828, d5hieA_, 0.7729, 2.57, 0.300, 258, 247, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2829, d4tn6A_, 0.7729, 3.26, 0.183, 292, 262, CK1D IN COMPLEX WITH INHIBITOR
2830, d4o0wA_, 0.7729, 2.63, 0.254, 259, 248, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2831, d4btjB_, 0.7729, 3.20, 0.158, 293, 259, TTBK1 IN COMPLEX WITH ATP
2832, d2wmaC1, 0.7729, 2.72, 0.276, 264, 250, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2833, d5m4iA_, 0.7728, 3.15, 0.178, 331, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2834, p3vuhA_, 0.7728, 2.86, 0.217, 355, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
2835, d3sv0A_, 0.7728, 3.43, 0.177, 294, 265, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
2836, d2xngA_, 0.7728, 2.56, 0.263, 253, 247, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
2837, d2i40A_, 0.7728, 2.79, 0.259, 291, 251, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2838, d2i0eB_, 0.7728, 2.79, 0.246, 300, 252, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2839, d1uwjA_, 0.7728, 2.66, 0.301, 264, 249, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
2840, d5d11A_, 0.7727, 2.16, 0.320, 254, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2841, d5uitB_, 0.7726, 2.60, 0.286, 283, 245, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
2842, d5hd7A_, 0.7726, 3.28, 0.201, 347, 259, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
2843, d4qo9A_, 0.7726, 2.91, 0.263, 280, 255, MST3 IN COMPLEX WITH DANUSERTIB
2844, d4bhnA_, 0.7726, 2.49, 0.272, 256, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2845, d2vwuA_, 0.7726, 2.46, 0.327, 253, 245, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2846, d4ty1A_, 0.7725, 2.66, 0.194, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2847, d4lmnA1, 0.7725, 3.26, 0.239, 291, 259, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
2848, d3vvhC1, 0.7725, 3.15, 0.240, 282, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
2849, d3og7B_, 0.7725, 2.42, 0.305, 254, 246, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
2850, d5oq8A_, 0.7724, 2.97, 0.244, 261, 250, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2851, d5ng3D_, 0.7724, 2.77, 0.266, 278, 252, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2852, d5m44A_, 0.7724, 2.80, 0.187, 329, 252, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2853, d3etaA_, 0.7724, 2.70, 0.317, 293, 249, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
2854, d1h27A1, 0.7724, 2.93, 0.264, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2855, d3tl8H_, 0.7723, 2.81, 0.262, 303, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2856, d5lqfD1, 0.7722, 2.68, 0.256, 282, 246, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2857, d4cfvC1, 0.7722, 2.72, 0.265, 263, 249, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2858, p3vudA_, 0.7722, 2.86, 0.217, 355, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
2859, d5aafA_, 0.7721, 2.52, 0.263, 254, 247, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
2860, d4arkA1, 0.7721, 3.30, 0.239, 290, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
2861, d3pj2A_, 0.7721, 2.10, 0.336, 248, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
2862, d1q99B_, 0.7721, 3.27, 0.192, 364, 260, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
2863, d5i8aA1, 0.7720, 2.10, 0.403, 265, 238, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
2864, d5buiA_, 0.7720, 2.82, 0.203, 338, 251, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
2865, d4ztmC_, 0.7720, 2.66, 0.285, 282, 246, IRAK4-INHIBITOR CO-STRUCTURE
2866, d4pmtA1, 0.7720, 2.36, 0.394, 269, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
2867, d1yxtA_, 0.7720, 2.58, 0.190, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2868, d1okvA_, 0.7720, 3.03, 0.258, 295, 256, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
2869, d5w4wD_, 0.7719, 3.22, 0.185, 287, 260, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2870, d5vamA_, 0.7719, 2.78, 0.290, 269, 252, BRAF IN COMPLEX WITH RAF709
2871, d5kx8D_, 0.7719, 2.93, 0.279, 283, 247, IRAK4-INHIBITOR CO-STRUCTURE
2872, d5eykB_, 0.7719, 2.89, 0.185, 275, 254, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2873, d4itjB_, 0.7719, 2.81, 0.286, 276, 248, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
2874, d4btmB_, 0.7718, 3.20, 0.162, 293, 259, TTBK1 IN COMPLEX WITH INHIBITOR
2875, d2w1gA1, 0.7718, 2.66, 0.262, 254, 248, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2876, d2vgpB_, 0.7718, 2.92, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2877, d5t1tD_, 0.7717, 2.61, 0.286, 283, 245, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2878, d5hlnB_, 0.7717, 3.26, 0.228, 346, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2879, d4c2wB_, 0.7717, 2.92, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2880, d3qrkA1, 0.7717, 2.73, 0.390, 268, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
2881, d3qriB_, 0.7717, 2.49, 0.399, 262, 243, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
2882, d2o5kA1, 0.7716, 3.26, 0.222, 350, 257, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
2883, d5ih4A_, 0.7715, 3.28, 0.185, 286, 259, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
2884, d4bieB_, 0.7715, 2.47, 0.275, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2885, d3tnwA1, 0.7715, 2.88, 0.265, 294, 253, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2886, d3octA_, 0.7715, 2.04, 0.325, 244, 240, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
2887, d3ii5A_, 0.7715, 2.70, 0.301, 262, 249, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
2888, d3f5xA_, 0.7715, 2.95, 0.260, 297, 254, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2889, d1cmkE_, 0.7715, 2.87, 0.206, 348, 253, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
2890, d5lpyA_, 0.7714, 2.65, 0.247, 282, 247, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
2891, d4yp8A_, 0.7714, 2.64, 0.285, 284, 246, IRAK4-INHIBITOR CO-STRUCTURE
2892, d3zonA_, 0.7714, 2.27, 0.251, 261, 243, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
2893, p3v3vA_, 0.7714, 2.85, 0.222, 351, 252, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
2894, d3eqhA_, 0.7714, 3.12, 0.241, 314, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
2895, d3dlsF_, 0.7714, 2.79, 0.226, 281, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2896, d3cs9D_, 0.7714, 2.63, 0.388, 263, 245, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2897, d2wipA1, 0.7714, 2.78, 0.252, 293, 250, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2898, d2qoqA_, 0.7714, 2.58, 0.336, 284, 247, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
2899, d2og8B2, 0.7714, 2.39, 0.368, 247, 242, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
2900, d5d12B_, 0.7713, 2.15, 0.321, 253, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
2901, d3tubA_, 0.7713, 2.49, 0.341, 253, 246, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
2902, d3sayA_, 0.7713, 3.24, 0.223, 347, 256, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2903, d3piyA_, 0.7713, 2.55, 0.347, 262, 245, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
2904, d1j1bB_, 0.7713, 3.28, 0.218, 364, 257, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2905, d4knbB_, 0.7712, 2.67, 0.332, 256, 244, C-MET IN COMPLEX WITH OSI LIGAND
2906, d4fc0A_, 0.7712, 2.42, 0.302, 254, 245, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
2907, d3zlsA_, 0.7712, 3.17, 0.241, 315, 257, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
2908, d3vw6A_, 0.7712, 2.45, 0.273, 255, 242, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
2909, d1s9iA_, 0.7712, 3.39, 0.236, 303, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
2910, d5ur1B_, 0.7711, 2.53, 0.391, 265, 248, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
2911, d4qp3B_, 0.7711, 3.17, 0.198, 331, 257, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
2912, p3vuiA_, 0.7711, 2.90, 0.217, 355, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
2913, d2hyyB1, 0.7711, 2.06, 0.392, 252, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2914, d1r0pA_, 0.7711, 3.05, 0.323, 301, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
2915, d1h4lA_, 0.7711, 2.59, 0.228, 278, 246, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
2916, d5li9A1, 0.7710, 2.71, 0.187, 328, 252, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
2917, d5cwzA_, 0.7710, 2.86, 0.240, 284, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2918, d2y6mA_, 0.7710, 2.57, 0.344, 262, 247, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
2919, d2qq7A_, 0.7710, 2.02, 0.325, 251, 237, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
2920, d2chlA_, 0.7710, 3.34, 0.163, 298, 263, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
2921, d1unhA_, 0.7709, 2.51, 0.221, 276, 244, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
2922, d1q8yA_, 0.7709, 3.13, 0.202, 351, 253, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
2923, d5mqvA_, 0.7708, 3.16, 0.189, 286, 259, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2924, d2wihC1, 0.7708, 3.02, 0.263, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2925, d5ct7A_, 0.7707, 2.56, 0.305, 257, 246, BRAF IN COMPLEX WITH RAF265
2926, d4qp4A_, 0.7707, 2.83, 0.194, 337, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
2927, d3dzqA_, 0.7707, 2.71, 0.332, 268, 247, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
2928, d1q41A_, 0.7707, 3.31, 0.222, 339, 257, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2929, d4mtaA_, 0.7706, 2.58, 0.198, 273, 247, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2930, d5jsmC1, 0.7705, 2.61, 0.305, 259, 246, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2931, d5ar4A_, 0.7705, 2.23, 0.273, 274, 242, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2932, d4ztmD_, 0.7705, 2.72, 0.286, 282, 245, IRAK4-INHIBITOR CO-STRUCTURE
2933, d3r21A_, 0.7705, 2.69, 0.262, 254, 248, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2934, d3of0B_, 0.7705, 2.07, 0.315, 251, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
2935, d3dlsE_, 0.7705, 2.89, 0.225, 282, 249, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2936, d1unhB_, 0.7705, 2.52, 0.221, 276, 244, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
2937, d5hlwA_, 0.7704, 3.10, 0.325, 284, 252, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
2938, d2hz0B_, 0.7704, 1.76, 0.397, 243, 232, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
2939, d1ctpE_, 0.7704, 2.79, 0.206, 332, 252, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2940, d4ztnC_, 0.7703, 2.79, 0.279, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
2941, d4qp1B_, 0.7703, 2.99, 0.193, 343, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
2942, p4h3pA_, 0.7703, 2.89, 0.206, 342, 253, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2943, d4c8bB_, 0.7703, 2.54, 0.261, 281, 245, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2944, d3fxzA_, 0.7703, 3.03, 0.215, 292, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2945, d1ungA_, 0.7703, 2.86, 0.223, 288, 251, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
2946, d4au8A1, 0.7702, 2.58, 0.233, 274, 245, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
2947, d4alvA_, 0.7702, 2.69, 0.190, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2948, d3dv3A_, 0.7702, 3.29, 0.240, 288, 258, MEK1 WITH PF-04622664 BOUND
2949, d5t1sD_, 0.7701, 2.54, 0.284, 281, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2950, d4u80A_, 0.7701, 3.35, 0.239, 286, 259, MEK 1 KINASE BOUND TO G799
2951, p4ux9D_, 0.7700, 2.92, 0.219, 344, 251, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
2952, d4nm5A1, 0.7700, 3.29, 0.218, 360, 257, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
2953, d3a8xB1, 0.7700, 2.79, 0.178, 325, 253, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2954, d5t1sC_, 0.7699, 2.68, 0.289, 284, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2955, d5hesA_, 0.7699, 2.65, 0.321, 287, 246, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
2956, d5diaA_, 0.7699, 2.68, 0.194, 273, 248, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2957, d5dhjA_, 0.7699, 2.68, 0.194, 273, 248, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2958, d3vvhB1, 0.7699, 3.23, 0.240, 289, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
2959, p3vukA_, 0.7699, 2.91, 0.217, 355, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
2960, d1h4lB_, 0.7699, 2.61, 0.228, 278, 246, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
2961, d4wrsA_, 0.7698, 2.69, 0.194, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2962, d4qq5A1, 0.7698, 2.66, 0.357, 272, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
2963, d4k0yA_, 0.7698, 2.69, 0.194, 274, 248, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2964, d4jbpA_, 0.7698, 2.61, 0.263, 255, 247, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2965, p3zu7A_, 0.7698, 3.07, 0.188, 344, 255, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
2966, d5kgdA_, 0.7697, 2.69, 0.194, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2967, d5h3qA_, 0.7697, 2.73, 0.375, 302, 248, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
2968, d5cwzB_, 0.7697, 2.81, 0.241, 284, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2969, d5ax9B_, 0.7697, 2.70, 0.244, 274, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2970, d5ar7B_, 0.7697, 2.44, 0.269, 278, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
2971, d4wt6A_, 0.7697, 2.69, 0.194, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2972, d3qtiA_, 0.7697, 2.91, 0.331, 292, 248, C-MET KINASE IN COMPLEX WITH NVP-BVU972
2973, d1pyxB_, 0.7697, 3.34, 0.222, 338, 257, GSK-3 BETA COMPLEXED WITH AMP-PNP
2974, d5mqvF_, 0.7696, 3.18, 0.189, 286, 259, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2975, d5c01A_, 0.7696, 2.30, 0.259, 258, 243, CRYSTAL STRUCTURE OF KINASE
2976, d4n70A_, 0.7696, 2.70, 0.190, 274, 248, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2977, d4kbkC_, 0.7696, 3.27, 0.181, 280, 260, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2978, d4at4A1, 0.7696, 2.97, 0.369, 289, 252, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
2979, d3zduA_, 0.7696, 2.89, 0.250, 297, 248, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
2980, d1q5kB_, 0.7696, 3.31, 0.222, 344, 257, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2981, d1q5kA_, 0.7696, 3.33, 0.222, 345, 257, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2982, d5uabA_, 0.7695, 2.63, 0.346, 288, 243, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
2983, d4wovA_, 0.7695, 2.28, 0.255, 258, 243, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
2984, d4prjA_, 0.7695, 2.46, 0.258, 251, 244, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
2985, d4hgsA1, 0.7695, 3.53, 0.155, 301, 265, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
2986, d4aszA1, 0.7695, 2.99, 0.367, 286, 251, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
2987, d3l1sA_, 0.7695, 3.32, 0.222, 336, 257, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2988, d3kk8A_, 0.7695, 3.18, 0.189, 283, 259, CAMKII SUBSTRATE COMPLEX A
2989, p6g93A_, 0.7694, 3.23, 0.202, 343, 257, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2990, d4nm7A1, 0.7694, 3.28, 0.222, 354, 257, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
2991, d4xj0B_, 0.7693, 3.04, 0.197, 338, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
2992, d4dtkA_, 0.7693, 2.70, 0.190, 273, 248, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2993, d3amyA_, 0.7693, 2.73, 0.173, 318, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
2994, d2jd5B_, 0.7693, 3.31, 0.196, 360, 260, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2995, d5nguA_, 0.7692, 2.99, 0.198, 339, 253, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2996, d5mqvD_, 0.7692, 3.12, 0.190, 287, 258, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2997, d5dgzA_, 0.7692, 2.70, 0.194, 273, 248, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2998, d4c8bA_, 0.7692, 2.33, 0.260, 279, 242, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2999, d5l6pA_, 0.7691, 2.83, 0.329, 274, 249, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
3000, d4kbaC_, 0.7691, 3.19, 0.187, 277, 257, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3001, d4kb8C_, 0.7691, 3.13, 0.187, 277, 256, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3002, d4g16A1, 0.7691, 3.53, 0.155, 301, 265, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3003, d3r00A_, 0.7691, 2.60, 0.190, 274, 247, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3004, d2o64A_, 0.7691, 2.60, 0.194, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
3005, d1q99A_, 0.7691, 3.04, 0.194, 354, 253, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
3006, d1q97A_, 0.7691, 3.16, 0.202, 351, 253, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
3007, p6g9aA_, 0.7690, 3.31, 0.205, 341, 258, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3008, d5eolA_, 0.7690, 2.71, 0.194, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
3009, d4qqcA1, 0.7690, 2.52, 0.360, 271, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3010, d4kbcA_, 0.7690, 3.26, 0.177, 288, 260, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3011, d2x7fB_, 0.7690, 2.87, 0.248, 288, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3012, d2w1fA1, 0.7690, 2.65, 0.263, 253, 247, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3013, d2henA1, 0.7690, 2.64, 0.321, 258, 246, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3014, d1j1cB_, 0.7690, 3.30, 0.218, 364, 257, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
3015, d3eqcA_, 0.7689, 3.25, 0.240, 312, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
3016, d3c4eD_, 0.7689, 2.71, 0.190, 273, 248, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3017, d2vgpA_, 0.7689, 2.83, 0.187, 265, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
3018, d2aypA_, 0.7689, 2.91, 0.236, 268, 250, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
3019, d4g17A1, 0.7688, 3.53, 0.155, 301, 265, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
3020, d4bckC1, 0.7688, 2.99, 0.261, 291, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3021, d5uq0B_, 0.7687, 2.28, 0.405, 256, 242, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
3022, d5kggA_, 0.7687, 2.61, 0.194, 273, 247, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
3023, d5ipjA_, 0.7687, 2.71, 0.198, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
3024, d4kbaB_, 0.7687, 3.24, 0.186, 285, 258, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3025, d3vc4A_, 0.7687, 2.71, 0.190, 274, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3026, d3mygA_, 0.7687, 2.48, 0.261, 252, 245, AURORA A KINASE COMPLEXED WITH SCH 1473759
3027, d3eqfA_, 0.7687, 3.16, 0.242, 314, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
3028, d1q97B_, 0.7687, 3.30, 0.188, 361, 260, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
3029, d5v82A_, 0.7686, 2.66, 0.190, 273, 247, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
3030, d5ng3B_, 0.7686, 2.74, 0.268, 275, 250, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3031, d5kgiA_, 0.7686, 2.71, 0.194, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
3032, d4qp2B_, 0.7686, 3.04, 0.197, 329, 254, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3033, d4ic7D_, 0.7686, 3.26, 0.189, 353, 259, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
3034, d1yxxA_, 0.7686, 2.59, 0.190, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
3035, d5lpwA_, 0.7685, 2.81, 0.251, 280, 247, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
3036, d4btjA_, 0.7685, 3.22, 0.155, 292, 258, TTBK1 IN COMPLEX WITH ATP
3037, d3f2aA_, 0.7685, 2.73, 0.194, 276, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
3038, d2xj2A_, 0.7685, 2.67, 0.190, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3039, d1uwjB_, 0.7685, 2.91, 0.299, 263, 251, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3040, d1q41B_, 0.7685, 3.35, 0.222, 343, 257, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
3041, d4zy4A_, 0.7684, 2.95, 0.213, 288, 253, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3042, d4bckA1, 0.7684, 3.07, 0.259, 296, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3043, d3zlxA_, 0.7684, 3.31, 0.240, 312, 258, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
3044, d3eqbA1, 0.7684, 3.25, 0.245, 288, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3045, d3d5xA_, 0.7684, 2.72, 0.245, 279, 249, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
3046, d2bfxB_, 0.7684, 2.75, 0.200, 275, 250, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
3047, d1ywnA_, 0.7684, 2.51, 0.367, 279, 245, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
3048, d4wsyA_, 0.7683, 2.60, 0.198, 273, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
3049, d4qyyA_, 0.7683, 3.30, 0.198, 337, 258, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
3050, d2xj0A_, 0.7683, 2.70, 0.194, 274, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3051, d1q8zA_, 0.7683, 3.15, 0.197, 354, 254, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
3052, d5mqvB_, 0.7682, 3.26, 0.188, 287, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3053, d5bx0A_, 0.7682, 3.28, 0.240, 315, 258, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
3054, d4rmzA_, 0.7682, 3.03, 0.277, 284, 249, CRYSTAL STRUCTURE OF IRAK-4
3055, d3zrkB_, 0.7682, 3.25, 0.223, 348, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3056, d3uytA_, 0.7682, 3.25, 0.203, 287, 261, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3057, d3qupA_, 0.7682, 1.91, 0.323, 241, 235, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
3058, d2henC1, 0.7682, 2.65, 0.321, 258, 246, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3059, d1h24A1, 0.7682, 2.98, 0.260, 292, 254, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
3060, d1finC_, 0.7682, 3.08, 0.259, 298, 255, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
3061, d1ckiB_, 0.7682, 3.31, 0.200, 286, 260, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3062, d6brcB_, 0.7681, 2.89, 0.245, 260, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3063, d5kgeA_, 0.7681, 2.71, 0.194, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
3064, d4xj0A_, 0.7681, 3.17, 0.200, 345, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3065, d4k18A_, 0.7681, 2.75, 0.193, 277, 249, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3066, d4aluA_, 0.7681, 2.61, 0.190, 274, 247, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3067, d2xruA_, 0.7681, 2.62, 0.271, 253, 247, AURORA-A T288E COMPLEXED WITH PHA-828300
3068, d1howA_, 0.7681, 3.06, 0.194, 346, 253, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
3069, d5ar8B_, 0.7680, 2.42, 0.263, 274, 243, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
3070, d5aaeA_, 0.7680, 2.59, 0.260, 252, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3071, d2bpmC2, 0.7680, 3.08, 0.263, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
3072, d4u81A1, 0.7679, 3.31, 0.240, 288, 258, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
3073, d3v04A1, 0.7679, 3.29, 0.236, 288, 259, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3074, d2vrxB_, 0.7679, 2.76, 0.204, 274, 250, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
3075, d4ptgB_, 0.7678, 3.36, 0.218, 332, 257, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
3076, d4ibmA_, 0.7678, 2.86, 0.315, 301, 251, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3077, d4dglC_, 0.7678, 3.13, 0.176, 334, 255, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
3078, d3ulzA_, 0.7678, 2.95, 0.271, 291, 247, CRYSTAL STRUCTURE OF APO BAK1
3079, d3dlsC_, 0.7678, 3.06, 0.224, 281, 250, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3080, d2xj1A_, 0.7678, 2.68, 0.194, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
3081, d2oicD_, 0.7678, 2.60, 0.276, 284, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3082, d5obrA_, 0.7677, 2.63, 0.259, 255, 247, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3083, d5jsmB1, 0.7677, 2.82, 0.297, 259, 249, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3084, d5f94B_, 0.7677, 3.37, 0.218, 349, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3085, d4hglA1, 0.7677, 3.54, 0.155, 301, 265, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
3086, d4alwA_, 0.7677, 2.58, 0.195, 273, 246, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3087, d3sayB_, 0.7677, 3.29, 0.223, 347, 256, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
3088, d3k5uA_, 0.7677, 2.63, 0.259, 260, 247, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3089, d3i4bA_, 0.7677, 3.33, 0.218, 359, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
3090, d3fy0A_, 0.7677, 3.08, 0.215, 292, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
3091, d3eqiA_, 0.7677, 3.23, 0.241, 315, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
3092, d2p55A2, 0.7677, 3.38, 0.235, 288, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3093, d5ct7B_, 0.7676, 2.35, 0.300, 254, 243, BRAF IN COMPLEX WITH RAF265
3094, d4mygB_, 0.7676, 2.91, 0.214, 335, 252, MAPK13 ACTIVE FORM
3095, d4jx7A_, 0.7676, 2.61, 0.190, 274, 247, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
3096, p3teiA_, 0.7676, 2.66, 0.198, 339, 248, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3097, d3eqdA_, 0.7676, 3.28, 0.236, 315, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
3098, d2ojgA_, 0.7676, 3.23, 0.199, 337, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3099, d1yxuD_, 0.7676, 2.73, 0.194, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3100, d1j1bA_, 0.7676, 3.35, 0.222, 354, 257, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
3101, d4btmA_, 0.7675, 3.23, 0.155, 292, 258, TTBK1 IN COMPLEX WITH INHIBITOR
3102, d2qo7A_, 0.7675, 2.59, 0.354, 278, 246, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
3103, d5hlnA_, 0.7674, 3.33, 0.224, 346, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
3104, d4y73B_, 0.7674, 2.63, 0.287, 289, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3105, d4tw9B_, 0.7674, 3.26, 0.189, 289, 259, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3106, d4mneE_, 0.7674, 3.41, 0.238, 286, 260, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3107, d3i4bB_, 0.7674, 3.33, 0.222, 347, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
3108, d3fdnA_, 0.7674, 2.67, 0.258, 261, 248, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3109, d5telA_, 0.7673, 2.61, 0.198, 273, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3110, d5e1sA_, 0.7673, 2.46, 0.306, 284, 245, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
3111, d4yc3A1, 0.7673, 3.10, 0.259, 294, 255, CDK1/CYCLINB1/CKS2 APO
3112, d4o0uA_, 0.7673, 2.69, 0.237, 259, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3113, d3m1sA_, 0.7673, 3.33, 0.222, 348, 257, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
3114, d2qi8B_, 0.7673, 2.00, 0.314, 249, 236, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
3115, d2hyyC1, 0.7673, 2.20, 0.392, 249, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3116, d2f9gA_, 0.7673, 2.55, 0.234, 332, 244, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
3117, d1i44A_, 0.7673, 2.51, 0.317, 282, 246, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3118, d5jrsB1, 0.7672, 2.17, 0.347, 239, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
3119, d5dewA_, 0.7672, 3.15, 0.214, 295, 257, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3120, d4ztlA_, 0.7672, 2.74, 0.287, 280, 244, IRAK4-INHIBITOR CO-STRUCTURE
3121, d4xhkB_, 0.7672, 2.73, 0.194, 269, 248, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
3122, d4kb8B_, 0.7672, 3.29, 0.185, 285, 259, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3123, d4dbnA_, 0.7672, 2.51, 0.307, 257, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3124, d3r01A_, 0.7672, 2.61, 0.190, 274, 247, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3125, d2ofvB2, 0.7672, 1.70, 0.372, 243, 231, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
3126, d4qp6B_, 0.7671, 3.20, 0.187, 334, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3127, d3zlwA_, 0.7671, 3.25, 0.237, 312, 257, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
3128, d3vbqA_, 0.7671, 2.65, 0.191, 271, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3129, d3l1sB_, 0.7671, 3.36, 0.222, 330, 257, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
3130, d5dwrA_, 0.7670, 2.69, 0.190, 273, 247, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
3131, d3zrmB_, 0.7670, 3.29, 0.223, 347, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
3132, d3uqfB_, 0.7670, 2.16, 0.315, 253, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
3133, d3jyaA_, 0.7670, 2.63, 0.194, 274, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3134, d2oi4X_, 0.7670, 2.66, 0.194, 275, 248, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
3135, d1xqzA_, 0.7670, 2.77, 0.193, 277, 249, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
3136, d5mqvE_, 0.7669, 3.23, 0.189, 287, 259, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3137, d4mblA_, 0.7669, 2.62, 0.198, 274, 247, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
3138, d1gngB_, 0.7669, 3.39, 0.224, 355, 259, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
3139, d4ntsB_, 0.7668, 2.83, 0.198, 341, 252, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3140, d4lueB3, 0.7668, 2.19, 0.371, 256, 237, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
3141, d4d4rB_, 0.7668, 3.17, 0.307, 270, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3142, d3zrlB_, 0.7668, 3.30, 0.223, 347, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3143, d3uimA_, 0.7668, 2.96, 0.271, 291, 247, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
3144, d1s9jA1, 0.7668, 3.40, 0.235, 288, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3145, d5uitA_, 0.7667, 2.66, 0.287, 284, 244, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
3146, d5iisA_, 0.7667, 2.63, 0.194, 273, 247, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
3147, d4yp8D_, 0.7667, 3.00, 0.277, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
3148, d4qpaA_, 0.7667, 3.17, 0.199, 331, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3149, d4n6zA_, 0.7667, 2.59, 0.191, 272, 246, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3150, d3qlfA_, 0.7667, 2.00, 0.314, 249, 236, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
3151, d2zv2A_, 0.7667, 2.72, 0.249, 256, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3152, d2wipC1, 0.7667, 2.89, 0.256, 291, 250, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
3153, d2objA_, 0.7667, 2.70, 0.194, 272, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
3154, d2iztA_, 0.7667, 3.37, 0.153, 296, 262, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3155, d5cs6B_, 0.7666, 2.68, 0.194, 316, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
3156, d4pteB_, 0.7666, 3.36, 0.222, 347, 257, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
3157, d4bcqC1, 0.7666, 2.96, 0.270, 291, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3158, d3tucA_, 0.7666, 2.64, 0.341, 257, 246, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
3159, d3o71A_, 0.7666, 3.17, 0.191, 340, 257, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
3160, d2ofvA2, 0.7666, 1.97, 0.372, 243, 234, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
3161, d1yxvA_, 0.7666, 2.62, 0.198, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
3162, d4y73D_, 0.7665, 2.99, 0.278, 288, 248, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3163, d4l44A_, 0.7665, 3.03, 0.255, 321, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
3164, d3bhhC1, 0.7665, 2.94, 0.210, 284, 252, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3165, d5jznA_, 0.7664, 2.79, 0.212, 268, 250, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3166, d5f94A_, 0.7664, 3.36, 0.222, 346, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3167, d4gt4B_, 0.7664, 2.67, 0.343, 273, 248, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3168, d3dcvA_, 0.7664, 2.76, 0.194, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
3169, d2o3pA_, 0.7664, 2.62, 0.194, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
3170, d2bzhB_, 0.7664, 2.67, 0.198, 275, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
3171, d3ctjA_, 0.7663, 2.74, 0.328, 289, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
3172, d2xizA_, 0.7663, 2.70, 0.194, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3173, d5uiuA_, 0.7662, 2.97, 0.279, 286, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
3174, d4nt4A1, 0.7662, 3.32, 0.157, 299, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
3175, d3o7lD_, 0.7662, 2.85, 0.202, 333, 252, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
3176, d2bujB1, 0.7662, 3.24, 0.216, 277, 259, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3177, d1j3hB_, 0.7662, 2.88, 0.198, 327, 252, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3178, d4n6yA_, 0.7661, 2.74, 0.194, 273, 248, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
3179, d4jbqA_, 0.7661, 2.64, 0.263, 257, 247, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3180, d3nizA1, 0.7661, 3.04, 0.262, 284, 252, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
3181, d3naxA_, 0.7661, 3.00, 0.237, 278, 253, PDK1 IN COMPLEX WITH INHIBITOR MP7
3182, d3cqeA_, 0.7661, 2.64, 0.224, 258, 246, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3183, d1jowB_, 0.7661, 2.66, 0.241, 277, 245, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
3184, d1cm8B_, 0.7661, 2.81, 0.213, 327, 249, PHOSPHORYLATED MAP KINASE P38-GAMMA
3185, d1cm8A_, 0.7661, 2.82, 0.213, 327, 249, PHOSPHORYLATED MAP KINASE P38-GAMMA
3186, d5t1tA_, 0.7660, 2.64, 0.287, 283, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3187, d4xh6A_, 0.7660, 2.63, 0.194, 273, 247, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
3188, d4ptgA_, 0.7660, 3.35, 0.222, 333, 257, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
3189, d4k1bA_, 0.7660, 2.74, 0.194, 273, 248, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3190, d3p08A_, 0.7660, 2.68, 0.316, 252, 244, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3191, d2wtkC1, 0.7660, 2.74, 0.233, 261, 249, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3192, d2qo2A_, 0.7660, 2.74, 0.350, 282, 246, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
3193, d2a1aB1, 0.7660, 2.68, 0.248, 266, 246, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
3194, d3v01A1, 0.7659, 3.36, 0.236, 288, 259, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3195, d2izuA_, 0.7659, 3.36, 0.157, 297, 261, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3196, d1zysA_, 0.7659, 3.29, 0.232, 271, 254, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
3197, d4tn6B_, 0.7658, 3.34, 0.185, 285, 259, CK1D IN COMPLEX WITH INHIBITOR
3198, d4p4cA_, 0.7658, 2.62, 0.354, 266, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3199, d2e9oA_, 0.7658, 3.27, 0.236, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
3200, d2cguA_, 0.7658, 3.18, 0.238, 263, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3201, d5j95A_, 0.7657, 2.96, 0.240, 284, 250, MAP4K4 IN COMPLEX WITH INHIBITOR
3202, d5k76B_, 0.7656, 2.60, 0.288, 281, 243, IRAK4 IN COMPLEX WITH COMPOUND 28
3203, d5jsmD1, 0.7656, 2.69, 0.297, 255, 246, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3204, d4bidA_, 0.7656, 2.48, 0.274, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3205, d3m11A_, 0.7656, 2.59, 0.264, 256, 246, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3206, d3bgpA_, 0.7656, 2.72, 0.194, 272, 247, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
3207, d1yxuC_, 0.7656, 2.69, 0.194, 272, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3208, d5uiuB_, 0.7655, 2.97, 0.279, 287, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
3209, d5kgkA_, 0.7655, 2.73, 0.194, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
3210, d5jzjA_, 0.7655, 2.79, 0.237, 271, 249, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3211, d4jx3A_, 0.7655, 2.73, 0.194, 274, 248, CRYSTAL STRUCTURE OF PIM1 KINASE
3212, d4j7bA_, 0.7655, 2.82, 0.249, 284, 249, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3213, d2izsA_, 0.7655, 3.58, 0.151, 298, 265, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3214, d2hyyD1, 0.7655, 2.14, 0.390, 251, 236, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3215, d1x8bA_, 0.7655, 2.61, 0.224, 259, 245, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3216, d1jstA_, 0.7655, 3.03, 0.264, 297, 254, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
3217, d4qp1A_, 0.7654, 3.13, 0.189, 342, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3218, d3r02A_, 0.7654, 2.56, 0.192, 271, 245, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3219, d3jxwA_, 0.7654, 2.65, 0.202, 274, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3220, d2xiyA_, 0.7654, 2.60, 0.195, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3221, d2j2iB_, 0.7654, 2.73, 0.194, 273, 248, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
3222, d1q4lA_, 0.7654, 3.39, 0.222, 342, 257, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
3223, d5hieD_, 0.7653, 2.40, 0.296, 253, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3224, d5c1qB_, 0.7653, 2.73, 0.194, 273, 248, SERINE/THREONINE-PROTEIN KINASE PIM-1
3225, d3jpvA_, 0.7653, 2.64, 0.194, 273, 247, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
3226, d2cjmA_, 0.7653, 3.00, 0.262, 285, 252, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
3227, d1wzyA_, 0.7653, 3.08, 0.201, 350, 254, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
3228, d4xs2C_, 0.7652, 3.01, 0.274, 281, 248, IRAK4-INHIBITOR CO-STRUCTURE
3229, d4bibA_, 0.7652, 2.50, 0.270, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3230, d3zrkA_, 0.7652, 3.46, 0.224, 345, 259, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3231, d4zy5A_, 0.7651, 2.89, 0.215, 283, 251, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3232, d4xs2D_, 0.7651, 2.68, 0.276, 277, 243, IRAK4-INHIBITOR CO-STRUCTURE
3233, d4wovB_, 0.7651, 2.29, 0.257, 256, 241, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
3234, d4cxaC_, 0.7651, 3.15, 0.253, 330, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
3235, d4bzoA_, 0.7651, 2.71, 0.190, 272, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
3236, d4bznA_, 0.7651, 2.61, 0.195, 272, 246, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
3237, d3ztxB_, 0.7651, 2.76, 0.205, 272, 249, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
3238, d2hwoA_, 0.7651, 2.02, 0.305, 251, 236, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
3239, d5k7gD_, 0.7650, 2.98, 0.280, 283, 246, IRAK4 IN COMPLEX WITH AZ3862
3240, d5acbC_, 0.7650, 3.18, 0.245, 324, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3241, d4qpaB_, 0.7650, 3.00, 0.190, 345, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3242, d4ptcA_, 0.7650, 3.38, 0.218, 342, 257, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
3243, d4hgtA_, 0.7650, 3.27, 0.198, 283, 258, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3244, d3zlyA_, 0.7650, 3.33, 0.237, 310, 257, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
3245, d3m1sB_, 0.7650, 3.37, 0.222, 349, 257, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
3246, d3krwA2, 0.7650, 3.16, 0.190, 349, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
3247, d2x7fC_, 0.7650, 2.83, 0.250, 285, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3248, d2e9vA_, 0.7650, 3.28, 0.245, 268, 253, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3249, d5kcxA_, 0.7649, 2.61, 0.195, 272, 246, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
3250, d3dkoA1, 0.7649, 2.74, 0.328, 272, 247, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
3251, d2ojiA_, 0.7649, 3.22, 0.200, 344, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3252, d1zltA_, 0.7649, 3.22, 0.234, 272, 252, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
3253, d4r6vA1, 0.7648, 2.62, 0.346, 271, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3254, d4mbiA_, 0.7648, 2.65, 0.194, 274, 247, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
3255, p2y4iC_, 0.7648, 3.34, 0.234, 313, 256, KSR2-MEK1 HETERODIMER
3256, d2cgxA_, 0.7648, 3.20, 0.242, 265, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3257, p6g9hA_, 0.7647, 3.26, 0.204, 343, 255, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3258, d3w55A_, 0.7647, 2.75, 0.198, 335, 248, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
3259, d3du8A_, 0.7647, 3.38, 0.222, 336, 257, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
3260, d3bgqA_, 0.7647, 2.61, 0.191, 272, 246, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
3261, d2e14A_, 0.7647, 2.75, 0.198, 335, 248,  
3262, d2cgvA_, 0.7647, 3.20, 0.238, 264, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3263, d5uoxB_, 0.7646, 2.47, 0.278, 252, 241, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3264, d5nhfA_, 0.7646, 3.06, 0.202, 339, 253, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3265, d5jznB_, 0.7646, 2.88, 0.236, 266, 250, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3266, d4s33A_, 0.7646, 3.09, 0.205, 347, 254, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
3267, d4fv2A_, 0.7646, 3.06, 0.206, 344, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
3268, d3du8B_, 0.7646, 3.38, 0.222, 339, 257, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
3269, d3bgzA_, 0.7646, 2.73, 0.194, 267, 247, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
3270, d2pk9A_, 0.7646, 3.05, 0.250, 287, 252, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
3271, d1yxuB_, 0.7646, 2.65, 0.194, 273, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3272, d1p4oA_, 0.7646, 2.92, 0.320, 308, 250, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3273, d4ptcB_, 0.7645, 3.38, 0.222, 347, 257, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
3274, d4nm0A1, 0.7645, 3.39, 0.222, 355, 257, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
3275, d4j7bD_, 0.7645, 2.75, 0.239, 281, 247, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3276, d4hokM_, 0.7645, 3.48, 0.189, 291, 265, CRYSTAL STRUCTURE OF APO CK1E
3277, d4fv3A_, 0.7645, 3.17, 0.201, 346, 254, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
3278, d2e9uA_, 0.7645, 3.20, 0.234, 269, 252, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
3279, p4ux9A_, 0.7644, 2.84, 0.224, 343, 250, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3280, d3zm4A_, 0.7644, 3.33, 0.242, 309, 256, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
3281, d3vw6B_, 0.7644, 2.40, 0.279, 253, 240, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3282, d1p4oB_, 0.7644, 2.93, 0.320, 314, 250, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3283, d1j1cA_, 0.7644, 3.39, 0.222, 354, 257, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
3284, d5toeA_, 0.7643, 2.62, 0.199, 272, 246, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3285, d4rmzB_, 0.7643, 3.02, 0.279, 282, 247, CRYSTAL STRUCTURE OF IRAK-4
3286, d3pizA_, 0.7643, 2.07, 0.353, 245, 238, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
3287, d3krxA2, 0.7643, 3.17, 0.190, 349, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
3288, d5turA_, 0.7642, 2.61, 0.199, 270, 246, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3289, d5fdpA_, 0.7642, 3.26, 0.323, 285, 254, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
3290, d4fv1A_, 0.7642, 3.06, 0.206, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
3291, d3zrlA_, 0.7642, 3.37, 0.223, 345, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3292, d2in6A_, 0.7642, 2.65, 0.224, 256, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3293, d4ficA_, 0.7641, 1.98, 0.306, 251, 235, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
3294, d3uysD_, 0.7641, 3.24, 0.171, 284, 257, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3295, d3q3bA_, 0.7641, 3.40, 0.222, 344, 257, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
3296, d3eidC_, 0.7641, 2.91, 0.255, 290, 251, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3297, d2ojjA_, 0.7641, 3.08, 0.205, 344, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3298, d4l46A_, 0.7640, 3.10, 0.255, 317, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
3299, d4a7cA_, 0.7640, 2.80, 0.194, 273, 248, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
3300, d3slsB1, 0.7640, 3.07, 0.249, 291, 253, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
3301, d2z2wA_, 0.7640, 2.75, 0.223, 260, 247, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3302, d2ydiA_, 0.7640, 3.35, 0.235, 279, 255, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3303, d2qodA_, 0.7640, 2.72, 0.343, 274, 245, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
3304, d2oibB_, 0.7640, 2.67, 0.280, 278, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3305, d2e9vB_, 0.7640, 3.27, 0.233, 268, 253, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3306, p6g9mA_, 0.7639, 3.28, 0.196, 341, 255, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3307, d5fdxA_, 0.7639, 3.19, 0.364, 280, 253, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3308, d1tvoA_, 0.7639, 3.29, 0.213, 350, 258, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3309, d5oq7A_, 0.7638, 2.98, 0.250, 259, 248, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3310, d5ng3C_, 0.7638, 2.77, 0.270, 272, 248, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3311, d5k5nA_, 0.7638, 3.21, 0.232, 331, 254, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3312, d5jrqA1, 0.7638, 2.73, 0.310, 257, 248, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
3313, d4hnfA_, 0.7638, 3.50, 0.179, 289, 263, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3314, d3qtiB_, 0.7638, 2.74, 0.335, 280, 245, C-MET KINASE IN COMPLEX WITH NVP-BVU972
3315, d2bzjA_, 0.7638, 2.65, 0.194, 273, 247, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
3316, d1q4lB_, 0.7638, 3.43, 0.222, 337, 257, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
3317, d4rpvA_, 0.7637, 2.75, 0.194, 273, 248, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
3318, d4ae6A_, 0.7637, 2.94, 0.206, 319, 253, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3319, d4acgA_, 0.7637, 3.40, 0.222, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3320, d3vbvA_, 0.7637, 2.58, 0.196, 268, 245, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3321, d3pyyB1, 0.7637, 1.82, 0.392, 244, 232, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3322, d2x8dA_, 0.7637, 3.35, 0.239, 279, 255, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3323, d1q3wB_, 0.7637, 3.41, 0.222, 341, 257, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
3324, d5w84A_, 0.7636, 2.71, 0.280, 279, 243, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
3325, d4rc4A_, 0.7636, 2.62, 0.199, 272, 246, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3326, d2ywpA_, 0.7636, 3.24, 0.233, 269, 253, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
3327, d5lcjA_, 0.7635, 2.98, 0.194, 345, 252, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3328, d5f95B_, 0.7635, 3.42, 0.222, 338, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3329, d5f95A_, 0.7635, 3.39, 0.222, 345, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3330, d2izrA_, 0.7635, 3.51, 0.152, 298, 263, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3331, d1yi3A_, 0.7635, 2.69, 0.195, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
3332, p6g91A_, 0.7634, 3.21, 0.193, 344, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3333, d4l3lA_, 0.7634, 3.17, 0.254, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
3334, d3vbtA_, 0.7634, 2.59, 0.196, 267, 245, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3335, d2fgaA_, 0.7634, 3.24, 0.233, 269, 253,  
3336, d5x18A_, 0.7633, 3.56, 0.155, 294, 265, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3337, d5vc4A_, 0.7633, 2.83, 0.200, 261, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3338, d4rc2A_, 0.7633, 2.62, 0.195, 272, 246, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3339, d2qoiA_, 0.7633, 2.68, 0.343, 274, 245, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
3340, d5v5yA_, 0.7632, 2.77, 0.206, 259, 248, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
3341, d5k7gC_, 0.7632, 2.98, 0.280, 283, 246, IRAK4 IN COMPLEX WITH AZ3862
3342, d2qooA_, 0.7632, 2.73, 0.339, 273, 245, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
3343, d2c3kA_, 0.7632, 3.19, 0.243, 262, 251, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3344, d1yxuA_, 0.7632, 2.67, 0.194, 273, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3345, d6b16A_, 0.7631, 3.03, 0.213, 285, 253, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3346, d5di1A_, 0.7631, 2.99, 0.240, 285, 250, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3347, d4pteA_, 0.7631, 3.29, 0.224, 341, 255, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
3348, d4mygA_, 0.7631, 2.99, 0.210, 335, 252, MAPK13 ACTIVE FORM
3349, d4as0A_, 0.7631, 2.66, 0.194, 273, 247, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
3350, d3zrmA_, 0.7631, 3.50, 0.224, 344, 259, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
3351, d3c4dA1, 0.7631, 2.54, 0.298, 257, 245,  
3352, d5vt1A1, 0.7630, 3.04, 0.246, 264, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
3353, d5o13A_, 0.7630, 2.55, 0.197, 270, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3354, d5k75C_, 0.7630, 2.66, 0.287, 282, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
3355, d3dlsB_, 0.7630, 3.04, 0.226, 280, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3356, d3c4eB_, 0.7630, 2.66, 0.194, 273, 247, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3357, d2w1eA1, 0.7630, 2.66, 0.248, 252, 246, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3358, d2fysB_, 0.7630, 2.80, 0.193, 338, 249, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3359, d5itaB_, 0.7629, 2.24, 0.292, 252, 240, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
3360, d4iq6A_, 0.7629, 3.43, 0.222, 324, 257, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3361, d3q96A_, 0.7629, 2.60, 0.306, 253, 245, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3362, d3c4eC_, 0.7629, 2.73, 0.194, 272, 247, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3363, d3c4cA1, 0.7629, 2.57, 0.294, 257, 245, B-RAF KINASE IN COMPLEX WITH PLX4720
3364, d2jldA_, 0.7629, 3.41, 0.222, 349, 257, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3365, d5op7A_, 0.7628, 3.04, 0.245, 261, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3366, d3h0zA_, 0.7628, 2.45, 0.267, 248, 243, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3367, d3bwfA_, 0.7628, 2.67, 0.198, 273, 247, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
3368, d2xixA_, 0.7628, 2.70, 0.195, 272, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3369, d1q3wA_, 0.7628, 3.41, 0.222, 344, 257, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
3370, d1p14A_, 0.7628, 2.43, 0.313, 287, 243, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3371, p6g8xA_, 0.7627, 3.34, 0.195, 338, 257, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3372, d4ll5A_, 0.7627, 2.61, 0.195, 268, 246, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3373, d3rk5A_, 0.7627, 2.90, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
3374, d3r04A_, 0.7627, 2.59, 0.196, 271, 245, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3375, d3qtwA_, 0.7627, 2.95, 0.263, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
3376, d5texA_, 0.7626, 2.69, 0.190, 274, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3377, d5k75B_, 0.7626, 2.54, 0.289, 274, 242, IRAK4 IN COMPLEX WITH COMPOUND 1
3378, d4un0C_, 0.7626, 3.24, 0.245, 308, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3379, d3f88B_, 0.7626, 3.25, 0.224, 340, 255, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
3380, d3f7zB1, 0.7626, 3.46, 0.224, 338, 259, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
3381, d3cr0A_, 0.7626, 2.72, 0.224, 257, 246, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3382, d2jldB_, 0.7626, 3.41, 0.222, 349, 257, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3383, d2gdoA_, 0.7626, 3.28, 0.242, 269, 252, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
3384, d2oibC_, 0.7625, 2.74, 0.280, 278, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3385, d1xr1A_, 0.7625, 2.91, 0.193, 277, 249, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
3386, d5k4iA_, 0.7624, 2.71, 0.199, 336, 246, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
3387, d4pnkA2, 0.7624, 3.07, 0.191, 350, 257, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
3388, d4lggB_, 0.7624, 2.07, 0.314, 245, 236, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3389, d4i41A_, 0.7624, 2.64, 0.195, 272, 246, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
3390, d3vvhA1, 0.7624, 3.25, 0.237, 286, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3391, d1o9uA_, 0.7624, 3.37, 0.223, 349, 256, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
3392, d6bqlA1, 0.7623, 3.07, 0.246, 276, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
3393, d5he1A2, 0.7623, 3.18, 0.190, 342, 258, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
3394, d4u40A_, 0.7623, 3.12, 0.240, 295, 254, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3395, d4hyhA_, 0.7623, 3.14, 0.244, 263, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
3396, d4gcjA1, 0.7623, 2.82, 0.263, 298, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3397, d3gb2A_, 0.7622, 3.49, 0.224, 340, 259, GSK3BETA INHIBITOR COMPLEX
3398, d2qofA_, 0.7622, 2.70, 0.343, 280, 245, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
3399, d4kaoA_, 0.7621, 2.70, 0.318, 252, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
3400, d3bi6A_, 0.7621, 2.75, 0.223, 258, 247, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3401, d1yxsA_, 0.7621, 2.79, 0.194, 274, 248, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
3402, d3my0X_, 0.7620, 2.50, 0.273, 257, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3403, d5t1sB_, 0.7619, 2.72, 0.277, 282, 242, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3404, d4mneA_, 0.7619, 3.42, 0.239, 286, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3405, d4apcB1, 0.7619, 2.90, 0.221, 291, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3406, d4achA_, 0.7619, 3.44, 0.222, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3407, d3vbxA_, 0.7619, 2.61, 0.196, 268, 245, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3408, d3nlbA_, 0.7619, 3.23, 0.248, 261, 250, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
3409, d4xrlA_, 0.7618, 3.22, 0.193, 337, 254, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3410, d4fuxA_, 0.7618, 3.23, 0.193, 342, 254, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
3411, d4afjB_, 0.7618, 3.16, 0.226, 346, 252, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
3412, d1yhsA_, 0.7618, 2.60, 0.196, 267, 245, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
3413, d5he0A2, 0.7617, 3.20, 0.186, 346, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
3414, d4xp2A_, 0.7617, 3.28, 0.184, 337, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3415, d3jy0A_, 0.7617, 2.88, 0.194, 275, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3416, d3c4eA_, 0.7617, 2.68, 0.194, 273, 247, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3417, d3a8wB1, 0.7617, 2.75, 0.184, 324, 250, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3418, d2e9nA_, 0.7617, 3.27, 0.233, 269, 253, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
3419, p6g92A_, 0.7616, 3.23, 0.193, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3420, d4erkA_, 0.7616, 3.41, 0.198, 350, 258, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
3421, d2f57A1, 0.7616, 3.06, 0.185, 290, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3422, d1q8yB_, 0.7616, 3.31, 0.187, 357, 257, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
3423, d5flfE_, 0.7615, 2.56, 0.399, 258, 243, DISEASE LINKED MUTATION IN FGFR
3424, d4zp5A_, 0.7615, 3.00, 0.240, 284, 250, MAP4K4 IN COMPLEX WITH INHIBITOR
3425, d4s32A_, 0.7615, 3.49, 0.200, 346, 260, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
3426, d4c3rA_, 0.7615, 2.62, 0.244, 252, 246, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3427, d3qc4B1, 0.7615, 2.80, 0.243, 268, 247, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3428, d3f88A_, 0.7615, 3.49, 0.224, 340, 259, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
3429, d2x7fA_, 0.7615, 2.80, 0.256, 276, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3430, d5uiqB_, 0.7614, 2.57, 0.282, 272, 241, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3431, p5nzzG_, 0.7614, 2.70, 0.215, 342, 246, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3432, d5he2A2, 0.7614, 3.20, 0.186, 353, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
3433, d4j71A_, 0.7614, 3.49, 0.224, 347, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3434, d3vbyA_, 0.7614, 2.61, 0.196, 267, 245, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3435, d3unjA_, 0.7614, 2.90, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
3436, d3zfyA_, 0.7613, 2.78, 0.328, 260, 244, CRYSTAL STRUCTURE OF EPHB3
3437, d2w1dA1, 0.7613, 2.62, 0.249, 251, 245, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3438, d2nryD_, 0.7613, 2.99, 0.273, 282, 245, CRYSTAL STRUCTURE OF IRAK-4
3439, d1ywvA_, 0.7613, 2.79, 0.194, 274, 248, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
3440, d1h8fB_, 0.7613, 3.44, 0.222, 350, 257, GLYCOGEN SYNTHASE KINASE 3 BETA.
3441, d5eykA_, 0.7612, 2.93, 0.188, 263, 250, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
3442, d4zzoA_, 0.7612, 3.30, 0.191, 339, 256, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3443, d4gt4A_, 0.7612, 2.65, 0.333, 274, 246, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3444, d3oriB_, 0.7612, 2.53, 0.217, 267, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3445, d2o63A_, 0.7612, 2.80, 0.194, 274, 248, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
3446, d5l4qB_, 0.7611, 2.73, 0.207, 287, 242, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3447, d3cs9C_, 0.7611, 2.17, 0.403, 243, 236, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3448, d1i09B_, 0.7611, 3.44, 0.222, 341, 257, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3449, d1h8fA_, 0.7611, 3.44, 0.222, 352, 257, GLYCOGEN SYNTHASE KINASE 3 BETA.
3450, d5uorA_, 0.7610, 2.31, 0.273, 249, 238, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3451, d4j1rD_, 0.7610, 3.51, 0.228, 345, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3452, d4j1rB_, 0.7610, 3.50, 0.224, 346, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3453, d4achB_, 0.7610, 3.45, 0.222, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3454, d3slsA1, 0.7610, 3.03, 0.246, 289, 252, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
3455, d3pupB_, 0.7610, 3.45, 0.222, 347, 257, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
3456, d3f7zA1, 0.7610, 3.39, 0.223, 338, 256, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
3457, d5oq5A_, 0.7609, 3.21, 0.246, 265, 252, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3458, d5itaA_, 0.7609, 2.37, 0.307, 250, 241, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
3459, d4lmuA_, 0.7609, 2.57, 0.197, 265, 244, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
3460, d4j1rA_, 0.7609, 3.51, 0.228, 343, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3461, d3i60A_, 0.7609, 2.61, 0.193, 335, 243, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
3462, d2i6lA_, 0.7609, 2.66, 0.217, 292, 244, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
3463, d5opuA_, 0.7608, 2.99, 0.239, 261, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3464, d4acgB_, 0.7608, 3.43, 0.222, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3465, d3we8A_, 0.7608, 2.70, 0.194, 273, 247, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
3466, d3qu0A_, 0.7608, 2.95, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
3467, d3p08B_, 0.7608, 2.75, 0.320, 258, 244, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3468, d3lokA_, 0.7608, 1.98, 0.321, 248, 234, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3469, d2xmyA_, 0.7608, 2.99, 0.259, 295, 251, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3470, d2bziB_, 0.7608, 2.65, 0.199, 272, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
3471, d5vc6A_, 0.7607, 2.82, 0.201, 259, 249, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3472, d4xp3A_, 0.7607, 3.21, 0.196, 339, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3473, d4medA_, 0.7607, 2.76, 0.194, 272, 247, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
3474, d4j1rC_, 0.7607, 3.51, 0.228, 344, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3475, d3qzfA_, 0.7607, 2.93, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
3476, d3pupA_, 0.7607, 3.45, 0.222, 346, 257, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
3477, d2xnbA_, 0.7607, 3.04, 0.267, 296, 251, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3478, d1xwsA_, 0.7607, 2.78, 0.194, 273, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
3479, d5k5nB_, 0.7606, 3.26, 0.232, 334, 254, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3480, d4ztnB_, 0.7606, 2.59, 0.278, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
3481, d4lm5A_, 0.7606, 2.58, 0.197, 264, 244, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
3482, d4iq6B_, 0.7606, 3.45, 0.222, 332, 257, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3483, d3uokB_, 0.7606, 2.79, 0.268, 265, 246, AURORA A IN COMPLEX WITH YL5-81-1
3484, d3uokA_, 0.7606, 2.79, 0.268, 265, 246, AURORA A IN COMPLEX WITH YL5-81-1
3485, d3c4dB1, 0.7606, 2.55, 0.295, 256, 244,  
3486, d1i09A_, 0.7606, 3.41, 0.218, 338, 257, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3487, p6g9dA_, 0.7605, 3.38, 0.195, 345, 257, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3488, p5nzzE_, 0.7605, 2.87, 0.213, 343, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3489, d5byyA_, 0.7605, 3.02, 0.223, 338, 251, ERK5 IN COMPLEX WITH SMALL MOLECULE
3490, d4twnA1, 0.7605, 3.04, 0.356, 275, 250, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
3491, d4afjA_, 0.7605, 3.36, 0.227, 342, 256, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
3492, d3r9dA_, 0.7605, 2.96, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
3493, d3qqkA_, 0.7605, 2.96, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L4
3494, d4rvtA_, 0.7604, 2.94, 0.238, 281, 248, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3495, d3q3bB_, 0.7604, 3.46, 0.222, 341, 257, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
3496, d3ekkA_, 0.7604, 2.51, 0.311, 285, 244, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3497, d2ydkA_, 0.7604, 3.17, 0.239, 263, 251, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3498, p6gdmA_, 0.7603, 3.08, 0.198, 341, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3499, d4xneA_, 0.7603, 3.19, 0.182, 344, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3500, d4m67A_, 0.7603, 2.41, 0.223, 264, 242, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
3501, d3rpvA_, 0.7603, 2.95, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
3502, d4acdB_, 0.7602, 3.45, 0.222, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3503, d3qtuA_, 0.7602, 2.96, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
3504, d3qruA_, 0.7602, 2.98, 0.267, 295, 251, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
3505, d3c4cB1, 0.7602, 2.48, 0.295, 256, 244, B-RAF KINASE IN COMPLEX WITH PLX4720
3506, d3a8wA1, 0.7602, 2.90, 0.179, 323, 251, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3507, d4rc3A_, 0.7601, 2.73, 0.199, 271, 246, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3508, d4bf2A_, 0.7601, 2.48, 0.271, 253, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3509, d4aguA_, 0.7601, 2.61, 0.239, 277, 243, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3510, d3rk7A_, 0.7601, 2.94, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
3511, d3my0K_, 0.7601, 2.57, 0.277, 261, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3512, d3erkA_, 0.7601, 3.33, 0.200, 350, 255, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
3513, d5vuaB_, 0.7600, 2.70, 0.192, 270, 245, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3514, d5uisB_, 0.7600, 2.60, 0.286, 274, 241, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
3515, d4qp8A_, 0.7600, 2.71, 0.195, 335, 246, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3516, p4h3pD_, 0.7600, 2.72, 0.203, 338, 246, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3517, d3uo6A_, 0.7600, 2.81, 0.268, 264, 246, AURORA A IN COMPLEX WITH YL5-083
3518, d3oriA_, 0.7600, 2.54, 0.217, 267, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3519, d2hxlA_, 0.7600, 3.24, 0.239, 272, 251, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
3520, p6c3eA_, 0.7599, 2.86, 0.266, 258, 244, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
3521, d4zznA_, 0.7599, 3.12, 0.198, 338, 253, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
3522, d4ae9A_, 0.7599, 2.97, 0.206, 321, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
3523, d4acdA_, 0.7599, 3.46, 0.222, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3524, d3uo6B_, 0.7599, 2.81, 0.268, 264, 246, AURORA A IN COMPLEX WITH YL5-083
3525, d1m7nB_, 0.7599, 2.99, 0.320, 299, 250, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3526, d5ar7A_, 0.7598, 2.71, 0.268, 278, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3527, d4nfnA_, 0.7598, 3.36, 0.162, 293, 259, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
3528, d4kbkA_, 0.7598, 3.15, 0.185, 283, 254, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3529, d4ditA_, 0.7598, 3.25, 0.226, 328, 252, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
3530, d1v0oA_, 0.7598, 2.89, 0.252, 276, 246, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
3531, d5umoA_, 0.7597, 3.33, 0.196, 347, 255, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
3532, d5lckA_, 0.7597, 3.04, 0.187, 345, 251, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3533, d3ti1A_, 0.7597, 2.97, 0.260, 294, 250, CDK2 IN COMPLEX WITH SUNITINIB
3534, d3pvuA2, 0.7597, 3.22, 0.190, 340, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
3535, p5nzzF_, 0.7596, 2.85, 0.214, 341, 248, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3536, d4h58C_, 0.7596, 2.76, 0.300, 272, 247, BRAF IN COMPLEX WITH COMPOUND 3
3537, d4enxA_, 0.7596, 2.55, 0.193, 266, 243, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
3538, d3mvjB_, 0.7596, 3.10, 0.185, 320, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
3539, d2qg5A1, 0.7596, 3.24, 0.193, 268, 254, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3540, d1golA_, 0.7596, 3.23, 0.197, 357, 254, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
3541, d6bu6A_, 0.7595, 3.43, 0.148, 322, 264, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3542, d5hlpA_, 0.7595, 3.54, 0.228, 337, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
3543, d3unzB_, 0.7595, 2.78, 0.268, 263, 246, AURORA A IN COMPLEX WITH RPM1679
3544, d3unzA_, 0.7595, 2.78, 0.268, 263, 246, AURORA A IN COMPLEX WITH RPM1679
3545, d3sd0B_, 0.7595, 3.46, 0.222, 349, 257, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
3546, d3qtxA_, 0.7595, 2.94, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
3547, p6g9nA_, 0.7594, 3.41, 0.195, 344, 257, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3548, d5w85B_, 0.7594, 2.60, 0.278, 279, 241, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
3549, d5l4qA_, 0.7594, 2.76, 0.211, 293, 242, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3550, d5ko1A_, 0.7594, 2.47, 0.226, 265, 243, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
3551, d4ztrA_, 0.7594, 2.49, 0.259, 249, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3552, d4cjyC_, 0.7594, 3.23, 0.246, 303, 256,  
3553, d2xneA_, 0.7594, 2.52, 0.263, 246, 243, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3554, d4l3jA_, 0.7593, 3.12, 0.251, 291, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
3555, d4jjrA_, 0.7593, 3.02, 0.190, 284, 252, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3556, d4b9dB1, 0.7593, 2.95, 0.225, 291, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3557, d3uojB_, 0.7593, 2.79, 0.264, 263, 246, AURORA A IN COMPLEX WITH RPM1715
3558, d2c47D1, 0.7593, 3.40, 0.158, 289, 259, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3559, d4iz7A_, 0.7592, 3.14, 0.197, 344, 254, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3560, d4g6nA_, 0.7592, 3.25, 0.193, 341, 254, CRYSTAL STRUCTURE OF THE ERK2
3561, d3uojA_, 0.7592, 2.79, 0.264, 263, 246, AURORA A IN COMPLEX WITH RPM1715
3562, d3uohB_, 0.7592, 2.81, 0.268, 264, 246, AURORA A IN COMPLEX WITH RPM1722
3563, d3uohA_, 0.7592, 2.81, 0.268, 264, 246, AURORA A IN COMPLEX WITH RPM1722
3564, d3rk9A_, 0.7592, 2.98, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
3565, d4s34A_, 0.7591, 3.46, 0.197, 343, 259, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
3566, d4s2zA_, 0.7591, 3.34, 0.196, 346, 255, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
3567, d3qtzA_, 0.7591, 2.94, 0.264, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
3568, d3py0A_, 0.7591, 2.91, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR SU9516
3569, d3dkgA_, 0.7591, 2.90, 0.322, 281, 245, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
3570, d4zzmA_, 0.7590, 3.38, 0.202, 344, 257, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3571, d4accB_, 0.7590, 3.47, 0.222, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3572, d3o23A_, 0.7590, 2.96, 0.325, 293, 249, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
3573, d2fumD_, 0.7590, 2.59, 0.219, 258, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3574, d1yi4A_, 0.7590, 2.64, 0.196, 267, 245, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3575, d5ukfA_, 0.7589, 3.51, 0.143, 322, 265, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3576, d5jzjB_, 0.7589, 2.82, 0.239, 261, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3577, d4lghB_, 0.7589, 2.07, 0.319, 247, 235, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3578, d4g6oA_, 0.7589, 3.18, 0.198, 339, 252, CRYSTAL STRUCTURE OF THE ERK2
3579, d4accA_, 0.7589, 3.47, 0.222, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3580, d3ii5B_, 0.7589, 2.70, 0.305, 257, 246, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3581, d3c9wA2, 0.7589, 2.80, 0.198, 335, 247, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3582, d2ghgA1, 0.7589, 3.37, 0.240, 269, 254, H-CHK1 COMPLEXED WITH A431994
3583, p6ge0A_, 0.7588, 3.35, 0.195, 343, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3584, p6cpwA_, 0.7588, 3.18, 0.182, 328, 253, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
3585, d5vc5A_, 0.7588, 2.90, 0.200, 261, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
3586, d4j71B_, 0.7588, 3.54, 0.224, 347, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3587, d4iaaA_, 0.7588, 2.77, 0.194, 272, 247, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
3588, d3oz6B_, 0.7588, 2.81, 0.267, 341, 247, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
3589, d4yfiC_, 0.7587, 2.65, 0.272, 269, 239, TNNI3K COMPLEXED WITH INHIBITOR 1
3590, d4gt3A_, 0.7587, 3.14, 0.206, 347, 253, ATP-BOUND FORM OF THE ERK2 KINASE
3591, d3rniA_, 0.7587, 2.95, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
3592, d3rjcA_, 0.7587, 2.97, 0.264, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L4-12
3593, d3dy7A_, 0.7587, 3.10, 0.247, 260, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3594, d5w85A_, 0.7586, 2.69, 0.286, 278, 241, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
3595, d5fdxB_, 0.7586, 3.16, 0.329, 274, 249, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3596, d3ql8A_, 0.7586, 2.94, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
3597, d3pyyA1, 0.7586, 2.38, 0.392, 251, 237, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3598, d3pvwA2, 0.7586, 3.24, 0.182, 343, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
3599, d2o65A_, 0.7586, 2.73, 0.194, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
3600, d1pxnA_, 0.7586, 2.96, 0.272, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
3601, d1erkA_, 0.7586, 3.36, 0.196, 357, 255, STRUCTURE OF SIGNAL-REGULATED KINASE
3602, d5vubB_, 0.7585, 2.68, 0.189, 269, 244, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3603, d3qqgA_, 0.7585, 2.91, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2-5
3604, d2f49A_, 0.7585, 2.87, 0.237, 335, 249, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3605, d4hniA_, 0.7584, 3.28, 0.183, 284, 257, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3606, d1m7nA_, 0.7584, 2.94, 0.321, 299, 249, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3607, d4joaA_, 0.7583, 2.33, 0.314, 250, 236, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 7-AZAINDOLE BASED INHIBITOR
3608, d4aguB_, 0.7583, 2.65, 0.239, 276, 243, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3609, d3unkA_, 0.7583, 3.02, 0.263, 295, 251, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
3610, d3qqjA_, 0.7583, 2.95, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2
3611, d2j4zA_, 0.7583, 2.81, 0.247, 263, 247, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3612, d2hxqA_, 0.7583, 3.31, 0.242, 272, 252, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
3613, d2exmA_, 0.7583, 3.08, 0.266, 298, 252, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
3614, d1s9iB_, 0.7583, 3.25, 0.241, 291, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3615, d1pxpA_, 0.7583, 2.97, 0.260, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
3616, d6b8uA_, 0.7582, 2.68, 0.306, 253, 245, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
3617, d4zy6A_, 0.7582, 3.07, 0.214, 284, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3618, d4ez3A_, 0.7582, 2.87, 0.262, 294, 248, CDK2 IN COMPLEX WITH NSC 134199
3619, d4aguC_, 0.7582, 2.64, 0.239, 278, 243, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3620, d5oq7B_, 0.7581, 2.94, 0.253, 256, 245, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3621, d2a0cX_, 0.7581, 3.00, 0.268, 294, 250, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
3622, d5k75D_, 0.7580, 2.65, 0.285, 280, 242, IRAK4 IN COMPLEX WITH COMPOUND 1
3623, d4kd1A_, 0.7580, 3.06, 0.266, 298, 252, CDK2 IN COMPLEX WITH DINACICLIB
3624, d4bgqA_, 0.7580, 2.69, 0.229, 276, 245, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
3625, d1gngA_, 0.7580, 3.54, 0.224, 348, 259, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
3626, d5v24A_, 0.7579, 2.39, 0.282, 249, 238, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3627, d5es1A_, 0.7579, 2.49, 0.293, 304, 242, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3628, d4l43A_, 0.7579, 3.02, 0.258, 316, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
3629, d3a99A_, 0.7579, 2.82, 0.194, 273, 247, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
3630, d2nryC_, 0.7579, 2.86, 0.272, 280, 243, CRYSTAL STRUCTURE OF IRAK-4
3631, d5byzA_, 0.7578, 3.35, 0.227, 348, 255, ERK5 IN COMPLEX WITH SMALL MOLECULE
3632, d4ztsA_, 0.7578, 2.52, 0.259, 249, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3633, d4nfmA_, 0.7578, 3.39, 0.158, 293, 259, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
3634, d4l45A_, 0.7578, 3.05, 0.262, 317, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
3635, d1v0oB_, 0.7578, 2.81, 0.258, 274, 244, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
3636, d5hlpB_, 0.7577, 3.56, 0.228, 335, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
3637, p4ux9C_, 0.7577, 2.84, 0.226, 333, 248, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3638, d4ithB_, 0.7577, 2.89, 0.265, 270, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
3639, d3pxyA_, 0.7577, 2.95, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS648
3640, d3c9wB2, 0.7577, 2.84, 0.198, 335, 247, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3641, d3uolB_, 0.7576, 2.82, 0.268, 263, 246, AURORA A IN COMPLEX WITH SO2-162
3642, d3uolA_, 0.7576, 2.82, 0.268, 263, 246, AURORA A IN COMPLEX WITH SO2-162
3643, d3uixA_, 0.7576, 2.57, 0.193, 266, 243, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3644, d3r63A_, 0.7576, 3.37, 0.195, 347, 257, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
3645, d2a19B1, 0.7576, 2.88, 0.248, 261, 246, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
3646, d6bruA_, 0.7575, 3.46, 0.148, 322, 264, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3647, d5vdkA_, 0.7575, 2.88, 0.214, 260, 248, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3648, d5ukmA2, 0.7575, 3.31, 0.167, 353, 258, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
3649, d5hzeA_, 0.7575, 3.15, 0.245, 305, 253, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
3650, d3v5wA2, 0.7575, 3.23, 0.183, 355, 257, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
3651, d5vucB_, 0.7574, 2.59, 0.189, 269, 243, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3652, d4rblA_, 0.7574, 2.75, 0.195, 271, 246, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3653, d4hokE_, 0.7574, 3.49, 0.192, 291, 261, CRYSTAL STRUCTURE OF APO CK1E
3654, d2cgwA_, 0.7574, 3.25, 0.243, 262, 251, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3655, d5vd2A_, 0.7573, 2.80, 0.206, 258, 248, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3656, d3qzgA_, 0.7573, 2.97, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
3657, d3qywA_, 0.7573, 3.37, 0.210, 340, 257, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3658, d2z7lA_, 0.7573, 3.29, 0.192, 329, 255, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
3659, d1j3hA_, 0.7573, 2.93, 0.199, 329, 251, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3660, d4s31A_, 0.7572, 3.47, 0.190, 347, 258, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
3661, d3we4A_, 0.7572, 3.13, 0.260, 286, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
3662, d3cikA2, 0.7572, 3.28, 0.182, 347, 258, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3663, d4qp3A_, 0.7571, 2.94, 0.185, 339, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
3664, d4hokU_, 0.7571, 3.50, 0.192, 289, 261, CRYSTAL STRUCTURE OF APO CK1E
3665, d3pj1A_, 0.7571, 2.09, 0.352, 241, 236, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
3666, d2bcjA3, 0.7571, 3.19, 0.187, 348, 257, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
3667, d4lg4C_, 0.7570, 2.95, 0.256, 288, 250, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3668, d5valB_, 0.7569, 2.60, 0.303, 254, 244, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3669, d4qp7B_, 0.7569, 2.76, 0.195, 335, 246, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3670, d3pj3A_, 0.7569, 1.92, 0.343, 240, 233, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
3671, d2bikB_, 0.7569, 2.69, 0.195, 272, 246, HUMAN PIM1 PHOSPHORYLATED ON SER261
3672, d2b54A_, 0.7569, 3.06, 0.255, 298, 251, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
3673, d4qygB_, 0.7568, 3.28, 0.244, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3674, d4hokI_, 0.7568, 3.47, 0.192, 291, 261, CRYSTAL STRUCTURE OF APO CK1E
3675, d4fv6A_, 0.7568, 2.71, 0.201, 332, 244, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
3676, d4enyA_, 0.7568, 2.55, 0.198, 261, 242, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
3677, d3qxpA_, 0.7568, 3.03, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3678, d1ia8A_, 0.7568, 3.33, 0.242, 272, 252, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
3679, d5v19A_, 0.7567, 2.30, 0.283, 250, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3680, d5k00A_, 0.7567, 2.55, 0.240, 311, 242, MELK IN COMPLEX WITH NVS-MELK5
3681, d4mneD_, 0.7567, 3.38, 0.242, 285, 256, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3682, d3tiyA_, 0.7567, 2.97, 0.269, 293, 249, CDK2 IN COMPLEX WITH NSC 35676
3683, d3r8lA_, 0.7567, 2.99, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L3-4
3684, d1ym7D3, 0.7567, 3.18, 0.183, 340, 257, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3685, d4yfiA_, 0.7566, 2.60, 0.261, 268, 238, TNNI3K COMPLEXED WITH INHIBITOR 1
3686, d4s30A_, 0.7566, 3.45, 0.199, 342, 256, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
3687, d1ym7C3, 0.7566, 3.18, 0.183, 346, 257, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3688, d1ym7A3, 0.7566, 3.18, 0.183, 347, 257, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3689, d6bu6D_, 0.7565, 3.56, 0.152, 318, 264, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3690, d5uirB_, 0.7565, 2.63, 0.282, 273, 241, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
3691, d5he3A2, 0.7565, 3.26, 0.186, 346, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
3692, d5d9kB_, 0.7565, 2.90, 0.214, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3693, d5ci6B_, 0.7565, 2.72, 0.213, 350, 244, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
3694, d3r9hA_, 0.7565, 3.01, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
3695, d3qtqA_, 0.7565, 3.01, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
3696, d3pscA2, 0.7565, 3.28, 0.182, 344, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3697, d1ym7B3, 0.7565, 3.19, 0.183, 347, 257, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3698, d5vc3A_, 0.7564, 2.86, 0.205, 260, 249, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3699, d5uirA_, 0.7564, 2.70, 0.290, 270, 241, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
3700, d5op5A_, 0.7564, 3.05, 0.239, 259, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3701, d4l42A_, 0.7564, 3.17, 0.259, 299, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
3702, d3umwA_, 0.7564, 2.60, 0.189, 264, 243, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
3703, d4tthB_, 0.7563, 2.74, 0.239, 256, 243, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
3704, d4bf2B_, 0.7563, 2.46, 0.280, 252, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3705, d3tizA_, 0.7563, 2.96, 0.269, 293, 249, CDK2 IN COMPLEX WITH NSC 111848
3706, d4hokW_, 0.7562, 3.49, 0.192, 289, 260, CRYSTAL STRUCTURE OF APO CK1E
3707, d4dbnB_, 0.7562, 2.59, 0.305, 263, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3708, d4btkA_, 0.7562, 3.30, 0.152, 287, 256, TTBK1 IN COMPLEX WITH INHIBITOR
3709, d3qqhA_, 0.7562, 2.94, 0.264, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2-2
3710, d3h0yA_, 0.7562, 2.66, 0.262, 250, 244, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3711, d2qvsE_, 0.7562, 3.08, 0.202, 323, 253, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
3712, d2c47B_, 0.7562, 3.39, 0.159, 289, 258, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3713, d4n4sA_, 0.7561, 3.11, 0.190, 342, 252, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
3714, d4hyiA_, 0.7561, 3.27, 0.239, 269, 251, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
3715, d3vapA_, 0.7561, 2.68, 0.266, 249, 244, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
3716, d2x8eA_, 0.7561, 3.08, 0.246, 259, 248, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3717, d2oibA_, 0.7561, 2.78, 0.273, 280, 242, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3718, d2brnA_, 0.7561, 3.30, 0.226, 268, 252, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3719, d4ztmB_, 0.7560, 2.73, 0.279, 280, 240, IRAK4-INHIBITOR CO-STRUCTURE
3720, d4itjA_, 0.7560, 2.76, 0.269, 261, 242, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3721, d3ormA_, 0.7560, 2.62, 0.217, 266, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
3722, d2x8iA_, 0.7560, 3.13, 0.238, 261, 248, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3723, d2br1A_, 0.7560, 3.33, 0.238, 272, 252, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3724, d1fotA_, 0.7560, 3.03, 0.206, 299, 252, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
3725, d5imeA1, 0.7559, 2.69, 0.221, 279, 244, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3726, d4iz7C_, 0.7559, 2.85, 0.202, 340, 248, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3727, d2qolA_, 0.7559, 2.72, 0.331, 271, 242, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
3728, d3rm7A_, 0.7558, 2.99, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
3729, d3idpA_, 0.7558, 2.79, 0.305, 255, 246, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3730, d3d2kA_, 0.7558, 2.48, 0.254, 245, 240, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
3731, d2clxA_, 0.7558, 2.97, 0.261, 293, 249, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
3732, d4qyhB_, 0.7557, 3.24, 0.245, 264, 249, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3733, d3sd0A_, 0.7557, 3.52, 0.222, 350, 257, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
3734, d1r0eB_, 0.7557, 3.49, 0.222, 344, 257, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
3735, d3qxoA_, 0.7556, 2.97, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
3736, d2ow3B_, 0.7556, 3.50, 0.223, 351, 256, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
3737, d1pf8A_, 0.7556, 2.87, 0.263, 298, 247, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
3738, d5oneA_, 0.7555, 2.87, 0.269, 257, 245, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
3739, d5o11A_, 0.7555, 2.57, 0.194, 268, 242, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3740, d4kspB_, 0.7555, 2.57, 0.306, 256, 242, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3741, d3qyzA_, 0.7555, 3.51, 0.216, 339, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3742, d5jt2B1, 0.7554, 2.69, 0.322, 250, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3743, d3zhpC1, 0.7554, 2.96, 0.268, 267, 250, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3744, d3t9iA_, 0.7554, 2.81, 0.187, 273, 246, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3745, d2broA_, 0.7554, 3.43, 0.225, 272, 253, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3746, p4ux9B_, 0.7553, 2.80, 0.220, 327, 246, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3747, d4p41B_, 0.7553, 2.78, 0.243, 256, 243,  
3748, d3uzpB_, 0.7553, 3.31, 0.195, 284, 256, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3749, d3s0oA_, 0.7553, 3.03, 0.256, 293, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
3750, d5k72A_, 0.7552, 2.56, 0.280, 277, 239, IRAK4 IN COMPLEX WITH COMPOUND 21
3751, d4qygA_, 0.7552, 3.13, 0.239, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3752, d4itiB_, 0.7552, 2.72, 0.266, 270, 241, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3753, d3qrjB1, 0.7552, 2.54, 0.392, 252, 237, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
3754, d1ykrA_, 0.7552, 3.10, 0.263, 298, 251, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
3755, d4fkuA_, 0.7551, 3.01, 0.261, 293, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3756, d2qlqB_, 0.7551, 2.08, 0.321, 248, 234, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
3757, d1r0eA_, 0.7551, 3.50, 0.222, 344, 257, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
3758, d4hniB_, 0.7550, 3.19, 0.189, 284, 254, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3759, d3op5A_, 0.7550, 3.52, 0.144, 320, 264, HUMAN VACCINIA-RELATED KINASE 1
3760, d5o21A_, 0.7549, 3.01, 0.272, 272, 250, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3761, d5hesB_, 0.7549, 2.55, 0.322, 278, 239, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
3762, d4xrjA_, 0.7549, 3.36, 0.189, 344, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3763, d4xozA_, 0.7549, 3.36, 0.189, 341, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3764, d4qp4B_, 0.7549, 2.78, 0.195, 335, 246, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3765, d4fv8A_, 0.7549, 2.73, 0.201, 333, 244, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
3766, d3r28A_, 0.7549, 2.95, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
3767, d5ootA_, 0.7548, 3.13, 0.242, 260, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3768, d3qwkA_, 0.7548, 3.03, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
3769, d4qtaA_, 0.7547, 2.76, 0.209, 335, 244, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3770, d4itiA_, 0.7547, 2.96, 0.265, 272, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3771, d3v6rA_, 0.7547, 2.86, 0.206, 349, 248, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
3772, d2ow3A_, 0.7547, 3.57, 0.229, 346, 258, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
3773, d2fa2A_, 0.7547, 2.93, 0.233, 333, 249, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
3774, d4xp0A_, 0.7546, 3.39, 0.192, 336, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3775, d3repA_, 0.7546, 3.02, 0.255, 268, 251, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
3776, d3f69A_, 0.7546, 2.77, 0.215, 270, 247, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3777, d1jqhA_, 0.7546, 3.15, 0.296, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
3778, d3r8zA_, 0.7545, 3.07, 0.268, 290, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
3779, d3r1qA_, 0.7545, 2.95, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
3780, d2qlqA_, 0.7545, 1.93, 0.312, 245, 231, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
3781, p6g9jA_, 0.7544, 3.38, 0.188, 347, 255, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3782, d5k72D_, 0.7544, 2.63, 0.287, 276, 240, IRAK4 IN COMPLEX WITH COMPOUND 21
3783, d4qp6A_, 0.7544, 2.98, 0.185, 339, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3784, d4kbkD_, 0.7544, 3.28, 0.173, 281, 254, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3785, d3kmwA_, 0.7544, 3.03, 0.255, 268, 251, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
3786, d2io6A_, 0.7544, 2.61, 0.216, 252, 241, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
3787, d2c47A_, 0.7544, 3.37, 0.156, 288, 257, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3788, d1jqhC_, 0.7544, 3.11, 0.302, 291, 252, IGF-1 RECEPTOR KINASE DOMAIN
3789, d4ntsA_, 0.7543, 2.98, 0.199, 341, 251, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3790, d3qqfA_, 0.7543, 3.00, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L1
3791, d2c3jA_, 0.7543, 3.05, 0.240, 257, 246, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3792, d1hckA_, 0.7543, 3.05, 0.268, 294, 250, HUMAN CYCLIN-DEPENDENT KINASE 2
3793, d5uklA2, 0.7542, 3.17, 0.164, 353, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
3794, d5oopA_, 0.7542, 3.21, 0.240, 261, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
3795, d4kb8D_, 0.7542, 3.20, 0.182, 278, 253, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3796, d4erwA_, 0.7542, 3.02, 0.257, 292, 249, CDK2 IN COMPLEX WITH STAUROSPORINE
3797, d3q4zA1, 0.7542, 2.79, 0.207, 281, 246, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3798, d2brbA_, 0.7542, 3.33, 0.239, 272, 251, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3799, d5k72C_, 0.7541, 2.98, 0.284, 277, 243, IRAK4 IN COMPLEX WITH COMPOUND 21
3800, d5d9kA_, 0.7541, 2.90, 0.215, 280, 247, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3801, d5acbD_, 0.7541, 3.29, 0.251, 319, 255, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3802, d4qp2A_, 0.7541, 3.00, 0.185, 336, 248, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3803, d3p86A_, 0.7541, 2.51, 0.328, 250, 241, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
3804, d3en7A_, 0.7541, 1.99, 0.310, 247, 232, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
3805, d2qg5D1, 0.7541, 3.22, 0.194, 267, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3806, d5csxA_, 0.7540, 2.98, 0.302, 261, 248, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
3807, d1pmeA_, 0.7540, 3.20, 0.203, 333, 251, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
3808, d5uiqA_, 0.7539, 2.70, 0.276, 268, 239, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3809, d3s00A_, 0.7539, 3.01, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L4-14
3810, d3qzhA_, 0.7539, 2.97, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
3811, d4o6eA_, 0.7538, 2.82, 0.204, 328, 245, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
3812, d4kbcB_, 0.7538, 3.18, 0.190, 277, 252, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3813, d3zfyB_, 0.7538, 2.68, 0.325, 255, 240, CRYSTAL STRUCTURE OF EPHB3
3814, d3royA_, 0.7538, 2.97, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
3815, d2f49B_, 0.7538, 2.94, 0.233, 337, 249, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3816, p5nzzH_, 0.7537, 2.86, 0.215, 335, 247, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3817, d4xs2B_, 0.7537, 2.84, 0.274, 278, 241, IRAK4-INHIBITOR CO-STRUCTURE
3818, d3r8pA_, 0.7536, 3.03, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
3819, p5lw1H_, 0.7535, 3.11, 0.210, 355, 252, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3820, d4fv0A_, 0.7535, 3.29, 0.194, 341, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
3821, d3r7vA_, 0.7535, 3.01, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
3822, d5t1tB_, 0.7534, 2.61, 0.280, 280, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3823, d3r8mA_, 0.7534, 2.95, 0.258, 286, 248, CDK2 IN COMPLEX WITH INHIBITOR L3-3
3824, d3qx4A_, 0.7534, 3.02, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
3825, d3py3A1, 0.7534, 3.03, 0.212, 352, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
3826, d4f0gA1, 0.7533, 2.57, 0.282, 260, 241, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
3827, d3r8uA_, 0.7533, 3.05, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
3828, d3r6xA_, 0.7533, 2.98, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
3829, d1q3dB_, 0.7533, 3.55, 0.222, 339, 257, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3830, d2cmwA_, 0.7532, 3.38, 0.163, 294, 258, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
3831, d2c6oA_, 0.7532, 2.97, 0.258, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3832, d5d10A_, 0.7531, 2.18, 0.302, 248, 235, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
3833, d4bcqA1, 0.7531, 3.07, 0.260, 289, 250, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3834, d3r1sA_, 0.7531, 3.03, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
3835, d3qqlA_, 0.7531, 3.02, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L3
3836, d5o21B_, 0.7530, 3.07, 0.276, 273, 250, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3837, d4u42A_, 0.7530, 3.06, 0.241, 282, 249, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
3838, d4ez7A1, 0.7530, 3.17, 0.260, 298, 250, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
3839, d3zhpD_, 0.7530, 2.91, 0.250, 264, 248, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3840, d3rkbA_, 0.7530, 3.09, 0.264, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
3841, d3r73A_, 0.7530, 2.98, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
3842, d3r1yA_, 0.7530, 3.08, 0.272, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
3843, d3k54A_, 0.7530, 2.22, 0.322, 243, 236, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
3844, d1pxjA_, 0.7530, 3.06, 0.268, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
3845, d5tkdB_, 0.7529, 2.23, 0.254, 247, 236, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
3846, d5c9cA_, 0.7529, 2.82, 0.306, 254, 245, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3847, d3r7eA_, 0.7529, 3.02, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
3848, d3py1A1, 0.7529, 3.22, 0.253, 298, 249, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3849, d5op4A_, 0.7528, 3.11, 0.239, 259, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
3850, d3qwjA_, 0.7528, 3.03, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
3851, d2fumC_, 0.7528, 2.42, 0.223, 254, 238, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3852, d2b53A_, 0.7528, 3.00, 0.253, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
3853, d5ukkA2, 0.7527, 3.31, 0.190, 348, 258, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
3854, d5oorA_, 0.7527, 3.24, 0.245, 273, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
3855, d4mneH_, 0.7527, 3.20, 0.245, 275, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3856, d4hokO_, 0.7527, 3.60, 0.191, 290, 262, CRYSTAL STRUCTURE OF APO CK1E
3857, d3rpoA_, 0.7527, 3.04, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
3858, d4fv5A_, 0.7526, 2.50, 0.197, 330, 239, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
3859, d4ficB_, 0.7526, 2.05, 0.323, 245, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
3860, d1omwA3, 0.7526, 3.31, 0.178, 344, 258, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
3861, d5bujA_, 0.7525, 2.66, 0.202, 331, 242, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
3862, d3uysA_, 0.7525, 3.37, 0.173, 281, 255, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3863, d5opvA_, 0.7524, 3.15, 0.243, 261, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3864, d4hokS_, 0.7524, 3.56, 0.188, 286, 261, CRYSTAL STRUCTURE OF APO CK1E
3865, d4b99A_, 0.7524, 3.15, 0.223, 335, 251, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
3866, d3r8vA_, 0.7524, 3.06, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
3867, d3q96B_, 0.7524, 2.68, 0.300, 262, 243, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3868, d2hwpA_, 0.7524, 1.96, 0.290, 245, 231, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3869, d1pxoA_, 0.7524, 3.04, 0.264, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
3870, p5lw1B_, 0.7523, 3.13, 0.210, 355, 252, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3871, d5hx6A_, 0.7523, 2.90, 0.272, 259, 243, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
3872, d4wa9A1, 0.7523, 2.10, 0.366, 236, 232, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3873, d4aotA1, 0.7523, 2.84, 0.263, 276, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3874, d3qrtA_, 0.7523, 3.03, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
3875, d2brmA_, 0.7523, 3.18, 0.229, 263, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3876, d3i5zA_, 0.7522, 2.51, 0.197, 331, 239, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
3877, d2e9pA_, 0.7522, 3.31, 0.235, 269, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
3878, d5x18B_, 0.7521, 3.75, 0.154, 294, 266, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3879, p5lw1E_, 0.7521, 3.14, 0.214, 355, 252, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3880, d4qyhA_, 0.7521, 3.18, 0.243, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3881, d3r7yA_, 0.7521, 3.06, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3882, d3qx2A_, 0.7521, 3.05, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
3883, d3pxrA_, 0.7521, 2.99, 0.256, 294, 250, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
3884, d3oriD_, 0.7521, 2.64, 0.217, 267, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3885, d1ol6A_, 0.7520, 2.59, 0.244, 245, 242, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3886, d5oprA_, 0.7519, 3.08, 0.244, 258, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
3887, d4lggA_, 0.7519, 2.03, 0.302, 241, 232, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3888, d1r1wA_, 0.7519, 2.97, 0.328, 287, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
3889, d5eakA_, 0.7518, 2.92, 0.285, 305, 246, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3890, d2j4zB_, 0.7518, 3.00, 0.247, 269, 247, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3891, d1q3dA_, 0.7518, 3.59, 0.222, 339, 257, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3892, d5valA_, 0.7517, 2.55, 0.307, 254, 241, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3893, d3oz6A_, 0.7517, 2.98, 0.250, 343, 248, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
3894, d4kbaD_, 0.7516, 3.28, 0.178, 274, 253, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3895, d4hokA_, 0.7516, 3.72, 0.186, 290, 263, CRYSTAL STRUCTURE OF APO CK1E
3896, d3ag9A_, 0.7516, 3.07, 0.183, 323, 251, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
3897, d4b9dA1, 0.7515, 3.03, 0.222, 286, 248, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3898, d3v6sA_, 0.7515, 3.03, 0.211, 349, 251, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
3899, d3ggfA_, 0.7515, 2.97, 0.289, 275, 249, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
3900, d3bizA_, 0.7515, 2.62, 0.216, 250, 241, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
3901, d2uzoA_, 0.7515, 2.99, 0.258, 290, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3902, d2bdwA_, 0.7515, 3.44, 0.216, 309, 259, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3903, d5opsA_, 0.7513, 3.05, 0.245, 258, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3904, d5k7gA_, 0.7513, 2.86, 0.275, 277, 240, IRAK4 IN COMPLEX WITH AZ3862
3905, d4zsjA_, 0.7513, 3.34, 0.203, 344, 256, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3906, d4fsuA_, 0.7513, 3.31, 0.250, 260, 248, CRYSTAL STRUCTURE OF THE CHK1
3907, d3zfmA_, 0.7513, 2.61, 0.322, 248, 239, CRYSTAL STRUCTURE OF EPHB2
3908, d1pxlA_, 0.7513, 2.90, 0.264, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
3909, d5ajqA_, 0.7512, 3.21, 0.253, 280, 249, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3910, d4n0sA_, 0.7512, 3.10, 0.203, 348, 251, COMPLEX OF ERK2 WITH CAFFEIC ACID
3911, d3cohB_, 0.7512, 2.58, 0.249, 247, 241, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3912, d4fc0B_, 0.7511, 2.73, 0.303, 263, 244, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3913, d4apcA1, 0.7510, 3.03, 0.222, 289, 248, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3914, d3uliA_, 0.7510, 3.05, 0.258, 286, 248, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
3915, d3qziA_, 0.7510, 2.99, 0.256, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
3916, d3oriC_, 0.7510, 2.65, 0.217, 267, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3917, d3cohA_, 0.7510, 2.58, 0.249, 247, 241, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3918, d2c6iA_, 0.7510, 3.01, 0.262, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3919, d5bueA_, 0.7509, 2.77, 0.202, 329, 243, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
3920, d4rvmA_, 0.7509, 3.25, 0.242, 264, 248, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
3921, d3sa0A_, 0.7509, 3.47, 0.187, 354, 256, COMPLEX OF ERK2 WITH NORATHYRIOL
3922, d1y8yA_, 0.7509, 2.99, 0.262, 292, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3923, d1jqhB_, 0.7509, 3.24, 0.296, 287, 253, IGF-1 RECEPTOR KINASE DOMAIN
3924, d3raiA_, 0.7508, 3.05, 0.260, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
3925, d1sykA_, 0.7508, 3.16, 0.175, 348, 252, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3926, d1f5qA_, 0.7508, 3.20, 0.259, 296, 251, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
3927, d5uiqD_, 0.7507, 2.68, 0.277, 271, 238, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3928, d3my0J_, 0.7507, 2.20, 0.286, 252, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3929, d1sykB_, 0.7507, 3.17, 0.175, 323, 252, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3930, d5cswB_, 0.7506, 2.63, 0.306, 252, 242, B-RAF IN COMPLEX WITH DABRAFENIB
3931, d4zxtA_, 0.7506, 3.20, 0.198, 348, 252, COMPLEX OF ERK2 WITH CATECHOL
3932, d2oj9A_, 0.7506, 3.11, 0.301, 295, 249, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
3933, d2wmrA_, 0.7505, 3.00, 0.246, 254, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3934, d5k7gB_, 0.7504, 2.80, 0.292, 275, 240, IRAK4 IN COMPLEX WITH AZ3862
3935, d4fv9A_, 0.7504, 2.72, 0.202, 331, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
3936, d3rm6A_, 0.7504, 3.06, 0.273, 293, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
3937, d3r71A_, 0.7504, 3.08, 0.268, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
3938, d5aneA_, 0.7503, 3.09, 0.268, 294, 250, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3939, d4zsgA_, 0.7503, 3.36, 0.188, 347, 255, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3940, d3umxA_, 0.7503, 2.59, 0.195, 261, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3941, d5bvdA_, 0.7502, 2.68, 0.203, 330, 241, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
3942, d5o26A_, 0.7501, 3.39, 0.292, 271, 257, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
3943, d5nttA1, 0.7501, 3.06, 0.229, 268, 249, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
3944, d5cswA_, 0.7501, 2.70, 0.296, 254, 243, B-RAF IN COMPLEX WITH DABRAFENIB
3945, d1hclA_, 0.7501, 3.11, 0.268, 294, 250, HUMAN CYCLIN-DEPENDENT KINASE 2
3946, d4x7qB_, 0.7500, 2.33, 0.212, 243, 236, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
3947, d4gsbA_, 0.7500, 3.13, 0.196, 343, 250, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
3948, d2c6eA_, 0.7500, 2.77, 0.249, 251, 245, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3949, d5ceoA_, 0.7499, 2.53, 0.346, 269, 240, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
3950, p4looA_, 0.7499, 3.03, 0.224, 349, 250, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
3951, d1pxmA_, 0.7499, 2.92, 0.264, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
3952, d5ieyA_, 0.7498, 3.06, 0.258, 286, 248, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
3953, d4rvkA_, 0.7498, 3.23, 0.250, 264, 248, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
3954, d3pxzA1, 0.7498, 3.20, 0.258, 298, 248, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
3955, d3nw7A_, 0.7498, 3.05, 0.304, 297, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
3956, d3idpB_, 0.7498, 2.81, 0.306, 256, 245, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3957, d2c6kA_, 0.7498, 3.00, 0.262, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3958, d1pw2A_, 0.7498, 3.10, 0.268, 294, 250, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
3959, d5ih9A_, 0.7497, 2.60, 0.249, 308, 241, MELK IN COMPLEX WITH NVS-MELK8A
3960, d4ftiA_, 0.7496, 3.27, 0.246, 270, 248, CRYSTAL STRUCTURE OF THE CHK1
3961, d1pxiA_, 0.7496, 3.07, 0.260, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
3962, d4hokK_, 0.7495, 3.52, 0.192, 290, 260, CRYSTAL STRUCTURE OF APO CK1E
3963, d3vn9A_, 0.7495, 3.40, 0.218, 291, 257, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
3964, d3r83A_, 0.7495, 3.10, 0.272, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
3965, d3an0A_, 0.7495, 3.40, 0.218, 291, 257,  
3966, d1pxkA_, 0.7495, 2.94, 0.264, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
3967, d5oq6A_, 0.7494, 3.12, 0.248, 257, 246, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3968, d5c9cB_, 0.7494, 2.72, 0.309, 251, 243, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3969, d4ft3A_, 0.7494, 3.04, 0.245, 269, 245, CRYSTAL STRUCTURE OF THE CHK1
3970, d1irkA_, 0.7494, 3.03, 0.321, 303, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
3971, d5o12A_, 0.7493, 2.56, 0.187, 264, 240, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3972, d4jjrB_, 0.7493, 3.39, 0.195, 283, 257, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3973, d4ibmB_, 0.7493, 2.98, 0.317, 294, 249, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3974, d2c5yA_, 0.7492, 2.96, 0.263, 290, 247, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3975, d1h0vA_, 0.7492, 2.98, 0.263, 288, 247, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
3976, d4yffA_, 0.7491, 2.72, 0.276, 264, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
3977, d3op5B_, 0.7491, 3.55, 0.141, 319, 263, HUMAN VACCINIA-RELATED KINASE 1
3978, d2v0dA_, 0.7491, 3.02, 0.258, 292, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3979, d2iwiB_, 0.7491, 2.45, 0.197, 249, 238, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
3980, d5jt2A1, 0.7490, 2.84, 0.305, 253, 243, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3981, d5bveA_, 0.7490, 2.69, 0.203, 330, 241, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
3982, d4d4rA_, 0.7490, 2.94, 0.336, 251, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3983, d4b0gA_, 0.7490, 2.58, 0.262, 247, 240, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3984, d3vbwA_, 0.7490, 2.61, 0.191, 264, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3985, d3tkiA_, 0.7490, 3.28, 0.246, 272, 248, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
3986, d3nw6A_, 0.7490, 3.06, 0.309, 301, 249, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
3987, d4hgtB_, 0.7489, 3.17, 0.175, 280, 251, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3988, d4ft0A_, 0.7489, 3.25, 0.243, 266, 247, CRYSTAL STRUCTURE OF THE CHK1
3989, d4ae6B_, 0.7489, 3.09, 0.187, 321, 251, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3990, d2qq7B_, 0.7489, 2.03, 0.320, 244, 231, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
3991, d4yfiB_, 0.7488, 2.77, 0.254, 262, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
3992, d4gvaA_, 0.7488, 3.38, 0.201, 345, 254, ADP-BOUND FORM OF THE ERK2 KINASE
3993, d3ot3A_, 0.7488, 3.22, 0.255, 259, 247, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
3994, d3h10B_, 0.7488, 2.90, 0.233, 267, 245, AURORA A INHIBITOR COMPLEX
3995, d2c6mA_, 0.7488, 3.02, 0.262, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3996, d2c47C_, 0.7488, 3.38, 0.157, 282, 255, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3997, d4hokQ_, 0.7487, 3.63, 0.188, 290, 261, CRYSTAL STRUCTURE OF APO CK1E
3998, d3qquA_, 0.7487, 3.08, 0.321, 285, 249, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
3999, d3e7oA_, 0.7486, 3.21, 0.233, 342, 253, CRYSTAL STRUCTURE OF JNK2
4000, d2c69A_, 0.7486, 3.02, 0.258, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4001, d4fsnA_, 0.7484, 3.24, 0.243, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
4002, d2c68A_, 0.7483, 3.01, 0.258, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4003, d4yffB_, 0.7482, 2.73, 0.276, 264, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
4004, d2r3oA_, 0.7482, 2.94, 0.264, 289, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4005, d4u97A_, 0.7481, 2.68, 0.277, 272, 238, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4006, d5mrbA1, 0.7480, 3.02, 0.219, 259, 247, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
4007, d5iexA_, 0.7480, 2.93, 0.260, 285, 246, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
4008, d4qyeA_, 0.7480, 3.27, 0.246, 271, 248, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
4009, d4fuyA_, 0.7480, 3.04, 0.206, 329, 247, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
4010, d3od6X_, 0.7480, 3.40, 0.209, 344, 253, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
4011, d2fa2B_, 0.7480, 3.10, 0.201, 332, 249, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4012, d4u9aA_, 0.7479, 2.69, 0.277, 272, 238, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4013, d3oroA_, 0.7478, 2.86, 0.195, 272, 246, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4014, d5kx8B_, 0.7477, 2.61, 0.283, 278, 237, IRAK4-INHIBITOR CO-STRUCTURE
4015, d5ih8A_, 0.7477, 2.55, 0.243, 306, 239, MELK IN COMPLEX WITH NVS-MELK1
4016, d5anjA_, 0.7477, 3.15, 0.272, 291, 250, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4017, d4lynA_, 0.7477, 3.02, 0.263, 287, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
4018, d4kkeA_, 0.7477, 2.95, 0.210, 354, 248, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
4019, d1b38A_, 0.7477, 2.96, 0.264, 290, 246, HUMAN CYCLIN-DEPENDENT KINASE 2
4020, d3r9oA_, 0.7475, 2.86, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
4021, d3og7A_, 0.7474, 2.56, 0.304, 247, 240, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4022, d3dtcA_, 0.7474, 2.17, 0.349, 245, 232, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
4023, d3h10A_, 0.7473, 2.92, 0.233, 268, 245, AURORA A INHIBITOR COMPLEX
4024, d2hy0A_, 0.7473, 3.25, 0.243, 272, 247, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
4025, d5tx5A_, 0.7472, 3.00, 0.272, 259, 243, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4026, d4fv4A_, 0.7472, 2.70, 0.203, 329, 241, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
4027, d3sqqA_, 0.7472, 2.98, 0.252, 288, 246, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
4028, d3pj8A1, 0.7472, 3.13, 0.265, 287, 249, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
4029, d3p9jA_, 0.7472, 2.63, 0.252, 249, 242, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4030, d2c6lA_, 0.7472, 3.01, 0.267, 291, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4031, d1b39A_, 0.7472, 2.96, 0.264, 290, 246, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
4032, d5ceqA_, 0.7471, 2.55, 0.331, 269, 239, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
4033, d3pxfA1, 0.7471, 3.36, 0.263, 298, 251, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
4034, d4yfiD_, 0.7470, 2.86, 0.267, 261, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
4035, d2qg5B1, 0.7470, 3.25, 0.182, 275, 253, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4036, d2c3lA_, 0.7470, 3.31, 0.238, 265, 248, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4037, d1y91A_, 0.7470, 2.95, 0.261, 286, 245, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
4038, d1h0uA_, 0.7470, 2.97, 0.263, 291, 247,  
4039, d5k7iA_, 0.7469, 2.55, 0.284, 272, 236, IRAK4 IN COMPLEX WITH AZ3864
4040, d5ievA_, 0.7469, 3.01, 0.260, 284, 246, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
4041, d4qyfA_, 0.7468, 3.29, 0.246, 269, 248, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
4042, d4qtdA_, 0.7468, 3.19, 0.203, 355, 251, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
4043, d5k76A_, 0.7467, 2.61, 0.274, 270, 237, IRAK4 IN COMPLEX WITH COMPOUND 28
4044, d4ztqA_, 0.7467, 2.59, 0.266, 247, 241, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4045, d2hogA_, 0.7467, 3.30, 0.246, 272, 248, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
4046, d1e1xA_, 0.7467, 2.95, 0.264, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
4047, d3is5F1, 0.7466, 3.13, 0.233, 259, 249, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4048, d3h0zC_, 0.7466, 2.52, 0.259, 246, 239, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4049, d5d10B_, 0.7464, 2.18, 0.326, 247, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4050, d4usdA_, 0.7464, 2.82, 0.263, 268, 243, HUMAN STK10 (LOK) WITH SB-633825
4051, d3comB_, 0.7464, 3.16, 0.231, 279, 251, CRYSTAL STRUCTURE OF MST1 KINASE
4052, d2w1hA_, 0.7464, 2.93, 0.269, 283, 245, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
4053, d2oidD_, 0.7463, 2.72, 0.278, 274, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4054, d2brgA_, 0.7463, 3.15, 0.248, 257, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4055, p4lopD_, 0.7462, 3.06, 0.213, 351, 249, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4056, d4lg4B_, 0.7462, 2.72, 0.270, 284, 241, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4057, d3lfnA_, 0.7462, 3.13, 0.267, 285, 247, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
4058, d3ggfB_, 0.7462, 2.93, 0.286, 270, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4059, d4rj3A_, 0.7460, 2.96, 0.256, 287, 246, CDK2 WITH EGFR INHIBITOR COMPOUND 8
4060, d4ftuA_, 0.7460, 3.28, 0.247, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
4061, d4ft9A_, 0.7460, 3.23, 0.248, 270, 246, CRYSTAL STRUCTURE OF THE CHK1
4062, d2oidB_, 0.7459, 2.67, 0.277, 272, 238, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4063, d6bp0A_, 0.7458, 3.56, 0.146, 317, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4064, d3wf9A_, 0.7458, 3.27, 0.260, 287, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
4065, d3iggA_, 0.7458, 2.99, 0.264, 290, 246, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
4066, d2rioA_, 0.7458, 2.72, 0.230, 396, 239, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4067, d3w16A_, 0.7457, 2.75, 0.263, 249, 243, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4068, d4yp8B_, 0.7456, 2.60, 0.283, 278, 237, IRAK4-INHIBITOR CO-STRUCTURE
4069, d4jikA_, 0.7456, 3.02, 0.247, 256, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
4070, d3w10A_, 0.7456, 2.98, 0.232, 263, 246, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
4071, p5o7iA_, 0.7455, 3.42, 0.193, 340, 254, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
4072, d5cwzC_, 0.7455, 2.64, 0.244, 271, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
4073, d4yo6B_, 0.7455, 2.59, 0.284, 277, 236, IRAK4-INHIBITOR CO-STRUCTURE
4074, d4ae9B_, 0.7455, 3.10, 0.188, 321, 250, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
4075, d2r3rA_, 0.7455, 2.99, 0.264, 290, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4076, d1nvqA_, 0.7455, 3.32, 0.246, 264, 248, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
4077, d5uvfA_, 0.7454, 3.56, 0.149, 317, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4078, d5ukfC_, 0.7454, 3.51, 0.146, 317, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4079, d4lg4A_, 0.7454, 3.06, 0.241, 289, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4080, d3wf8A_, 0.7454, 3.25, 0.256, 287, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
4081, d2vtrA_, 0.7454, 2.98, 0.264, 290, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4082, d2b52A_, 0.7454, 2.99, 0.257, 283, 245, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
4083, d4zslA_, 0.7453, 3.46, 0.192, 341, 255, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4084, d4yffD_, 0.7453, 2.71, 0.261, 257, 238, TNNI3K COMPLEXED WITH INHIBITOR 2
4085, d5o26B_, 0.7452, 3.25, 0.296, 265, 253, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
4086, d4j8mA_, 0.7452, 2.99, 0.265, 265, 245, AURORA A IN COMPLEX WITH CD532
4087, d1nvsA_, 0.7452, 3.33, 0.246, 264, 248, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
4088, d3rzbA_, 0.7451, 2.92, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
4089, d4hokG_, 0.7450, 3.79, 0.186, 290, 263, CRYSTAL STRUCTURE OF APO CK1E
4090, d4ft7A_, 0.7450, 3.28, 0.247, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
4091, d4fszA_, 0.7450, 3.20, 0.249, 268, 245, CRYSTAL STRUCTURE OF THE CHK1
4092, d4byjA_, 0.7450, 2.63, 0.262, 246, 240, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4093, d3zzwA_, 0.7450, 3.37, 0.324, 269, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4094, d2j50B_, 0.7450, 2.68, 0.231, 249, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4095, d2j50A_, 0.7450, 2.68, 0.231, 249, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4096, d5n87A1, 0.7449, 2.91, 0.220, 252, 245, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
4097, d4cqeB_, 0.7449, 2.44, 0.294, 248, 238, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4098, d4fsrA_, 0.7448, 3.25, 0.244, 269, 246, CRYSTAL STRUCTURE OF THE CHK1
4099, d3pxqA1, 0.7448, 3.20, 0.263, 294, 247, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
4100, d3ns9A_, 0.7448, 2.95, 0.265, 289, 245, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
4101, d5vo2A_, 0.7447, 2.59, 0.331, 269, 239, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
4102, d6btwA_, 0.7446, 3.57, 0.149, 317, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4103, d5vo1A_, 0.7446, 2.60, 0.331, 269, 239, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
4104, d2vtmA_, 0.7446, 2.99, 0.264, 290, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4105, d2vtlA_, 0.7445, 3.00, 0.264, 290, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4106, d3qtrA_, 0.7444, 2.93, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
4107, d2c6eB_, 0.7444, 2.57, 0.246, 246, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4108, d5up3B_, 0.7443, 2.25, 0.280, 243, 232, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4109, d4fkqA_, 0.7443, 2.96, 0.261, 283, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4110, d3u9nA_, 0.7443, 3.11, 0.249, 257, 245, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4111, d3o50B_, 0.7443, 2.60, 0.233, 249, 240, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4112, d2wtvC_, 0.7443, 2.74, 0.230, 261, 243, AURORA-A INHIBITOR STRUCTURE
4113, d2c6dA_, 0.7443, 2.97, 0.253, 254, 245, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
4114, d5tkdA_, 0.7442, 2.28, 0.256, 248, 234, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4115, d2wtvB_, 0.7442, 2.75, 0.230, 261, 243, AURORA-A INHIBITOR STRUCTURE
4116, d2r3hA_, 0.7442, 2.93, 0.261, 289, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4117, d2c30A_, 0.7442, 3.26, 0.191, 289, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
4118, d5drbA_, 0.7441, 3.19, 0.272, 273, 250, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
4119, d4y46A_, 0.7441, 2.99, 0.210, 340, 248, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4120, d1w8cA_, 0.7441, 3.04, 0.263, 290, 247, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
4121, d1gz8A_, 0.7441, 3.04, 0.263, 290, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
4122, d1e1vA_, 0.7441, 3.00, 0.264, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
4123, d5m57A1, 0.7440, 2.64, 0.243, 253, 239, NEK2 BOUND TO ARYLAMINOPURINE 6
4124, d4hokC_, 0.7440, 3.72, 0.191, 289, 262, CRYSTAL STRUCTURE OF APO CK1E
4125, d2ds1A_, 0.7440, 3.02, 0.260, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4126, d1muoA_, 0.7440, 2.86, 0.247, 251, 243, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
4127, d1buhA_, 0.7440, 2.88, 0.258, 287, 244, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
4128, d4nifD_, 0.7439, 3.17, 0.220, 313, 245, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4129, d4fkoA_, 0.7439, 2.99, 0.258, 291, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4130, d3qquB_, 0.7439, 3.10, 0.323, 288, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4131, d2rioB_, 0.7439, 2.58, 0.232, 395, 237, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4132, d2r3pA_, 0.7439, 3.01, 0.264, 289, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4133, d4uzhA1, 0.7438, 2.65, 0.264, 250, 239, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4134, p4lopA_, 0.7437, 3.10, 0.221, 351, 249, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4135, d3pa3A_, 0.7437, 3.19, 0.248, 259, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
4136, d1h08A_, 0.7437, 2.99, 0.262, 283, 244, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4137, d1nvrA_, 0.7436, 3.35, 0.246, 264, 248, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
4138, d3lokB_, 0.7435, 2.02, 0.328, 242, 229, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4139, d1h07A_, 0.7435, 2.85, 0.262, 285, 244, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4140, d2iwiA_, 0.7434, 2.44, 0.203, 244, 236, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4141, d5uisA_, 0.7433, 2.60, 0.281, 269, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4142, d5d9lA_, 0.7432, 2.89, 0.209, 299, 244, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
4143, d2vtoA_, 0.7432, 2.93, 0.266, 283, 244, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4144, d1ungB_, 0.7432, 2.54, 0.225, 268, 236, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4145, d5cepA_, 0.7431, 2.60, 0.331, 269, 239, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
4146, d4usdB_, 0.7431, 2.84, 0.260, 267, 242, HUMAN STK10 (LOK) WITH SB-633825
4147, d4fg7A_, 0.7431, 2.49, 0.253, 250, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4148, d4ek5A_, 0.7431, 2.98, 0.265, 289, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4149, d2r3iA_, 0.7430, 3.01, 0.264, 289, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4150, d1szmB_, 0.7430, 3.13, 0.188, 320, 250, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
4151, d4o6lB_, 0.7429, 2.96, 0.217, 256, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4152, d3qrjA1, 0.7429, 2.27, 0.409, 246, 230, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4153, d2hwoB_, 0.7429, 2.03, 0.314, 242, 229, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
4154, d5na0A1, 0.7428, 2.79, 0.218, 250, 243, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4155, d5eakB_, 0.7428, 2.74, 0.286, 300, 241, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
4156, d5dlsA_, 0.7428, 3.23, 0.248, 257, 246, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
4157, d4p90A_, 0.7428, 2.61, 0.222, 272, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4158, d4fkvA_, 0.7428, 2.92, 0.262, 282, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4159, d4w4wA_, 0.7427, 3.02, 0.210, 349, 248, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
4160, d4kkgA_, 0.7427, 3.12, 0.220, 353, 250, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
4161, d3comA_, 0.7427, 3.03, 0.243, 264, 247, CRYSTAL STRUCTURE OF MST1 KINASE
4162, d2r3fA_, 0.7427, 3.02, 0.264, 290, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4163, d1fvtA_, 0.7427, 2.95, 0.262, 282, 244, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
4164, d5uvfB_, 0.7426, 3.52, 0.146, 316, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4165, d3lauA1, 0.7426, 2.67, 0.264, 250, 239, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
4166, d2zdtA_, 0.7426, 2.91, 0.212, 342, 245, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4167, d6bu6B_, 0.7425, 3.50, 0.147, 307, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4168, p5ax3A_, 0.7425, 3.27, 0.198, 329, 247, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
4169, d5ap7A1, 0.7425, 3.03, 0.224, 253, 245, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4170, d2ym6A_, 0.7425, 3.12, 0.254, 253, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4171, d3wf7A_, 0.7424, 3.31, 0.256, 288, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
4172, d3vquA_, 0.7423, 3.04, 0.233, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
4173, d3lfsA_, 0.7423, 3.01, 0.268, 290, 246, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
4174, d3hmpA_, 0.7423, 3.11, 0.219, 258, 247, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
4175, d1di8A_, 0.7423, 3.03, 0.261, 283, 245, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
4176, d4yffC_, 0.7422, 2.71, 0.262, 258, 237, TNNI3K COMPLEXED WITH INHIBITOR 2
4177, d4b8lA_, 0.7422, 2.57, 0.202, 249, 238, AURORA B KINASE P353G MUTANT
4178, d3pa4A_, 0.7422, 3.17, 0.249, 257, 245, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
4179, d3wblA_, 0.7421, 3.00, 0.257, 283, 245, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
4180, d3h10D_, 0.7421, 2.69, 0.237, 255, 241, AURORA A INHIBITOR COMPLEX
4181, d2pmiC_, 0.7421, 2.97, 0.235, 285, 243, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4182, d1jnkA_, 0.7421, 2.91, 0.212, 346, 245, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
4183, d5k7iB_, 0.7420, 2.55, 0.289, 271, 235, IRAK4 IN COMPLEX WITH AZ3864
4184, d4y5hA_, 0.7420, 3.04, 0.210, 349, 248, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4185, p4lopC_, 0.7420, 3.03, 0.214, 341, 248, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4186, d4kb8A_, 0.7419, 3.05, 0.215, 265, 246, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4187, d4fkiA_, 0.7419, 3.02, 0.261, 287, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4188, d3lfqA_, 0.7419, 2.98, 0.261, 289, 245, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
4189, d2z7rA_, 0.7419, 2.67, 0.235, 265, 238, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
4190, d4oboA_, 0.7417, 3.06, 0.237, 275, 245, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4191, p4lopB_, 0.7417, 3.07, 0.214, 350, 248, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4192, d4ftrA_, 0.7417, 3.23, 0.242, 258, 244, CRYSTAL STRUCTURE OF THE CHK1
4193, d1h0wA_, 0.7417, 2.93, 0.262, 283, 244, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
4194, d6b8uB_, 0.7416, 2.63, 0.305, 248, 239, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4195, d4fkrA_, 0.7416, 2.97, 0.262, 282, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4196, d4fg8B_, 0.7416, 2.75, 0.228, 268, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4197, d4cqeA_, 0.7416, 2.71, 0.295, 250, 241, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4198, d3wyyA_, 0.7416, 2.97, 0.234, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4199, d3cgfA_, 0.7416, 2.92, 0.212, 346, 245, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4200, d1ke8A_, 0.7416, 2.96, 0.262, 282, 244, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
4201, d5mhqA1, 0.7415, 2.92, 0.258, 288, 244, CCT068127 IN COMPLEX WITH CDK2
4202, d5m51A1, 0.7415, 2.68, 0.243, 253, 239, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
4203, d4ek4A_, 0.7415, 2.99, 0.265, 287, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4204, d4acmA_, 0.7415, 2.76, 0.266, 277, 241, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
4205, d3le6A_, 0.7415, 2.98, 0.265, 283, 245, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
4206, d5jt2C1, 0.7414, 2.73, 0.314, 247, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4207, d5ihcA_, 0.7414, 2.53, 0.236, 305, 237, MELK IN COMPLEX WITH NVS-MELK12B
4208, d4kkhA_, 0.7414, 3.04, 0.210, 351, 248, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
4209, d4izaC_, 0.7414, 2.96, 0.180, 335, 244, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4210, d3e3pB_, 0.7414, 3.39, 0.224, 337, 250, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
4211, d1wccA_, 0.7414, 2.99, 0.273, 283, 245, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
4212, d5n93A1, 0.7413, 2.92, 0.247, 256, 243, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
4213, d3wf6A_, 0.7413, 2.96, 0.264, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4214, d2wtvD_, 0.7413, 2.80, 0.235, 262, 243, AURORA-A INHIBITOR STRUCTURE
4215, d1f5qC_, 0.7413, 3.35, 0.253, 288, 249, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
4216, p5oatF_, 0.7412, 3.45, 0.198, 359, 253, PINK1 STRUCTURE
4217, d3ma3A_, 0.7412, 2.68, 0.192, 266, 240, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
4218, d2w17A_, 0.7412, 2.77, 0.253, 278, 241, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
4219, d2w06A_, 0.7412, 2.97, 0.262, 282, 244, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
4220, d3wyxA_, 0.7411, 2.85, 0.223, 258, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4221, d3is5B1, 0.7411, 3.02, 0.236, 255, 246, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4222, d2wtvA_, 0.7411, 2.80, 0.235, 262, 243, AURORA-A INHIBITOR STRUCTURE
4223, d1oirA_, 0.7411, 2.94, 0.258, 286, 244, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4224, d4d2rA_, 0.7410, 3.24, 0.321, 300, 249, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
4225, d3tkhA_, 0.7410, 3.26, 0.249, 269, 245, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
4226, d3fz1A_, 0.7410, 3.05, 0.261, 284, 245, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
4227, d2jboA_, 0.7410, 2.89, 0.223, 295, 242, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4228, p5oo0A_, 0.7409, 3.02, 0.264, 288, 246, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
4229, d4u41A_, 0.7409, 3.09, 0.237, 275, 245, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4230, d3uysB_, 0.7409, 3.46, 0.185, 279, 254, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4231, d2xf0A_, 0.7409, 3.03, 0.245, 251, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4232, d2vv9A_, 0.7409, 2.76, 0.257, 279, 241, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
4233, d4zegA_, 0.7408, 2.91, 0.239, 260, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4234, d4usfB1, 0.7408, 3.32, 0.243, 283, 247, HUMAN SLK WITH SB-440719
4235, d5ehlA1, 0.7407, 2.95, 0.224, 254, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4236, d3dajA_, 0.7407, 2.56, 0.251, 245, 239, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4237, d4fklA_, 0.7406, 3.04, 0.264, 290, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4238, d4ewqA_, 0.7406, 3.07, 0.218, 346, 248, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
4239, d3nw5A_, 0.7406, 3.22, 0.306, 302, 248, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4240, d5k4jA1, 0.7404, 2.91, 0.263, 281, 243, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
4241, d4nifA_, 0.7404, 3.23, 0.220, 313, 245, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4242, d3uytD_, 0.7404, 3.11, 0.194, 268, 247, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4243, d1ke5A_, 0.7404, 2.91, 0.263, 281, 243, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
4244, d4maoA_, 0.7403, 3.16, 0.244, 298, 246, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH RMM58
4245, d4knbD_, 0.7403, 2.89, 0.336, 247, 238, C-MET IN COMPLEX WITH OSI LIGAND
4246, d4aa4A_, 0.7403, 3.09, 0.223, 347, 247, P38ALPHA MAP KINASE BOUND TO CMPD 22
4247, d3pzeA_, 0.7403, 2.93, 0.217, 347, 244, JNK1 IN COMPLEX WITH INHIBITOR
4248, d1v0bA_, 0.7403, 3.30, 0.252, 286, 250, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
4249, d5n9sA1, 0.7402, 3.09, 0.220, 256, 246, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
4250, d4xoyA_, 0.7402, 2.94, 0.210, 326, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4251, d5bvfA_, 0.7401, 2.77, 0.205, 327, 239, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4252, d4usfA1, 0.7401, 3.14, 0.254, 275, 244, HUMAN SLK WITH SB-440719
4253, d4i5hA_, 0.7401, 3.03, 0.206, 335, 243, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
4254, d4fsyA_, 0.7401, 3.23, 0.250, 267, 244, CRYSTAL STRUCTURE OF THE CHK1
4255, d4w4yA_, 0.7400, 3.12, 0.209, 350, 249, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4256, d4lghA_, 0.7400, 2.07, 0.323, 243, 229, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4257, d3wf5A_, 0.7400, 2.98, 0.264, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4258, d3en7B_, 0.7400, 1.89, 0.319, 237, 226, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
4259, d2r3gA_, 0.7400, 2.91, 0.267, 287, 243, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4260, d2oicC_, 0.7400, 2.82, 0.283, 277, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4261, d1ke9A_, 0.7400, 2.92, 0.263, 281, 243, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
4262, d4ek3A_, 0.7399, 3.01, 0.265, 287, 245, CRYSTAL STRUCTURE OF APO CDK2
4263, d3i81A_, 0.7399, 3.26, 0.317, 296, 249, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4264, d1ke7A_, 0.7399, 2.91, 0.263, 281, 243, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
4265, d6bp0C_, 0.7398, 3.56, 0.150, 315, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4266, d5jrqB1, 0.7398, 2.45, 0.314, 245, 236, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4267, p4loqD_, 0.7398, 3.06, 0.210, 351, 248, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4268, d4yc6E_, 0.7396, 3.05, 0.265, 285, 245, CDK1/CKS1
4269, d4obqA_, 0.7396, 2.81, 0.242, 275, 240, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4270, d6bp0B_, 0.7394, 3.55, 0.148, 304, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4271, d5uisC_, 0.7394, 2.65, 0.285, 270, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4272, d5ihaA_, 0.7394, 2.53, 0.242, 303, 236, MELK IN COMPLEX WITH NVS-MELK8F
4273, d3r7uA_, 0.7394, 2.97, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
4274, d3p86B_, 0.7394, 2.24, 0.342, 239, 231, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4275, d4ftjA_, 0.7393, 3.24, 0.246, 266, 244, CRYSTAL STRUCTURE OF THE CHK1
4276, d3r7iA_, 0.7393, 2.96, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
4277, d3dbqA_, 0.7393, 3.14, 0.232, 259, 246, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
4278, d2vtsA_, 0.7393, 3.05, 0.270, 282, 244, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4279, d6bu6C_, 0.7392, 3.47, 0.147, 315, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4280, d5o23B1, 0.7392, 3.31, 0.267, 276, 251, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4281, d4awiA_, 0.7392, 2.98, 0.216, 352, 245, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
4282, d3rmfA_, 0.7392, 2.75, 0.258, 278, 240, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
4283, d1w0xC_, 0.7392, 2.89, 0.264, 280, 242, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
4284, d1jsvA_, 0.7392, 2.94, 0.267, 287, 243, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
4285, d5fxsA1, 0.7391, 3.21, 0.306, 307, 248, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4286, d4zy5B_, 0.7391, 3.30, 0.226, 287, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
4287, d4fkwA_, 0.7391, 2.86, 0.264, 280, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4288, d1pmvA_, 0.7391, 3.09, 0.214, 347, 248, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
4289, d6bruC_, 0.7390, 3.58, 0.150, 315, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4290, d5ljjA1, 0.7390, 2.87, 0.248, 260, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4291, d5jq5A_, 0.7390, 2.94, 0.263, 287, 243, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
4292, d4w4xA_, 0.7390, 3.12, 0.209, 342, 249, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4293, d3eljA_, 0.7390, 3.07, 0.206, 347, 247, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
4294, d2qhnA_, 0.7390, 3.26, 0.242, 268, 244, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
4295, d3cgoA_, 0.7389, 2.94, 0.212, 332, 245, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4296, d1ob3A_, 0.7389, 3.18, 0.263, 277, 247, STRUCTURE OF P. FALCIPARUM PFPK5
4297, d5k75A_, 0.7388, 2.62, 0.277, 271, 235, IRAK4 IN COMPLEX WITH COMPOUND 1
4298, d4d9uA_, 0.7388, 3.03, 0.234, 307, 244, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4299, d5ew9A_, 0.7387, 3.18, 0.219, 257, 247, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4300, d5ehoA1, 0.7387, 2.83, 0.223, 255, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4301, d5ap0A1, 0.7387, 2.91, 0.218, 250, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4302, d4fkgA_, 0.7387, 3.02, 0.266, 286, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4303, d1ke6A_, 0.7386, 2.89, 0.264, 280, 242, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
4304, d5ap1A1, 0.7385, 2.94, 0.247, 264, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4305, p4loqB_, 0.7385, 3.07, 0.214, 351, 248, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4306, d2qhmA_, 0.7385, 3.25, 0.242, 268, 244, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
4307, d4zjiB_, 0.7384, 3.13, 0.238, 276, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4308, p4loqC_, 0.7384, 3.07, 0.214, 337, 248, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4309, d4gh2A_, 0.7384, 2.99, 0.249, 266, 241, CRYSTAL STRUCTURE OF THE CHK1
4310, d3e3pA_, 0.7384, 3.37, 0.210, 337, 252, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
4311, d5ei6A1, 0.7383, 2.93, 0.225, 261, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4312, d4fttA_, 0.7383, 3.19, 0.244, 266, 242, CRYSTAL STRUCTURE OF THE CHK1
4313, d2vtpA_, 0.7383, 2.96, 0.263, 281, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4314, d3qtsA_, 0.7382, 2.99, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
4315, d2wtkF1, 0.7382, 2.75, 0.230, 250, 239, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4316, d4l7fA1, 0.7381, 2.97, 0.217, 343, 244, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
4317, d4c4fA1, 0.7381, 2.93, 0.218, 250, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4318, d2brhA_, 0.7381, 3.31, 0.244, 257, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4319, d3sw7A_, 0.7380, 2.76, 0.258, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4320, d3o50A_, 0.7380, 2.60, 0.235, 246, 238, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4321, d2r3mA_, 0.7380, 2.83, 0.266, 278, 241, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4322, d4kbaA_, 0.7379, 3.03, 0.213, 263, 244, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4323, d4bi0A1, 0.7379, 2.91, 0.218, 251, 243, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4324, d3kc3E_, 0.7379, 2.61, 0.223, 287, 238, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4325, d2x9eA_, 0.7379, 2.85, 0.236, 253, 242, HUMAN MPS1 IN COMPLEX WITH NMS-P715
4326, d4aacA_, 0.7378, 3.07, 0.224, 350, 246, P38ALPHA MAP KINASE BOUND TO CMPD 29
4327, d3bqrA1, 0.7378, 2.80, 0.247, 273, 239, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
4328, d6bp0D_, 0.7377, 3.61, 0.151, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4329, d4zy4B_, 0.7377, 3.36, 0.222, 292, 252, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
4330, d2wmvA_, 0.7377, 3.01, 0.250, 251, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4331, d2j9mA_, 0.7377, 2.61, 0.266, 275, 237, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
4332, d6bruD_, 0.7376, 3.65, 0.147, 311, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4333, d4ftcA_, 0.7376, 3.23, 0.251, 266, 243, CRYSTAL STRUCTURE OF THE CHK1
4334, d2r0uA_, 0.7376, 3.27, 0.242, 269, 244, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
4335, d2p33A_, 0.7376, 2.95, 0.212, 332, 245, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4336, d2a4lA_, 0.7375, 2.92, 0.269, 286, 242, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
4337, d4fsmA_, 0.7374, 3.19, 0.244, 265, 242, CRYSTAL STRUCTURE OF THE CHK1
4338, d3s1hA_, 0.7374, 2.74, 0.259, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
4339, d3rpyA_, 0.7374, 2.73, 0.259, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
4340, d2vtiA_, 0.7374, 2.91, 0.264, 280, 242, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4341, d4eqmF_, 0.7373, 2.93, 0.230, 268, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4342, d3ralA_, 0.7373, 2.74, 0.259, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
4343, d3f9nA_, 0.7373, 3.14, 0.252, 253, 242, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
4344, d2r3qA_, 0.7373, 2.95, 0.267, 286, 243, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4345, d4ek8A_, 0.7372, 2.95, 0.264, 280, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4346, d4d9tA_, 0.7372, 3.24, 0.236, 299, 246, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4347, d3rprA_, 0.7372, 3.00, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
4348, d3en6B_, 0.7372, 1.94, 0.314, 239, 226, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
4349, d3en5A_, 0.7372, 2.01, 0.317, 238, 227, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4350, d2o8yB_, 0.7372, 2.65, 0.289, 266, 235, APO IRAK4 KINASE DOMAIN
4351, d4w4vA_, 0.7371, 3.30, 0.210, 342, 252, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4352, d4m8tA_, 0.7371, 3.19, 0.240, 303, 246, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH 3-(3-(1H-PYRAZOL- 4-YL)PHENYL)-2-CYANOACRYLAMIDE
4353, d4bzdA_, 0.7371, 2.75, 0.259, 277, 239, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
4354, d6btwC_, 0.7370, 3.55, 0.147, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4355, d4eqmD_, 0.7370, 2.94, 0.230, 268, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4356, p4loqA_, 0.7369, 3.09, 0.214, 352, 248, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4357, d4jg8A_, 0.7369, 3.20, 0.244, 300, 246, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
4358, d5n84A1, 0.7368, 3.02, 0.220, 253, 245, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
4359, d5fp6A_, 0.7368, 2.81, 0.261, 278, 241, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
4360, d5nadA1, 0.7367, 2.92, 0.228, 253, 241, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4361, d5hx6B_, 0.7366, 2.93, 0.273, 264, 238, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4362, d2ozaB_, 0.7366, 3.03, 0.229, 340, 245, STRUCTURE OF P38ALPHA COMPLEX
4363, d3a62A_, 0.7365, 2.92, 0.268, 263, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
4364, d4zjiA_, 0.7364, 3.15, 0.238, 278, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4365, d4o2zA1, 0.7364, 3.09, 0.230, 357, 244, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
4366, d4eqmE_, 0.7364, 2.95, 0.226, 268, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4367, d3zzwB_, 0.7364, 3.35, 0.321, 265, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4368, d3g90X_, 0.7364, 3.06, 0.220, 345, 246, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
4369, d3fv8A_, 0.7364, 2.84, 0.228, 331, 241, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
4370, d2r64A_, 0.7364, 2.86, 0.266, 279, 241, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
4371, d3mj1A1, 0.7363, 1.78, 0.339, 226, 224, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR RO5191614
4372, d2x81A_, 0.7363, 2.53, 0.254, 242, 236, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4373, d2hwpB_, 0.7363, 1.94, 0.305, 239, 226, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4374, d5awmA_, 0.7362, 3.18, 0.215, 345, 247, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
4375, d5ap4A1, 0.7362, 2.97, 0.226, 253, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4376, d4fswA_, 0.7362, 3.20, 0.244, 265, 242, CRYSTAL STRUCTURE OF THE CHK1
4377, p4e3cF1, 0.7362, 3.17, 0.257, 290, 249, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4378, d4aa5A_, 0.7362, 3.03, 0.224, 340, 245, P38ALPHA MAP KINASE BOUND TO CMPD 33
4379, d3rakA_, 0.7362, 2.75, 0.259, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
4380, d3jvrA_, 0.7362, 3.27, 0.246, 258, 244, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4381, d2vtaA_, 0.7362, 2.83, 0.267, 278, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4382, d2r3jA_, 0.7362, 2.86, 0.266, 278, 241, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4383, d2o0uA_, 0.7362, 2.97, 0.212, 331, 245, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
4384, d1h01A_, 0.7362, 3.01, 0.262, 286, 244, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4385, d2wmtA_, 0.7361, 2.99, 0.243, 248, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4386, d1v0pA_, 0.7361, 3.23, 0.259, 277, 247, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
4387, d5deyB_, 0.7360, 3.21, 0.238, 281, 248, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
4388, d4uynA_, 0.7360, 2.79, 0.258, 249, 240, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4389, d4ft5A_, 0.7360, 3.21, 0.248, 265, 242, CRYSTAL STRUCTURE OF THE CHK1
4390, d1ckpA_, 0.7360, 2.86, 0.266, 279, 241, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
4391, d3sw4A_, 0.7359, 2.92, 0.266, 279, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4392, d3rahA_, 0.7358, 3.02, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
4393, d3r9nA_, 0.7358, 3.02, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
4394, d5imeB_, 0.7357, 2.75, 0.237, 280, 241, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4395, d4ftaA_, 0.7357, 3.17, 0.249, 264, 241, CRYSTAL STRUCTURE OF THE CHK1
4396, d4aotB1, 0.7357, 3.18, 0.246, 277, 244, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4397, d3hmoA_, 0.7357, 3.04, 0.216, 257, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4398, d2zduA_, 0.7357, 2.92, 0.218, 330, 243, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4399, d4zy6B_, 0.7356, 3.14, 0.239, 280, 247, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
4400, d2r3nA_, 0.7356, 2.69, 0.261, 275, 238, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4401, d4cvaA1, 0.7355, 2.97, 0.222, 250, 243, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4402, d3g9nA_, 0.7355, 3.11, 0.215, 346, 247, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
4403, d6b16B_, 0.7354, 3.08, 0.227, 281, 247, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
4404, d4zjjA_, 0.7354, 3.10, 0.235, 280, 247, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4405, d3kc3F_, 0.7353, 2.72, 0.226, 293, 239, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4406, d3is5A1, 0.7353, 3.05, 0.241, 254, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4407, d2wajA_, 0.7353, 3.09, 0.215, 348, 247, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
4408, d4c4eA1, 0.7352, 3.14, 0.216, 253, 245, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4409, d2r3kA_, 0.7352, 2.80, 0.267, 277, 240, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4410, d1giiA_, 0.7352, 2.90, 0.261, 279, 241, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4411, d5we8A_, 0.7351, 3.30, 0.257, 270, 245, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4412, d3op5C_, 0.7351, 3.63, 0.148, 308, 257, HUMAN VACCINIA-RELATED KINASE 1
4413, d5w5jB_, 0.7350, 2.43, 0.259, 257, 232, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4414, d4bi2A1, 0.7350, 2.90, 0.219, 250, 242, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4415, d2ydjA_, 0.7350, 3.15, 0.248, 252, 242, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4416, d2xeyA_, 0.7350, 3.11, 0.253, 252, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4417, d2jfmA_, 0.7350, 3.01, 0.257, 287, 241, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4418, d4yc6A_, 0.7349, 3.09, 0.261, 285, 245, CDK1/CKS1
4419, d4fktA_, 0.7349, 2.97, 0.264, 278, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4420, d4o6lA_, 0.7348, 2.97, 0.220, 257, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4421, d2uznA_, 0.7348, 2.90, 0.266, 279, 241, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4422, d2j51A_, 0.7348, 2.99, 0.253, 288, 241, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4423, d5l8jA_, 0.7347, 2.97, 0.219, 253, 242, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
4424, d3s2pA_, 0.7346, 2.89, 0.266, 279, 241, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
4425, d2vthA_, 0.7346, 2.85, 0.267, 278, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
4426, d4fkpA_, 0.7345, 2.89, 0.266, 279, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4427, d4bi1A1, 0.7345, 2.85, 0.216, 249, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4428, d4rvlA_, 0.7344, 3.22, 0.248, 258, 242, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
4429, d4un0D_, 0.7343, 3.09, 0.261, 276, 245, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4430, d1vyzA_, 0.7343, 2.94, 0.266, 279, 241, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
4431, d4yc6C_, 0.7342, 3.10, 0.261, 285, 245, CDK1/CKS1
4432, d5fxqA1, 0.7341, 3.37, 0.310, 301, 248, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4433, p4e3cC1, 0.7341, 3.09, 0.262, 290, 248, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4434, d3ig7A_, 0.7341, 2.87, 0.267, 278, 240, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
4435, d3en6A_, 0.7341, 1.93, 0.311, 236, 225, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
4436, d2qkrA1, 0.7341, 2.93, 0.259, 269, 239, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
4437, d5ehyA1, 0.7340, 3.02, 0.217, 251, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4438, d2w5aA1, 0.7340, 3.23, 0.240, 259, 246, HUMAN NEK2 KINASE ADP-BOUND
4439, d2bvaB_, 0.7340, 2.93, 0.185, 274, 243, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4440, d5anoA_, 0.7339, 2.81, 0.268, 277, 239, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4441, d3dxnA_, 0.7339, 3.23, 0.247, 258, 247, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
4442, d5aniA_, 0.7338, 2.98, 0.264, 280, 242, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4443, d2xezA_, 0.7338, 3.12, 0.249, 249, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4444, d5b2lA_, 0.7337, 3.24, 0.233, 288, 249, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4445, d4fg8A_, 0.7337, 2.48, 0.226, 263, 234, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4446, d3ttiA_, 0.7337, 3.12, 0.215, 341, 247, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
4447, d2w5bA1, 0.7336, 3.02, 0.242, 263, 244, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
4448, d2w05A_, 0.7336, 2.72, 0.265, 276, 238, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
4449, d5k72B_, 0.7335, 2.57, 0.289, 267, 232, IRAK4 IN COMPLEX WITH COMPOUND 21
4450, d5ei2A_, 0.7335, 2.98, 0.226, 256, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4451, d2zmdA_, 0.7335, 3.20, 0.224, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4452, d4fksA_, 0.7334, 2.79, 0.268, 275, 239, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4453, d3ot8A_, 0.7334, 3.21, 0.253, 251, 241, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
4454, d3mvlA_, 0.7334, 3.00, 0.230, 339, 243, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4455, d4u40B_, 0.7333, 3.65, 0.230, 299, 256, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4456, d4rzvB1, 0.7333, 2.99, 0.311, 254, 241, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4457, d4n4sB_, 0.7333, 3.09, 0.188, 337, 245, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
4458, d4ithA_, 0.7333, 2.53, 0.272, 247, 232, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4459, d4fkjA_, 0.7333, 2.85, 0.267, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4460, d2jflA_, 0.7333, 2.93, 0.250, 286, 240, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
4461, d1g5sA_, 0.7333, 2.71, 0.262, 275, 237, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
4462, d3ma6B_, 0.7332, 3.34, 0.261, 266, 249, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4463, d5ajqB_, 0.7331, 2.96, 0.250, 267, 240, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
4464, d3pa5A_, 0.7331, 2.97, 0.247, 255, 239, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4465, d1oukA_, 0.7330, 3.23, 0.222, 348, 248, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
4466, d1dm2A_, 0.7330, 2.64, 0.263, 274, 236, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
4467, d5ap3A1, 0.7329, 2.95, 0.219, 250, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4468, d4ftqA_, 0.7329, 3.13, 0.254, 254, 240, CRYSTAL STRUCTURE OF THE CHK1
4469, d4cv9A1, 0.7329, 3.01, 0.236, 250, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4470, d3kc3A_, 0.7329, 2.55, 0.233, 288, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4471, d3ezvA_, 0.7329, 2.80, 0.259, 277, 239, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
4472, d3dt1A2, 0.7329, 3.15, 0.219, 352, 247, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
4473, d3kc3B_, 0.7328, 2.66, 0.228, 290, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4474, d2oo8X_, 0.7328, 2.32, 0.379, 259, 227, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
4475, d5uvfC_, 0.7327, 3.54, 0.149, 301, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4476, d5ci6A_, 0.7327, 2.76, 0.219, 335, 237, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4477, p4whzA_, 0.7327, 2.99, 0.212, 342, 245, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
4478, d4js8A_, 0.7327, 3.07, 0.239, 259, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4479, d5tx5B_, 0.7326, 2.96, 0.274, 263, 237, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4480, d3ttjA_, 0.7326, 3.16, 0.215, 333, 247, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
4481, d3o0gB_, 0.7326, 2.70, 0.234, 264, 235, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
4482, d5ap6A1, 0.7325, 3.02, 0.225, 259, 244, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4483, d4cv8A1, 0.7325, 3.00, 0.227, 252, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4484, d3w1fA_, 0.7325, 3.18, 0.241, 259, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4485, d2uv2A1, 0.7325, 3.03, 0.250, 286, 240, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
4486, d1zz2A_, 0.7325, 2.94, 0.227, 337, 242, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
4487, d5fxrA1, 0.7324, 3.29, 0.301, 299, 246, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4488, d5larA_, 0.7323, 3.44, 0.210, 350, 252, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
4489, d5n7vA1, 0.7322, 3.08, 0.225, 257, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4490, d4fg9B_, 0.7322, 2.77, 0.227, 279, 238, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4491, d4zjjB_, 0.7321, 3.12, 0.236, 277, 246, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4492, d3kc3L_, 0.7321, 2.59, 0.229, 291, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4493, d1h00A_, 0.7321, 2.91, 0.262, 278, 240, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4494, d3mvlB_, 0.7320, 3.01, 0.230, 339, 243, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4495, d5ar8A_, 0.7319, 2.30, 0.274, 255, 230, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4496, d4feqA_, 0.7319, 2.00, 0.344, 224, 224, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
4497, d4lg4E_, 0.7318, 2.89, 0.253, 275, 241, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4498, d2weiA1, 0.7318, 3.53, 0.246, 269, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
4499, d1gihA_, 0.7318, 2.77, 0.269, 276, 238, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4500, d2zmcA_, 0.7317, 3.23, 0.219, 260, 247, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
4501, d1wbwA_, 0.7317, 3.21, 0.223, 351, 247, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4502, d1di9A_, 0.7317, 3.25, 0.218, 348, 248, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
4503, d4ek6A_, 0.7316, 2.91, 0.267, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4504, d2ja0A_, 0.7316, 3.05, 0.250, 285, 240,  
4505, d4fstA_, 0.7315, 3.12, 0.251, 253, 239, CRYSTAL STRUCTURE OF THE CHK1
4506, d3is5C1, 0.7315, 3.15, 0.229, 254, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4507, d3orkA1, 0.7314, 2.81, 0.212, 272, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
4508, d2ydjB_, 0.7314, 2.88, 0.256, 251, 238, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4509, d2w99B_, 0.7314, 3.11, 0.251, 291, 243, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4510, d2vtjA_, 0.7314, 2.76, 0.269, 276, 238, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4511, d2r3lA_, 0.7314, 2.76, 0.269, 275, 238, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4512, d1h06A_, 0.7314, 2.81, 0.268, 277, 239,  
4513, d4c4iA1, 0.7313, 3.04, 0.218, 250, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4514, d3hmnA_, 0.7313, 3.14, 0.216, 255, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4515, d3jvsA_, 0.7312, 3.02, 0.243, 256, 239, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4516, d2wmxA_, 0.7311, 3.02, 0.248, 248, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4517, d5jq8A_, 0.7310, 2.95, 0.267, 278, 240, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
4518, d5andA_, 0.7310, 2.86, 0.268, 273, 239, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4519, d2btsA_, 0.7310, 2.69, 0.267, 274, 236, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
4520, d4ftkA_, 0.7309, 3.20, 0.246, 263, 240, CRYSTAL STRUCTURE OF THE CHK1
4521, d2w9zB_, 0.7309, 3.25, 0.248, 287, 246, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4522, d1w82A_, 0.7309, 3.18, 0.232, 351, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4523, d4u3yA_, 0.7307, 3.66, 0.212, 295, 255, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4524, d4ftoA_, 0.7307, 3.24, 0.246, 252, 240, CRYSTAL STRUCTURE OF THE CHK1
4525, d4fgbA_, 0.7307, 3.18, 0.241, 282, 249, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
4526, p3vumA_, 0.7307, 3.30, 0.234, 347, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
4527, p5xyyA_, 0.7306, 3.28, 0.234, 350, 248, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
4528, d4x21A_, 0.7306, 2.83, 0.222, 336, 239, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
4529, d3qquD_, 0.7306, 3.47, 0.320, 292, 250, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4530, d1pmuA_, 0.7306, 3.21, 0.214, 342, 248, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
4531, d4ztlB_, 0.7305, 2.87, 0.279, 269, 233, IRAK4-INHIBITOR CO-STRUCTURE
4532, d4yc6G_, 0.7305, 3.17, 0.265, 285, 245, CDK1/CKS1
4533, d3wzkA_, 0.7305, 3.20, 0.242, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4534, d4fsqA_, 0.7304, 3.21, 0.250, 263, 240, CRYSTAL STRUCTURE OF THE CHK1
4535, d2wmuA_, 0.7304, 3.00, 0.249, 246, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4536, d2balA_, 0.7304, 2.97, 0.224, 337, 241, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
4537, d1pmnA_, 0.7304, 3.21, 0.214, 344, 248, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
4538, d6btwD_, 0.7303, 3.64, 0.145, 307, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4539, d4u9aB_, 0.7303, 2.95, 0.274, 270, 234, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4540, d4c3pA_, 0.7303, 3.13, 0.236, 264, 242, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4541, d3cekA1, 0.7303, 3.02, 0.222, 252, 243, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4542, d2wqnA_, 0.7303, 2.93, 0.256, 259, 242, STRUCTURE OF ADP-BOUND HUMAN NEK7
4543, d4bhzA1, 0.7302, 2.88, 0.217, 248, 240, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4544, d3qquC_, 0.7302, 3.48, 0.320, 293, 250, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4545, d2ym7A_, 0.7302, 3.13, 0.251, 248, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4546, d2vtnA_, 0.7302, 2.69, 0.263, 274, 236, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4547, d2qr8A_, 0.7302, 3.23, 0.237, 298, 245, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
4548, d4jg7A_, 0.7301, 3.22, 0.234, 307, 244, STRUCTURE OF RSK2 CTD BOUND TO 3-(3-(1H-PYRROLO[23-B]PYRIDINE-3- CARBONYL)PHENYL)-2-CYANOACRYLAMIDE
4549, d4bghA_, 0.7301, 2.73, 0.270, 275, 237, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
4550, d5d9hA_, 0.7300, 3.49, 0.211, 290, 246, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4551, d4u3zA_, 0.7300, 3.45, 0.224, 282, 250, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4552, d4ftnA_, 0.7300, 3.18, 0.247, 253, 239, CRYSTAL STRUCTURE OF THE CHK1
4553, d4ftmA_, 0.7300, 3.22, 0.246, 263, 240, CRYSTAL STRUCTURE OF THE CHK1
4554, d4c4jA1, 0.7300, 3.05, 0.236, 258, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4555, d3orpA_, 0.7300, 2.91, 0.211, 274, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4556, d2o8yA_, 0.7300, 2.72, 0.289, 269, 235, APO IRAK4 KINASE DOMAIN
4557, d2cn5A1, 0.7300, 2.90, 0.244, 281, 234, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4558, d1aq1A_, 0.7300, 2.86, 0.268, 277, 239, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
4559, d3kvxA_, 0.7299, 2.93, 0.232, 327, 241, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
4560, d3kc3I_, 0.7299, 2.66, 0.228, 295, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4561, d2bhhA_, 0.7299, 2.68, 0.275, 274, 236, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
4562, d3v6rB_, 0.7298, 3.28, 0.214, 346, 248, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4563, d2r0iB_, 0.7298, 2.81, 0.259, 300, 239, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4564, d4u97B_, 0.7297, 2.84, 0.275, 270, 233, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4565, d4jt3A_, 0.7297, 3.09, 0.222, 254, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
4566, d4eqmB_, 0.7297, 3.12, 0.229, 269, 245, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4567, d6bruB_, 0.7296, 3.60, 0.154, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4568, d4c4gA1, 0.7296, 2.88, 0.221, 247, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4569, d3wzjA_, 0.7296, 3.21, 0.234, 257, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4570, d3ocgA_, 0.7296, 2.90, 0.221, 336, 240, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
4571, d3nnwA_, 0.7295, 3.23, 0.228, 349, 246, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
4572, d2ym5A_, 0.7295, 3.09, 0.243, 248, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4573, d1ouyA_, 0.7295, 3.30, 0.234, 350, 248, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
4574, d3nwwA_, 0.7294, 3.06, 0.230, 339, 243, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
4575, d3kc3H_, 0.7294, 2.56, 0.221, 290, 235, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4576, d2vtqA_, 0.7294, 2.70, 0.263, 274, 236, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4577, d3txoA_, 0.7293, 2.80, 0.264, 317, 235, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4578, d3efwB_, 0.7293, 2.66, 0.272, 242, 235, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4579, d3d7zA_, 0.7293, 3.23, 0.235, 348, 247, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4580, d3dakD_, 0.7292, 3.39, 0.220, 284, 245, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4581, d2r0iA_, 0.7292, 2.83, 0.259, 300, 239, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4582, d2bheA_, 0.7292, 2.69, 0.258, 274, 236, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
4583, d4ftlA_, 0.7291, 3.22, 0.242, 263, 240, CRYSTAL STRUCTURE OF THE CHK1
4584, d4eqmC_, 0.7291, 3.14, 0.229, 269, 245, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4585, d5horA_, 0.7290, 2.56, 0.338, 247, 228, CRYSTAL STRUCTURE OF C-MET-M1250T IN COMPLEX WITH SAR125844.
4586, d4eqmA_, 0.7290, 3.13, 0.229, 269, 245, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4587, p3vulA_, 0.7290, 3.24, 0.235, 344, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
4588, d4u42B_, 0.7289, 2.88, 0.232, 265, 237, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4589, d4kipB_, 0.7288, 3.22, 0.224, 338, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4590, d3gc0A_, 0.7288, 3.21, 0.248, 278, 246, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
4591, d1m7qA_, 0.7288, 3.28, 0.223, 348, 247, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4592, d3mvmA_, 0.7287, 3.02, 0.219, 335, 242, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4593, d2pzyA_, 0.7287, 2.78, 0.228, 291, 237, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4594, d2btrA_, 0.7287, 2.77, 0.270, 275, 237, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
4595, d5hnvA1, 0.7286, 2.63, 0.171, 278, 234, CRYSTAL STRUCTURE OF PPKA
4596, d1v1kA_, 0.7285, 2.84, 0.268, 277, 239, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4597, d6btwB_, 0.7284, 3.60, 0.154, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4598, d4cjyD_, 0.7284, 3.03, 0.264, 272, 242,  
4599, d3mptA_, 0.7283, 3.17, 0.228, 347, 246, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
4600, d2xrwA1, 0.7283, 2.91, 0.221, 346, 240, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4601, d5d9hB_, 0.7282, 3.51, 0.211, 293, 246, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4602, p5o90A_, 0.7281, 3.11, 0.209, 330, 244, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
4603, d4wo5A1, 0.7281, 3.01, 0.312, 250, 240, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4604, d3w8qA_, 0.7281, 3.29, 0.243, 318, 243, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
4605, d2ym3A_, 0.7281, 3.05, 0.248, 247, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4606, d2r9sA_, 0.7281, 2.81, 0.231, 325, 238, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
4607, d5eymA_, 0.7280, 3.28, 0.242, 292, 244, MEK1 IN COMPLEX WITH BI 847325
4608, d3gc9B_, 0.7280, 3.16, 0.226, 339, 243, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4609, d3ds6D_, 0.7280, 3.21, 0.202, 349, 247, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4610, d2wmwA_, 0.7280, 3.02, 0.245, 247, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4611, d4u44B_, 0.7278, 3.58, 0.226, 296, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
4612, d3gc8B_, 0.7277, 3.32, 0.229, 346, 245, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4613, d2b55A_, 0.7277, 2.89, 0.261, 276, 238, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
4614, d4lg4F_, 0.7276, 2.99, 0.253, 276, 241, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4615, d3fmhA_, 0.7276, 3.23, 0.220, 347, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4616, d5eymB_, 0.7275, 3.21, 0.239, 292, 243, MEK1 IN COMPLEX WITH BI 847325
4617, d4z9lA_, 0.7275, 3.22, 0.215, 333, 246, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
4618, d2xm9A_, 0.7274, 3.00, 0.239, 287, 234, STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
4619, d2zb0A_, 0.7273, 3.24, 0.223, 349, 247, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4620, d2pmiA_, 0.7273, 3.11, 0.242, 284, 240, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4621, d2pzyC_, 0.7272, 3.00, 0.225, 307, 240, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4622, d4nj3A_, 0.7271, 2.99, 0.267, 277, 240, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
4623, d3nnuA_, 0.7271, 3.28, 0.228, 348, 246, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
4624, d3fpqA_, 0.7271, 3.12, 0.302, 262, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4625, d2oscA_, 0.7271, 2.13, 0.371, 255, 224, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
4626, d4bc6A_, 0.7270, 3.33, 0.255, 285, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4627, d3nnvA_, 0.7270, 3.27, 0.228, 348, 246, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
4628, d3gfwA1, 0.7270, 3.06, 0.227, 249, 242, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4629, d2ym8A_, 0.7270, 3.04, 0.253, 246, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4630, d2r9sB_, 0.7270, 2.83, 0.231, 325, 238, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
4631, d4useA_, 0.7269, 3.25, 0.269, 286, 242, HUMAN STK10 (LOK) WITH SB-633825
4632, d2vu3A_, 0.7269, 2.96, 0.269, 285, 238, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4633, d2ac3A1, 0.7269, 3.04, 0.228, 275, 241, STRUCTURE OF HUMAN MNK2 KINASE DOMAIN
4634, d1yojA_, 0.7268, 1.94, 0.309, 233, 223, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN
4635, d5o23A_, 0.7266, 3.29, 0.271, 269, 247, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4636, d2pzyD_, 0.7266, 2.68, 0.234, 288, 235, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4637, d5dewB_, 0.7265, 3.42, 0.225, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
4638, d1gijA_, 0.7265, 2.68, 0.268, 273, 235, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4639, d3u8wA_, 0.7264, 3.31, 0.230, 349, 248, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
4640, d3iphA_, 0.7264, 3.12, 0.217, 345, 244, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
4641, d3dakC_, 0.7264, 3.37, 0.224, 281, 245, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4642, d3gfeA_, 0.7263, 3.31, 0.231, 352, 247, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
4643, d2pzyB_, 0.7263, 2.60, 0.222, 283, 234, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4644, d2p4iB_, 0.7263, 2.37, 0.376, 258, 226, EVOLUTION OF A HIGHLY SELECTIVE AND POTENT 2-(PYRIDIN-2-YL)- 135-TRIAZINE TIE-2 KINASE INHIBITOR
4645, d2ym4A_, 0.7262, 3.24, 0.254, 251, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4646, d3gc8A_, 0.7261, 3.66, 0.229, 347, 249, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4647, d5we8B_, 0.7260, 3.33, 0.263, 272, 243, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4648, d4yomB1, 0.7260, 3.19, 0.240, 320, 246, STRUCTURE OF SAD KINASE
4649, p3hdmA_, 0.7260, 3.25, 0.218, 285, 243, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4650, d3ds6A_, 0.7260, 3.20, 0.203, 343, 246, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4651, d4a9tA1, 0.7259, 3.01, 0.239, 288, 234, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4652, d3kc3J_, 0.7259, 2.65, 0.231, 288, 234, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4653, d1wboA_, 0.7259, 3.29, 0.219, 351, 247, FRAGMENT BASED P38 INHIBITORS
4654, d4kiqA_, 0.7258, 3.19, 0.216, 338, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4655, d4fg9A_, 0.7258, 2.59, 0.239, 278, 234, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4656, d4kipA_, 0.7257, 3.09, 0.219, 337, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4657, d3e92A_, 0.7257, 3.20, 0.208, 348, 245, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4658, d2wzjC_, 0.7257, 3.08, 0.269, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4659, d3flyA_, 0.7256, 3.28, 0.224, 347, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4660, d2z7sA_, 0.7256, 2.59, 0.241, 256, 232, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4661, d2wzjB_, 0.7256, 2.98, 0.274, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4662, d2hakF_, 0.7256, 3.24, 0.285, 318, 246, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4663, d5ap5A1, 0.7254, 2.98, 0.220, 248, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4664, d4rvtB_, 0.7254, 3.79, 0.220, 297, 255, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4665, d3f61A_, 0.7254, 2.87, 0.209, 271, 239, CRYSTAL STRUCTURE OF M. TUBERCULOSIS PKNB LEU33ASP/VAL222ASP DOUBLE MUTANT IN COMPLEX WITH ADP
4666, d2zb1A_, 0.7254, 3.14, 0.225, 345, 244, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4667, d2wqmA_, 0.7254, 2.94, 0.254, 258, 240, STRUCTURE OF APO HUMAN NEK7
4668, d2wqeA_, 0.7254, 2.64, 0.235, 241, 234, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4669, d3op5D_, 0.7253, 3.64, 0.150, 302, 254, HUMAN VACCINIA-RELATED KINASE 1
4670, d3hllA_, 0.7253, 3.10, 0.223, 337, 242, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
4671, d3gbzA_, 0.7253, 3.11, 0.251, 274, 243, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
4672, d2vttA_, 0.7253, 2.69, 0.265, 272, 234, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4673, d1wbsA_, 0.7252, 3.29, 0.228, 351, 246, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4674, d1urwA_, 0.7252, 2.85, 0.262, 274, 237, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
4675, d1r78A_, 0.7252, 2.71, 0.264, 273, 235, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
4676, d5tf9A_, 0.7251, 3.28, 0.261, 262, 241, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4677, d5kbrA_, 0.7250, 2.56, 0.237, 259, 232, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4678, d4o0rB_, 0.7250, 3.10, 0.239, 282, 243, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4679, d3bv3A_, 0.7250, 3.11, 0.228, 338, 241, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
4680, d1bl6A_, 0.7250, 3.35, 0.211, 351, 247, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
4681, d5ankA_, 0.7249, 2.85, 0.270, 273, 237, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4682, d3rocA_, 0.7248, 3.12, 0.219, 337, 242, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
4683, d3bx5A_, 0.7248, 3.10, 0.215, 338, 242, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
4684, d3e7oB_, 0.7247, 2.76, 0.234, 326, 235, CRYSTAL STRUCTURE OF JNK2
4685, d2onlB1, 0.7247, 3.18, 0.226, 339, 243, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4686, p5w5qB_, 0.7246, 3.59, 0.226, 297, 252, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4687, d5ap2A1, 0.7246, 3.04, 0.220, 253, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4688, d6eimB_, 0.7245, 3.46, 0.266, 295, 244, HUMAN STK10 BOUND TO GW683134A
4689, d4o0tB_, 0.7245, 3.12, 0.233, 280, 245, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4690, d1zmwA_, 0.7245, 3.08, 0.274, 302, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4691, d5uvfD_, 0.7243, 3.45, 0.147, 296, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4692, d2wzjF_, 0.7243, 3.00, 0.270, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4693, d1r3cA_, 0.7243, 3.38, 0.219, 349, 247, THE STRUCTURE OF P38ALPHA C162S MUTANT
4694, d1p2aA_, 0.7243, 2.61, 0.253, 271, 233, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
4695, d1w84A_, 0.7242, 3.33, 0.223, 351, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4696, d4d1xA_, 0.7241, 2.86, 0.267, 274, 236, CDK2 IN COMPLEX WITH LUCIFERIN
4697, d1zmwB_, 0.7241, 3.13, 0.257, 302, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4698, d3hl7A_, 0.7240, 3.10, 0.231, 336, 242, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
4699, d2lgcA1, 0.7240, 3.30, 0.208, 353, 245, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
4700, d4zp5B_, 0.7239, 3.65, 0.222, 300, 252, MAP4K4 IN COMPLEX WITH INHIBITOR
4701, d4u3yB_, 0.7239, 3.83, 0.224, 300, 255, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4702, d1blxA_, 0.7239, 3.36, 0.246, 305, 248, P19INK4D/CDK6 COMPLEX
4703, d4aaaA1, 0.7238, 3.79, 0.264, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
4704, d5di1B_, 0.7237, 3.65, 0.222, 300, 252, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4705, d1wbtA_, 0.7237, 3.33, 0.228, 351, 246, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4706, d6b4wA_, 0.7236, 3.19, 0.230, 259, 244, TTK IN COMPLEX WITH INHIBITOR
4707, d3da6A_, 0.7236, 3.11, 0.217, 328, 244, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
4708, d3bv2A_, 0.7236, 3.04, 0.225, 337, 240, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
4709, d2z7qA_, 0.7236, 2.58, 0.247, 255, 231, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4710, d4a9uA1, 0.7235, 3.05, 0.231, 286, 234, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4711, d3h9fA1, 0.7235, 3.25, 0.225, 256, 244, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
4712, d2w5hA1, 0.7235, 3.04, 0.245, 257, 241, HUMAN NEK2 KINASE APO
4713, d5etcA_, 0.7234, 3.39, 0.219, 355, 247, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
4714, d4x7nA_, 0.7234, 3.03, 0.218, 259, 238, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4715, d3wi6B_, 0.7234, 2.55, 0.227, 283, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4716, d3kc3K_, 0.7234, 2.68, 0.226, 280, 234, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4717, d3flzA_, 0.7234, 3.30, 0.224, 347, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4718, d2ycfA_, 0.7234, 3.05, 0.243, 286, 235, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1531
4719, p2xs0A_, 0.7234, 3.06, 0.207, 346, 242, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4720, d3wi6F_, 0.7233, 2.62, 0.222, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4721, d3wi6C_, 0.7233, 2.54, 0.227, 283, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4722, d1oitA_, 0.7233, 2.76, 0.268, 273, 235, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4723, d4jg6A_, 0.7232, 3.19, 0.232, 302, 241, RSK2 CTD BOUND TO 2-CYANO-3-(1H-INDAZOL-5-YL)ACRYLAMIDE
4724, d3h0zB_, 0.7232, 2.60, 0.253, 240, 233, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4725, d3dakB_, 0.7232, 3.37, 0.221, 278, 244, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4726, d2ok1A_, 0.7232, 3.02, 0.212, 333, 241, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4727, d2fvdA_, 0.7232, 2.89, 0.258, 284, 236, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
4728, d1vzoA_, 0.7232, 3.34, 0.220, 319, 245, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
4729, d3itzA1, 0.7231, 3.41, 0.211, 353, 247, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4730, d2okrA_, 0.7231, 3.22, 0.226, 339, 243, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4731, d5m53A1, 0.7230, 2.70, 0.258, 248, 233, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4732, d4c3pD_, 0.7230, 3.11, 0.237, 260, 240, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4733, d3wi6E_, 0.7230, 2.63, 0.226, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4734, d1lewA_, 0.7230, 3.25, 0.225, 341, 244, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
4735, d4kiqC_, 0.7229, 3.10, 0.219, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4736, d3s3iA_, 0.7229, 3.41, 0.230, 349, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4737, d4kiqB_, 0.7228, 3.12, 0.219, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4738, d3fklA_, 0.7228, 3.22, 0.217, 344, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
4739, d2duvA_, 0.7228, 2.70, 0.278, 272, 234, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
4740, d2qnjB1, 0.7227, 3.33, 0.287, 321, 247, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4741, d2onlA1, 0.7227, 3.16, 0.227, 338, 242, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4742, d4fk3B1, 0.7226, 2.51, 0.316, 241, 231, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4743, d4ehvA_, 0.7226, 3.13, 0.224, 337, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
4744, d4rzvA1, 0.7225, 2.69, 0.313, 245, 233, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4745, d4kiqD_, 0.7225, 3.11, 0.223, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4746, d3flwA_, 0.7224, 3.27, 0.224, 345, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
4747, d4bbmA1, 0.7223, 4.02, 0.265, 306, 253, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
4748, d3nnxA_, 0.7223, 3.31, 0.226, 336, 243, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
4749, d3gc9A_, 0.7223, 3.63, 0.219, 335, 247, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4750, d2gtnA_, 0.7223, 3.14, 0.216, 337, 241, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
4751, d4zk5B_, 0.7222, 3.54, 0.228, 294, 250, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
4752, d4fa2A_, 0.7222, 3.12, 0.216, 339, 241, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
4753, d4u43B_, 0.7221, 3.59, 0.232, 302, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4754, d4c4hA1, 0.7221, 2.90, 0.218, 245, 238, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4755, d3ptgA_, 0.7221, 3.20, 0.238, 340, 244, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
4756, d2vwiD_, 0.7221, 3.37, 0.222, 284, 243, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4757, d2xbjA_, 0.7220, 2.95, 0.245, 286, 233, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4758, d2wzjA_, 0.7220, 3.03, 0.270, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4759, d1zy5A1, 0.7220, 3.44, 0.245, 269, 249, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4760, d5etiA1, 0.7218, 3.45, 0.198, 352, 247, STRUCTURE OF DEAD KINASE MAPK14
4761, d3wi6D_, 0.7218, 2.60, 0.223, 282, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4762, d4kinC_, 0.7217, 3.14, 0.223, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4763, d2wtjA1, 0.7217, 3.09, 0.231, 286, 234, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4764, d1ywrA_, 0.7217, 3.15, 0.227, 338, 242, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
4765, d4tyhB_, 0.7216, 3.02, 0.225, 335, 240, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
4766, d3zxtA_, 0.7216, 2.67, 0.246, 249, 232, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4767, d3kc3G_, 0.7216, 2.62, 0.223, 276, 233, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4768, d2zazA_, 0.7216, 3.19, 0.226, 345, 243, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
4769, d2wmqA_, 0.7216, 3.11, 0.253, 246, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4770, d3ctqA_, 0.7215, 2.97, 0.209, 336, 239, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
4771, d5wdyA_, 0.7214, 3.18, 0.259, 260, 239, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
4772, d5j95B_, 0.7214, 3.67, 0.239, 300, 251, MAP4K4 IN COMPLEX WITH INHIBITOR
4773, d4x7kA_, 0.7214, 2.96, 0.219, 260, 237, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4774, d3mvmB_, 0.7214, 2.94, 0.210, 332, 238, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4775, d4yr8E_, 0.7213, 3.04, 0.208, 317, 240, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4776, d3ds6C_, 0.7213, 3.42, 0.222, 349, 248, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4777, d1w83A_, 0.7213, 3.36, 0.228, 351, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4778, d1lezA_, 0.7213, 3.29, 0.224, 343, 245, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
4779, d4x7hA_, 0.7212, 2.95, 0.219, 256, 237, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4780, d2rg6A_, 0.7212, 3.02, 0.226, 335, 239, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
4781, d2qnjA1, 0.7212, 3.28, 0.293, 317, 246, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4782, p5yj9D_, 0.7211, 3.16, 0.195, 333, 241, CRYSTAL STRUCTURE OF TRIBOLIUM CASTANEUM PINK1 KINASE DOMAIN IN COMPLEX WITH AMP-PNP 
4783, d5w84B_, 0.7211, 2.59, 0.276, 261, 228, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4784, d3wi6A_, 0.7211, 2.54, 0.228, 282, 232, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4785, d2wzjD_, 0.7211, 3.06, 0.274, 313, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4786, d1bl7A_, 0.7211, 3.41, 0.219, 351, 247, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
4787, d5mz3A_, 0.7210, 3.34, 0.228, 350, 246, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
4788, d3kf7A_, 0.7210, 3.17, 0.211, 337, 242, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
4789, d2hw7A1, 0.7210, 3.03, 0.214, 269, 238, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4790, d3kq7A_, 0.7209, 3.34, 0.228, 348, 246, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
4791, d4x7lA_, 0.7207, 2.97, 0.219, 260, 237, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4792, d3dakA_, 0.7207, 3.28, 0.219, 279, 242, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4793, d2excX_, 0.7207, 3.02, 0.217, 335, 240, INHIBITOR COMPLEX OF JNK3
4794, d3g51A_, 0.7206, 3.06, 0.235, 280, 238, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4795, d2o2uA_, 0.7206, 3.03, 0.220, 319, 241, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
4796, d4kinD_, 0.7205, 3.23, 0.217, 339, 244, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4797, d3g9lX_, 0.7204, 3.16, 0.211, 336, 242, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
4798, d4bdiA1, 0.7203, 2.88, 0.247, 289, 231, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4799, d3ds6B_, 0.7203, 3.31, 0.211, 343, 247, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4800, d2ghmA_, 0.7203, 3.10, 0.237, 336, 241, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
4801, d4zthA_, 0.7202, 3.15, 0.216, 339, 241, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
4802, d4yr8A_, 0.7202, 3.09, 0.212, 320, 240, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4803, d3fe3B_, 0.7202, 3.26, 0.293, 317, 246, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4804, d2bvaA_, 0.7202, 2.98, 0.192, 272, 239, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4805, d1zzlA_, 0.7202, 3.44, 0.211, 351, 247, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
4806, d4x7jA_, 0.7200, 2.94, 0.220, 257, 236, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4807, d3uvqA_, 0.7200, 2.92, 0.215, 333, 237, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
4808, d2bmcD_, 0.7200, 2.89, 0.233, 256, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4809, d1yqjA2, 0.7200, 3.43, 0.202, 351, 247, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
4810, d4ka3A_, 0.7199, 3.20, 0.223, 340, 242, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
4811, d3ezrA_, 0.7199, 2.79, 0.264, 273, 235, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
4812, d1zmuB_, 0.7199, 2.76, 0.260, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4813, d3v6sB_, 0.7198, 3.15, 0.219, 340, 242, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4814, d2wtiA_, 0.7198, 2.91, 0.233, 286, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4815, d1wbvA_, 0.7198, 3.32, 0.233, 351, 245, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4816, d4u41B_, 0.7197, 3.71, 0.222, 297, 252, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4817, d3w18B_, 0.7197, 2.74, 0.270, 236, 233, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4818, d3flsA_, 0.7197, 3.18, 0.215, 343, 242, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4819, d2bmcE_, 0.7197, 2.91, 0.233, 256, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4820, d4m69B_, 0.7196, 3.09, 0.239, 264, 243, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4821, d3w18A_, 0.7195, 2.46, 0.258, 234, 229, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4822, d4x21B_, 0.7193, 3.28, 0.230, 336, 244, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
4823, d2yitA_, 0.7193, 2.99, 0.239, 286, 234, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV1162 A NOVEL INHIBITOR
4824, d2yixA_, 0.7192, 3.49, 0.202, 351, 247, TRIAZOLOPYRIDINE INHIBITORS OF P38
4825, d2wtcA_, 0.7192, 3.01, 0.237, 284, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4826, d3o8uA_, 0.7191, 3.06, 0.221, 332, 240, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4827, d3kc3C_, 0.7191, 2.52, 0.235, 281, 230, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4828, d3hp2A_, 0.7191, 3.21, 0.212, 341, 241, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
4829, d3flnC_, 0.7191, 3.07, 0.232, 343, 241, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
4830, d3efwA_, 0.7191, 2.61, 0.241, 240, 232, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4831, d2wzjE_, 0.7191, 3.01, 0.275, 310, 240, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4832, d2vwiC_, 0.7191, 3.17, 0.222, 270, 239, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4833, d2qr7A_, 0.7191, 3.26, 0.245, 292, 241, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2: SE-MET DERIVATIVE
4834, d1bmkA_, 0.7191, 3.41, 0.211, 351, 247, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
4835, d4oboB_, 0.7190, 3.66, 0.223, 297, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4836, d4a9rA_, 0.7190, 3.04, 0.228, 285, 232, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4837, d2okrD_, 0.7190, 3.19, 0.228, 339, 241, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4838, d2j7tA_, 0.7190, 3.17, 0.256, 285, 238, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4839, d4zjiD_, 0.7189, 3.37, 0.224, 280, 246, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4840, d4l8mA_, 0.7189, 3.10, 0.218, 339, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
4841, d3e93A_, 0.7188, 3.26, 0.234, 346, 244, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4842, d1r39A_, 0.7188, 3.35, 0.205, 345, 244, THE STRUCTURE OF P38ALPHA
4843, d4u45B_, 0.7187, 3.66, 0.228, 295, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
4844, d4u79A_, 0.7186, 3.17, 0.214, 337, 243, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
4845, d5a6nA1, 0.7185, 2.89, 0.249, 270, 237, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4846, d4zloB_, 0.7185, 2.78, 0.226, 263, 234, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4847, d3fmkA_, 0.7184, 3.32, 0.220, 346, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4848, d3ortA_, 0.7183, 2.99, 0.212, 271, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 6)
4849, d2pk9C_, 0.7183, 2.82, 0.239, 266, 234, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
4850, d4f9wA_, 0.7182, 3.12, 0.228, 336, 241, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
4851, d5w5jA_, 0.7181, 2.33, 0.262, 251, 225, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4852, d2bmcA_, 0.7180, 2.90, 0.233, 256, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4853, p3lhjA_, 0.7179, 3.26, 0.210, 341, 243, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
4854, d2yirA_, 0.7179, 3.01, 0.239, 286, 234, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1352
4855, d1gzoA_, 0.7179, 2.82, 0.252, 271, 234, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4856, d3q4zB_, 0.7178, 3.11, 0.231, 279, 242, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4857, d3g33C_, 0.7177, 3.26, 0.252, 291, 242, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4858, d3a2cF_, 0.7177, 3.32, 0.217, 287, 240, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4859, d4kinA_, 0.7176, 3.35, 0.224, 338, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4860, d3queA_, 0.7176, 3.23, 0.212, 343, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
4861, d1g3nE_, 0.7176, 3.12, 0.251, 293, 239, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
4862, d4eh7A_, 0.7174, 3.14, 0.209, 337, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
4863, d3rinA_, 0.7174, 3.46, 0.219, 349, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4864, d3fknA_, 0.7174, 3.33, 0.213, 346, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
4865, d2dylA_, 0.7173, 3.02, 0.227, 272, 238, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
4866, p5etaB_, 0.7172, 3.17, 0.224, 335, 241, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
4867, d4obqB_, 0.7172, 3.56, 0.229, 293, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4868, d4f9yA_, 0.7172, 3.29, 0.222, 339, 243, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
4869, d4d2sA_, 0.7172, 2.86, 0.225, 249, 236, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
4870, d2wtdA_, 0.7172, 2.87, 0.234, 285, 231, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4871, d1zmuA_, 0.7172, 2.79, 0.265, 293, 234, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4872, d1zmvB_, 0.7171, 2.83, 0.260, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4873, d1yw2A_, 0.7171, 3.23, 0.207, 341, 241, MUTATED MUS MUSCULUS P38 KINASE (MP38)
4874, d5knjB_, 0.7170, 2.78, 0.212, 259, 236, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4875, d1zy4A1, 0.7170, 3.51, 0.245, 269, 249, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
4876, d3zz2A_, 0.7168, 3.37, 0.262, 281, 240,  
4877, d2wmsA_, 0.7168, 3.02, 0.253, 243, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4878, d2bmcB_, 0.7168, 2.92, 0.233, 258, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4879, d4eh2A_, 0.7167, 3.12, 0.218, 337, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
4880, d1gzkA_, 0.7167, 2.84, 0.252, 271, 234, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4881, d4zjiC_, 0.7166, 3.26, 0.225, 281, 244, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4882, d3ma6A_, 0.7166, 3.54, 0.255, 267, 251, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4883, d3fmeA1, 0.7166, 3.25, 0.244, 267, 238, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4884, d2y4pC_, 0.7166, 2.72, 0.253, 264, 233, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4885, d1g3nA_, 0.7166, 3.14, 0.251, 293, 239, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
4886, d4kinB_, 0.7165, 3.68, 0.221, 341, 249, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4887, d3p7aA_, 0.7165, 2.96, 0.224, 332, 237, P38 INHIBITOR-BOUND
4888, d3ckwA_, 0.7165, 2.74, 0.266, 255, 233, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4889, d2w96B_, 0.7165, 3.02, 0.256, 267, 238, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4890, d3zyaA1, 0.7163, 3.13, 0.208, 341, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
4891, d2ycqA_, 0.7162, 2.98, 0.240, 285, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1115
4892, d1p38A_, 0.7162, 3.50, 0.211, 351, 247, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
4893, d1gznA_, 0.7162, 2.83, 0.252, 271, 234, STRUCTURE OF PKB KINASE DOMAIN
4894, d2i6lB_, 0.7161, 2.82, 0.219, 269, 233, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
4895, d1a9uA_, 0.7161, 3.51, 0.198, 351, 247, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
4896, d3hv4A_, 0.7159, 3.37, 0.226, 339, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4897, d3db8A_, 0.7159, 2.73, 0.246, 261, 232, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4898, d4wo5B1, 0.7158, 2.54, 0.306, 241, 229, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4899, d3g33A_, 0.7158, 3.24, 0.249, 291, 241, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4900, d5l2sA_, 0.7157, 2.91, 0.254, 263, 236, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
4901, d1ua2A_, 0.7157, 3.31, 0.233, 286, 240, CRYSTAL STRUCTURE OF HUMAN CDK7
4902, d5a14A_, 0.7156, 3.31, 0.275, 284, 240, HUMAN CDK2 WITH TYPE II INHIBITOR
4903, d3zxtB_, 0.7155, 2.85, 0.250, 253, 232, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4904, d2ghlA_, 0.7155, 3.10, 0.222, 334, 239, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
4905, d3qudA_, 0.7154, 3.19, 0.212, 345, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
4906, d2xk9A_, 0.7154, 2.95, 0.241, 284, 232, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 (CHK2) IN COMPLEX WITH INHIBITOR PV1533
4907, d5tbeA_, 0.7153, 3.39, 0.212, 332, 241, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
4908, d5fp5A_, 0.7153, 2.66, 0.277, 264, 231, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
4909, d1zycC1, 0.7153, 3.63, 0.244, 269, 250, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4910, d1wbnA_, 0.7153, 3.42, 0.232, 351, 246, FRAGMENT BASED P38 INHIBITORS
4911, d3rtpA_, 0.7152, 3.03, 0.218, 331, 238, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
4912, d3dfaA1, 0.7152, 3.57, 0.235, 262, 247, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
4913, d2rg5A_, 0.7152, 3.17, 0.220, 333, 241, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
4914, d5o1vB_, 0.7149, 3.33, 0.272, 270, 239, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4915, d3dbdA_, 0.7149, 2.75, 0.250, 261, 232, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4916, d2oidA_, 0.7149, 2.65, 0.281, 263, 228, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4917, d1zyjA_, 0.7149, 3.06, 0.222, 331, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
4918, d4u3zB_, 0.7148, 3.54, 0.226, 294, 248, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4919, d4a9sA_, 0.7148, 2.96, 0.239, 282, 230, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4920, d3zxtC_, 0.7147, 2.69, 0.242, 259, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4921, d2w7xA_, 0.7146, 2.96, 0.241, 285, 232, CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019
4922, d2oidC_, 0.7146, 2.80, 0.272, 256, 228, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4923, d1wfcA_, 0.7146, 3.26, 0.219, 340, 242, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
4924, d5kbqB_, 0.7145, 3.16, 0.229, 273, 240, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
4925, d3nuxA_, 0.7145, 2.69, 0.250, 261, 232, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
4926, d1ua2D_, 0.7144, 3.20, 0.232, 286, 237, CRYSTAL STRUCTURE OF HUMAN CDK7
4927, d4eh8A_, 0.7143, 3.11, 0.210, 336, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
4928, d3fmmA_, 0.7143, 3.35, 0.213, 346, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
4929, d5tf9B_, 0.7141, 3.34, 0.255, 266, 239, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4930, d2jc6A_, 0.7141, 2.82, 0.226, 278, 235, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4931, d2j90B_, 0.7141, 2.71, 0.243, 262, 230, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4932, d4ic8B_, 0.7140, 3.46, 0.208, 336, 245, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
4933, d2j90A1, 0.7140, 2.63, 0.255, 259, 231, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4934, d1zmvA_, 0.7140, 2.75, 0.253, 293, 233, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4935, d1ukiA_, 0.7140, 3.11, 0.229, 328, 240, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
4936, d4m68A_, 0.7138, 3.42, 0.235, 268, 243, CRYSTAL STRUCTURE OF THE MOUSE MLKL KINASE-LIKE DOMAIN
4937, d3fe3A_, 0.7138, 3.43, 0.291, 317, 247, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4938, d2gtmA_, 0.7138, 3.12, 0.214, 341, 238, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
4939, d1w7hA_, 0.7138, 3.52, 0.206, 351, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4940, d5l2iA_, 0.7137, 2.78, 0.263, 260, 232, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
4941, d3flqA_, 0.7137, 3.40, 0.230, 345, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
4942, d1jsuA_, 0.7137, 3.46, 0.237, 285, 241, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
4943, d3mh0A_, 0.7136, 2.99, 0.228, 332, 237, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4944, d3fi2A_, 0.7136, 2.97, 0.228, 326, 237, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
4945, d5o1vA_, 0.7135, 3.21, 0.269, 278, 238, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4946, d4xv9A1, 0.7135, 2.58, 0.309, 244, 230, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
4947, d4equB_, 0.7135, 3.01, 0.248, 282, 234, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4948, d4bdfA1, 0.7135, 2.93, 0.245, 284, 229, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4949, d3gp0A1, 0.7134, 3.61, 0.219, 332, 242, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
4950, d2bmcC_, 0.7133, 3.11, 0.236, 257, 237, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4951, d3r2bB_, 0.7132, 2.76, 0.222, 272, 230, MK2 KINASE BOUND TO COMPOUND 5B
4952, d3p7cA_, 0.7132, 3.14, 0.225, 332, 240, P38 INHIBITOR-BOUND
4953, d3kmuA_, 0.7132, 3.06, 0.265, 253, 238, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (APO)
4954, d3hv5A_, 0.7132, 3.42, 0.226, 339, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
4955, d2ycrA_, 0.7132, 3.00, 0.238, 282, 231, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV976
4956, d2b1pA_, 0.7132, 3.08, 0.222, 331, 239, INHIBITOR COMPLEX OF JNK3
4957, d4ynoA_, 0.7131, 3.42, 0.205, 342, 244, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
4958, d3lffA_, 0.7131, 3.21, 0.225, 335, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
4959, d3gcuA_, 0.7131, 3.41, 0.226, 339, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4960, d3fkoA_, 0.7131, 3.24, 0.223, 343, 242, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
4961, d2x7fE_, 0.7131, 2.58, 0.254, 251, 228, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4962, d2xkdA1, 0.7128, 2.84, 0.244, 243, 234, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4963, d4eh9A_, 0.7127, 3.06, 0.229, 334, 236, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
4964, d3o8pA_, 0.7127, 3.22, 0.208, 336, 240, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4965, d3fmjA_, 0.7127, 3.32, 0.226, 344, 243, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
4966, d2bmcF_, 0.7127, 3.02, 0.237, 257, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4967, d3mpaA_, 0.7126, 2.97, 0.220, 331, 236, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4968, d2w9fB_, 0.7126, 3.11, 0.253, 261, 237, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4969, d5jt2D1, 0.7124, 2.45, 0.329, 232, 225, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4970, d1oveA_, 0.7124, 3.54, 0.219, 349, 247, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
4971, d5hniX_, 0.7123, 2.76, 0.338, 245, 225, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
4972, d4fk3A1, 0.7123, 2.53, 0.311, 238, 228, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4973, d3p5kA_, 0.7123, 3.15, 0.212, 332, 240, P38 INHIBITOR-BOUND
4974, d4eh6A_, 0.7122, 3.05, 0.211, 335, 237, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
4975, d3oy1A_, 0.7122, 3.09, 0.218, 329, 239, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
4976, d3oxiA_, 0.7122, 3.04, 0.231, 322, 238, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
4977, d3orlA_, 0.7122, 3.07, 0.213, 268, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 3)
4978, d2pkjA_, 0.7122, 3.14, 0.229, 332, 240,  
4979, d1oz1A_, 0.7122, 3.36, 0.230, 344, 243, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
4980, d5a6nB1, 0.7121, 2.97, 0.220, 265, 236, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4981, d5l2tA_, 0.7120, 2.66, 0.260, 261, 231, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
4982, d4eh4A_, 0.7120, 3.12, 0.215, 337, 237, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
4983, d4bdgA1, 0.7120, 2.97, 0.248, 285, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4984, d1ua2B_, 0.7120, 3.30, 0.234, 286, 239, CRYSTAL STRUCTURE OF HUMAN CDK7
4985, d3newA_, 0.7118, 3.14, 0.222, 334, 239, P38-ALPHA COMPLEXED WITH COMPOUND 10
4986, d5angA_, 0.7117, 2.80, 0.272, 268, 232, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4987, d4obpB_, 0.7117, 3.60, 0.222, 290, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4988, d3hv4B_, 0.7116, 3.33, 0.227, 338, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4989, d2jc6C_, 0.7115, 2.83, 0.226, 277, 234, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4990, d4pwnA_, 0.7114, 2.97, 0.278, 245, 234, CRYSTAL STRUCTURE OF ACTIVE WNK1 KINASE
4991, d4eh3A_, 0.7114, 3.22, 0.209, 339, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
4992, d3r2bE_, 0.7114, 2.77, 0.226, 272, 230, MK2 KINASE BOUND TO COMPOUND 5B
4993, d3p7bA_, 0.7114, 3.16, 0.212, 332, 240, P38 INHIBITOR-BOUND
4994, d3p78A_, 0.7114, 3.03, 0.211, 332, 237, P38 INHIBITOR-BOUND
4995, d1ua2C_, 0.7114, 3.27, 0.223, 286, 238, CRYSTAL STRUCTURE OF HUMAN CDK7
4996, d3r2bA_, 0.7113, 2.60, 0.232, 272, 228, MK2 KINASE BOUND TO COMPOUND 5B
4997, d3fi4A_, 0.7112, 3.08, 0.227, 339, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
4998, d3kc3D_, 0.7111, 2.56, 0.232, 269, 228, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4999, d3r2bL_, 0.7110, 2.60, 0.228, 272, 228, MK2 KINASE BOUND TO COMPOUND 5B
5000, d3d5vA_, 0.7110, 2.83, 0.241, 260, 232, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
